Column1,Category,Medicine name,Therapeutic area,International non-proprietary name (INN) / common name,Active substance,Product number,Patient safety,Authorisation status,ATC code,Additional monitoring,Generic,Conditional approval,Exceptional circumstances,Accelerated assessment,Orphan medicine,Marketing authorisation date,Date of refusal of marketing authorisation,Marketing authorisation holder/company name,Human pharmacotherapeutic group,Date of opinion,Decision date,Revision number,Condition / indication,First published,Revision date,URL,InChI_Keys,Mol,MolWt
94,Human,Fetcroja,Gram-Negative Bacterial Infections,cefiderocol,CEFIDEROCOL SULFATE TOSILATE,EMEA/H/C/004829,no,Authorised,J01D,yes,no,no,no,no,no,23/04/2020,,Shionogi B.V.,"Antibacterials for systemic use, ",,21/11/2023,7,"Fetcroja is indicated for the treatment of infections   due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",29/04/2020,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja,LTUONTFKVOUYHB-SDAZKDLGSA-N,"InChI=1S/3C30H34ClN7O10S2.4C7H8O3S.H2O4S/c3*1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31;4*1-6-2-4-7(5-3-6)11(8,9)10;1-5(2,3)4/h3*5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47);4*2-5H,1H3,(H,8,9,10);(H2,1,2,3,4)/t3*20-,26-;;;;;/m111...../s1",3043.582999999989
253,Human,Sugammadex Adroiq,Neuromuscular Blockade,sugammadex,SUGAMMADEX SODIUM,EMEA/H/C/006046,no,Authorised,"V03, V03AB",no,no,no,no,no,no,26/05/2023,,Extrovis EU Ltd.,All other therapeutic products,,11/10/2023,1,Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.,16/06/2023,12/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-adroiq,KMGKABOMYQLLDJ-VKHHSAQNSA-F,"InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1",2178.032000000001
557,Human,Sugammadex Piramal,Neuromuscular Blockade,sugammadex,SUGAMMADEX SODIUM,EMEA/H/C/006083,no,Authorised,V03AB35,no,yes,no,no,no,no,23/06/2023,,Piramal Critical Care B.V.,sugammadex,26/04/2023,23/06/2023,,Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.,24/04/2023,18/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-piramal,KMGKABOMYQLLDJ-VKHHSAQNSA-F,"InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1",2178.032000000001
608,Human,Sugammadex Amomed,Neuromuscular Blockade,sugammadex,SUGAMMADEX SODIUM,EMEA/H/C/005935,no,Authorised,V03AB35,no,yes,no,no,no,no,10/01/2023,,AOP Orphan Pharmaceuticals GmbH,All other therapeutic products,10/11/2022,06/07/2023,1,Reversal of neuromuscular blockade induced by rocuronium or vecuronium.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.,04/11/2022,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-amomed,KMGKABOMYQLLDJ-VKHHSAQNSA-F,"InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1",2178.032000000001
670,Human,Sugammadex Mylan,Neuromuscular Blockade,sugammadex,SUGAMMADEX SODIUM,EMEA/H/C/005403,no,Authorised,V03AB35,no,yes,no,no,no,no,15/11/2021,,Mylan Ireland Limited,All other therapeutic products,16/09/2021,08/06/2023,2,Reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.,22/11/2021,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-mylan,KMGKABOMYQLLDJ-VKHHSAQNSA-F,"InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1",2178.032000000001
1186,Human,Sugammadex Fresenius Kabi,Neuromuscular Blockade,sugammadex,SUGAMMADEX SODIUM,EMEA/H/C/005760,no,Authorised,V03AB35,no,yes,no,no,no,no,15/07/2022,,Fresenius Kabi Deutschland GmbH,All other therapeutic products,19/05/2022,15/07/2022,,Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.,17/05/2022,21/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-fresenius-kabi,KMGKABOMYQLLDJ-VKHHSAQNSA-F,"InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1",2178.032000000001
332,Human,Bridion,Neuromuscular Blockade,sugammadex,SUGAMMADEX,EMEA/H/C/000885,no,Authorised,V03AB35,no,no,no,no,no,no,25/07/2008,,Merck Sharp & Dohme B.V.,All other therapeutic products,,13/04/2023,22,Reversal of neuromuscular blockade induced by rocuronium or vecuronium.For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.,02/12/2016,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bridion,WHRODDIHRRDWEW-VTHZAVIASA-N,"InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1",2002.1760000000024
581,Human,Arixtra,"Venous Thrombosis;  Pulmonary Embolism;  Myocardial Infarction;  Angina, Unstable",fondaparinux sodium,FONDAPARINUX SODIUM,EMEA/H/C/000403,no,Authorised,B01AX05,no,no,no,no,no,no,20/03/2002,,Mylan IRE Healthcare Limited,Antithrombotic agents,22/07/2010,13/07/2023,35,"1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.",21/03/2018,14/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra,XEKSTYNIJLDDAZ-JASSWCPGSA-D,"InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1",1728.0930000000014
1992,Human,Quixidar,"Venous Thrombosis;  Pulmonary Embolism;  Myocardial Infarction;  Angina, Unstable",fondaparinux sodium,FONDAPARINUX SODIUM,EMEA/H/C/000404,no,Withdrawn,B01AX05,no,no,no,no,no,no,21/03/2002,,Glaxo Group Ltd.,Antithrombotic agents,,24/10/2007,10,"1.5 mg/0.3 ml and 2.5 mg/0.5 ml, solution for injection:, 	Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery., 	Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1)., 	Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease., 	, 	2.5 mg/0.5 ml, solution for injection:, 	Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1)., 	Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy., 	, 	5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml solution for injection:, 	Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy., ",24/10/2007,16/05/2008,https://www.ema.europa.eu/en/medicines/human/EPAR/quixidar,XEKSTYNIJLDDAZ-JASSWCPGSA-D,"InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1",1728.0930000000014
1034,Human,Cubicin,"Gram-Positive Bacterial Infections;  Bacteremia;  Soft Tissue Infections;  Endocarditis, Bacterial",daptomycin,DAPTOMYCIN,EMEA/H/C/000637,no,Authorised,J01XX09,no,no,no,no,no,no,19/01/2006,,Merck Sharp & Dohme B.V.,"Antibacterials for systemic use, ",17/11/2005,06/12/2022,37,"Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.",08/08/2018,15/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin,DOAKLVKFURWEDJ-QCMAZARJSA-N,"InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1",1620.6930000000016
1267,Human,Daptomycin Hospira,"Soft Tissue Infections;  Skin Diseases, Bacterial",daptomycin,DAPTOMYCIN,EMEA/H/C/004310,no,Authorised,J01XX09,no,yes,no,no,no,no,22/03/2017,,Pfizer Europe MA EEIG,"Antibacterials for systemic use, ",26/01/2017,25/03/2022,13,"Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",13/04/2018,06/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/daptomycin-hospira,DOAKLVKFURWEDJ-QCMAZARJSA-N,"InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1",1620.6930000000016
347,Human,Lutathera,Neuroendocrine Tumors,lutetium (177Lu) oxodotreotide,LUTETIUM (177LU) OXODOTREOTIDE,EMEA/H/C/004123,no,Authorised,V10XX04,no,no,no,no,no,yes,26/09/2017,,Advanced Accelerator Applications,Other therapeutic radiopharmaceuticals,20/07/2017,19/09/2023,10,"Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults.",21/03/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera,MXDPZUIOZWKRAA-PRDSJKGBSA-K,"InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2",1609.5677581000007
1944,Human,NeoSpect,Radionuclide Imaging,depreotide,DEPREOTIDE TRIFLUOROACETATE,EMEA/H/C/000263,no,Withdrawn,V09IA05,no,no,no,no,no,no,29/11/2000,,CIS bio international,Diagnostic radiopharmaceuticals,,28/10/2010,10,"This medicinal product is for diagnostic use only.For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, incombination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.",28/10/2010,18/11/2010,https://www.ema.europa.eu/en/medicines/human/EPAR/neospect,ULBLQSNGKAZIES-KTABZWLNSA-N,"InChI=1S/C65H96N16O12S2.C2HF3O2/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68;3-2(4,5)1(6)7/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87);(H,6,7)/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-;/m0./s1",1471.7390000000007
301,Human,SomaKit TOC,Neuroendocrine Tumors;  Radionuclide Imaging,edotreotide,EDOTREOTIDE,EMEA/H/C/004140,no,Authorised,V09IX,no,no,no,no,no,yes,08/12/2016,,Advanced Accelerator Applications,Diagnostic radiopharmaceuticals,15/09/2016,28/09/2023,15,"This medicinal product is for diagnostic use only.After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.",12/06/2017,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc,RZHKDBRREKOZEW-AAXZNHDCSA-N,"InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1",1421.6650000000009
1474,Human,Icatibant Accord,"Angioedemas, Hereditary",icatibant,ICATIBANT ACETATE,EMEA/H/C/005083,no,Authorised,B06AC02,no,yes,no,no,no,no,16/07/2021,,Accord Healthcare S.L.U.,Other hematological agents,20/05/2021,16/07/2021,,"Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor deficiency.",06/09/2021,,https://www.ema.europa.eu/en/medicines/human/EPAR/icatibant-accord,HKMZRZUEADSZDQ-DZJWSCHMSA-N,"InChI=1S/C59H89N19O13S.C2H4O2/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66;1-2(3)4/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69);1H3,(H,3,4)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+;/m0./s1",1364.6000000000001
1725,Human,Cyanokit,Poisoning,hydroxocobalamin,HYDROXOCOBALAMIN,EMEA/H/C/000806,no,Authorised,V03AB33,no,no,no,no,no,no,23/11/2007,,SERB SA,All other therapeutic products,,27/11/2018,10,Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures.,20/07/2017,18/01/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/cyanokit,YOZNUFWCRFCGIH-WZHZPDAFSA-K,"InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",1346.377
801,Human,Firazyr,"Angioedemas, Hereditary",icatibant,ICATIBANT,EMEA/H/C/000899,no,Authorised,B06AC02,no,no,no,no,no,no,11/07/2008,,Takeda Pharmaceuticals International AG,Cardiac therapy,24/04/2008,20/04/2023,23,Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).,26/04/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr,QURWXBZNHXJZBE-SKXRKSCCSA-N,"InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1",1304.5480000000002
860,Human,Mycamine,Candidiasis,micafungin,MICAFUNGIN,EMEA/H/C/000734,no,Authorised,J02AX05,no,no,no,no,no,no,25/04/2008,,Astellas Pharma Europe B.V.,Antimycotics for systemic use,,09/02/2023,18,"Mycamine is indicated for:Adults, adolescents ? 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.",20/02/2018,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine,PIEUQSKUWLMALL-YABMTYFHSA-N,"InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1",1270.2910000000008
580,Human,Mepact,Osteosarcoma,mifamurtide,MIFAMURTIDE,EMEA/H/C/000802,no,Authorised,L03AX15,no,no,no,no,no,no,06/03/2009,,Takeda France SAS,"Immunostimulants, ",,12/07/2023,18,"Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.",14/12/2016,14/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mepact,ZVLWUMPAHCEZAW-KRNLDFAISA-N,"InChI=1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79)/t43-,44-,45+,47+,48+,49-,50+,54+,55+/m0/s1",1237.5180000000007
164,Human,Xospata,"Leukemia, Myeloid, Acute",gilteritinib,GILTERITINIB FUMARATE,EMEA/H/C/004752,no,Authorised,L01EX13,yes,no,no,no,no,yes,24/10/2019,,Astellas Pharma Europe B.V.,Antineoplastic agents,19/09/2019,12/10/2023,5,"Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation., ",08/11/2019,07/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xospata,UJOUWHLYTQFUCU-WXXKFALUSA-N,"InChI=1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+",1221.519999999999
431,Human,Lupkynis,Lupus Nephritis,voclosporin,VOCLOSPORIN,EMEA/H/C/005256,no,Authorised,L04AD03,yes,no,no,no,no,no,15/09/2022,,Otsuka Pharmaceutical Netherlands B.V.,Immunosuppressants,21/07/2022,20/07/2023,2,"Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).",19/07/2022,29/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis,BICRTLVBTLFLRD-PTWUADNWSA-N,"InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1",1214.646
1485,Human,Caspofungin Accord,Candidiasis;  Aspergillosis,caspofungin,CASPOFUNGIN ACETATE,EMEA/H/C/004134,no,Withdrawn,J02AX04,no,yes,no,no,no,no,11/02/2016,,Accord Healthcare S.L.U.,Antimycotics for systemic use,,06/02/2020,6,"Treatment of invasive candidiasis in adult or paediatric patients.Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.",20/12/2016,20/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/caspofungin-accord,OGUJBRYAAJYXQP-IJFZAWIJSA-N,"InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1",1213.4350000000004
810,Human,Verkazia,Conjunctivitis;  Keratitis,ciclosporin,CICLOSPORIN,EMEA/H/C/004411,no,Authorised,S01XA18,no,no,no,no,yes,yes,06/07/2018,,Santen Oy,Ophthalmologicals,20/07/2017,31/03/2023,7,Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.,06/07/2018,25/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia,PMATZTZNYRCHOR-CGLBZJNRSA-N,"InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",1202.635
931,Human,Ikervis,Corneal Diseases,ciclosporin,CICLOSPORIN,EMEA/H/C/002066,no,Authorised,S01XA18,no,no,no,no,no,no,19/03/2015,,Santen Oy,Ophthalmologicals,,27/02/2023,10,"Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.",09/01/2017,27/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis,PMATZTZNYRCHOR-CGLBZJNRSA-N,"InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",1202.635
919,Human,Cotellic,Melanoma,cobimetinib,COBIMETINIB HEMIFUMARATE,EMEA/H/C/003960,no,Authorised,L01XE38,no,no,no,no,no,no,20/11/2015,,Roche Registration GmbH,Antineoplastic agents,24/09/2015,12/01/2023,14,Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,09/08/2018,06/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic,RESIMIUSNACMNW-BXRWSSRYSA-N,"InChI=1S/2C21H21F3IN3O2.C4H4O4/c2*22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17;5-3(6)1-2-4(7)8/h2*4-7,9,17,26-27,30H,1-3,8,10-11H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*17-;/m00./s1",1178.7039999999995
473,Human,Mayzent,"Multiple Sclerosis, Relapsing-Remitting",siponimod,SIPONIMOD FUMARIC ACID,EMEA/H/C/004712,no,Authorised,L04,yes,no,no,no,no,no,13/01/2020,,Novartis Europharm Limited ,Selective immunosuppressants,14/11/2019,06/07/2023,10,Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.,23/01/2020,14/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent,JNLIKIBISICTMS-PEJBKAKVSA-N,"InChI=1S/2C29H35F3N2O3.C4H4O4/c2*1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32;5-3(6)1-2-4(7)8/h2*9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36);1-2H,(H,5,6)(H,7,8)/b2*33-19+;2-1+",1149.2799999999993
646,Human,Ecalta,Candidiasis,anidulafungin,ANIDULAFUNGIN,EMEA/H/C/000788,no,Authorised,J02AX06,no,no,no,no,no,no,20/09/2007,,Pfizer Europe MA EEIG,Antimycotics for systemic use,,27/06/2023,26,Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.,28/08/2017,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ecalta,JHVAMHSQVVQIOT-MFAJLEFUSA-N,"InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1",1140.2540000000008
890,Human,Imcivree,Obesity,setmelanotide,SETMELANOTIDE,EMEA/H/C/005089,no,Authorised,A08AA,yes,no,no,no,no,yes,16/07/2021,,Rhythm Pharmaceuticals Netherlands B.V.,"Antiobesity preparations, excl. diet products",20/05/2021,18/03/2023,7,"Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.",19/05/2021,22/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree,HDHDTKMUACZDAA-PHNIDTBTSA-N,"InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1",1117.3339999999998
693,Human,Maviret,"Hepatitis C, Chronic","glecaprevir, pibrentasvir",PIBRENTASVIR,EMEA/H/C/004430,no,Authorised,J05AP57,no,no,no,no,yes,no,26/07/2017,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,22/06/2017,02/03/2023,22,Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.,15/06/2018,09/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/maviret,VJYSBPDEJWLKKJ-NLIMODCCSA-N,"InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1",1113.199
723,Human,Vemlidy,Hepatitis B,tenofovir alafenamide,TENOFOVIR ALAFENAMIDE FUMARATE,EMEA/H/C/004169,no,Authorised,J05AF13,no,no,no,no,no,no,09/01/2017,,Gilead Sciences Ireland UC,Antivirals for systemic use,10/11/2016,26/05/2023,16,Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).,28/05/2018,31/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vemlidy,SVUJNSGGPUCLQZ-FQQAACOVSA-N,"InChI=1S/2C21H29N6O5P.C4H4O4/c2*1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h2*5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*15-,16+,33+;/m11./s1",1069.0199999999998
1021,Human,Dificlir,Clostridium Infections,fidaxomicin,FIDAXOMICIN,EMEA/H/C/002087,no,Authorised,A07AA12,no,no,no,no,no,no,05/12/2011,,Tillotts Pharma GmbH,"Antidiarrheals, intestinal antiinflammatory / antiinfective agents",22/09/2011,12/12/2022,17,Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.,17/05/2018,22/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir,ZVGNESXIJDCBKN-UUEYKCAUSA-N,"InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1",1058.0520000000008
1057,Human,Pyrukynd,"Genetic Diseases, Inborn;  Anemia, Hemolytic",mitapivat,MITAPIVAT SULFATE,EMEA/H/C/005540,no,Authorised,B06AX04,yes,no,no,no,no,yes,09/11/2022,,Agios Netherlands B.V.,Other hematological agents,15/09/2022,,,Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).,14/09/2022,05/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd,DMRIPASJCJRBMV-UHFFFAOYSA-N,"InChI=1S/2C24H26N4O3S.H2O4S.3H2O/c2*29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22;1-5(2,3)4;;;/h2*1-5,8-12,18,26H,6-7,13-17H2;(H2,1,2,3,4);3*1H2",1053.2519999999997
1169,Human,Signifor,Acromegaly;  Pituitary ACTH Hypersecretion,pasireotide,PASIREOTIDE,EMEA/H/C/002052,no,Authorised,H01CB05,no,no,no,no,no,yes,24/04/2012,,Recordati Rare Diseases,Pituitary and hypothalamic hormones and analogues,,08/08/2022,14,Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.,12/04/2018,09/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/signifor,VMZMNAABQBOLAK-DBILLSOUSA-N,"InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1",1047.2269999999999
198,Human,Pemetrexed Accord,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM HEMIPENTAHYDRATE,EMEA/H/C/004072,no,Authorised,L01BA04,no,yes,no,no,no,no,18/01/2016,,Accord Healthcare S.L.U.,Antineoplastic agents,19/11/2015,13/10/2023,10,Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,20/04/2018,27/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-accord,ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,"InChI=1S/2C20H21N5O6.4Na.5H2O/c2*21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h2*1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;;;5*1H2/q;;4*+1;;;;;/p-4/t2*13-;;;;;;;;;/m00........./s1",1032.837
1135,Human,Pemetrexed Pfizer (previously Pemetrexed Hospira),"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM HEMIPENTAHYDRATE,EMEA/H/C/003970,no,Authorised,L01BA04,no,yes,no,no,no,no,19/11/2015,,Pfizer Europe MA EEIG,Antineoplastic agents,23/09/2015,29/08/2022,14,Malignant pleural mesotheliomaPemetrexed Pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,24/04/2018,21/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-pemetrexed-hospira,ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,"InChI=1S/2C20H21N5O6.4Na.5H2O/c2*21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h2*1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;;;5*1H2/q;;4*+1;;;;;/p-4/t2*13-;;;;;;;;;/m00........./s1",1032.837
1162,Human,Ciambra,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM HEMIPENTAHYDRATE,EMEA/H/C/003788,no,Authorised,L01BA04,no,yes,no,no,no,no,02/12/2015,,Menarini International Operations Luxembourg S.A.,Antineoplastic agents,24/09/2015,17/08/2022,6,"Malignant pleural mesothelioma, , Ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., ",03/08/2018,17/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ciambra,ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,"InChI=1S/2C20H21N5O6.4Na.5H2O/c2*21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h2*1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;;;5*1H2/q;;4*+1;;;;;/p-4/t2*13-;;;;;;;;;/m00........./s1",1032.837
1177,Human,Pemetrexed Sandoz,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM HEMIPENTAHYDRATE,EMEA/H/C/004011,no,Authorised,L01BA04,no,yes,no,no,no,no,18/09/2015,,Sandoz GmbH,Antineoplastic agents,23/07/2015,26/07/2022,7,"Malignant pleural mesothelioma, , Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Pemetrexed Sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Pemetrexed Sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., ",24/04/2018,27/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-sandoz,ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,"InChI=1S/2C20H21N5O6.4Na.5H2O/c2*21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h2*1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;;;5*1H2/q;;4*+1;;;;;/p-4/t2*13-;;;;;;;;;/m00........./s1",1032.837
1225,Human,Torisel,"Carcinoma, Renal Cell;  Lymphoma, Mantle-Cell",temsirolimus,TEMSIROLIMUS,EMEA/H/C/000799,no,Authorised,L01XE09,no,no,no,no,no,no,19/11/2007,,Pfizer Europe MA EEIG,Antineoplastic agents,20/09/2007,20/06/2022,33,Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).,08/08/2018,21/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/torisel,CBPNZQVSJQDFBE-FUXHJELOSA-N,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",1030.3030000000008
649,Human,Sunlenca,HIV Infections,lenacapavir,LENACAPAVIR SODIUM,EMEA/H/C/005638,no,Authorised,J05AX,yes,no,no,no,no,no,17/08/2022,,Gilead Sciences Ireland Unlimited Company,Antivirals for systemic use,23/06/2022,23/06/2023,1,"Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1).Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1).",22/06/2022,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca,SSXPGMNGIORJAQ-PZNXWHLTSA-M,"InChI=1S/C39H32ClF10N7O5S2.Na/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47;/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H2,52,54,55,58);/q;+1/p-1/t24-,25+,27-;/m0./s1",991.2860000000006
1220,Human,Votubia,Tuberous Sclerosis,everolimus,EVEROLIMUS,EMEA/H/C/002311,no,Authorised,L01XE10,no,no,no,no,no,no,02/09/2011,,Novartis Europharm Limited,Antineoplastic agents,23/06/2011,24/06/2022,30,"Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease?related symptoms, has not been demonstrated.",12/07/2018,27/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/votubia,HKVAMNSJSFKALM-GKUWKFKPSA-N,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",958.2400000000008
1221,Human,Afinitor,"Carcinoma, Renal Cell;  Breast Neoplasms;  Pancreatic Neoplasms",everolimus,EVEROLIMUS,EMEA/H/C/001038,no,Authorised,L01XE10,no,no,no,no,no,no,02/08/2009,,Novartis Europharm Limited,Antineoplastic agents,,24/06/2022,30,"Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.",08/05/2018,27/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor,HKVAMNSJSFKALM-GKUWKFKPSA-N,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",958.2400000000008
1929,Human,Ablavar (previously Vasovist),Magnetic Resonance Angiography,gadofosveset trisodium,GADOFOSVESET TRISODIUM,EMEA/H/C/000601,no,Withdrawn,V08CA,no,no,no,no,no,no,03/10/2005,,TMC Pharma Services Ltd.,Contrast media,,15/05/2011,10,"This medicinal product is for diagnostic use only.Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease.",15/05/2011,14/11/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/ablavar-previously-vasovist,XGOSYNSWSRUASG-SSMZTGFVSA-H,"InChI=1S/C33H44N3O14P.Gd.3Na/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;/q;+3;3*+1/p-6/t26-;;;;/m1..../s1",957.8680000000006
298,Human,Locametz,Radionuclide Imaging,gozetotide,GOZETOTIDE,EMEA/H/C/005488,no,Authorised,V09I,no,no,no,no,no,no,09/12/2022,,Novartis Europharm Limited ,Diagnostic radiopharmaceuticals,13/10/2022,27/09/2023,2,"This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high risk PCa prior to primary curative therapy,Suspected PCa recurrence in patients with increasing levels of serum prostate specific antigen (PSA) after primary curative therapy,Identification of patients with PSMA positive progressive metastatic castration resistant prostate cancer (mCRPC) for whom PSMA targeted therapy is indicated (see section 4.4).",21/12/2022,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/locametz,QJUIUFGOTBRHKP-LQJZCPKCSA-N,"InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1",947.0050000000008
424,Human,Eurartesim,Malaria,"piperaquine tetraphosphate, artenimol",PIPERAQUINE TETRAPHOSPHATE,EMEA/H/C/001199,no,Authorised,P01BF05,no,no,no,no,no,no,27/10/2011,,Alfasigma S.p.A.,Antiprotozoals,,25/08/2023,13,"Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more.Consideration should be given to official guidance on the appropriate use of antimalarial agents.",14/09/2017,30/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim,OAKKJVUSSVZQRF-UHFFFAOYSA-N,"InChI=1S/C29H32Cl2N6.4H3O4P/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29;4*1-5(2,3)4/h2-9,20-21H,1,10-19H2;4*(H3,1,2,3,4)",927.499
1051,Human,Tookad,Prostatic Neoplasms,padeliporfin,PADELIPORFIN DI-POTASSIUM,EMEA/H/C/004182,no,Authorised,L01XD07,yes,no,no,no,no,no,10/11/2017,,STEBA Biotech S.A,Antineoplastic agents,14/09/2017,07/12/2022,6,"Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ? 10 years and:Clinical stage T1c or T2a;Gleason Score ? 6, based on high-resolution biopsy strategies;PSA ? 10 ng/mL;3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ? 50 % cancer involvement in any one core or a PSA density ? 0.15 ng/mL/cm³.",21/09/2017,07/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/tookad,AOSMIFSJINLACN-NAEAMVODSA-J,"InChI=1S/C37H45N5O9S.2K.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;;;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);;;/q;2*+1;+2/p-4/t17-,18+,22-,23+;;;/m1.../s1",916.4440000000003
326,Human,Hyftor,Angiofibroma;  Tuberous Sclerosis,sirolimus,SIROLIMUS,EMEA/H/C/005896,no,Authorised,,no,no,no,no,no,yes,15/05/2023,,Plusultra pharma GmbH,,23/02/2023,22/09/2023,2,Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.,08/06/2023,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor,QFJCIRLUMZQUOT-HPLJOQBZSA-N,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",914.1870000000008
1182,Human,Rapamune,Graft Rejection;  Kidney Transplantation,sirolimus,SIROLIMUS,EMEA/H/C/000273,no,Authorised,L04AA10,no,no,no,no,no,no,13/03/2001,,Pfizer Europe MA EEIG,Immunosuppressants,16/11/2000,22/07/2022,46,"Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function., ",02/08/2018,25/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune,QFJCIRLUMZQUOT-HPLJOQBZSA-N,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",914.1870000000008
839,Human,Viekirax,"Hepatitis C, Chronic","ombitasvir, paritaprevir, ritonavir",OMBITASVIR,EMEA/H/C/003839,no,Authorised,J05AP53,no,no,no,no,no,no,14/01/2015,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,20/11/2014,12/08/2022,28,Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.,31/08/2018,12/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax,PIDFDZJZLOTZTM-KHVQSSSXSA-N,"InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1",894.1270000000002
318,Human,Harvoni,"Hepatitis C, Chronic","ledispavir, sofosbuvir",LEDIPASVIR,EMEA/H/C/003850,no,Authorised,J05AX65,no,no,no,no,yes,no,17/11/2014,,Gilead Sciences Ireland UC,Antivirals for systemic use,,12/01/2023,28,"Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",07/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni,VRTWBAAJJOHBQU-KMWAZVGDSA-N,"InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1",889.017
319,Human,Epclusa,"Hepatitis C, Chronic","sofosbuvir, velpatasvir",VELPATASVIR,EMEA/H/C/004210,no,Authorised,J05A,no,no,no,no,yes,no,06/07/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,26/05/2016,07/08/2023,22,"Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).",14/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa,FHCUMDQMBHQXKK-CDIODLITSA-N,"InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1",883.0190000000001
1077,Human,Zepatier,"Hepatitis C, Chronic","elbasvir, grazoprevir",ELBASVIR,EMEA/H/C/004126,no,Authorised,J05AP54,no,no,no,no,no,no,22/07/2016,,Merck Sharp & Dohme B.V.,"Direct acting antivirals, Antivirals for systemic use, Antivirals for treatment of HCV infections",26/05/2016,21/11/2022,13,"ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",15/06/2018,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier,BVAZQCUMNICBAQ-PZHYSIFUSA-N,"InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1",882.035
1126,Human,Rayvow,Migraine Disorders,lasmiditan,LASMIDITAN SUCCINATE,EMEA/H/C/005332,no,Authorised,N02CC08,yes,no,no,no,no,no,17/08/2022,,Eli Lilly Nederland B.V.,Analgesics,16/12/2021,,,"RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.",14/09/2021,03/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow,MSOIHUHNGPOCTH-UHFFFAOYSA-N,"InChI=1S/2C19H18F3N3O2.C4H6O4/c2*1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22;5-3(6)1-2-4(7)8/h2*2-4,9-11H,5-8H2,1H3,(H,23,24,27);1-2H2,(H,5,6)(H,7,8)",872.82
180,Human,Venclyxto,"Leukemia, Lymphocytic, Chronic, B-Cell",venetoclax,VENETOCLAX,EMEA/H/C/004106,no,Authorised,L01XX52,yes,no,no,no,no,no,04/12/2016,,AbbVie Deutschland GmbH  Co. KG,Antineoplastic agents,,11/08/2023,16,"Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.",31/05/2018,31/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto,LQBVNQSMGBZMKD-UHFFFAOYSA-N,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",868.4570000000001
1681,Human,Taxespira (previously Docetaxel Hospira UK Limited ),"Stomach Neoplasms;  Prostatic Neoplasms;  Breast Neoplasms;  Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung",docetaxel,DOCETAXEL TRIHYDRATE,EMEA/H/C/003925,no,Withdrawn,L01CD02,no,yes,no,no,no,no,28/08/2015,,Hospira UK Limited,Antineoplastic agents,20/05/2015,30/10/2018,8,"Breast cancerTaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small cell lung cancer Taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancer Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinoma Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancer Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",09/07/2018,15/10/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/taxespira-previously-docetaxel-hospira-uk-limited,XCDIRYDKECHIPE-QHEQPUDQSA-N,"InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1",861.9350000000007
370,Human,Apealea,Ovarian Neoplasms,paclitaxel,PACLITAXEL,EMEA/H/C/004154,no,Authorised,L01CD01,no,no,no,no,no,no,20/11/2018,,Inceptua AB,"Antineoplastic agents, Taxanes",,11/09/2023,7,"Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum?sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.",05/12/2018,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/apealea,RCINICONZNJXQF-MZXODVADSA-N,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",853.9180000000006
1250,Human,Abraxane,"Breast Neoplasms;  Pancreatic Neoplasms;  Carcinoma, Non-Small-Cell Lung",paclitaxel,PACLITAXEL,EMEA/H/C/000778,no,Authorised,L01CD01,no,no,no,no,no,no,11/01/2008,,Bristol-Myers Squibb Pharma EEIG,Antineoplastic agents,18/10/2007,13/09/2021,29,"Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.",30/07/2018,13/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane,RCINICONZNJXQF-MZXODVADSA-N,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",853.9180000000006
1293,Human,Pazenir,Breast Neoplasms,paclitaxel,PACLITAXEL,EMEA/H/C/004441,no,Authorised,L01CD01,no,yes,no,no,no,no,06/05/2019,,ratiopharm GmbH,Antineoplastic agents,28/02/2019,09/03/2022,7,"Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.",23/05/2019,15/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pazenir,RCINICONZNJXQF-MZXODVADSA-N,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",853.9180000000006
1953,Human,Paxene,"Sarcoma, Kaposi;  Carcinoma, Non-Small-Cell Lung;  Ovarian Neoplasms;  Breast Neoplasms",paclitaxel,PACLITAXEL,EMEA/H/C/000216,no,Withdrawn,L01CD01,no,no,no,no,no,no,19/07/1999,,Norton Healthcare Ltd.,Antineoplastic agents,,14/07/2009,14,"Paxene is indicated for the treatment of patients with:• advanced AIDS-related Kaposi's sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. Limited efficacy data supports this indication (see section 5.1).",14/07/2009,22/03/2010,https://www.ema.europa.eu/en/medicines/human/EPAR/paxene,RCINICONZNJXQF-MZXODVADSA-N,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",853.9180000000006
50,Human,Trixeo Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol, glycopyrronium bromide, budesonide",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004983,no,Authorised,R03AL,no,no,no,no,no,no,09/12/2020,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",15/10/2020,23/11/2023,5,Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.,05/01/2021,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
57,Human,Riltrava Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol fumarate dihydrate, glycopyrronium, budesonide",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/005311,no,Authorised,R03AL11,no,no,no,no,no,no,06/01/2022,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",11/11/2021,23/11/2023,3,Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,10/11/2021,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riltrava-aerosphere,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
323,Human,Brimica Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium, formoterol fumarate dihydrate",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/003969,no,Authorised,R03AL05,yes,no,no,no,no,no,19/11/2014,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",,25/09/2023,14,Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,26/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
324,Human,Bevespi Aerosphere,"Pulmonary Disease, Chronic Obstructive","glycopyrronium, formoterol fumarate dihydrate",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004245,no,Authorised,R03AL07,no,no,no,no,no,no,18/12/2018,,AstraZeneca AB,formoterol and glycopyrronium bromide,18/10/2018,15/09/2023,6,Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,05/02/2019,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
623,Human,Trydonis,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004702,no,Authorised,R03AL09,no,no,no,no,no,no,26/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,02/12/2022,5,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,26/04/2018,04/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
630,Human,Trimbow,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004257,no,Authorised,R03AL09,no,no,no,no,no,no,17/07/2017,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",18/05/2017,24/03/2022,7,"Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. ",17/07/2017,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
631,Human,Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004836,no,Authorised,R03AL09,no,no,no,no,no,no,23/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,09/12/2022,4,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,23/04/2018,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riarify,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
773,Human,BiResp Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/003890,no,Authorised,R03AK07,no,no,no,no,no,no,28/04/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,04/05/2023,12,"Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) ",25/06/2018,15/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
780,Human,DuoResp Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/002348,no,Authorised,R03AK07,no,no,no,no,no,no,28/04/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,04/05/2023,12,"Asthma DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.COPDDuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) ",10/07/2018,11/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duoresp-spiromax,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
1006,Human,Duaklir Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium bromide, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/003745,no,Authorised,R03AL,yes,no,no,no,no,no,19/11/2014,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",25/09/2014,09/01/2023,15,Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,11/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duaklir-genuair,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
1382,Human,Budesonide/Formoterol Teva Pharma B.V.,"Asthma;  Pulmonary Disease, Chronic Obstructive","budesonide, formoterol fumarate dihydrate",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/004882,no,Authorised,R03AK07,no,no,no,no,no,no,03/04/2020,,Teva Pharma B.V. ,"Drugs for obstructive airway diseases, ",30/01/2020,07/12/2021,2,"Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) ",07/04/2020,08/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonide-formoterol-teva-pharma-bv,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
1802,Human,Budesonide/Formoterol Teva,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/003951,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,16/12/2016,2,"Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.",16/12/2016,31/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonideformoterol-teva,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
1804,Human,Vylaer Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",FORMOTEROL FUMARATE DIHYDRATE,EMEA/H/C/003952,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,09/01/2017,3,"Vylaer Spiromax is indicated in adults 18 years of age and older only.AsthmaVylaer Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.",09/01/2017,26/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/vylaer-spiromax,RATSWNOMCHFQGJ-AYJOUMQSSA-N,"InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m11.../s1",840.9240000000003
693,Human,Maviret,"Hepatitis C, Chronic","glecaprevir, pibrentasvir",GLECAPREVIR,EMEA/H/C/004430,no,Authorised,J05AP57,no,no,no,no,yes,no,26/07/2017,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,22/06/2017,02/03/2023,22,Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.,15/06/2018,09/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/maviret,MLSQGNCUYAMAHD-ITNVBOSISA-N,"InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1",838.8780000000004
521,Human,Cabazitaxel Accord,"Prostatic Neoplasms, Castration-Resistant",cabazitaxel,CABAZITAXEL,EMEA/H/C/005178,no,Authorised,L01CD04,no,yes,no,no,no,no,28/08/2020,,Accord Healthcare S.L.U.,Antineoplastic agents,30/04/2020,27/07/2023,5,Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.,28/10/2020,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord,BMQGVNUXMIRLCK-OAGWZNDDSA-N,"InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1",835.9440000000005
616,Human,Jevtana,Prostatic Neoplasms,cabazitaxel,CABAZITAXEL,EMEA/H/C/002018,no,Authorised,L01CD,no,no,no,no,no,no,17/03/2011,,Sanofi Winthrop Industrie,Antineoplastic agents,20/01/2011,22/06/2023,23,Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.,22/01/2018,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana,BMQGVNUXMIRLCK-OAGWZNDDSA-N,"InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1",835.9440000000005
819,Human,Eptifibatide Accord,Myocardial Infarction,eptifibatide,EPTIFIBATIDE,EMEA/H/C/004104,no,Authorised,B01AC16,no,yes,no,no,no,no,11/01/2016,,Accord Healthcare S.L.U.,Antithrombotic agents,19/11/2015,21/04/2023,6,"Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).",11/01/2016,21/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord,CZKPOZZJODAYPZ-LROMGURASA-N,"InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1",831.9790000000004
1287,Human,Integrilin,"Angina, Unstable;  Myocardial Infarction",eptifibatide,EPTIFIBATIDE,EMEA/H/C/000230,no,Authorised,B01AC16,no,no,no,no,no,no,01/07/1999,,GlaxoSmithKline (Ireland) Limited,Antithrombotic agents,02/07/1999,24/09/2021,26,Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes.Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).,12/04/2017,17/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/integrilin,CZKPOZZJODAYPZ-LROMGURASA-N,"InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1",831.9790000000004
1011,Human,Tacforius,Liver Transplantation;  Kidney Transplantation,tacrolimus,TACROLIMUS MONOHYDRATE,EMEA/H/C/004435,no,Authorised,L04AD02,no,yes,no,no,no,no,08/12/2017,,Teva B.V.,Immunosuppressants,12/10/2017,10/01/2023,7,Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.,08/12/2017,10/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tacforius,NWJQLQGQZSIBAF-MLAUYUEBSA-N,"InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1",822.0460000000005
1070,Human,Javlor,"Carcinoma, Transitional Cell;  Urologic Neoplasms",vinflunine,VINFLUNINE,EMEA/H/C/000983,no,Authorised,L01CA05,no,no,no,no,no,no,21/09/2009,,Pierre Fabre Medicament,Antineoplastic agents,,07/11/2022,10,Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.Efficacy and safety of vinflunine have not been studied in patients with performance status ? 2.,19/02/2018,23/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/javlor,NMDYYWFGPIMTKO-KLCPSUAYSA-N,"InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1",816.9430000000003
1696,Human,Ketek,"Sinusitis;  Tonsillitis;  Bronchitis, Chronic;  Pharyngitis;  Community-Acquired Infections;  Pneumonia, Bacterial",telithromycin,TELITHROMYCIN,EMEA/H/C/000354,no,Withdrawn,J01FA15,no,no,no,no,no,no,09/07/2001,,Aventis Pharma S.A.,"Antibacterials for systemic use, ",,07/02/2017,25,"When prescribing Ketek, consideration should be given to official guidance on the appropriate use ofantibacterial agents and the local prevalence of resistance.Ketek is indicated for the treatment of the following infections:In patients of 18 years and oldercommunity-acquired pneumonia, mild or moderate.when treating infections caused by known or suspected beta-lactam- and / or macrolide-resistant strains (according to history of patients or national and / or regional resistance data) covered by the antibacterial spectrum of telithromycin:acute exacerbation of chronic bronchitis;acute sinusitis;In patients of 12 years and oldertonsillitis / pharyngitis caused by Streptococcus pyogenes, as an alternative when beta-lactam antibiotics are not appropriate in countries / regions with a significant prevalence of macrolide-resistant S. pyogenes, when mediated by ermTR or mefA.",07/02/2017,19/06/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/ketek,LJVAJPDWBABPEJ-PNUFFHFMSA-N,"InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1",812.0180000000003
1995,Human,Levviax,"Community-Acquired Infections;  Pharyngitis;  Bronchitis, Chronic;  Pneumonia;  Tonsillitis;  Sinusitis",telithromycin,TELITHROMYCIN,EMEA/H/C/000355,no,Withdrawn,J01FA15,no,no,no,no,no,no,09/07/2001,,Aventis Pharma S.A.,"Antibacterials for systemic use, ",,31/05/2007,10,"When prescribing Levviax consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1).Levviax is indicated for the treatment of the following infections:In patients of 18 years and older:-Community-acquired pneumonia, mild or moderate (see section 4.4).- When treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1):- Acute exacerbation of chronic bronchitis,- Acute sinusitisIn patients of 12 years and older:- Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1).",31/05/2007,14/02/2008,https://www.ema.europa.eu/en/medicines/human/EPAR/levviax,LJVAJPDWBABPEJ-PNUFFHFMSA-N,"InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1",812.0180000000003
1686,Human,Daklinza,"Hepatitis C, Chronic",daclatasvir,DACLATASVIR DIHYDROCHLORIDE,EMEA/H/C/003768,no,Withdrawn,J05AP07,no,no,no,no,yes,no,22/08/2014,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,26/06/2014,24/07/2019,15,"Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1)., , For HCV genotype specific activity, see sections 4.4 and 5.1., ",14/06/2018,30/08/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza,BVZLLUDATICXCI-JMSCDMLISA-N,"InChI=1S/C40H50N8O6.2ClH/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6;;/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52);2*1H/t31-,32-,33-,34-;;/m0../s1",811.8120000000002
299,Human,Docetaxel Kabi,"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/002325,no,Authorised,L01CD02,no,yes,no,no,no,no,22/05/2012,,Fresenius Kabi Deutschland GmbH,Antineoplastic agents,15/03/2012,26/09/2023,15,"Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",02/07/2018,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
383,Human,Docetaxel Accord,"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/002539,no,Authorised,L01CD02,no,yes,no,no,no,no,22/05/2012,,Accord Healthcare S.L.U.,Antineoplastic agents,15/03/2012,12/09/2023,17,"Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",18/06/2018,14/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-accord,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
882,Human,Taxotere,"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Stomach Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/000073,no,Authorised,L01CD02,no,no,no,no,no,no,27/11/1995,,Sanofi Mature IP,Antineoplastic agents,12/07/1995,15/12/2022,50,"Breast cancerTaxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerTaxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerTaxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",01/02/2018,24/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
1243,Human,Docetaxel Zentiva (previously Docetaxel Winthrop),"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Stomach Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/000808,no,Withdrawn,L01CD02,no,no,no,no,no,no,20/04/2007,,Zentiva k.s.,Antineoplastic agents,,25/04/2022,30,"Breast cancerDocetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",01/02/2018,20/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
1377,Human,Docetaxel Teva,"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Stomach Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/001107,no,Withdrawn,L01CD02,no,yes,no,no,no,no,26/01/2010,,Teva B.V. ,Antineoplastic agents,19/11/2009,28/04/2020,18,"Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",25/06/2018,14/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-teva,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
1843,Human,Docetaxel Mylan,"Head and Neck Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Adenocarcinoma;  Prostatic Neoplasms;  Breast Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/002317,no,Withdrawn,L01CD02,no,yes,no,no,no,no,31/01/2012,,Mylan S.A.S.,Antineoplastic agents,,01/02/2015,6,"Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.",01/02/2015,12/03/2015,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-mylan-0,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
1874,Human,Docetaxel Teva Pharma,"Carcinoma, Non-Small-Cell Lung;  Breast Neoplasms;  Prostatic Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/002032,no,Withdrawn,L01CD02,no,yes,no,no,no,no,21/01/2011,,Teva Pharma B.V.,Antineoplastic agents,,21/01/2014,6,"Breast cancerDocetaxel Teva Pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Non-small-cell lung cancerDocetaxel Teva Pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva Pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.",21/01/2014,21/01/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-teva-pharma,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
1921,Human,Docefrez,"Stomach Neoplasms;  Adenoma;  Breast Neoplasms;  Carcinoma, Non-Small-Cell Lung;  Prostatic Neoplasms",docetaxel,DOCETAXEL,EMEA/H/C/001074,no,Withdrawn,L01CD02,no,yes,no,no,no,no,10/05/2010,,Sun Pharmaceutical Industries Europe B.V.,Antineoplastic agents,,25/05/2012,1,"Breast cancerDocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small cell lung cancerDocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.",25/05/2012,14/06/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/docefrez,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",807.8900000000008
196,Human,Advagraf,Graft Rejection,tacrolimus,TACROLIMUS,EMEA/H/C/000712,no,Authorised,L04AD02,no,no,no,no,no,no,23/04/2007,,Astellas Pharma Europe BV,Immunosuppressants,,25/10/2023,26,Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.,17/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",804.0310000000005
235,Human,Modigraf,Graft Rejection,tacrolimus,TACROLIMUS,EMEA/H/C/000954,no,Authorised,L04AD02,no,no,no,no,no,no,15/05/2009,,Astellas Pharma Europe B.V.,Immunosuppressants,,18/10/2023,19,"Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.",17/05/2018,18/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/modigraf,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",804.0310000000005
989,Human,Envarsus,Graft Rejection,tacrolimus,TACROLIMUS,EMEA/H/C/002655,no,Authorised,L04AD02,no,no,no,no,no,no,18/07/2014,,Chiesi Farmaceutici S.p.A.,Immunosuppressants,22/05/2014,18/01/2023,12,Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.,05/05/2017,23/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/envarsus,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",804.0310000000005
1010,Human,Protopic,"Dermatitis, Atopic",tacrolimus,TACROLIMUS,EMEA/H/C/000374,no,Authorised,D11AH01,no,no,no,no,no,no,27/02/2002,,LEO Pharma A/S,Other dermatological preparations,,23/11/2022,26,"Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).",30/06/2018,11/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/protopic,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",804.0310000000005
1990,Human,Protopy,"Dermatitis, Atopic",tacrolimus,TACROLIMUS,EMEA/H/C/000375,no,Withdrawn,D11AX14,no,no,no,no,no,no,28/02/2002,,Astellas Pharma GmbH,Other dermatological preparations,,03/05/2007,10,"Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).",03/05/2007,29/10/2008,https://www.ema.europa.eu/en/medicines/human/EPAR/protopy,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",804.0310000000005
491,Human,Arikayce liposomal,Respiratory Tract Infections,amikacin,AMIKACIN SULFATE,EMEA/H/C/005264,no,Authorised,J01GB06,no,no,no,no,no,yes,27/10/2020,,Insmed Netherlands B.V.,"Antibacterials for systemic use, ",23/07/2020,29/06/2023,2,Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.,18/11/2020,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal,FXKSEJFHKVNEFI-GCZBSULCSA-N,"InChI=1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1",781.7660000000006
995,Human,Kengrexal,Acute Coronary Syndrome;  Vascular Surgical Procedures,cangrelor,CANGRELOR,EMEA/H/C/003773,no,Authorised,B01,yes,no,no,no,no,no,23/03/2015,,Chiesi Farmaceutici S.p.A.,Antithrombotic agents,22/01/2015,16/01/2023,15,"Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.",12/04/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal,PAEBIVWUMLRPSK-IDTAVKCVSA-N,"InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1",776.3660000000003
97,Human,Rezolsta,HIV Infections,"darunavir, cobicistat",COBICISTAT,EMEA/H/C/002819,no,Authorised,J05,no,no,no,no,no,no,19/11/2014,,Janssen-Cilag International N.V.,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,22/06/2023,16,"Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older.Genotypic testing should guide the use of Rezolsta.",29/06/2018,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
813,Human,Evotaz,HIV Infections,"atazanavir, cobicistat",COBICISTAT,EMEA/H/C/003904,no,Authorised,J05AR15,no,no,no,no,no,no,13/07/2015,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,21/05/2015,16/03/2023,14,EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).,22/02/2018,25/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
897,Human,Symtuza,HIV Infections,"darunavir, cobicistat, emtricitabine, tenofovir alafenamide",COBICISTAT,EMEA/H/C/004391,no,Authorised,J05,no,no,no,no,no,no,21/09/2017,,Janssen-Cilag International NV,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",19/07/2017,07/03/2023,17,Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).Genotypic testing should guide the use of Symtuza.,06/07/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
967,Human,Tybost,HIV Infections,cobicistat,COBICISTAT,EMEA/H/C/002572,no,Authorised,V03AX03,no,no,no,no,no,no,19/09/2013,,Gilead Sciences Ireland UC,Antivirals for systemic use,,13/02/2023,15,Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co?administered with atazanavir orweighing at least 40 kg co?administered with darunavir.,26/07/2018,14/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tybost,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
978,Human,Stribild,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil",COBICISTAT,EMEA/H/C/002574,no,Authorised,J05AR09,no,no,no,no,no,no,24/05/2013,,Gilead Sciences Ireland UC,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,12/01/2023,25,Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.,19/07/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stribild,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
1066,Human,Genvoya,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",COBICISTAT,EMEA/H/C/004042,no,Authorised,J05AR,no,no,no,no,no,no,19/11/2015,,Gilead Sciences Ireland UC,Antivirals for systemic use,24/09/2015,03/10/2022,27,"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.",26/07/2018,28/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",776.0420000000003
191,Human,Trelegy Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",VILANTEROL TRIFENATATE,EMEA/H/C/004363,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,11,Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta,KLOLZALDXGTNQE-JIDHJSLPSA-N,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",774.782
194,Human,Elebrato Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",VILANTEROL TRIFENATATE,EMEA/H/C/004781,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,12,Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/elebrato-ellipta,KLOLZALDXGTNQE-JIDHJSLPSA-N,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",774.782
418,Human,Revinty Ellipta,Asthma,"fluticasone furoate, vilanterol",VILANTEROL TRIFENATATE,EMEA/H/C/002745,no,Authorised,R03AK10,no,no,no,no,no,no,02/05/2014,,GlaxoSmithKline (Ireland) Limited,Adrenergics and other drugs for obstructive airway diseases,20/03/2014,06/07/2023,22,"Asthma IndicationRevinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.COPD IndicationRevinty Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 ",21/08/2018,04/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/revinty-ellipta,KLOLZALDXGTNQE-JIDHJSLPSA-N,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",774.782
1069,Human,Temybric Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",VILANTEROL TRIFENATATE,EMEA/H/C/005254,no,Withdrawn,R03AL08,yes,no,no,no,no,no,12/06/2019,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",,11/12/2021,4,Temybric Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist or a combination of a long-acting ?2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).,23/09/2019,24/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta,KLOLZALDXGTNQE-JIDHJSLPSA-N,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",774.782
1072,Human,Anoro Ellipta (previously Anoro),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol",VILANTEROL TRIFENATATE,EMEA/H/C/002751,no,Authorised,R03AL03,yes,no,no,no,no,no,08/05/2014,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases, ",20/02/2014,18/11/2022,18,Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,13/07/2017,22/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta,KLOLZALDXGTNQE-JIDHJSLPSA-N,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",774.782
1077,Human,Zepatier,"Hepatitis C, Chronic","elbasvir, grazoprevir",GRAZOPREVIR,EMEA/H/C/004126,no,Authorised,J05AP54,no,no,no,no,no,no,22/07/2016,,Merck Sharp & Dohme B.V.,"Direct acting antivirals, Antivirals for systemic use, Antivirals for treatment of HCV infections",26/05/2016,21/11/2022,13,"ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",15/06/2018,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier,OBMNJSNZOWALQB-NCQNOWPTSA-N,"InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1",766.9180000000003
1140,Human,Yellox,"Pain, Postoperative;  Ophthalmologic Surgical Procedures",bromfenac,BROMFENAC SODIUM SESQUIHYDRATE,EMEA/H/C/001198,no,Authorised,S01BC11,no,no,no,no,no,no,18/05/2011,,Bausch + Lomb Ireland Limited,Ophthalmologicals,17/03/2011,04/02/2022,11,Treatment of postoperative ocular inflammation following cataract extraction in adults.,05/04/2017,15/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/yellox,PPOSVVJOVKVBPW-UHFFFAOYSA-L,"InChI=1S/2C15H12BrNO3.2Na.3H2O/c2*16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;;;;/h2*1-7H,8,17H2,(H,18,19);;;3*1H2/q;;2*+1;;;/p-2",766.3470000000002
839,Human,Viekirax,"Hepatitis C, Chronic","ombitasvir, paritaprevir, ritonavir",PARITAPREVIR,EMEA/H/C/003839,no,Authorised,J05AP53,no,no,no,no,no,no,14/01/2015,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,20/11/2014,12/08/2022,28,Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.,31/08/2018,12/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax,UAUIUKWPKRJZJV-QPLHLKROSA-N,"InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1",765.8930000000003
1517,Human,Doptelet,Thrombocytopenia,avatrombopag,AVATROMBOPAG MALEATE,EMEA/H/C/004722,no,Authorised,B02BX,yes,no,no,no,no,no,20/06/2019,,Swedish Orphan Biovitrum AB (publ),Antihemorrhagics,26/04/2019,20/06/2022,5,"Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).",24/04/2019,20/06/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet,MISPBGHDNZYFNM-BTJKTKAUSA-N,"InChI=1S/C29H34Cl2N6O3S2.C4H4O4/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40;5-3(6)1-2-4(7)8/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38);1-2H,(H,5,6)(H,7,8)/b;2-1-",765.7420000000004
832,Human,Zerbaxa,Bacterial Infections,"ceftolozane, tazobactam",CEFTOLOZANE SULFATE,EMEA/H/C/003772,no,Authorised,J01,no,no,no,no,no,no,18/09/2015,,Merck Sharp & Dohme B.V. ,"Antibacterials for systemic use, ",23/07/2015,25/07/2022,15,"Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",08/05/2018,14/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa,UJDQGRLTPBVSFN-TVNHLQOTSA-N,"InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11-;/t12-,18-;/m1./s1",764.7820000000006
1282,Human,Yondelis,Ovarian Neoplasms;  Sarcoma,trabectedin,TRABECTEDIN,EMEA/H/C/000773,no,Authorised,L01CX01,no,no,no,no,no,no,17/09/2007,,Pharma Mar S.A.,Antineoplastic agents,,22/07/2021,27,"Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.",25/06/2018,25/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis,PKVRCIRHQMSYJX-AIFWHQITSA-N,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1",761.8500000000006
1199,Human,Crixivan,HIV Infections,indinavir,INDINAVIR SULFATE ETHANOLATE,EMEA/H/C/000128,no,Withdrawn,J05AE02,no,no,no,no,no,no,04/10/1996,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,,03/08/2018,39,"Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults., ",19/06/2018,12/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/crixivan,QDNVAYDEAGXHTB-NOYQBWMBSA-N,"InChI=1S/C36H47N5O4.C2H6O.H2O4S/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;1-2-3;1-5(2,3)4/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);3H,2H2,1H3;(H2,1,2,3,4)/t28-,29+,31+,32-,33+;;/m1../s1",757.9510000000006
1046,Human,Xermelo,Carcinoid Tumor;  Neuroendocrine Tumors,telotristat ethyl,TELOTRISTAT ETIPRATE,EMEA/H/C/003937,no,Authorised,A16A,no,no,no,no,no,yes,17/09/2017,,SERB SAS,Other alimentary tract and metabolism products,19/07/2017,12/12/2022,15,Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.,19/04/2018,12/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo,XSFPZBUIBYMVEA-CELUQASASA-N,"InChI=1S/C27H26ClF3N6O3.C9H9NO3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37;11-8(12)6-10-9(13)7-4-2-1-3-5-7/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35);1-5H,6H2,(H,10,13)(H,11,12)/t20-,24+;/m0./s1",754.166
1757,Human,Olysio,"Hepatitis C, Chronic",simeprevir,SIMEPREVIR,EMEA/H/C/002777,no,Withdrawn,J05AE14,yes,no,no,no,no,no,14/05/2014,,Janssen-Cilag International NV,Antivirals for systemic use,20/03/2014,08/02/2018,13,Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.For hepatitis C virus (HCV) genotype specific activity.,08/02/2018,23/05/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/olysio,JTZZSQYMACOLNN-VDWJNHBNSA-N,"InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1",749.9560000000004
160,Human,Rizmoic,Constipation,naldemedine,NALDEMEDINE TOSILATE,EMEA/H/C/004256,no,Authorised,A06AH05,no,no,no,no,no,no,18/02/2019,,Shionogi B.V.,"Drugs for constipation, Peripheral opioid receptor antagonists",13/12/2018,03/11/2023,10,Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.,01/03/2019,08/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic,WCYDLROFMZJJLE-RTMHEQJQSA-N,"InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1",742.8510000000005
139,Human,Moventig,Constipation;  Opioid-Related Disorders,naloxegol,NALOXEGOL OXALATE,EMEA/H/C/002810,no,Authorised,A06AH03,no,no,no,no,no,no,07/12/2014,,Kyowa Kirin Holdings B.V.,"Peripheral opioid receptor antagonists, Drugs for constipation",,07/07/2022,15,Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).,23/07/2018,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/moventig,MNYIRXLCPODKLG-VUTNLTPYSA-N,"InChI=1S/C34H53NO11.C2H2O4/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2;3-1(4)2(5)6/h3-5,28-29,32,36-37H,1,6-25H2,2H3;(H,3,4)(H,5,6)/t28-,29+,32-,33-,34+;/m0./s1",741.8280000000007
619,Human,Bylvay,"Cholestasis, Intrahepatic",odevixibat,ODEVIXIBAT,EMEA/H/C/004691,no,Authorised,A05AX,no,no,no,yes,yes,yes,16/07/2021,,Albireo,Bile and liver therapy,20/05/2021,12/05/2023,3,Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1).,20/04/2021,05/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay,XULSCZPZVQIMFM-IPZQJPLYSA-N,"InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1",740.9450000000007
216,Human,Halaven,Breast Neoplasms;  Liposarcoma,eribulin,ERIBULIN,EMEA/H/C/002084,no,Authorised,L01XX41,no,no,no,no,no,no,17/03/2011,,Eisai GmbH,Antineoplastic agents,,09/11/2022,29,Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).,16/11/2017,23/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/halaven,UFNVPOGXISZXJD-JBQZKEIOSA-N,"InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1",729.9080000000002
74,Human,Pradaxa,"Arthroplasty, Replacement;  Venous Thromboembolism",dabigatran etexilate,DABIGATRAN ETEXILATE MESILATE,EMEA/H/C/000829,no,Authorised,B01AE07,no,no,no,no,no,no,17/03/2008,,Boehringer Ingelheim International GmbH,Antithrombotic agents,,20/11/2023,40,"Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ? 75 years; heart failure (NYHA Class ? II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ? 75 years; heart failure (NYHA Class ? II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",07/06/2018,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa,XETBXHPXHHOLOE-UHFFFAOYSA-N,"InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)",723.8530000000005
724,Human,Dabigatran Etexilate Accord,"Venous Thromboembolism;  Arthroplasty, Replacement",dabigatran etexilate,DABIGATRAN ETEXILATE MESILATE,EMEA/H/C/005639,no,Authorised,B01AE07,no,yes,no,no,no,no,26/05/2023,,Accord Healthcare S.L.U.,Antithrombotic agents,30/03/2023,,,Prevention of venous thromboembolic events,24/01/2023,31/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dabigatran-etexilate-accord,XETBXHPXHHOLOE-UHFFFAOYSA-N,"InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)",723.8530000000005
209,Human,Norvir,HIV Infections,ritonavir,RITONAVIR,EMEA/H/C/000127,no,Authorised,J05AE03,no,no,no,no,no,no,25/08/1996,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,23/05/1996,31/08/2023,69,Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).,24/05/2018,25/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/norvir,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
226,Human,Kaletra,HIV Infections,"lopinavir, ritonavir",RITONAVIR,EMEA/H/C/000368,no,Authorised,J05AR10,no,no,no,no,no,no,19/03/2001,,AbbVie Deutschland GmbH  Co. KG,"Antivirals for systemic use, Protease inhibitors",14/12/2000,31/08/2023,61,"Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",23/05/2018,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kaletra,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
230,Human,Paxlovid,COVID-19 virus infection,"nirmatrelvir, ritonavir",RITONAVIR,EMEA/H/C/005973,no,Authorised,J05AE30,no,no,no,no,no,no,28/01/2022,,Pfizer Europe MA EEIG,,27/01/2022,26/10/2023,15,Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID 19.,28/01/2022,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
747,Human,Lopinavir/Ritonavir Mylan,HIV Infections,"lopinavir, ritonavir",RITONAVIR,EMEA/H/C/004025,no,Authorised,J05AR10,no,yes,no,no,no,no,14/01/2016,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,19/11/2015,24/05/2023,16,"Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",14/06/2018,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lopinavir-ritonavir-mylan,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
765,Human,Ritonavir Mylan,HIV Infections,ritonavir,RITONAVIR,EMEA/H/C/004549,no,Authorised,J05AE03,no,yes,no,no,no,no,09/11/2017,,Mylan S.A.S,Antivirals for systemic use,14/09/2017,17/05/2023,14,Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).,03/05/2018,17/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ritonavir-mylan,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
839,Human,Viekirax,"Hepatitis C, Chronic","ombitasvir, paritaprevir, ritonavir",RITONAVIR,EMEA/H/C/003839,no,Authorised,J05AP53,no,no,no,no,no,no,14/01/2015,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,20/11/2014,12/08/2022,28,Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.,31/08/2018,12/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",720.9620000000003
291,Human,Lixiana,Stroke;  Venous Thromboembolism,edoxaban,EDOXABAN TOSILATE,EMEA/H/C/002629,no,Authorised,B01,no,no,no,no,no,no,19/06/2015,,Daiichi Sankyo Europe GmbH,Antithrombotic agents,23/04/2015,26/07/2023,18,"Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",26/07/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana,ZLFZITWZOYXXAW-QXXZOGQOSA-N,"InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1",720.2740000000002
292,Human,Roteas,Stroke;  Venous Thromboembolism,edoxaban,EDOXABAN TOSILATE,EMEA/H/C/004339,no,Authorised,B01AF03,no,no,no,no,no,no,19/04/2017,,Berlin-Chemie AG,Antithrombotic agents,22/02/2017,09/08/2023,11,"Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",30/11/2017,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/roteas,ZLFZITWZOYXXAW-QXXZOGQOSA-N,"InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1",720.2740000000002
1228,Human,Kyprolis,Multiple Myeloma,carfilzomib,CARFILZOMIB,EMEA/H/C/003790,no,Authorised,L01XX45,no,no,no,no,yes,yes,19/11/2015,,Amgen Europe B.V.,Antineoplastic agents,24/09/2015,01/04/2022,20,"Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",04/06/2018,15/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis,BLMPQMFVWMYDKT-NZTKNTHTSA-N,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",719.9240000000005
138,Human,Livmarli,Alagille Syndrome,Maralixibat chloride,MARALIXIBAT CHLORIDE,EMEA/H/C/005857,no,Authorised,A05AX04,yes,no,no,yes,no,yes,09/12/2022,,Mirum Pharmaceuticals International B.V.,Other drugs for bile therapy,13/10/2022,08/11/2023,3,Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.,12/10/2022,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli,POMVPJBWDDJCMP-RUKDTIIFSA-M,"InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1",710.4250000000006
813,Human,Evotaz,HIV Infections,"atazanavir, cobicistat",ATAZANAVIR,EMEA/H/C/003904,no,Authorised,J05AR15,no,no,no,no,no,no,13/07/2015,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,21/05/2015,16/03/2023,14,EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).,22/02/2018,25/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz,AXRYRYVKAWYZBR-GASGPIRDSA-N,"InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1",704.8690000000005
260,Human,Rukobia,HIV Infections,fostemsavir,FOSTEMSAVIR TROMETAMOL,EMEA/H/C/005011,no,Authorised,J05AX,yes,no,no,no,no,no,04/02/2021,,ViiV Healthcare B.V.,Antivirals for systemic use,10/12/2020,14/09/2023,4,"Rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.",12/02/2021,11/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rukobia,RRGJSMBMTOKHTE-UHFFFAOYSA-N,"InChI=1S/C25H26N7O8P.C4H11NO3/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17;5-4(1-6,2-7)3-8/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38);6-8H,1-3,5H2",704.6340000000001
123,Human,Posaconazole AHCL,Mycoses,posaconazole,POSACONAZOLE,EMEA/H/C/005028,no,Authorised,J02AC04,no,yes,no,no,no,no,25/07/2019,,Accord Healthcare S.L.U.,Antimycotics for systemic use,29/05/2019,09/10/2023,6,"Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.",28/08/2019,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl,RAGOYPUPXAKGKH-XAKZXMRKSA-N,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",700.791
674,Human,Noxafil,Candidiasis;  Mycoses;  Coccidioidomycosis;  Aspergillosis,posaconazole,POSACONAZOLE,EMEA/H/C/000610,no,Authorised,J02AC04,no,no,no,no,no,no,25/10/2005,,Merck Sharp and Dohme B.V,Antimycotics for systemic use,27/07/2005,16/06/2023,37,"Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. ",21/04/2017,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil,RAGOYPUPXAKGKH-XAKZXMRKSA-N,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",700.791
1029,Human,Posaconazole Accord,Mycoses,posaconazole,POSACONAZOLE,EMEA/H/C/005005,no,Authorised,J02AC04,no,yes,no,no,no,no,25/07/2019,,Accord Healthcare S.L.U.,Antimycotics for systemic use,29/05/2019,16/12/2022,7,"Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.",28/08/2019,19/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord,RAGOYPUPXAKGKH-XAKZXMRKSA-N,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",700.791
1976,Human,Posaconazole SP,Candidiasis;  Mycoses;  Coccidioidomycosis;  Aspergillosis,posaconazole,POSACONAZOLE,EMEA/H/C/000611,no,Withdrawn,J02AC04,no,no,no,no,no,no,25/10/2005,,Schering-Plough Europe,Antimycotics for systemic use,,04/12/2008,5,"Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.",04/12/2008,04/08/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-sp,RAGOYPUPXAKGKH-XAKZXMRKSA-N,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",700.791
1839,Human,Quadramet,Pain;  Cancer,samarium [153Sm] lexidronam pentasodium,SAMARIUM (153SM) LEXIDRONAM PENTASODIUM,EMEA/H/C/000150,no,Authorised,V10BX02,no,no,no,no,no,no,04/02/1998,,CIS bio international,Therapeutic radiopharmaceuticals,,03/05/2015,15,Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan.The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy.,04/05/2015,03/06/2015,https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet,SZZACTGRBZTAKY-NKNBZPHVSA-F,"InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3",695.9320974
172,Human,Lojuxta,Hypercholesterolemia,lomitapide,LOMITAPIDE,EMEA/H/C/002578,no,Authorised,C10AX12,yes,no,no,yes,no,no,31/07/2013,,Amryt Pharmaceuticals DAC,Lipid modifying agents,30/05/2013,12/10/2023,18,"Lojuxta is indicated as an adjunct to a low?fat diet and other lipid?lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded., ",27/08/2018,06/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta,MBBCVAKAJPKAKM-UHFFFAOYSA-N,"InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)",693.7320000000008
1185,Human,Zinforo,"Community-Acquired Infections;  Skin Diseases, Infectious;  Pneumonia",ceftaroline fosamil,CEFTAROLINE FOSAMIL,EMEA/H/C/002252,no,Authorised,J01DI02,no,no,no,no,no,no,22/08/2012,,Pfizer Ireland Pharmaceuticals,"Antibacterials for systemic use, ",21/06/2012,01/06/2021,26,"Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:, , , 	Complicated skin and soft tissue infections (cSSTI), 	Community-acquired pneumonia (CAP), , , Consideration should be given to official guidance on the appropriate use of antibacterial agents., ",21/12/2017,22/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo,ZCCUWMICIWSJIX-NQJJCJBVSA-N,"InChI=1S/C22H21N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37)/b26-13-/t14-,19-/m1/s1",684.7000000000003
1537,Human,Odomzo,"Carcinoma, Basal Cell",sonidegib,SONIDEGIB DIPHOSPHATE,EMEA/H/C/002839,no,Authorised,L01XJ02,no,no,no,no,no,no,14/08/2015,,Sun Pharmaceutical Industries Europe B.V.,Antineoplastic agents,25/06/2015,07/04/2021,10,Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.,25/01/2018,26/04/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo,RWIVSVMMGFFZIJ-VWDRLOGHSA-N,"InChI=1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;",681.4940000000006
1188,Human,Kapruvia,Pruritus,difelikefalin,DIFELIKEFALIN,EMEA/H/C/005612,no,Authorised,V03AX,yes,no,no,no,no,no,25/04/2022,,Vifor Fresenius Medical Care Renal Pharma France,All other therapeutic products,24/02/2022,21/07/2022,1,Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).,22/02/2022,21/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia,FWMNVWWHGCHHJJ-SKKKGAJSSA-N,"InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1",679.8630000000004
1810,Human,Incivo,"Hepatitis C, Chronic",telaprevir,TELAPREVIR,EMEA/H/C/002313,no,Withdrawn,J05AE,yes,no,no,no,no,no,19/09/2011,,Janssen-Cilag International N.V.,Antivirals for systemic use,,25/06/2015,19,"Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.",25/06/2015,06/10/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/incivo,BBAWEDCPNXPBQM-GDEBMMAJSA-N,"InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1",679.8630000000003
771,Human,Sirturo,"Tuberculosis, Multidrug-Resistant",bedaquiline,BEDAQUILINE FUMARATE,EMEA/H/C/002614,no,Authorised,J04AK05,yes,no,yes,no,no,yes,05/03/2014,,Janssen-Cilag International NV,Antimycobacterials,,23/02/2023,21,Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.,05/03/2018,16/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo,ZLVSPMRFRHMMOY-WWCCMVHESA-N,"InChI=1S/C32H31BrN2O2.C4H4O4/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3;5-3(6)1-2-4(7)8/h4-17,20-21,30,36H,18-19H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t30-,32-;/m1./s1",671.5880000000004
327,Human,Invirase,HIV Infections,saquinavir,SAQUINAVIR,EMEA/H/C/000113,no,Withdrawn,J05AE01,no,no,no,no,no,no,03/10/1996,,Roche Registration GmbH,Antivirals for systemic use,,10/03/2023,50,Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.,13/08/2018,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/invirase,QWAXKHKRTORLEM-UGJKXSETSA-N,"InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1",670.8550000000005
2003,Human,Fortovase,HIV Infections,saquinavir,SAQUINAVIR,EMEA/H/C/000178,no,Withdrawn,J05AE01,no,no,no,no,no,no,20/08/1998,,Roche Registration Ltd.,Antivirals for systemic use,,20/08/1998,11,Fortovase is indicated for treatment of HIV-1 infected adult patients. Fortovase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).,20/08/1998,07/08/2006,https://www.ema.europa.eu/en/medicines/human/EPAR/fortovase,QWAXKHKRTORLEM-UGJKXSETSA-N,"InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1",670.8550000000005
1495,Human,Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited),"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DITROMETHAMINE,EMEA/H/C/004488,no,Withdrawn,L01BA04,no,yes,no,no,no,no,24/04/2017,,Pfizer Europe MA EEIG,"Folic acid analogues, ANTIMETABOLITES",23/02/2017,21/10/2020,7,Malignant pleural mesotheliomaPemetrexed Hospira UK Limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Hospira UK Limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).Pemetrexed Hospira UK Limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see SmPC section 5.1).Pemetrexed Hospira UK Limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).,24/04/2018,29/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-known-pemetrexed-hospira-uk-limited,HNJZWVKZQZMXHP-GXKRWWSZSA-N,"InChI=1S/C20H21N5O6.2C4H11NO3/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;2*5-4(1-6,2-7)3-8/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);2*6-8H,1-3,5H2/t13-;;/m0../s1",669.6890000000002
634,Human,Mysildecard,"Hypertension, Pulmonary",sildenafil,SILDENAFIL CITRATE,EMEA/H/C/004186,no,Authorised,G04BE03,no,yes,no,no,no,no,15/09/2016,,Viatris Limited,Urologicals,21/07/2016,30/11/2022,7,"AdultsTreatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease (see section 5.1).",15/09/2016,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mysildecard,DEIYFTQMQPDXOT-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",666.7100000000004
843,Human,Granpidam,"Hypertension, Pulmonary",sildenafil,SILDENAFIL CITRATE,EMEA/H/C/004289,no,Authorised,G04BE03,no,yes,no,no,no,no,14/11/2016,,Accord Healthcare S.L.U.,Urologicals,15/09/2016,30/03/2023,8,"AdultsTreatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.",17/01/2017,11/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/granpidam,DEIYFTQMQPDXOT-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",666.7100000000004
239,Human,Xeplion,Schizophrenia,paliperidone,PALIPERIDONE PALMITATE,EMEA/H/C/002105,no,Authorised,N05AX13,no,no,no,no,no,no,04/03/2011,,Janssen-Cilag International N.V.,Psycholeptics,,25/05/2023,16,"Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.",31/05/2018,17/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion,VOMKSBFLAZZBOW-UHFFFAOYSA-N,"InChI=1S/C39H57FN4O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-36(45)47-34-17-16-24-44-38(34)41-29(2)32(39(44)46)23-27-43-25-21-30(22-26-43)37-33-20-19-31(40)28-35(33)48-42-37/h19-20,28,30,34H,3-18,21-27H2,1-2H3",664.9070000000003
660,Human,Trevicta (previously Paliperidone Janssen),Schizophrenia,paliperidone,PALIPERIDONE PALMITATE,EMEA/H/C/004066,no,Authorised,N05AX13,no,no,no,no,no,no,05/12/2014,,Janssen-Cilag International NV,Psycholeptics,,25/05/2023,12,"Trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.",31/05/2018,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trevicta,VOMKSBFLAZZBOW-UHFFFAOYSA-N,"InChI=1S/C39H57FN4O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-36(45)47-34-17-16-24-44-38(34)41-29(2)32(39(44)46)23-27-43-25-21-30(22-26-43)37-33-20-19-31(40)28-35(33)48-42-37/h19-20,28,30,34H,3-18,21-27H2,1-2H3",664.9070000000003
661,Human,Byannli (previously Paliperidone Janssen-Cilag International),Schizophrenia,paliperidone,PALIPERIDONE PALMITATE,EMEA/H/C/005486,no,Authorised,N05AX13,no,no,no,no,no,no,18/06/2020,,Janssen-Cilag International N.V.  ,Psycholeptics,30/04/2020,25/05/2023,3,"Byannli (previously Paliperidone Janssen-Cilag International) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.1).",07/07/2020,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international,VOMKSBFLAZZBOW-UHFFFAOYSA-N,"InChI=1S/C39H57FN4O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-36(45)47-34-17-16-24-44-38(34)41-29(2)32(39(44)46)23-27-43-25-21-30(22-26-43)37-33-20-19-31(40)28-35(33)48-42-37/h19-20,28,30,34H,3-18,21-27H2,1-2H3",664.9070000000003
1779,Human,Optimark,Magnetic Resonance Imaging,gadoversetamide,GADOVERSETAMIDE,EMEA/H/C/000745,no,Withdrawn,V08CA06,no,no,no,no,no,no,23/07/2007,,Mallinckrodt Deutschland GmbH,Contrast media,,11/04/2017,14,This medicinal product is for diagnostic use only.Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology.,11/04/2017,11/12/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/optimark,HBEAOBRDTOXWRZ-UHFFFAOYSA-K,"InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3",661.7670000000002
963,Human,Roclanda,"Glaucoma, Open-Angle;  Ocular Hypertension",latanoprost / netarsudil,NETARSUDIL MESILATE,EMEA/H/C/005107,no,Authorised,S01EE,yes,no,no,no,no,no,07/01/2021,,Santen Oy,Ophthalmologicals,12/11/2020,12/12/2022,4,Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.,21/01/2021,16/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/roclanda,QQDRLKRHJOAQDC-FBHGDYMESA-N,"InChI=1S/C28H27N3O3.2CH4O3S/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;2*1-5(2,3)4/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);2*1H3,(H,2,3,4)/t26-;;/m1../s1",645.7560000000004
153,Human,Zokinvy,Progeria;  Laminopathies,lonafarnib,LONAFARNIB,EMEA/H/C/005271,no,Authorised,,yes,no,no,yes,no,yes,18/07/2022,,EigerBio Europe Limited,"Other alimentary tract and metabolism products, ",19/05/2022,19/10/2023,2,Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.,01/08/2022,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy,DHMTURDWPRKSOA-RUZDIDTESA-N,"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1",638.8320000000001
665,Human,Emtricitabine/Tenofovir disoproxil Krka d.d.,HIV Infections,"emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL SUCCINATE,EMEA/H/C/004686,no,Authorised,J05AR03,no,yes,no,no,no,no,28/04/2017,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,23/02/2017,21/06/2023,10,"Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.",25/07/2018,22/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka-dd,CCGIINMVANPRGB-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.C4H6O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H2,(H,5,6)(H,7,8)/t14-;/m1./s1",637.5360000000002
668,Human,Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL SUCCINATE,EMEA/H/C/004215,no,Authorised,J05AR03,no,yes,no,no,no,no,09/12/2016,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,13/10/2016,21/06/2023,12,"Treatment of HIV-1 infectionEmtricitabine/tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.",25/07/2018,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka,CCGIINMVANPRGB-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.C4H6O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H2,(H,5,6)(H,7,8)/t14-;/m1./s1",637.5360000000002
677,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL SUCCINATE,EMEA/H/C/004274,no,Authorised,J05AR06,no,yes,no,no,no,no,08/02/2018,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,14/12/2017,15/06/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",08/02/2018,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-krka,CCGIINMVANPRGB-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.C4H6O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H2,(H,5,6)(H,7,8)/t14-;/m1./s1",637.5360000000002
1068,Human,Sorafenib Accord ,"Carcinoma, Hepatocellular;  Carcinoma, Renal Cell",sorafenib,SORAFENIB TOSILATE,EMEA/H/C/005921,no,Authorised,L01EX02,no,yes,no,no,no,no,09/11/2022,,Accord Healthcare S.L.U.,Antineoplastic agents,15/09/2022,,,Hepatocellular carcinomaSorafenib Accord is indicated for the treatment of hepatocellular carcinoma (see section 5.1).Renal cell carcinomaSorafenib Accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.,14/09/2022,25/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sorafenib-accord,IVDHYUQIDRJSTI-UHFFFAOYSA-N,"InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)",637.0360000000002
306,Human,Zavicefta,"Pneumonia, Bacterial;  Soft Tissue Infections;  Pneumonia;  Urinary Tract Infections;  Gram-Negative Bacterial Infections","ceftazidime, avibactam",CEFTAZIDIME PENTAHYDRATE,EMEA/H/C/004027,no,Authorised,J01,no,no,no,no,no,no,23/06/2016,,Pfizer Ireland Pharmaceuticals,"Antibacterials for systemic use, ",28/04/2016,22/04/2022,15,"Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.",14/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta,NMVPEQXCMGEDNH-TZVUEUGBSA-N,"InChI=1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1",636.662
1115,Human,Quofenix,Community-Acquired Infections,delafloxacin,DELAFLOXACIN MEGLUMINE,EMEA/H/C/004860,no,Authorised,J01MA23,yes,no,no,no,no,no,16/12/2019,,A. Menarini Industrie Farmaceutiche Riunite s.r.l.,"Antibacterials for systemic use, ",17/10/2019,13/10/2022,5,"Quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (ABSSSI),community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",20/12/2019,13/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/quofenix,AHJGUEMIZPMAMR-WZTVWXICSA-N,"InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1",635.9800000000004
112,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL MALEATE,EMEA/H/C/004240,no,Authorised,J05AR06,no,yes,no,no,no,no,05/09/2017,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,22/06/2017,03/11/2023,16,"Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",15/08/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan,VCMJCVGFSROFHV-VIEYUMQNSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-;/m1./s1",635.5200000000003
493,Human,Delstrigo,HIV Infections,"doravirine, lamivudine, tenofovir disoproxil",TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/004746,no,Authorised,J05AR,no,no,no,no,no,no,22/11/2018,,Merck Sharp & Dohme B.V.,"Antivirals for treatment of HIV infections, combinations",20/09/2018,23/06/2023,11,"Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir.Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.",21/09/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
527,Human,Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL MALEATE,EMEA/H/C/004050,no,Authorised,J05AR03,no,yes,no,no,no,no,16/12/2016,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,13/10/2016,05/07/2023,14,"Treatment of HIV-1 infection:Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1).Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1).Pre-exposure prophylaxis (PrEP):Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).",02/06/2017,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-mylan,VCMJCVGFSROFHV-VIEYUMQNSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-;/m1./s1",635.5200000000003
977,Human,Truvada,HIV Infections,"emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/000594,no,Authorised,J05AR03,no,no,no,no,no,no,20/02/2005,,Gilead Sciences Ireland UC,Antivirals for systemic use,18/11/2004,12/01/2023,46,"Treatment of HIV-1 infection:, , , 	Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults., 	Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years., , , Pre-exposure prophylaxis (PrEP):, , , 	Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk., , ",19/07/2017,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/truvada,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
978,Human,Stribild,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/002574,no,Authorised,J05AR09,no,no,no,no,no,no,24/05/2013,,Gilead Sciences Ireland UC,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,12/01/2023,25,Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.,19/07/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stribild,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
1018,Human,Viread,"Hepatitis B, Chronic;  HIV Infections",tenofovir disoproxil,TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/000419,no,Authorised,J05AF07,no,no,no,no,no,no,04/02/2002,,Gilead Sciences Ireland UC,Antivirals for systemic use,19/03/2008,20/12/2022,58,"HIV 1 infectionViread 123 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 17 kg to less than 22 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 123 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 17 kg to less than 22 kg, withcompensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 163 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 22 kg to less than 28 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 163 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 22 kg to less than 28 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 204 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 28 kg to less than 35 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 204 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 28 kg to less than 35 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels or histological evidence of moderate to severe inflammation and/or fibrosis.  With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 245 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Viread 245 mg film coated tablets are also indicated for the treatment of HIV 1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 33 mg/g granules are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate.Viread 33 mg/g granules are also indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults for whom a solid dosage form is not appropriate.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 33 mg/g granules are indicated for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis B in paediatric patients2 to < 18 years of age for whom a solid dosage form is not appropriate with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis.  With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.",19/07/2018,04/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viread,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
1043,Human,Eviplera,HIV Infections,"emtricitabine, rilpivirine, tenofovir disoproxil",TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/002312,no,Authorised,J05AR08,no,no,no,no,no,no,27/11/2011,,Gilead Sciences International Ltd ,Antivirals for systemic use,,12/12/2022,25,"Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.",19/07/2018,13/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
1338,Human,Atripla,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL FUMARATE,EMEA/H/C/000797,no,Withdrawn,J05AR06,no,no,no,no,no,no,13/12/2007,,Gilead Sciences Ireland UC,Antivirals for systemic use,,17/08/2021,36,"Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla.No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients.No data are available to support the combination of Atripla and other antiretroviral agents.",25/07/2018,21/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/atripla,VCMJCVGFSROFHV-WZGZYPNHSA-N,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",635.5200000000003
13,Human,Orladeyo,"Angioedemas, Hereditary",berotralstat,BEROTRALSTAT DIHYDROCHLORIDE,EMEA/H/C/005138,no,Authorised,B06AC,no,no,no,no,no,no,30/04/2021,,BioCryst Ireland Limited,Other hematological agents,25/02/2021,13/12/2022,5,Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.,24/02/2021,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo,XFZLBLTUANGZBD-QDSLRZTOSA-N,"InChI=1S/C30H26F4N6O.2ClH/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36;;/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41);2*1H/t28-;;/m1../s1",635.4930000000002
99,Human,Vanflyta,"Leukemia, Myeloid",quizartinib,QUIZARTINIB DIHYDROCHLORIDE,EMEA/H/C/005910,no,Authorised,L01EX11,yes,no,no,no,no,no,06/11/2023,,Daiichi Sankyo Europe GmbH,"Antineoplastic agents, Protein kinase inhibitors",14/09/2023,,,"Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.",14/09/2023,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta-0,DHYPGRVMIOATAE-UHFFFAOYSA-N,"InChI=1S/C29H32N6O4S.2ClH/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34;;/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);2*1H",633.6020000000002
226,Human,Kaletra,HIV Infections,"lopinavir, ritonavir",LOPINAVIR,EMEA/H/C/000368,no,Authorised,J05AR10,no,no,no,no,no,no,19/03/2001,,AbbVie Deutschland GmbH  Co. KG,"Antivirals for systemic use, Protease inhibitors",14/12/2000,31/08/2023,61,"Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",23/05/2018,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kaletra,KJHKTHWMRKYKJE-SUGCFTRWSA-N,"InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1",628.8140000000005
747,Human,Lopinavir/Ritonavir Mylan,HIV Infections,"lopinavir, ritonavir",LOPINAVIR,EMEA/H/C/004025,no,Authorised,J05AR10,no,yes,no,no,no,no,14/01/2016,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,19/11/2015,24/05/2023,16,"Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",14/06/2018,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lopinavir-ritonavir-mylan,KJHKTHWMRKYKJE-SUGCFTRWSA-N,"InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1",628.8140000000005
1143,Human,Tavlesse,Thrombocytopenia,fostamatinib,FOSTAMATINIB DISODIUM,EMEA/H/C/005012,no,Authorised,B02BX,yes,no,no,no,no,no,09/01/2020,,Instituto Grifols S.A.,Other systemic hemostatics,,09/09/2022,5,Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.,11/02/2020,12/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse,HSYBQXDGYCYSGA-UHFFFAOYSA-L,"InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2",624.4300000000003
1158,Human,Telzir,HIV Infections,fosamprenavir,FOSAMPRENAVIR CALCIUM,EMEA/H/C/000534,no,Authorised,J05AE07,no,no,no,no,no,no,12/07/2004,,ViiV Healthcare BV,Antivirals for systemic use,,19/08/2022,48,"Telzir in combination with low-dose ritonavir is indicated for the treatment of human-immunodeficiency-virus-type-1-infected adults, adolescents and children of six years and above in combination with other antiretroviral medicinal products., , In moderately antiretroviral-experienced adults, Telzir in combination with low-dose ritonavir has not been shown to be as effective as lopinavir / ritonavir. No comparative studies have been undertaken in children or adolescents., , In heavily pretreated patients, the use of Telzir in combination with low-dose ritonavir has not been sufficiently studied., , In protease-inhibitor-experienced patients, the choice of Telzir should be based on individual viral resistance testing and treatment history., ",10/03/2017,23/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/telzir,PMDQGYMGQKTCSX-HQROKSDRSA-L,"InChI=1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1",623.6780000000002
0,Human,Ryeqo,Leiomyoma,"relugolix, estradiol, norethisterone acetate",RELUGOLIX,EMEA/H/C/005267,no,Authorised,H01CC54,yes,no,no,no,no,no,16/07/2021,,Gedeon Richter Plc.,Pituitary and hypothalamic hormones and analogues,16/07/2021,30/10/2023,6,"Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.",19/05/2021,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo,AOMXMOCNKJTRQP-UHFFFAOYSA-N,"InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)",623.6420000000003
48,Human,Orgovyx,Prostatic Neoplasms,relugolix,RELUGOLIX,EMEA/H/C/005353,no,Authorised,L02BX,yes,no,no,no,no,no,29/04/2022,,Accord Healthcare S.L.U.,Endocrine therapy,24/02/2022,20/11/2023,8,Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.,22/02/2022,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orgovyx,AOMXMOCNKJTRQP-UHFFFAOYSA-N,"InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)",623.6420000000003
73,Human,Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL PHOSPHATE,EMEA/H/C/004137,no,Authorised,J05AR03,no,yes,no,no,no,no,09/11/2016,,Zentiva k.s.,Antivirals for systemic use,15/09/2016,23/05/2023,8,"Treatment of HIV-1 infectionEmtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.",13/10/2017,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-zentiva,DJCLNKKHALBVLK-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.H3O4P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;1-5(2,3)4/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);(H3,1,2,3,4)/t14-;/m1./s1",617.4420000000005
625,Human,Tenofovir disoproxil Zentiva,HIV Infections,tenofovir disoproxil,TENOFOVIR DISOPROXIL PHOSPHATE,EMEA/H/C/004120,no,Authorised,J05AF07,no,yes,no,no,no,no,15/09/2016,,Zentiva k.s.,Antivirals for systemic use,21/07/2016,03/07/2023,13,"HIV?1 infectionTenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV?1 infected adults.In adults, the demonstration of the benefit of tenofovir disoproxil in HIV?1 infection is based on results of one study in treatment?naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre?treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV?1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Tenofovir disoproxil Zentiva to treat antiretroviral?experienced patients with HIV?1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionTenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1);evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1);decompensated liver disease (see sections 4.4, 4.8 and 5.1).Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1).",18/01/2018,04/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-zentiva,DJCLNKKHALBVLK-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.H3O4P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;1-5(2,3)4/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);(H3,1,2,3,4)/t14-;/m1./s1",617.4420000000005
720,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",TENOFOVIR DISOPROXIL PHOSPHATE,EMEA/H/C/004250,no,Authorised,J05AR06,no,yes,no,no,no,no,17/07/2017,,Zentiva k.s.,Antivirals for systemic use,18/05/2017,30/05/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with combination efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",09/01/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-zentiva,DJCLNKKHALBVLK-PFEQFJNWSA-N,"InChI=1S/C19H30N5O10P.H3O4P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;1-5(2,3)4/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);(H3,1,2,3,4)/t14-;/m1./s1",617.4420000000005
422,Human,Tafinlar,Melanoma,dabrafenib,DABRAFENIB MESILATE,EMEA/H/C/002604,no,Authorised,L01EC02,no,no,no,no,no,no,26/08/2013,,Novartis Europharm Limited,Antineoplastic agents,27/06/2013,16/08/2023,29,"MelanomaDabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Adjuvant treatment of melanomaDabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.",27/08/2018,01/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar,YKGMKSIHIVVYKY-UHFFFAOYSA-N,"InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)",615.681
896,Human,Inrebic,Myeloproliferative Disorders;  Primary Myelofibrosis,fedratinib,FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/005026,no,Authorised,L01EJ02,yes,no,no,no,no,yes,08/02/2021,,Bristol Myers Squibb Pharma EEIG,Antineoplastic agents,10/12/2020,23/02/2023,4,"Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.",03/03/2021,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic,QAFZLTVOFJHYDF-UHFFFAOYSA-N,"InChI=1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2",615.6280000000002
929,Human,Mekinist,Melanoma,trametinib,TRAMETINIB,EMEA/H/C/002643,no,Authorised,L01EE01,no,no,no,no,no,no,30/06/2014,,Novartis Europharm Limited,Antineoplastic agents,30/06/2020,24/02/2023,29,"MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.",27/08/2018,27/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",615.4030000000001
1153,Human,Ivemend,Vomiting;  Cancer,fosaprepitant,FOSAPREPITANT,EMEA/H/C/000743,no,Authorised,A04AD12,no,no,no,no,no,no,11/01/2008,,Merck Sharp & Dohme B.V.,"Antiemetics and antinauseants, ",,25/08/2022,24,Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.Ivemend 150 mg is given as part of a combination therapy.,23/07/2018,26/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend,BARDROPHSZEBKC-OITMNORJSA-N,"InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1",614.4110000000002
794,Human,Yselty,Leiomyoma,linzagolix choline,LINZAGOLIX CHOLINE,EMEA/H/C/005442,no,Authorised,H01CC04,yes,no,no,no,no,no,14/06/2022,,Theramex Ireland Limited,Pituitary and hypothalamic hormones and analogues,16/12/2021,28/04/2023,3,Yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.,14/12/2021,02/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/yselty,IAIVRTFCYOGNBW-UHFFFAOYSA-M,"InChI=1S/C22H15F3N2O7S.C5H14NO/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30;1-6(2,3)4-5-7/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30);7H,4-5H2,1-3H3/q;+1/p-1",611.5949999999999
938,Human,Fulvestrant Mylan,Breast Neoplasms,fulvestrant,FULVESTRANT,EMEA/H/C/004649,no,Authorised,L02BA03,no,yes,no,no,no,no,08/01/2018,,Mylan Pharmaceuticals Limited,Endocrine therapy,09/11/2007,10/01/2023,5,"Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.",08/01/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fulvestrant-mylan,VWUXBMIQPBEWFH-WCCTWKNTSA-N,"InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1",606.7820000000003
1149,Human,Faslodex,Breast Neoplasms,fulvestrant,FULVESTRANT,EMEA/H/C/000540,no,Authorised,L02BA03,no,no,no,no,no,no,09/03/2004,,AstraZeneca AB,"Endocrine therapy, Anti-estrogens",,31/08/2022,23,"Faslodex is indicated, , , 	as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, 	, 		not previously treated with endocrine therapy, or, 		with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy., 	, 	, 	in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy., , , In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist., ",21/03/2018,31/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex,VWUXBMIQPBEWFH-WCCTWKNTSA-N,"InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1",606.7820000000003
1482,Human,BroPair Spiromax,Asthma,"salmeterol, fluticasone propionate",SALMETEROL XINAFOATE,EMEA/H/C/005591,no,Authorised,R03AK06,no,no,no,no,no,no,26/03/2021,,Teva B.V.,"Drugs for obstructive airway diseases, ",28/01/2021,15/07/2021,1,BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.,14/04/2021,27/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/bropair-spiromax,XTZNCVSCVHTPAI-UHFFFAOYSA-N,"InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)",603.7560000000003
1483,Human,Seffalair Spiromax,Asthma,"salmeterol, fluticasone propionate",SALMETEROL XINAFOATE,EMEA/H/C/004881,no,Authorised,R03AK06,no,no,no,no,no,no,26/03/2021,,Teva B.V.,"Drugs for obstructive airway diseases, ",,15/07/2021,,Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.,13/04/2021,23/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/seffalair-spiromax,XTZNCVSCVHTPAI-UHFFFAOYSA-N,"InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)",603.7560000000003
1671,Human,Aerivio Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","salmeterol, fluticasone propionate",SALMETEROL XINAFOATE,EMEA/H/C/002752,no,Withdrawn,R03AK06,no,no,no,no,no,no,18/08/2016,,Teva B.V.,"Drugs for obstructive airway diseases, ",23/06/2016,04/10/2019,2,"Aerivio Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAerivio Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting ?2 agonist) is appropriate:patients not adequately controlled on a lower strength corticosteroid combination product orpatients already controlled on a high dose inhaled corticosteroid and long-acting ?2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 ",09/06/2017,15/01/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/aerivio-spiromax,XTZNCVSCVHTPAI-UHFFFAOYSA-N,"InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)",603.7560000000003
446,Human,Aquipta,Migraine Disorders,atogepant,ATOGEPANT,EMEA/H/C/005871,no,Authorised,N02CD07,yes,no,no,no,no,no,11/08/2023,,AbbVie Deutschland GmbH & Co. KG,,22/06/2023,,,Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month,19/06/2023,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta,QIVUCLWGARAQIO-OLIXTKCUSA-N,"InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1",603.5230000000001
1159,Human,Aptivus,HIV Infections,tipranavir,TIPRANAVIR,EMEA/H/C/000631,no,Authorised,J05AE09,no,no,no,no,no,no,25/10/2005,,Boehringer Ingelheim International GmbH,Antivirals for systemic use,27/07/2005,28/07/2022,42,"Aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.This indication is based on the results of two phase-III studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of Aptivus. Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, co-administered with low-dose ritonavir.",10/11/2017,23/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus,SUJUHGSWHZTSEU-FYBSXPHGSA-N,"InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1",602.6750000000003
231,Human,Veklury,COVID-19 virus infection,remdesivir,REMDESIVIR,EMEA/H/C/005622,no,Authorised,,yes,no,no,no,no,no,03/07/2020,,Gilead Sciences Ireland UC,,25/06/2020,12/10/2023,22,Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19,06/07/2020,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/veklury,RWWYLEGWBNMMLJ-YSOARWBDSA-N,"InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1",602.5850000000003
534,Human,Kaftrio,Cystic Fibrosis,"ivacaftor, tezacaftor, elexacaftor",ELEXACAFTOR,EMEA/H/C/005269,no,Authorised,R07AX32,yes,no,no,no,no,yes,21/08/2020,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,25/06/2020,07/07/2023,15,Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,21/08/2020,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio,MVRHVFSOIWFBTE-INIZCTEOSA-N,"InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1",597.6640000000002
202,Human,Byfavo,Conscious Sedation,remimazolam,REMIMAZOLAM BESILATE,EMEA/H/C/005246,no,Authorised,N05CD14,yes,no,no,no,no,no,26/03/2021,,PAION Deutschland GmbH,Psycholeptics,10/12/2020,15/06/2023,6,Remimazolam is indicated in adults for procedural sedation.Remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.,20/04/2021,26/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo,QMTKNJZIWGTNTE-LMOVPXPDSA-N,"InChI=1S/C21H19BrN4O2.C6H6O3S/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21;7-10(8,9)6-4-2-1-3-5-6/h3-6,8,10-12,17H,7,9H2,1-2H3;1-5H,(H,7,8,9)/t17-;/m0./s1",597.4910000000002
991,Human,Pemetrexed Baxter,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM HEPTAHYDRATE,EMEA/H/C/005848,no,Authorised,L01BA04,no,yes,no,no,no,no,09/12/2022,,Baxter Holding B.V.,Antineoplastic agents,13/10/2022,,,Malignant pleural mesotheliomaPemetrexed Baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).Pemetrexed Baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).Pemetrexed Baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).,12/10/2022,19/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-baxter,QJVSMHJWAOSBMD-MYXYZBIASA-L,"InChI=1S/C20H21N5O6.2Na.7H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;7*1H2/q;2*+1;;;;;;;/p-2/t13-;;;;;;;;;/m0........./s1",597.486
113,Human,Tagrisso,"Carcinoma, Non-Small-Cell Lung",osimertinib,OSIMERTINIB MESILATE,EMEA/H/C/004124,no,Authorised,L01XE,no,no,no,no,yes,no,01/02/2016,,AstraZeneca AB,"Other antineoplastic agents, Protein kinase inhibitors",17/12/2015,28/09/2023,19,TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.,31/08/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso,FUKSNUHSJBTCFJ-UHFFFAOYSA-N,"InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4)",595.7260000000003
918,Human,Mulpleo (previously Lusutrombopag Shionogi),Thrombocytopenia,lusutrombopag,LUSUTROMBOPAG,EMEA/H/C/004720,no,Authorised,B02BX,yes,no,no,no,no,no,18/02/2019,,Shionogi B.V.,Antihemorrhagics,13/12/2018,07/03/2023,8,Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures,14/03/2019,08/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo,NOZIJMHMKORZBA-KJCUYJGMSA-N,"InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1",591.5570000000004
1787,Human,Zontivity,Myocardial Infarction,vorapaxar,VORAPAXAR SULFATE,EMEA/H/C/002814,no,Withdrawn,B01,yes,no,no,no,no,no,19/01/2015,,Merck Sharp  Dohme Limited,Antithrombotic agents,,29/07/2016,2,"Zontivityis indicated for the reduction of atherothrombotic events in adult patients with- a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or- symptomatic peripheral arterial disease(PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.",29/07/2016,20/09/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/zontivity,NQRYCIGCIAWEIC-CKLVGUEFSA-N,"InChI=1S/C29H33FN2O4.H2O4S/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18;1-5(2,3)4/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34);(H2,1,2,3,4)/b12-9+;/t17-,20+,23-,24-,25+,26-,27+;/m1./s1",590.6700000000002
229,Human,Imatinib Koanaa,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Myelodysplastic-Myeloproliferative Diseases;  Hypereosinophilic Syndrome;  Dermatofibrosarcoma;  Gastrointestinal Stromal Tumors",imatinib,IMATINIB MESILATE,EMEA/H/C/005595,no,Withdrawn,L01EA01,no,yes,no,no,no,no,22/09/2021,,Koanaa Healthcare GmbH,Antineoplastic agents,22/07/2021,22/09/2021,,"Imatinib Koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.adult patients with relapsed or refractory Ph+ ALL as monotherapy.adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.The effect of Imatinib on the outcome of bone marrow transplantation has not been determined.Imatinib Koanaa is indicated forthe treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.In adult and paediatric patients, the effectiveness of Imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.",01/10/2021,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-koanaa,YLMAHDNUQAMNNX-UHFFFAOYSA-N,"InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)",589.7220000000003
1738,Human,Imatinib Teva B.V.,"Dermatofibrosarcoma;  Gastrointestinal Stromal Tumors;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive",imatinib,IMATINIB MESILATE,EMEA/H/C/004748,no,Withdrawn,L01XE01,no,yes,no,no,no,no,15/11/2017,,Teva B.V.,Antineoplastic agents,,08/05/2018,0,"Imatinib Teva B.V. is indicated for the treatment of:, , , 	Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment., 	Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis., 	Adult patients with Ph+ CML in blast crisis., 	Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy., 	Adult patients with relapsed or refractory Ph+ ALL as monotherapy., 	 Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements., 	Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement., , , The effect of imatinib on the outcome of bone marrow transplantation has not been determined., , Imatinib Teva B.V. is indicated for:, , , 	The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)., 	The adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment., 	The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., ",15/11/2017,09/10/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva-bv,YLMAHDNUQAMNNX-UHFFFAOYSA-N,"InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)",589.7220000000003
166,Human,Opsumit,"Hypertension, Pulmonary",macitentan,MACITENTAN,EMEA/H/C/002697,no,Authorised,C02KX04,no,no,no,no,no,yes,20/12/2013,,Janssen-Cilag International N.V.  ,"Antihypertensives, ",,01/12/2022,23,"Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.",23/08/2018,07/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit,JGCMEBMXRHSZKX-UHFFFAOYSA-N,"InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)",588.282
338,Human,Alunbrig,"Carcinoma, Non-Small-Cell Lung",brigatinib,BRIGATINIB,EMEA/H/C/004248,no,Authorised,L01XE43,yes,no,no,no,no,no,22/11/2018,,Takeda Pharma A/S,Antineoplastic agents,19/09/2018,24/07/2023,9,Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.,26/11/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig,AILRADAXUVEEIR-UHFFFAOYSA-N,"InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)",584.1050000000001
778,Human,Tibsovo,"Leukemia, Myeloid, Acute;  Cholangiocarcinoma",ivosidenib,IVOSIDENIB,EMEA/H/C/005936,no,Authorised,L01XX62,yes,no,no,no,no,yes,04/05/2023,,Les Laboratoires Servier,Antineoplastic agents,23/02/2023,,,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1).Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,12/04/2023,12/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0,WIJZXSAJMHAVGX-DHLKQENFSA-N,"InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1",582.9700000000001
176,Human,Tavneos,Microscopic Polyangiitis;  Wegener Granulomatosis,avacopan,AVACOPAN,EMEA/H/C/005523,no,Authorised,L04,yes,no,no,no,no,yes,11/01/2022,,Vifor Fresenius Medical Care Renal Pharma France,Immunosuppressants,11/11/2021,31/10/2023,4,"Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).",10/11/2021,03/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos,PUKBOVABABRILL-YZNIXAGQSA-N,"InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1",581.6540000000002
922,Human,Cayston,Cystic Fibrosis;  Respiratory Tract Infections,aztreonam,AZTREONAM LYSINE,EMEA/H/C/000996,no,Authorised,J01DF01,no,no,no,no,no,no,21/09/2009,,Gilead Sciences Ireland UC,"Antibacterials for systemic use, ",,27/02/2023,20,Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,24/05/2018,03/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cayston,KPPBAEVZLDHCOK-JHBYREIPSA-N,"InChI=1S/C13H17N5O8S2.C6H14N2O2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22;7-4-2-1-3-5(8)6(9)10/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25);5H,1-4,7-8H2,(H,9,10)/b17-8-;/t5-,7-;5-/m00/s1",581.6300000000002
783,Human,Tyverb,Breast Neoplasms,lapatinib,LAPATINIB,EMEA/H/C/000795,no,Authorised,L01EH01,no,no,no,no,no,no,10/06/2008,,Novartis Europharm Limited,Protein kinase inhibitors,,10/05/2023,35,"Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting;in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy;in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.",30/07/2018,10/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb,BCFGMOOMADDAQU-UHFFFAOYSA-N,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",581.0690000000002
416,Human,Celdoxome pegylated liposomal,"Breast Neoplasms;  Ovarian Neoplasms;  Multiple Myeloma;  Sarcoma, Kaposi",doxorubicin hydrochloride,DOXORUBICIN HYDROCHLORIDE,EMEA/H/C/005330,no,Authorised,L01DB01,no,no,no,no,no,no,15/09/2022,,YES Pharmaceutical Development Services GmbH,Antineoplastic agents,21/07/2022,23/08/2023,2,"Celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.Celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).",20/06/2022,05/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/celdoxome-pegylated-liposomal,MWWSFMDVAYGXBV-RUELKSSGSA-N,"InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1",579.9860000000003
417,Human,Caelyx pegylated liposomal,"Sarcoma, Kaposi;  Multiple Myeloma;  Ovarian Neoplasms;  Breast Neoplasms",doxorubicin,DOXORUBICIN HYDROCHLORIDE,EMEA/H/C/000089,no,Authorised,L01DB,no,no,no,no,no,no,20/06/1996,,Baxter Holding B.V.,Antineoplastic agents,15/02/1996,25/08/2023,36,"Caelyx pegylated liposomal is indicated:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk;for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen;in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant;for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (",22/05/2018,05/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal,MWWSFMDVAYGXBV-RUELKSSGSA-N,"InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1",579.9860000000003
883,Human,Myocet liposomal (previously Myocet),Breast Neoplasms,doxorubicin,DOXORUBICIN HYDROCHLORIDE,EMEA/H/C/000297,no,Authorised,L01DB01,no,no,no,no,no,no,13/07/2000,,Teva B.V.,Antineoplastic agents,12/04/2000,15/12/2022,24,"Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.",20/07/2018,24/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/myocet-liposomal-previously-myocet,MWWSFMDVAYGXBV-RUELKSSGSA-N,"InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1",579.9860000000003
855,Human,Dzuveo,Pain,sufentanil,SUFENTANIL CITRATE,EMEA/H/C/004335,no,Authorised,N01AH03,no,no,no,no,no,no,25/06/2018,,Laboratoire Aguettant,Anesthetics,26/04/2018,24/03/2023,6,Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.,25/09/2018,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo,OJCZPLDERGDQRJ-UHFFFAOYSA-N,"InChI=1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",578.6840000000004
409,Human,Akynzeo,Vomiting;  Neoplasms;  Nausea;  Cancer,"netupitant, palonosetron",NETUPITANT,EMEA/H/C/003728,no,Authorised,A04AA,no,no,no,no,no,no,27/05/2015,,Helsinn Birex Pharmaceuticals Ltd,"Antiemetics and antinauseants, ",26/03/2015,05/09/2023,16,Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.,12/04/2018,08/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo,WAXQNWCZJDTGBU-UHFFFAOYSA-N,"InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3",578.601
676,Human,Prevymis,Cytomegalovirus Infections,letermovir,LETERMOVIR,EMEA/H/C/004536,no,Authorised,J05,no,no,no,no,no,yes,08/01/2018,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,12/10/2017,16/06/2023,15,Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Consideration should be given to official guidance on the appropriate use of antiviral agents.,23/07/2018,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis,FWYSMLBETOMXAG-QHCPKHFHSA-N,"InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1",572.5590000000002
529,Human,Xofluza,"Influenza, Human",baloxavir marboxil,BALOXAVIR MARBOXIL,EMEA/H/C/004974,no,Authorised,,yes,no,no,no,no,no,07/01/2021,,Roche Registration GmbH,Antivirals for systemic use,12/11/2020,10/01/2023,4,Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.,22/01/2021,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza,RZVPBGBYGMDSBG-GGAORHGYSA-N,"InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1",571.5580000000002
540,Human,Rydapt,"Leukemia, Myeloid, Acute;  Mastocytosis",midostaurin,MIDOSTAURIN,EMEA/H/C/004095,no,Authorised,L01XE,no,no,no,no,no,yes,18/09/2017,,Novartis Europharm Ltd,Antineoplastic agents,22/06/2017,22/06/2023,11,"Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).",30/04/2018,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt,BMGQWWVMWDBQGC-IIFHNQTCSA-N,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",570.6490000000005
1553,Human,Truberzi,Irritable Bowel Syndrome;  Diarrhea,eluxadoline,ELUXADOLINE,EMEA/H/C/004098,no,Withdrawn,A07,yes,no,no,no,no,no,19/09/2016,,Allergan Pharmaceuticals International Limited,"Antidiarrheals, intestinal antiinflammatory / antiinfective agents",21/07/2016,12/02/2020,6,Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D).,08/12/2017,25/02/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi,QFNHIDANIVGXPE-FNZWTVRRSA-N,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1",569.6620000000004
1288,Human,Edarbi,Hypertension,azilsartan medoxomil,AZILSARTAN MEDOXOMIL,EMEA/H/C/002293,no,Authorised,C09CA09,no,no,no,no,no,no,07/12/2011,,Takeda Pharma A/S,Agents acting on the renin-angiotensin system,22/09/2011,24/02/2022,10,Edarbi is indicated for the treatment of essential hypertension in adults.,20/03/2018,17/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi,QJFSABGVXDWMIW-UHFFFAOYSA-N,"InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)",568.5420000000004
1850,Human,Ipreziv,Hypertension,azilsartan medoxomil,AZILSARTAN MEDOXOMIL,EMEA/H/C/002517,no,Withdrawn,C09CA09,yes,no,no,no,no,no,07/12/2011,,Takeda Pharma A/S,Agents acting on the renin-angiotensin system,,27/10/2014,4,Ipreziv is indicated for the treatment of essential hypertension in adults.,27/10/2014,19/12/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/ipreziv,QJFSABGVXDWMIW-UHFFFAOYSA-N,"InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)",568.5420000000004
1867,Human,Viracept,HIV Infections,nelfinavir,NELFINAVIR,EMEA/H/C/000164,no,Withdrawn,J05AE04,no,no,no,no,no,no,22/01/1998,,Roche Registration Ltd.,Antivirals for systemic use,,23/01/2013,25,"Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.",23/01/2013,10/06/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/viracept,QAGYKUNXZHXKMR-HKWSIXNMSA-N,"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1",567.7960000000004
1509,Human,Xenleta,"Pneumonia, Bacterial;  Community-Acquired Infections",lefamulin,LEFAMULIN ACETATE,EMEA/H/C/005048,no,Authorised,J01XX,yes,no,no,no,no,no,27/07/2020,,Nabriva Therapeutics Ireland DAC,"Antibacterials for systemic use, ",,23/06/2021,1,Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,06/08/2020,08/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/xenleta,WSMXIQXWHPSVDE-QALMONEZSA-N,"InChI=1S/C28H45NO5S.C2H4O2/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28;1-2(3)4/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3;1H3,(H,3,4)/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-;/m0./s1",567.7890000000002
300,Human,Exforge HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",AMLODIPINE BESILATE,EMEA/H/C/001068,no,Authorised,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",07/06/2018,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct,ZPBWCRDSRKPIDG-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)",567.0600000000002
312,Human,Dafiro HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",AMLODIPINE BESILATE,EMEA/H/C/001160,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,15/12/2022,26,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",25/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro-hct,ZPBWCRDSRKPIDG-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)",567.0600000000002
464,Human,Amlodipine  / Valsartan Mylan ,Hypertension,"amlodipine, valsartan",AMLODIPINE BESILATE,EMEA/H/C/004037,no,Authorised,C09DB01,no,yes,no,no,no,no,22/03/2016,,Mylan Pharmaceuticals Limited,Agents acting on the renin-angiotensin system,28/01/2016,14/08/2023,11,Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,26/02/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan,ZPBWCRDSRKPIDG-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)",567.0600000000002
367,Human,Steglujan,"Diabetes Mellitus, Type 2","ertugliflozin, sitagliptin",ERTUGLIFLOZIN L-PYROGLUTAMIC ACID,EMEA/H/C/004313,no,Authorised,A10BD24,no,no,no,no,no,no,23/03/2018,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,18/09/2023,11,Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.,23/08/2018,19/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/steglujan,YHIUPZFKHZTLSH-LXYIGGQGSA-N,"InChI=1S/C22H25ClO7.C5H7NO3/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22;7-4-2-1-3(6-4)5(8)9/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t18-,19-,20+,21-,22-;3-/m00/s1",566.0030000000003
703,Human,Segluromet,"Diabetes Mellitus, Type 2","ertugliflozin, metformin hydrochloride",ERTUGLIFLOZIN L-PYROGLUTAMIC ACID,EMEA/H/C/004314,no,Authorised,A10BD23,no,no,no,no,no,no,23/03/2018,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/01/2018,14/04/2023,7,Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.,26/04/2018,07/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet,YHIUPZFKHZTLSH-LXYIGGQGSA-N,"InChI=1S/C22H25ClO7.C5H7NO3/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22;7-4-2-1-3(6-4)5(8)9/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t18-,19-,20+,21-,22-;3-/m00/s1",566.0030000000003
1054,Human,Steglatro,"Diabetes Mellitus, Type 2",ertugliflozin,ERTUGLIFLOZIN L-PYROGLUTAMIC ACID,EMEA/H/C/004315,no,Authorised,A10BK04,yes,no,no,no,no,no,21/03/2018,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Sodium-glucose co-transporter 2 (SGLT2) inhibitors",25/01/2018,05/12/2022,8,Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.in addition to other medicinal products for the treatment of diabetes.,26/04/2018,06/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro,YHIUPZFKHZTLSH-LXYIGGQGSA-N,"InChI=1S/C22H25ClO7.C5H7NO3/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22;7-4-2-1-3(6-4)5(8)9/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t18-,19-,20+,21-,22-;3-/m00/s1",566.0030000000003
323,Human,Brimica Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium, formoterol fumarate dihydrate",ACLIDINIUM BROMIDE,EMEA/H/C/003969,no,Authorised,R03AL05,yes,no,no,no,no,no,19/11/2014,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",,25/09/2023,14,Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,26/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair,XLAKJQPTOJHYDR-QTQXQZBYSA-M,"InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1",564.5670000000001
1006,Human,Duaklir Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium bromide, formoterol",ACLIDINIUM BROMIDE,EMEA/H/C/003745,no,Authorised,R03AL,yes,no,no,no,no,no,19/11/2014,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",25/09/2014,09/01/2023,15,Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,11/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duaklir-genuair,XLAKJQPTOJHYDR-QTQXQZBYSA-M,"InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1",564.5670000000001
1007,Human,Eklira Genuair,"Pulmonary Disease, Chronic Obstructive",aclidinium bromide,ACLIDINIUM BROMIDE,EMEA/H/C/002211,no,Authorised,R03BB,yes,no,no,no,no,no,20/07/2012,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",,09/01/2023,20,Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,11/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair,XLAKJQPTOJHYDR-QTQXQZBYSA-M,"InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1",564.5670000000001
1017,Human,Bretaris Genuair,"Pulmonary Disease, Chronic Obstructive",aclidinium bromide,ACLIDINIUM BROMIDE,EMEA/H/C/002706,no,Authorised,R03BB,yes,no,no,no,no,no,20/07/2012,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases, ",,16/12/2022,18,Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,18/05/2018,05/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bretaris-genuair,XLAKJQPTOJHYDR-QTQXQZBYSA-M,"InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1",564.5670000000001
103,Human,Vyxeos liposomal (previously known as Vyxeos),"Leukemia, Myeloid, Acute","daunorubicin, cytarabine",DAUNORUBICIN HYDROCHLORIDE,EMEA/H/C/004282,no,Authorised,L01XY01,no,no,no,no,no,yes,23/08/2018,,Jazz Pharmaceuticals Ireland Limited,Antineoplastic agents,26/04/2018,05/06/2023,9,"Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).",29/06/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal,GUGHGUXZJWAIAS-QQYBVWGSSA-N,"InChI=1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1",563.9870000000003
1919,Human,Fablyn,"Osteoporosis, Postmenopausal",lasofoxifene,LASOFOXIFENE TARTRATE,EMEA/H/C/000977,no,Withdrawn,G03,no,no,no,no,no,no,24/02/2009,,Dr. Friedrich Eberth Arzneimittel GmbH,"Sex hormones and modulators of the genital system, ",,27/02/2012,2,"Fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. A significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).When determining the choice of Fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).",27/02/2012,21/06/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn,INEHJXCWEVNEDZ-LUDNRVPPSA-N,"InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1",563.6470000000003
0,Human,Ryeqo,Leiomyoma,"relugolix, estradiol, norethisterone acetate",ESTRADIOL HEMIHYDRATE,EMEA/H/C/005267,no,Authorised,H01CC54,yes,no,no,no,no,no,16/07/2021,,Gedeon Richter Plc.,Pituitary and hypothalamic hormones and analogues,16/07/2021,30/10/2023,6,"Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.",19/05/2021,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo,ZVVGLAMWAQMPDR-WVEWYJOQSA-N,"InChI=1S/2C18H24O2.H2O/c2*1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20;/h2*3,5,10,14-17,19-20H,2,4,6-9H2,1H3;1H2/t2*14-,15-,16+,17+,18+;/m11./s1",562.7910000000005
560,Human,Rozlytrek,"Cancer;  Carcinoma, Non-Small-Cell Lung",entrectinib,ENTRECTINIB,EMEA/H/C/004936,no,Authorised,L01EX14,yes,no,yes,no,no,no,31/07/2020,,Roche Registration GmbH ,Antineoplastic agents,28/05/2020,07/07/2023,7,"Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior NTRK inhibitorwho have no satisfactory treatment options.Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",11/09/2020,18/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek,HAYYBYPASCDWEQ-UHFFFAOYSA-N,"InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)",560.6490000000001
130,Human,Lumykras,"Carcinoma, Non-Small-Cell Lung",sotorasib,SOTORASIB,EMEA/H/C/005522,no,Authorised,L01XX73,yes,no,yes,no,no,no,06/01/2022,,Amgen Europe BV,Antineoplastic agents,11/11/2021,19/10/2023,2,Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.,10/11/2021,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras,NXQKSXLFSAEQCZ-SFHVURJKSA-N,"InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1",560.6050000000004
1305,Human,Zykadia,"Carcinoma, Non-Small-Cell Lung",ceritinib,CERITINIB,EMEA/H/C/003819,no,Authorised,L01XE,no,no,no,no,no,no,06/05/2015,,Novartis Europharm Limited,Antineoplastic agents,26/02/2015,16/02/2022,18,Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.,06/07/2018,25/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia,VERWOWGGCGHDQE-UHFFFAOYSA-N,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",558.1480000000003
1389,Human,Pixuvri,"Lymphoma, Non-Hodgkin",pixantrone dimaleate,PIXANTRONE DIMALEATE,EMEA/H/C/002055,no,Authorised,L01DB11,no,no,no,no,no,no,10/05/2012,,Les Laboratoires Servier,Antineoplastic agents,,09/11/2021,23,Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.,23/08/2018,07/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri,SVAGFBGXEWPNJC-SPIKMXEPSA-N,"InChI=1S/C17H19N5O2.2C4H4O4/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24;2*5-3(6)1-2-4(7)8/h1-3,6,9,21-22H,4-5,7-8,18-19H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-",557.5160000000003
686,Human,Nerlynx,Breast Neoplasms,neratinib,NERATINIB,EMEA/H/C/004030,no,Authorised,L01EH02,no,no,no,no,no,no,31/08/2018,,Pierre Fabre Medicament,Antineoplastic agents,28/06/2018,26/05/2023,13,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy.,31/08/2018,15/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx,JWNPDZNEKVCWMY-VQHVLOKHSA-N,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",557.0540000000003
641,Human,Multaq,Atrial Fibrillation,dronedarone,DRONEDARONE,EMEA/H/C/001043,no,Authorised,C01BD07,no,no,no,no,no,no,25/11/2009,,Sanofi Winthrop Industrie,Cardiac therapy,24/09/2009,26/06/2023,19,"Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered.Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.",13/11/2017,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0,ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,"InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3",556.7690000000005
628,Human,Koselugo,Neurofibromatosis 1,selumetinib,SELUMETINIB SULFATE,EMEA/H/C/005244,no,Authorised,,yes,no,yes,no,no,yes,17/06/2021,,AstraZeneca AB,Antineoplastic agents,22/04/2021,31/05/2023,5,"Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above",13/10/2021,03/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo,GRKFGZYYYYISDX-UHFFFAOYSA-N,"InChI=1S/C17H15BrClFN4O3.H2O4S/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19;1-5(2,3)4/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26);(H2,1,2,3,4)",555.7660000000001
28,Human,Rubraca,Ovarian Neoplasms,rucaparib,RUCAPARIB CAMSYLATE,EMEA/H/C/004272,yes,Authorised,L01XX,yes,no,no,no,no,no,23/05/2018,,pharmaand GmbH,Antineoplastic agents,06/11/2017,15/11/2023,15,"Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",24/05/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca,INBJJAFXHQQSRW-STOWLHSFSA-N,"InChI=1S/C19H18FN3O.C10H16O4S/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24);7H,3-6H2,1-2H3,(H,12,13,14)/t;7-,10-/m.1/s1",555.6720000000003
104,Human,Kisqali,Breast Neoplasms,ribociclib,RIBOCICLIB SUCCINATE,EMEA/H/C/004213,no,Authorised,L01XE,no,no,no,no,no,no,22/08/2017,,Novartis Europharm Limited,Antineoplastic agents,22/06/2017,10/08/2023,14,"Kisqali is indicated for the treatment of women with hormone receptor (HR)?positive, human epidermal growth factor receptor 2 (HER2)?negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre? or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone?releasing hormone (LHRH) agonist.",22/08/2017,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali,NHANOMFABJQAAH-UHFFFAOYSA-N,"InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)",552.6360000000004
940,Human,Rasilez,Hypertension,aliskiren,ALISKIREN,EMEA/H/C/000780,no,Authorised,C09XA02,no,no,no,no,no,no,22/08/2007,,Noden Pharma DAC,Agents acting on the renin-angiotensin system,,23/02/2023,27,Treatment of essential hypertension.,04/05/2018,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1242,Human,Rasilez HCT,Hypertension,"aliskiren, hydrochlorothiazide",ALISKIREN,EMEA/H/C/000964,no,Withdrawn,C09XA52,no,no,no,no,no,no,16/01/2009,,Noden Pharma DAC,Agents acting on the renin-angiotensin system,,20/12/2021,17,"Treatment of essential hypertension in adults.Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",27/08/2018,20/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1801,Human,Rasilamlo,Hypertension,"aliskiren hemifumarate, amlodipine besilate",ALISKIREN,EMEA/H/C/002073,no,Withdrawn,C09XA53,no,no,no,no,no,no,14/04/2011,,Novartis Europharm Ltd,Agents acting on the renin-angiotensin system,,25/06/2015,7,Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.,25/06/2015,28/03/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilamlo,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1896,Human,Riprazo,Hypertension,aliskiren,ALISKIREN,EMEA/H/C/000853,no,Withdrawn,C09XA02,no,no,no,no,no,no,22/08/2007,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,17/08/2012,8,Treatment of essential hypertension.,17/08/2012,01/03/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/riprazo,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1903,Human,Rasitrio,Hypertension,"aliskiren, amlodipine, hydrochlorothiazide",ALISKIREN,EMEA/H/C/002017,no,Withdrawn,C09XA54,no,no,no,no,no,no,22/11/2011,,Novartis Europharm Ltd.,Cardiovascular system,,03/10/2013,1,"Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.",03/10/2013,20/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/rasitrio,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1904,Human,Riprazo HCT ,Hypertension,"aliskiren, hydrochlorothiazide",ALISKIREN,EMEA/H/C/002420,no,Withdrawn,C09XA52,no,no,no,no,no,no,13/04/2011,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,30/08/2012,0,"Treatment of essential hypertension in adults.Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",30/08/2012,20/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/riprazo-hct,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1905,Human,Sprimeo HCT,Hypertension,"aliskiren, hydrochlorothiazide",ALISKIREN,EMEA/H/C/002421,no,Withdrawn,C09XA52,no,no,no,no,no,no,23/06/2011,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,06/07/2012,0,"Treatment of essential hypertension in adults.Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",06/07/2012,28/08/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/sprimeo-hct,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1917,Human,Sprimeo,Hypertension,aliskiren,ALISKIREN,EMEA/H/C/000851,no,Withdrawn,C09XA02,no,no,no,no,no,no,22/08/2007,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,04/07/2012,5,Treatment of essential hypertension.,04/07/2012,23/07/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/sprimeo,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1938,Human,Enviage,Hypertension,aliskiren,ALISKIREN,EMEA/H/C/000850,no,Withdrawn,C09XA02,no,no,no,no,no,no,22/08/2007,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,22/04/2009,4,Treatment of essential hypertension,22/04/2009,19/05/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/enviage,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
1974,Human,Tekturna,Hypertension,aliskiren,ALISKIREN,EMEA/H/C/000852,no,Withdrawn,C09XA02,no,no,no,no,no,no,22/08/2007,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,22/04/2009,4,Treatment of essential hypertension,22/04/2009,25/09/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/tekturna,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",551.7690000000002
97,Human,Rezolsta,HIV Infections,"darunavir, cobicistat",DARUNAVIR,EMEA/H/C/002819,no,Authorised,J05,no,no,no,no,no,no,19/11/2014,,Janssen-Cilag International N.V.,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,22/06/2023,16,"Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older.Genotypic testing should guide the use of Rezolsta.",29/06/2018,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
759,Human,Darunavir Mylan,HIV Infections,darunavir,DARUNAVIR,EMEA/H/C/004068,no,Authorised,J05AE10,no,yes,no,no,no,no,03/01/2017,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,14/09/2016,12/05/2023,13,"Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2). Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ? 100 cells x 10?/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).",12/07/2018,23/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-mylan,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
775,Human,Darunavir Krka,HIV Infections,darunavir,DARUNAVIR,EMEA/H/C/004273,no,Authorised,J05AE10,no,yes,no,no,no,no,26/01/2018,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,09/11/2017,12/05/2023,10,"400 and 800 mgDarunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART)-naïve (see section 4.2).ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ? 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).600 mg Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.",13/06/2018,15/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-krka,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
897,Human,Symtuza,HIV Infections,"darunavir, cobicistat, emtricitabine, tenofovir alafenamide",DARUNAVIR,EMEA/H/C/004391,no,Authorised,J05,no,no,no,no,no,no,21/09/2017,,Janssen-Cilag International NV,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",19/07/2017,07/03/2023,17,Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).Genotypic testing should guide the use of Symtuza.,06/07/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
923,Human,Prezista,HIV Infections,darunavir,DARUNAVIR,EMEA/H/C/000707,no,Authorised,J05AE10,no,no,no,no,no,no,11/02/2007,,Janssen-Cilag International NV,Antivirals for systemic use,14/12/2006,10/11/2022,54,"PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).In deciding to initiate treatment with PREZISTA co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:For the treatment of HIV 1 infection in antiretroviral treatment (ART) experienced adult patients, including those that have been highly pre treated.For the treatment of HIV 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with PREZISTA co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).PREZISTA 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART) naïve.ART experienced with no darunavir resistance associated mutations (DRV RAMs) and who have plasma HIV 1 RNA < 100,000 copies/ml and CD4+ cell count ? 100 cells x 106/L. In deciding to initiate treatment with PREZISTA in such ART experienced patients, genotypic testing should guide the use of PREZISTA.",06/07/2018,03/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/prezista,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
976,Human,Darunavir Krka d.d.,HIV Infections,darunavir,DARUNAVIR,EMEA/H/C/004891,no,Withdrawn,J05AE10,no,yes,no,no,no,no,18/01/2018,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,,22/01/2023,8,"400mg and 800 mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d., co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection in adult patients (see section 4.2).Darunavir Krka d.d. 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART)-naïve (see section 4.2).ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ? 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).600mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d. 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.",13/06/2018,03/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-krka-dd,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",547.6740000000002
102,Human,Tepmetko,"Carcinoma, Non-Small-Cell Lung",tepotinib,TEPOTINIB HYDROCHLORIDE MONOHYDRATE,EMEA/H/C/005524,no,Authorised,L01EX21,yes,no,no,no,no,no,16/02/2022,,Merck Europe B.V.,Antineoplastic agents,16/12/2021,31/08/2023,2,"Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",05/05/2022,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko,KZVOMLRKFJUTLK-UHFFFAOYSA-N,"InChI=1S/C29H28N6O2.ClH.H2O/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30;;/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3;1H;1H2",547.0590000000003
530,Human,Jyseleca,"Arthritis, Rheumatoid",filgotinib,FILGOTINIB MALEATE,EMEA/H/C/005113,yes,Authorised,L04AA45,yes,no,no,no,no,no,24/09/2020,,"Gilead Sciences Ireland UC, Galapagos NV",Immunosuppressants,23/07/2020,29/05/2023,10,"Rheumatoid arthritisJyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).Ulcerative colitisJyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.",26/05/2020,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca,BFENHEAPFWQJFL-BTJKTKAUSA-N,"InChI=1S/C21H23N5O3S.C4H4O4/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25;5-3(6)1-2-4(7)8/h1-7,17H,8-14H2,(H,23,24,27);1-2H,(H,5,6)(H,7,8)/b;2-1-",541.5860000000001
1172,Human,Braftovi,Melanoma;  Colorectal Neoplasms,encorafenib,ENCORAFENIB,EMEA/H/C/004580,no,Authorised,L01EC03,no,no,no,no,no,no,19/09/2018,,Pierre Fabre Medicament,Antineoplastic agents,26/07/2018,23/06/2023,11,"Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy",27/07/2018,05/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,"InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1",540.0210000000001
135,Human,Vargatef,"Carcinoma, Non-Small-Cell Lung",nintedanib,NINTEDANIB,EMEA/H/C/002569,no,Authorised,L01XE3,no,no,no,no,no,no,21/11/2014,,Boehringer Ingelheim International GmbH,Antineoplastic agents,25/09/2014,23/08/2023,18,"Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.",26/07/2018,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef,XZXHXSATPCNXJR-ZIADKAODSA-N,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",539.6360000000003
507,Human,Ofev,Idiopathic Pulmonary Fibrosis,nintedanib,NINTEDANIB,EMEA/H/C/003821,no,Authorised,L01XE,no,no,no,no,yes,no,14/01/2015,,Boehringer Ingelheim International GmbH,Antineoplastic agents,20/11/2014,28/07/2023,24,Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).,26/07/2018,01/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ofev,XZXHXSATPCNXJR-ZIADKAODSA-N,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",539.6360000000003
157,Human,Relvar Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, vilanterol",FLUTICASONE FUROATE,EMEA/H/C/002673,no,Authorised,R03AK10,no,no,no,no,no,no,13/11/2013,,GlaxoSmithKline (Ireland) Limited,Adrenergics and other drugs for obstructive airway diseases,19/09/2013,06/07/2023,25,"Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 ",26/07/2018,08/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
191,Human,Trelegy Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",FLUTICASONE FUROATE,EMEA/H/C/004363,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,11,Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
194,Human,Elebrato Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",FLUTICASONE FUROATE,EMEA/H/C/004781,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,12,Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/elebrato-ellipta,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
418,Human,Revinty Ellipta,Asthma,"fluticasone furoate, vilanterol",FLUTICASONE FUROATE,EMEA/H/C/002745,no,Authorised,R03AK10,no,no,no,no,no,no,02/05/2014,,GlaxoSmithKline (Ireland) Limited,Adrenergics and other drugs for obstructive airway diseases,20/03/2014,06/07/2023,22,"Asthma IndicationRevinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.COPD IndicationRevinty Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 ",21/08/2018,04/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/revinty-ellipta,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
1069,Human,Temybric Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",FLUTICASONE FUROATE,EMEA/H/C/005254,no,Withdrawn,R03AL08,yes,no,no,no,no,no,12/06/2019,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",,11/12/2021,4,Temybric Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist or a combination of a long-acting ?2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).,23/09/2019,24/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
1278,Human,Avamys,"Rhinitis, Allergic, Seasonal;  Rhinitis, Allergic, Perennial",fluticasone furoate,FLUTICASONE FUROATE,EMEA/H/C/000770,no,Authorised,R01AD12,no,no,no,no,no,no,11/01/2008,,GlaxoSmithKline (Ireland) Limited,"Nasal preparations, Corticosteroids",,10/09/2021,22,"Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.",18/08/2017,29/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/avamys,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
1932,Human,Alisade,"Rhinitis, Allergic, Perennial;  Rhinitis, Allergic, Seasonal",fluticasone furoate,FLUTICASONE FUROATE,EMEA/H/C/001019,no,Withdrawn,R01AD12,no,no,no,no,no,no,06/10/2008,,Glaxo Group Ltd.,Nasal preparations,,17/02/2010,4,"Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.",17/02/2010,18/10/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/alisade,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",538.5840000000002
42,Human,Pepaxti,Multiple Myeloma,melphalan flufenamide,MELPHALAN FLUFENAMIDE HYDROCHLORIDE,EMEA/H/C/005681,no,Authorised,L01AA10,no,no,no,no,no,no,17/08/2022,,Oncopeptides AB,Antineoplastic agents,,27/11/2023,3,"Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).",21/06/2022,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pepaxti,ZCMWSKHHXLCVHI-VROPFNGYSA-N,"InChI=1S/C24H30Cl2FN3O3.ClH/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26;/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31);1H/t21-,22-;/m0./s1",534.8870000000001
706,Human,Vydura,Migraine Disorders,rimegepant,RIMEGEPANT,EMEA/H/C/005725,no,Authorised,N02CD06,yes,no,no,no,no,no,25/04/2022,,Pfizer Europe MA EEIG ,"Antimigraine preparations, calcitonin gene-related peptide (CGRP) antagonists",24/02/2022,02/06/2023,5,Vydura is indicated for theAcute treatment of migraine with or without aura in adults;Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.,22/02/2022,05/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vydura,KRNAOFGYEFKHPB-ANJVHQHFSA-N,"InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1",534.5670000000001
1201,Human,Emadine,"Conjunctivitis, Allergic",emedastine,EMEDASTINE DIFUMARATE,EMEA/H/C/000223,no,Authorised,S01GX06,no,no,no,no,no,no,27/01/1999,,Immedica Pharma AB,Ophthalmologicals,,12/12/2022,26,Symptomatic treatment of seasonal allergic conjunctivitis.,23/04/2018,10/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/emadine,FWLKKPKZQYVAFR-LVEZLNDCSA-N,"InChI=1S/C17H26N4O.2C4H4O4/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20;2*5-3(6)1-2-4(7)8/h4-5,7-8H,3,6,9-14H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+",534.5660000000003
472,Human,Deltyba,"Tuberculosis, Multidrug-Resistant",delamanid,DELAMANID,EMEA/H/C/002552,no,Authorised,J04AK06,yes,no,yes,no,no,yes,27/04/2014,25/07/2013,Otsuka Novel Products GmbH,Antimycobacterials,21/11/2013,06/07/2023,25,"Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",11/06/2018,14/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba,XDAOLTSRNUSPPH-XMMPIXPASA-N,"InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1",534.4910000000001
798,Human,Emend,Vomiting;  Postoperative Nausea and Vomiting;  Cancer,aprepitant,APREPITANT,EMEA/H/C/000527,no,Authorised,A04AD12,no,no,no,no,no,no,11/11/2003,,Merck Sharp & Dohme B.V.,"Antiemetics and antinauseants, ",24/07/2003,29/08/2022,30,"Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.",24/05/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emend,ATALOFNDEOCMKK-OITMNORJSA-N,"InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1",534.432
1060,Human,Iclusig,"Leukemia, Myeloid;  Leukemia, Lymphoid",ponatinib,PONATINIB,EMEA/H/C/002695,no,Authorised,L01EA05,no,no,no,no,yes,no,01/07/2013,,Incyte Biosciences Distribution B.V.,"Antineoplastic agents, Protein kinase inhibitors",,20/10/2022,25,"Iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutationPhiladelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.See sections 4.2 Assessment of cardiovascular status prior to start of therapy and 4.4 situations where an alternative treatment may be considered.",04/06/2018,30/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig,PHXJVRSECIGDHY-UHFFFAOYSA-N,"InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",532.5700000000002
1215,Human,Prasugrel Mylan,"Myocardial Infarction;  Acute Coronary Syndrome;  Angina, Unstable",prasugrel,PRASUGREL BESILATE,EMEA/H/C/004644,no,Authorised,B01AC22,no,yes,no,no,no,no,15/05/2018,,Mylan Pharmaceuticals Limited,Antithrombotic agents,,25/05/2022,8,"Prasugrel Mylan, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).",16/05/2018,28/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/prasugrel-mylan,UFXQKLQPHZRPDV-UHFFFAOYSA-N,"InChI=1S/C20H20FNO3S.C6H6O3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21;7-10(8,9)6-4-2-1-3-5-6/h2-5,10,13,19H,6-9,11H2,1H3;1-5H,(H,7,8,9)",531.6270000000002
1522,Human,Ketoconazole HRA,Cushing Syndrome,ketoconazole,KETOCONAZOLE,EMEA/H/C/003906,no,Authorised,J02AB02,yes,no,no,no,yes,yes,18/11/2014,,HRA Pharma Rare Diseases,Antimycotics for systemic use,,20/04/2021,10,Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.,22/08/2017,07/06/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ketoconazole-hra,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,"InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m1/s1",531.4400000000002
807,Human,Ravicti,"Urea Cycle Disorders, Inborn",glycerol phenylbutyrate,GLYCEROL PHENYLBUTYRATE,EMEA/H/C/003822,no,Authorised,A16AX09,no,no,no,no,no,yes,26/11/2015,,Immedica Pharma AB,"Other alimentary tract and metabolism products, ",23/09/2015,09/02/2023,16,"Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).",23/05/2018,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti,ZSDBFLMJVAGKOU-UHFFFAOYSA-N,"InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2",530.6610000000005
69,Human,Tasigna,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",nilotinib,NILOTINIB,EMEA/H/C/000798,no,Authorised,L01EA03,no,no,no,no,no,no,19/11/2007,,Novartis Europharm Limited,Antineoplastic agents,,24/11/2023,45,"Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",15/11/2017,27/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna,HHZIURLSWUIHRB-UHFFFAOYSA-N,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",529.5260000000002
316,Human,Sovaldi,"Hepatitis C, Chronic",sofosbuvir,SOFOSBUVIR,EMEA/H/C/002798,no,Authorised,J05AX15,no,no,no,no,yes,no,16/01/2014,,Gilead Sciences Ireland UC,Antivirals for systemic use,21/11/2013,12/01/2023,28,"Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.",06/08/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi,TTZHDVOVKQGIBA-IQWMDFIBSA-N,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1",529.4580000000002
318,Human,Harvoni,"Hepatitis C, Chronic","ledispavir, sofosbuvir",SOFOSBUVIR,EMEA/H/C/003850,no,Authorised,J05AX65,no,no,no,no,yes,no,17/11/2014,,Gilead Sciences Ireland UC,Antivirals for systemic use,,12/01/2023,28,"Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",07/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni,TTZHDVOVKQGIBA-IQWMDFIBSA-N,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1",529.4580000000002
319,Human,Epclusa,"Hepatitis C, Chronic","sofosbuvir, velpatasvir",SOFOSBUVIR,EMEA/H/C/004210,no,Authorised,J05A,no,no,no,no,yes,no,06/07/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,26/05/2016,07/08/2023,22,"Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).",14/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa,TTZHDVOVKQGIBA-IQWMDFIBSA-N,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1",529.4580000000002
225,Human,Instanyl,Pain;  Cancer,fentanyl,FENTANYL CITRATE,EMEA/H/C/000959,no,Authorised,N02AB03,no,no,no,no,no,no,20/07/2009,,Takeda Pharma A/S,Analgesics,,14/09/2023,36,"Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.",08/05/2018,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/instanyl,IVLVTNPOHDFFCJ-UHFFFAOYSA-N,"InChI=1S/C22H28N2O.C6H8O7/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-12,21H,2,13-18H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",528.6020000000003
1009,Human,Toviaz,"Urinary Bladder, Overactive",fesoterodine,FESOTERODINE FUMARATE,EMEA/H/C/000723,no,Authorised,G04BD11,no,no,no,no,no,no,20/04/2007,,Pfizer Europe MA EEIG,Urologicals,,10/01/2023,27,Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.,30/07/2018,11/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz,MWHXMIASLKXGBU-RNCYCKTQSA-N,"InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1",527.6580000000004
352,Human,Vitrakvi,Abdominal Neoplasms,larotrectinib,LAROTRECTINIB SULFATE,EMEA/H/C/004919,no,Authorised,L01XE53,yes,no,yes,no,no,no,19/09/2019,,Bayer AG,Antineoplastic agents,25/07/2019,16/08/2023,10,"Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have no satisfactory treatment options.",24/10/2019,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi,PXHANKVTFWSDSG-QLOBERJESA-N,"InChI=1S/C21H22F2N6O2.H2O4S/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27;1-5(2,3)4/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31);(H2,1,2,3,4)/t14-,18+;/m0./s1",526.522
350,Human,Retsevmo,"Carcinoma, Non-Small-Cell Lung;  Thyroid Neoplasms",selpercatinib,SELPERCATINIB,EMEA/H/C/005375,no,Authorised,L01EX22,yes,no,yes,no,no,no,11/02/2021,,Eli Lilly Nederland B.V.,Antineoplastic agents,10/12/2020,16/08/2023,8,Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment,23/04/2021,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo,XIIOFHFUYBLOLW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3",525.6130000000002
367,Human,Steglujan,"Diabetes Mellitus, Type 2","ertugliflozin, sitagliptin",SITAGLIPTIN PHOSPHATE MONOHYDRATE,EMEA/H/C/004313,no,Authorised,A10BD24,no,no,no,no,no,no,23/03/2018,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,18/09/2023,11,Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.,23/08/2018,19/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/steglujan,GQPYTJVDPQTBQC-KLQYNRQASA-N,"InChI=1S/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4;/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4);1H2/t9-;;/m1../s1",523.327
541,Human,Kisplyx,"Carcinoma, Renal Cell",lenvatinib,LENVATINIB MESILATE,EMEA/H/C/004224,no,Authorised,L01XE29,no,no,no,no,yes,no,25/08/2016,,Eisai GmbH,Antineoplastic agents,21/07/2016,25/07/2023,20,"Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.",21/06/2018,25/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx,HWLFIUUAYLEFCT-UHFFFAOYSA-N,"InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)",522.9670000000001
542,Human,Lenvima,Thyroid Neoplasms,lenvatinib,LENVATINIB MESILATE,EMEA/H/C/003727,no,Authorised,L01XE,yes,no,no,no,yes,no,28/05/2015,,Eisai GmbH,Antineoplastic agents,26/03/2015,25/07/2023,19,"Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.",21/06/2018,25/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima,HWLFIUUAYLEFCT-UHFFFAOYSA-N,"InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)",522.9670000000001
498,Human,Brilique,Peripheral Vascular Diseases;  Acute Coronary Syndrome,ticagrelor,TICAGRELOR,EMEA/H/C/001241,no,Authorised,B01AC24,no,no,no,no,no,no,03/12/2010,,AstraZeneca AB,Antithrombotic agents,,12/06/2023,21,"Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (ACS) ora history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventBrilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.",18/05/2017,03/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/brilique,OEKWJQXRCDYSHL-FNOIDJSQSA-N,"InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1",522.5780000000001
1891,Human,Possia,Peripheral Vascular Diseases;  Acute Coronary Syndrome,ticagrelor,TICAGRELOR,EMEA/H/C/002303,no,Withdrawn,B01AC24,no,no,no,no,no,no,03/12/2010,,AstraZeneca AB,Antithrombotic agents,,24/10/2012,2,"Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).",24/10/2012,22/04/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/possia,OEKWJQXRCDYSHL-FNOIDJSQSA-N,"InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1",522.5780000000001
241,Human,Atectura Breezhaler,Asthma,"indacaterol, mometasone",MOMETASONE FUROATE,EMEA/H/C/005067,no,Authorised,R03AK,no,no,no,no,no,no,30/05/2020,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",26/03/2020,07/09/2023,9,Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.,23/06/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/atectura-breezhaler,WOFMFGQZHJDGCX-ZULDAHANSA-N,"InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1",521.4370000000001
245,Human,Bemrist Breezhaler,Asthma,"indacaterol, mometasone",MOMETASONE FUROATE,EMEA/H/C/005516,no,Authorised,R03AK,no,no,no,no,no,no,30/05/2020,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",26/03/2020,07/09/2023,6,Bemrist Breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.,24/06/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bemrist-breezhaler,WOFMFGQZHJDGCX-ZULDAHANSA-N,"InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1",521.4370000000001
988,Human,Sitagliptin / Metformin hydrochloride Sun,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",SITAGLIPTIN FUMARATE,EMEA/H/C/005778,no,Authorised,A10BD07,no,yes,no,no,no,no,31/03/2023,,Sun Pharmaceutical Industries Europe B.V.,Drugs used in diabetes,26/01/2023,31/03/2023,,"For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",24/01/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-sun,YRKLLQIZVVYDQY-OIJPFUDISA-L,"InChI=1S/C16H15F6N5O.C4H4O4/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;5-3(6)1-2-4(7)8/h4,6,9H,1-3,5,7,23H2;1-2H,(H,5,6)(H,7,8)/p-2/b;2-1+/t9-;/m1./s1",521.3740000000001
1103,Human,Sitagliptin SUN,"Diabetes Mellitus, Type 2",sitagliptin fumarate,SITAGLIPTIN FUMARATE,EMEA/H/C/005741,no,Authorised,A10BH01,no,yes,no,no,no,no,09/12/2021,,Sun Pharmaceutical Industries Europe B.V.,Drugs used in diabetes,14/10/2021,08/07/2022,1,"For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Sitagliptin SUN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",12/10/2021,27/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-sun,YRKLLQIZVVYDQY-OIJPFUDISA-L,"InChI=1S/C16H15F6N5O.C4H4O4/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;5-3(6)1-2-4(7)8/h4,6,9H,1-3,5,7,23H2;1-2H,(H,5,6)(H,7,8)/p-2/b;2-1+/t9-;/m1./s1",521.3740000000001
623,Human,Trydonis,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",BECLOMETASONE DIPROPIONATE,EMEA/H/C/004702,no,Authorised,R03AL09,no,no,no,no,no,no,26/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,02/12/2022,5,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,26/04/2018,04/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis,KUVIULQEHSCUHY-XYWKZLDCSA-N,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",521.0500000000002
630,Human,Trimbow,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",BECLOMETASONE DIPROPIONATE,EMEA/H/C/004257,no,Authorised,R03AL09,no,no,no,no,no,no,17/07/2017,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",18/05/2017,24/03/2022,7,"Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. ",17/07/2017,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow,KUVIULQEHSCUHY-XYWKZLDCSA-N,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",521.0500000000002
631,Human,Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol",BECLOMETASONE DIPROPIONATE,EMEA/H/C/004836,no,Authorised,R03AL09,no,no,no,no,no,no,23/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,09/12/2022,4,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,23/04/2018,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riarify,KUVIULQEHSCUHY-XYWKZLDCSA-N,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",521.0500000000002
80,Human,Symkevi,Cystic Fibrosis,"tezacaftor, ivacaftor",TEZACAFTOR,EMEA/H/C/004682,no,Authorised,R07AX31,no,no,no,no,no,yes,31/10/2018,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,27/06/2018,23/08/2023,12,"Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F, R1070W, D1152H, 2789+5G?A, 3272 26A?G, and 3849+10kbC?T.",22/11/2018,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi,MJUVRTYWUMPBTR-MRXNPFEDSA-N,"InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1",520.5040000000001
534,Human,Kaftrio,Cystic Fibrosis,"ivacaftor, tezacaftor, elexacaftor",TEZACAFTOR,EMEA/H/C/005269,no,Authorised,R07AX32,yes,no,no,no,no,yes,21/08/2020,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,25/06/2020,07/07/2023,15,Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,21/08/2020,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio,MJUVRTYWUMPBTR-MRXNPFEDSA-N,"InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1",520.5040000000001
1749,Human,Victrelis,"Hepatitis C, Chronic",boceprevir,BOCEPREVIR,EMEA/H/C/002332,no,Withdrawn,J05AE,no,no,no,no,no,no,18/07/2011,,Merck Sharp  Dohme Ltd,Antivirals for systemic use,,29/06/2017,22,"Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.",29/06/2017,31/07/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis,LHHCSNFAOIFYRV-DOVBMPENSA-N,"InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1",519.6870000000002
1138,Human,Tenofovir disoproxil Mylan,HIV Infections,tenofovir disoproxil,TENOFOVIR DISOPROXIL,EMEA/H/C/004049,no,Authorised,J05AF07,no,yes,no,no,no,no,08/12/2016,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,13/10/2016,06/06/2023,18,"HIV-1 infectionTenofovir disoproxil 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.In adults, the demonstration of the benefit of tenofovir disoproxil in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Tenofovir disoproxil 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionTenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.evidence of lamivudine-resistant hepatitis B virus.decompensated liver disease.Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.",27/11/2017,20/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-mylan,JFVZFKDSXNQEJW-CQSZACIVSA-N,"InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1",519.4480000000002
867,Human,Alecensa,"Carcinoma, Non-Small-Cell Lung",alectinib,ALECTINIB HYDROCHLORIDE,EMEA/H/C/004164,no,Authorised,L01ED03,yes,no,no,no,no,no,16/02/2017,,Roche Registration GmbH,Antineoplastic agents,15/12/2016,15/03/2023,14,Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).Alecensa as monotherapy is indicated for the treatment of adult patients with ALK?positive advanced NSCLC previously treated with crizotinib.,09/08/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa,GYABBVHSRIHYJR-UHFFFAOYSA-N,"InChI=1S/C30H34N4O2.ClH/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29;/h5-6,15-17,21,32H,4,7-14H2,1-3H3;1H",519.0890000000003
98,Human,Ninlaro,Multiple Myeloma,ixazomib,IXAZOMIB CITRATE,EMEA/H/C/003844,no,Authorised,L01XG03,no,no,no,no,no,yes,21/11/2016,,Takeda Pharma A/S,Antineoplastic agents,15/09/2016,03/11/2023,17,Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.,17/09/2018,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro,MBOMYENWWXQSNW-AWEZNQCLSA-N,"InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1",517.1270000000002
835,Human,Exviera,"Hepatitis C, Chronic",dasabuvir,DASABUVIR SODIUM,EMEA/H/C/003837,no,Authorised,J05AP09,no,no,no,no,yes,no,14/01/2015,,AbbVie Ltd,Antivirals for systemic use,20/11/2004,12/08/2022,26,Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.,10/04/2018,13/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exviera,XHGMJAKIIJSQMF-UHFFFAOYSA-M,"InChI=1S/C26H27N3O5S.Na/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18;/h6-15,28H,1-5H3,(H,27,30,31);/q;+1/p-1",515.5670000000002
210,Human,Actelsar HCT,Essential Hypertension,"telmisartan, hydrochlorothiazide",TELMISARTAN,EMEA/H/C/002676,no,Authorised,C09DA07,no,yes,no,no,no,no,13/03/2013,,Actavis Group hf,"Agents acting on the renin-angiotensin system, Angiotensin II antagonists and diuretics",17/01/2013,23/10/2023,17,Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. ,19/06/2018,24/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
211,Human,Telmisartan Actavis,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/001168,no,Authorised,C09CA07,no,yes,no,no,no,no,29/09/2010,,Actavis Group PTC ehf,Agents acting on the renin-angiotensin system,24/06/2010,23/10/2023,13,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.",21/08/2018,24/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
448,Human,Tolucombi,Hypertension,"telmisartan, hydrochlorothiazide",TELMISARTAN,EMEA/H/C/002549,no,Authorised,C09DA07,no,yes,no,no,no,no,13/03/2013,,"Krka, d.d., Novo mesto",telmisartan and diuretics,17/01/2013,14/08/2023,11,Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.,14/02/2018,24/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tolucombi,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
588,Human,Twynsta,Hypertension,"telmisartan, amlodipine",TELMISARTAN,EMEA/H/C/001224,no,Authorised,C09DB04,no,no,no,no,no,no,07/10/2010,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,11/07/2023,13,Treatment of essential hypertension in adults:Add-on therapyTwynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.,22/05/2018,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/twynsta,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
891,Human,MicardisPlus,Hypertension,,TELMISARTAN,EMEA/H/C/000413,no,Authorised,C09DA07,no,no,no,no,no,no,19/04/2002,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,31/10/2022,33,"Treatment of essential hypertension.MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",06/04/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/micardisplus,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
950,Human,Tolura,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/001196,no,Authorised,C09CA07,no,yes,no,no,no,no,04/06/2010,,"Krka, d.d., Novo mesto ","Angiotensin II antagonists, plain",18/03/2010,26/01/2023,11,HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.,19/02/2018,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tolura,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1100,Human,Micardis,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/000209,no,Authorised,C09CA07,no,no,no,no,no,no,16/12/1998,,Boehringer Ingelheim International GmbH,"Angiotensin II antagonists, plain",,31/10/2022,27,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",22/05/2018,03/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/micardis,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1141,Human,PritorPlus,Hypertension,"telmisartan, hydrochlorothiazide",TELMISARTAN,EMEA/H/C/000414,no,Authorised,C09DA07,no,no,no,no,no,no,22/04/2002,,Bayer AG,Agents acting on the renin-angiotensin system,,24/08/2022,37,"Treatment of essential hypertension.PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",13/04/2018,14/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pritorplus,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1142,Human,Kinzalkomb,Hypertension,"telmisartan, hydrochlorothiazide",TELMISARTAN,EMEA/H/C/000415,no,Authorised,C09DA07,no,no,no,no,no,no,19/04/2002,,Bayer AG,Agents acting on the renin-angiotensin system,,24/08/2022,39,"Treatment of essential hypertension.Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",12/04/2018,14/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalkomb,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1423,Human,Telmisartan Teva Pharma,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/002511,no,Authorised,C09CA07,no,yes,no,no,no,no,03/10/2011,,Teva B.V.,Agents acting on the renin-angiotensin system,21/07/2011,08/10/2021,10,Treatment of essential hypertension in adults.,09/06/2016,26/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva-pharma,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1462,Human,Telmisartan Teva,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/001146,no,Withdrawn,C09CA07,no,yes,no,no,no,no,25/01/2010,,Teva B.V.,Agents acting on the renin-angiotensin system,19/11/2009,09/02/2021,11,Treatment of essential hypertension in adults,25/07/2018,17/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1590,Human,Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG),Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/000211,no,Authorised,C09CA07,no,no,no,no,no,no,16/12/1998,,Bayer AG,Agents acting on the renin-angiotensin system,23/07/1998,26/11/2020,30,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",04/04/2018,18/12/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1593,Human,Pritor,Hypertension,telmisartan,TELMISARTAN,EMEA/H/C/000210,no,Authorised,C09CA07,no,no,no,no,no,no,11/12/1998,,Bayer AG,Agents acting on the renin-angiotensin system,23/07/1998,26/11/2020,29,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",13/04/2018,10/12/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/pritor,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1872,Human,Onduarp,Hypertension,"telmisartan, amlodipine",TELMISARTAN,EMEA/H/C/002118,no,Withdrawn,C09DB04,no,no,no,no,no,no,24/11/2011,,Boehringer Ingelheim International GmbH,Cardiovascular system,,17/02/2014,2,Treatment of essential hypertension in adults:Add on therapyOnduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.,17/02/2014,02/04/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/onduarp,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",514.6290000000005
1644,Human,Osseor,"Osteoporosis, Postmenopausal",strontium ranelate,STRONTIUM RANELATE,EMEA/H/C/000561,no,Withdrawn,M05BX03,no,no,no,no,no,no,20/09/2004,,Les Laboratoires Servier,Drugs for treatment of bone diseases,,22/05/2018,19,Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures.Treatment of severe osteoporosis in adult men at increased risk of fracture.The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.,15/09/2016,19/05/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/osseor,XXUZFRDUEGQHOV-UHFFFAOYSA-J,"InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4",513.493
1645,Human,Protelos,"Osteoporosis, Postmenopausal",strontium ranelate,STRONTIUM RANELATE,EMEA/H/C/000560,no,Withdrawn,M05BX03,no,no,no,no,no,no,20/09/2004,,Les Laboratoires Servier,Drugs for treatment of bone diseases,,22/05/2018,19,"Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures., , Treatment of severe osteoporosis in adult men at increased risk of fracture., , The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks., ",15/09/2016,15/05/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/protelos,XXUZFRDUEGQHOV-UHFFFAOYSA-J,"InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4",513.493
710,Human,Akeega,"Prostatic Neoplasms, Castration-Resistant","niraparib, abiraterone acetate",NIRAPARIB TOSILATE MONOHYDRATE,EMEA/H/C/005932,no,Authorised,L01,no,no,no,no,no,no,19/04/2023,,Janssen-Cilag International N.V.,Antineoplastic agents,23/02/2023,19/04/2023,,Treatment of adult patients with prostate cancer.,02/06/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/akeega,ACNPUCQQZDAPJH-FMOMHUKBSA-N,"InChI=1S/C19H20N4O.C7H8O3S.H2O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10;/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10);1H2/t14-;;/m1../s1",510.6160000000001
426,Human,Qinlock,Gastrointestinal Stromal Tumors,ripretinib,RIPRETINIB,EMEA/H/C/005614,no,Authorised,L01,yes,no,no,no,no,yes,18/11/2021,,Deciphera Pharmaceuticals (Netherlands) B.V.,Antineoplastic agents,16/09/2021,21/06/2023,5,"Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.",23/11/2021,30/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock,CEFJVGZHQAGLHS-UHFFFAOYSA-N,"InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)",510.3670000000001
982,Human,Optruma,"Osteoporosis, Postmenopausal",raloxifene,RALOXIFENE HYDROCHLORIDE,EMEA/H/C/000185,no,Authorised,G03XC01,no,no,no,no,no,no,05/08/1998,,Eli Lilly Nederland B.V.,"Sex hormones and modulators of the genital system, ",,23/01/2023,26,"Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).",03/08/2017,30/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/optruma,BKXVVCILCIUCLG-UHFFFAOYSA-N,"InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H",510.05500000000023
1236,Human,Evista,"Osteoporosis, Postmenopausal",raloxifene,RALOXIFENE HYDROCHLORIDE,EMEA/H/C/000184,no,Authorised,G03XC01,no,no,no,no,no,no,05/08/1998,,Substipharm,"Sex hormones and modulators of the genital system, ",22/04/1998,02/06/2022,30,"Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.",17/11/2017,07/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/evista,BKXVVCILCIUCLG-UHFFFAOYSA-N,"InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H",510.05500000000023
1450,Human,Raloxifene Teva,"Osteoporosis, Postmenopausal",raloxifene,RALOXIFENE HYDROCHLORIDE,EMEA/H/C/001075,no,Authorised,G03XC01,no,yes,no,no,no,no,29/04/2010,,Teva B.V.,"Sex hormones and modulators of the genital system, ",18/02/2010,08/09/2021,10,"Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.",07/09/2016,27/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/raloxifene-teva,BKXVVCILCIUCLG-UHFFFAOYSA-N,"InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H",510.05500000000023
937,Human,Ulunar Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",INDACATEROL MALEATE,EMEA/H/C/003875,no,Authorised,R03AL04,no,no,no,no,no,no,23/04/2014,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",,15/11/2021,14,Ulunar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,08/05/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ulunar-breezhaler,IREJFXIHXRZFER-PCBAQXHCSA-N,"InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1",508.57100000000014
1458,Human,Onbrez Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,INDACATEROL MALEATE,EMEA/H/C/001114,no,Authorised,R03AC18,no,no,no,no,no,no,29/11/2009,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",24/09/2009,06/08/2021,17,Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,23/08/2018,23/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler,IREJFXIHXRZFER-PCBAQXHCSA-N,"InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1",508.57100000000014
1469,Human,Oslif Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,INDACATEROL MALEATE,EMEA/H/C/001210,no,Authorised,R03AC18,no,no,no,no,no,no,29/11/2009,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",,06/08/2021,17,Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,08/05/2018,08/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/oslif-breezhaler,IREJFXIHXRZFER-PCBAQXHCSA-N,"InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1",508.57100000000014
1470,Human,Hirobriz Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,INDACATEROL MALEATE,EMEA/H/C/001211,no,Authorised,R03AC18,no,no,no,no,no,no,30/11/2009,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",24/09/2009,06/08/2021,18,Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,23/08/2018,08/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/hirobriz-breezhaler,IREJFXIHXRZFER-PCBAQXHCSA-N,"InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1",508.57100000000014
191,Human,Trelegy Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",UMECLIDINIUM BROMIDE,EMEA/H/C/004363,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,11,Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
194,Human,Elebrato Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",UMECLIDINIUM BROMIDE,EMEA/H/C/004781,no,Authorised,R03AL08,no,no,no,no,no,no,15/11/2017,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",14/09/2017,31/08/2023,12,Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.,30/05/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/elebrato-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
1069,Human,Temybric Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol",UMECLIDINIUM BROMIDE,EMEA/H/C/005254,no,Withdrawn,R03AL08,yes,no,no,no,no,no,12/06/2019,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",,11/12/2021,4,Temybric Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist or a combination of a long-acting ?2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).,23/09/2019,24/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
1072,Human,Anoro Ellipta (previously Anoro),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol",UMECLIDINIUM BROMIDE,EMEA/H/C/002751,no,Authorised,R03AL03,yes,no,no,no,no,no,08/05/2014,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases, ",20/02/2014,18/11/2022,18,Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,13/07/2017,22/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
1074,Human,Rolufta Ellipta (previously Rolufta),"Pulmonary Disease, Chronic Obstructive",umeclidinium,UMECLIDINIUM BROMIDE,EMEA/H/C/004654,no,Authorised,R03BB07,yes,no,no,no,no,no,20/03/2017,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases, ",26/01/2017,09/11/2022,11,"Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)., ",27/06/2018,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rolufta-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
1075,Human,Laventair Ellipta (previously Laventair),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol",UMECLIDINIUM BROMIDE,EMEA/H/C/003754,no,Authorised,R03AL03,yes,no,no,no,no,no,08/05/2014,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases, ",20/02/2014,09/11/2022,17,Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,21/04/2017,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/laventair-ellipta,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
1080,Human,Incruse Ellipta (previously Incruse),"Pulmonary Disease, Chronic Obstructive",umeclidinium bromide,UMECLIDINIUM BROMIDE,EMEA/H/C/002809,no,Authorised,R03BB07,yes,no,no,no,no,no,28/04/2014,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases, ",20/02/2014,09/11/2022,18,"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)., ",13/07/2017,15/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse,PEJHHXHHNGORMP-UHFFFAOYSA-M,"InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1",508.5000000000003
199,Human,Emselex,"Urinary Incontinence, Urge;  Urinary Bladder, Overactive",darifenacin hydrobromide,DARIFENACIN HYDROBROMIDE,EMEA/H/C/000554,no,Authorised,G04BD10,no,no,no,no,no,no,22/10/2004,,pharmaand GmbH,"Urologicals, Drugs for urinary frequency and incontinence",29/07/2004,26/10/2023,26,Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.,15/02/2018,27/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emselex,UQAVIASOPREUIT-VQIWEWKSSA-N,"InChI=1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1",507.4720000000001
585,Human,Verzenios,Breast Neoplasms,abemaciclib,ABEMACICLIB,EMEA/H/C/004302,no,Authorised,L01EF03,no,no,no,no,no,no,26/09/2018,,Eli Lilly Nederland B.V.,Antineoplastic agents,25/07/2018,23/06/2023,10,"Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.",29/10/2018,12/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios,UZWDCWONPYILKI-UHFFFAOYSA-N,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",506.6050000000002
1937,Human,Agenerase,HIV Infections,amprenavir,AMPRENAVIR,EMEA/H/C/000264,no,Withdrawn,J05AE05,no,no,no,no,no,no,20/10/2000,,Glaxo Group Ltd.,Antivirals for systemic use,,29/04/2011,18,"Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years. Agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). The choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).The benefit of Agenerase boosted with ritonavir has not been demonstrated in PI nave patients (see section 5.1)",29/04/2011,21/06/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/agenerase,YMARZQAQMVYCKC-OEMFJLHTSA-N,"InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1",505.63700000000017
583,Human,Ivabradine Zentiva,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE HYDROCHLORIDE,EMEA/H/C/004117,no,Authorised,C01EB17,no,yes,no,no,no,no,11/11/2016,,"Zentiva, k.s.",Cardiac therapy,15/09/2016,13/07/2022,6,"Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersorin combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.",11/11/2016,13/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-zentiva,HLUKNZUABFFNQS-ZMBIFBSDSA-N,"InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1",505.05500000000023
1302,Human,Ivabradine Accord,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE HYDROCHLORIDE,EMEA/H/C/004241,no,Authorised,C01EB17,no,yes,no,no,no,no,22/05/2017,,Accord Healthcare S.L.U.,Cardiac therapy,23/03/2017,01/03/2022,6,"Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm.Ivabradine is indicated :- in adults unable to tolerate or with a contra-indication to the use of beta-blockers- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1)",23/03/2018,01/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-accord,HLUKNZUABFFNQS-ZMBIFBSDSA-N,"InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1",505.05500000000023
1370,Human,Corlentor,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE HYDROCHLORIDE,EMEA/H/C/000598,no,Authorised,C01EB17,no,no,no,no,no,no,25/10/2005,,Les Laboratoires Servier,,,30/09/2021,26,"Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.",11/01/2018,17/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor,HLUKNZUABFFNQS-ZMBIFBSDSA-N,"InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1",505.05500000000023
1371,Human,Procoralan,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE HYDROCHLORIDE,EMEA/H/C/000597,no,Authorised,C01EB17,no,no,no,no,no,no,25/10/2005,,Les Laboratoires Servier,Cardiac therapy,,30/09/2021,22,"Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.",11/01/2018,17/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/procoralan,HLUKNZUABFFNQS-ZMBIFBSDSA-N,"InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1",505.05500000000023
1728,Human,Ivabradine JensonR,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE HYDROCHLORIDE,EMEA/H/C/004217,no,Withdrawn,C01EB17,no,yes,no,no,no,no,11/11/2016,,JensonR+ Limited,Cardiac therapy,15/06/2016,11/11/2016,0,"Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated., ",11/11/2016,20/12/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-jensonr,HLUKNZUABFFNQS-ZMBIFBSDSA-N,"InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1",505.05500000000023
267,Human,Zubsolv,Opioid-Related Disorders,"buprenorphine, naloxone",BUPRENORPHINE HYDROCHLORIDE,EMEA/H/C/004407,no,Authorised,N07BC51,no,no,no,no,no,no,10/11/2017,,Accord Healthcare S.L.U.,Other nervous system drugs,,05/10/2023,10,"Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.",02/02/2018,10/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zubsolv,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,"InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29-;/m1./s1",504.11100000000016
959,Human,Sixmo,Opioid-Related Disorders,buprenorphine,BUPRENORPHINE HYDROCHLORIDE,EMEA/H/C/004743,no,Authorised,N07BC01,yes,no,no,no,no,no,19/06/2019,,L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.,Other nervous system drugs,26/04/2019,16/02/2023,4,"Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.",02/07/2019,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,"InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29-;/m1./s1",504.11100000000016
984,Human,Tabrecta,"Carcinoma, Non-Small-Cell Lung",capmatinib,CAPMATINIB DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/004845,no,Authorised,L01EX17,yes,no,no,no,no,no,20/06/2022,,Novartis Europharm Limited ,Antineoplastic agents,22/04/2022,01/12/2022,1,"Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.",13/04/2022,25/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta,COWBUPJEEDYWKD-UHFFFAOYSA-N,"InChI=1S/C23H17FN6O.2ClH.H2O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20;;;/h2-9,11-13H,10H2,1H3,(H,25,31);2*1H;1H2",503.3650000000001
499,Human,Ebymect,"Diabetes Mellitus, Type 2","dapagliflozin, metformin",DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,EMEA/H/C/004162,no,Authorised,A10BD15,no,no,no,no,no,no,15/11/2015,,AstraZeneca AB,Drugs used in diabetes,23/09/2015,30/05/2023,20,"Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ? 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.",20/12/2017,03/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect,GOADIQFWSVMMRJ-UPGAGZFNSA-N,"InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1",502.98800000000017
638,Human,Forxiga,"Diabetes Mellitus, Type 2;  Heart Failure, Systolic;  Heart Failure;  Renal Insufficiency, Chronic",dapagliflozin,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,EMEA/H/C/002322,no,Authorised,A10BK01,no,no,no,no,no,no,11/11/2012,,AstraZeneca AB,Drugs used in diabetes,,30/05/2023,29,"Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.",12/10/2017,28/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga,GOADIQFWSVMMRJ-UPGAGZFNSA-N,"InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1",502.98800000000017
728,Human,Edistride,"Diabetes Mellitus, Type 2;  Heart Failure, Systolic;  Heart Failure;  Renal Insufficiency, Chronic",dapagliflozin,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,EMEA/H/C/004161,no,Authorised,A10BK01,no,no,no,no,no,no,09/11/2015,,AstraZeneca AB,Drugs used in diabetes,23/09/2015,30/05/2023,22,"Type 2 diabetes mellitusEdistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureEdistride is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseEdistride is indicated in adults for the treatment of chronic kidney disease.",06/11/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/edistride,GOADIQFWSVMMRJ-UPGAGZFNSA-N,"InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1",502.98800000000017
729,Human,Xigduo,"Diabetes Mellitus, Type 2","dapagliflozin, metformin",DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,EMEA/H/C/002672,no,Authorised,A10BD15,no,no,no,no,no,no,16/01/2014,,AstraZeneca AB,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",20/11/2013,30/05/2023,21,"Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:•    in patients insufficiently controlled on their maximally tolerated dose of metformin alone •    in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products•    in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",20/12/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xigduo,GOADIQFWSVMMRJ-UPGAGZFNSA-N,"InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1",502.98800000000017
730,Human,Qtern,"Diabetes Mellitus, Type 2;  Diabetes Mellitus;  Nutritional and Metabolic Diseases;  Metabolic Diseases;  Glucose Metabolism Disorders","saxagliptin, dapagliflozin",DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,EMEA/H/C/004057,no,Authorised,A10BD21,no,no,no,no,no,no,15/07/2016,,Astra Zeneca AB,Drugs used in diabetes,,30/05/2023,11,"Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,when already being treated with the free combination of dapagliflozin and saxagliptin.(See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.)",20/12/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/qtern,GOADIQFWSVMMRJ-UPGAGZFNSA-N,"InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1",502.98800000000017
175,Human,Mozobil,Multiple Myeloma;  Hematopoietic Stem Cell Transplantation;  Lymphoma,plerixafor,PLERIXAFOR,EMEA/H/C/001030,no,Authorised,L03AX16,no,no,no,no,no,no,30/07/2009,,Sanofi B.V.,"Immunostimulants, ",29/05/2009,03/11/2023,23,"Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly., ",19/10/2017,06/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil,YIQPUIGJQJDJOS-UHFFFAOYSA-N,"InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2",502.79600000000016
483,Human,Plerixafor Accord,Multiple Myeloma;  Hematopoietic Stem Cell Transplantation,plerixafor,PLERIXAFOR,EMEA/H/C/005943,no,Authorised,L03AX16,yes,yes,no,no,no,no,16/12/2022,,Accord Healthcare S.L.U.,"Immunostimulants, ",13/10/2022,07/08/2023,1,"Adult patientsPlerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).Paediatric patients (1 to less than 18 years)Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).",06/02/2023,07/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/plerixafor-accord,YIQPUIGJQJDJOS-UHFFFAOYSA-N,"InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2",502.79600000000016
257,Human,Cometriq,Thyroid Neoplasms,cabozantinib,CABOZANTINIB,EMEA/H/C/002640,no,Authorised,L01XE,no,no,no,no,no,yes,21/03/2014,,Ipsen Pharma,Antineoplastic agents,19/12/2013,14/09/2023,28,"Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.",27/08/2018,12/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq,ONIQOQHATWINJY-UHFFFAOYSA-N,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",501.51400000000024
921,Human,Hepsera,"Hepatitis B, Chronic",adefovir dipivoxil,ADEFOVIR DIPIVOXIL,EMEA/H/C/000485,no,Withdrawn,J05AF08,no,no,no,no,no,no,06/03/2003,,Gilead Sciences Ireland UC,Nucleoside and nucleotide reverse transcriptase inhibitors,,20/04/2021,27,"Hepsera is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum-alanine-aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section 5.1);decompensated liver disease in combination with a second agent without cross-resistance to Hepsera. ",24/07/2018,06/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/hepsera,WOZSCQDILHKSGG-UHFFFAOYSA-N,"InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)",501.4770000000002
1482,Human,BroPair Spiromax,Asthma,"salmeterol, fluticasone propionate",FLUTICASONE PROPIONATE,EMEA/H/C/005591,no,Authorised,R03AK06,no,no,no,no,no,no,26/03/2021,,Teva B.V.,"Drugs for obstructive airway diseases, ",28/01/2021,15/07/2021,1,BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.,14/04/2021,27/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/bropair-spiromax,WMWTYOKRWGGJOA-CENSZEJFSA-N,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",500.5790000000002
1483,Human,Seffalair Spiromax,Asthma,"salmeterol, fluticasone propionate",FLUTICASONE PROPIONATE,EMEA/H/C/004881,no,Authorised,R03AK06,no,no,no,no,no,no,26/03/2021,,Teva B.V.,"Drugs for obstructive airway diseases, ",,15/07/2021,,Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.,13/04/2021,23/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/seffalair-spiromax,WMWTYOKRWGGJOA-CENSZEJFSA-N,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",500.5790000000002
1671,Human,Aerivio Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","salmeterol, fluticasone propionate",FLUTICASONE PROPIONATE,EMEA/H/C/002752,no,Withdrawn,R03AK06,no,no,no,no,no,no,18/08/2016,,Teva B.V.,"Drugs for obstructive airway diseases, ",23/06/2016,04/10/2019,2,"Aerivio Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAerivio Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting ?2 agonist) is appropriate:patients not adequately controlled on a lower strength corticosteroid combination product orpatients already controlled on a high dose inhaled corticosteroid and long-acting ?2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 ",09/06/2017,15/01/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/aerivio-spiromax,WMWTYOKRWGGJOA-CENSZEJFSA-N,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",500.5790000000002
1693,Human,Airexar Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","salmeterol xinafoate, fluticasone propionate",FLUTICASONE PROPIONATE,EMEA/H/C/004267,no,Withdrawn,R03AK06,no,no,no,no,no,no,18/08/2016,,Teva B.V.,"Drugs for obstructive airway diseases, ",23/06/2016,19/02/2018,2,"Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting ?2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting ?2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 ",09/03/2017,02/07/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/airexar-spiromax,WMWTYOKRWGGJOA-CENSZEJFSA-N,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",500.5790000000002
1235,Human,Travatan,"Glaucoma, Open-Angle;  Ocular Hypertension",travoprost,TRAVOPROST,EMEA/H/C/000390,no,Authorised,S01EE04,no,no,no,no,no,no,27/11/2001,,Novartis Europharm Limited,Ophthalmologicals,,29/09/2021,30,Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).,03/08/2018,07/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/travatan,MKPLKVHSHYCHOC-AHTXBMBWSA-N,"InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",500.5540000000001
1393,Human,Izba,"Ocular Hypertension;  Glaucoma, Open-Angle",travoprost,TRAVOPROST,EMEA/H/C/002738,no,Authorised,S01EE04,no,no,no,no,no,no,20/02/2014,,Novartis Europharm Limited,"Ophthalmologicals, Antiglaucoma preparations and miotics",,21/09/2021,6,Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.,15/02/2018,29/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/izba,MKPLKVHSHYCHOC-AHTXBMBWSA-N,"InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",500.5540000000001
1438,Human,DuoTrav,"Glaucoma, Open-Angle;  Ocular Hypertension","travoprost, timolol",TRAVOPROST,EMEA/H/C/000665,no,Authorised,S01ED51,no,no,no,no,no,no,23/04/2006,,Novartis Europharm Limited,Ophthalmologicals,23/02/2006,24/09/2021,18,Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.,15/02/2018,08/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/duotrav,MKPLKVHSHYCHOC-AHTXBMBWSA-N,"InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",500.5540000000001
1664,Human,Varuby,Vomiting;  Nausea;  Cancer,rolapitant,ROLAPITANT,EMEA/H/C/004196,no,Withdrawn,A04AD,yes,no,no,no,no,no,19/04/2017,,TESARO Bio Netherlands B.V.,"Antiemetics and antinauseants, ",22/02/2017,11/03/2019,3,Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.Varuby is given as part of combination therapy.,02/10/2017,02/03/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/varuby,FIVSJYGQAIEMOC-ZGNKEGEESA-N,"InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1",500.48300000000006
230,Human,Paxlovid,COVID-19 virus infection,"nirmatrelvir, ritonavir",NIRMATRELVIR,EMEA/H/C/005973,no,Authorised,J05AE30,no,no,no,no,no,no,28/01/2022,,Pfizer Europe MA EEIG,,27/01/2022,26/10/2023,15,Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID 19.,28/01/2022,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid,LIENCHBZNNMNKG-OJFNHCPVSA-N,"InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1",499.53400000000016
636,Human,Ayvakyt,Gastrointestinal Stromal Tumors,avapritinib,AVAPRITINIB,EMEA/H/C/005208,no,Authorised,L01EX18,yes,no,yes,no,no,yes,24/09/2020,,Blueprint Medicines (Netherlands) B.V.,"Other antineoplastic agents, Protein kinase inhibitors",23/07/2020,26/05/2023,7,Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.,30/09/2020,28/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt,DWYRIWUZIJHQKQ-SANMLTNESA-N,"InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1",498.5700000000002
1076,Human,Ertapenem SUN,Bacterial Infections,ertapenem,ERTAPENEM SODIUM,EMEA/H/C/005815,no,Authorised,,no,yes,no,no,no,no,15/07/2022,,SUN Pharmaceutical Industries (Europe) B.V.,ertapenem,19/05/2022,19/05/2022,,TreatmentErtapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- Intra-abdominal infections- Community acquired pneumonia- Acute gynaecological infections- Diabetic foot infections of the skin and soft tissue (see section 4.4)PreventionErtapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents.,17/05/2022,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ertapenem-sun,ZXNAQFZBWUNWJM-HRXMHBOMSA-M,"InChI=1S/C22H25N3O7S.Na/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30;/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32);/q;+1/p-1/t9-,10-,13+,14+,15-,16-;/m1./s1",497.50500000000017
1105,Human,Invanz,"Community-Acquired Infections;  Streptococcal Infections;  Staphylococcal Infections;  Gram-Negative Bacterial Infections;  Surgical Wound Infection;  Pneumonia, Bacterial",ertapenem,ERTAPENEM SODIUM,EMEA/H/C/000389,no,Authorised,J01DH03,no,no,no,no,no,no,18/04/2002,,Merck Sharp & Dohme B.V.,"Antibacterials for systemic use, ",,25/10/2022,26,TreatmentTreatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:intra-abdominal infections;community-acquired pneumonia;acute gynaecological infections;diabetic foot infections of the skin and soft tissue.PreventionInvanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,08/05/2018,25/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/invanz,ZXNAQFZBWUNWJM-HRXMHBOMSA-M,"InChI=1S/C22H25N3O7S.Na/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30;/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32);/q;+1/p-1/t9-,10-,13+,14+,15-,16-;/m1./s1",497.50500000000017
1209,Human,Uptravi,"Hypertension, Pulmonary",selexipag,SELEXIPAG,EMEA/H/C/003774,no,Authorised,B01AC27,no,no,no,no,no,no,12/05/2016,,Janssen Cilag International NV,Antithrombotic agents,28/01/2016,19/05/2022,13,"Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease., ",09/04/2018,01/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi,QXWZQTURMXZVHJ-UHFFFAOYSA-N,"InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)",496.6330000000002
220,Human,Alli (previously Orlistat GSK),Obesity,orlistat,ORLISTAT,EMEA/H/C/000854,no,Authorised,A08AB01,no,no,no,no,no,no,22/07/2007,,GlaxoSmithKline (Ireland) Limited,"Antiobesity preparations, excl. diet products",24/05/2007,19/10/2023,19,"Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ? 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.",29/06/2017,23/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/alli,AHLBNYSZXLDEJQ-FWEHEUNISA-N,"InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1",495.74500000000023
784,Human,Xenical,Obesity,orlistat,ORLISTAT,EMEA/H/C/000154,no,Authorised,A08AB01,no,no,no,no,no,no,29/07/1998,,CHEPLAPHARM Arzneimittel GmbH,"Antiobesity preparations, excl. diet products",,10/05/2023,25,"Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.",02/05/2017,10/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xenical,AHLBNYSZXLDEJQ-FWEHEUNISA-N,"InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1",495.74500000000023
145,Human,Silodosin Recordati,Prostatic Hyperplasia,silodosin,SILODOSIN,EMEA/H/C/004964,no,Authorised,G04CA04,no,yes,no,no,no,no,07/01/2019,,Recordati Ireland Ltd,"Urologicals, Alpha-adrenoreceptor antagonists",,06/11/2023,2,Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.,22/01/2019,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati,PNCPYILNMDWPEY-QGZVFWFLSA-N,"InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1",495.5420000000001
1121,Human,Silodyx,Prostatic Hyperplasia,silodosin,SILODOSIN,EMEA/H/C/001209,no,Authorised,G04CA04,no,no,no,no,no,no,29/01/2010,,Recordati Ireland Ltd,Urologicals,,10/10/2022,16,Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),12/04/2018,10/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/silodyx,PNCPYILNMDWPEY-QGZVFWFLSA-N,"InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1",495.5420000000001
1269,Human,Urorec,Prostatic Hyperplasia,silodosin,SILODOSIN,EMEA/H/C/001092,no,Authorised,G04CA04,no,no,no,no,no,no,29/01/2010,,Recordati Ireland Ltd,Urologicals,19/11/2009,04/04/2022,18,Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).,12/04/2018,06/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/urorec,PNCPYILNMDWPEY-QGZVFWFLSA-N,"InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1",495.5420000000001
330,Human,Amglidia,Diabetes Mellitus,glibenclamide,GLIBENCLAMIDE,EMEA/H/C/004379,no,Authorised,A10BB01,no,no,no,no,no,yes,24/05/2018,,Ammtek,Drugs used in diabetes,14/12/2017,25/07/2023,7,"Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the ?-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.",31/07/2018,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",494.01300000000015
131,Human,Glivec,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Gastrointestinal Stromal Tumors;  Dermatofibrosarcoma;  Myelodysplastic-Myeloproliferative Diseases;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Hypereosinophilic Syndrome",imatinib,IMATINIB,EMEA/H/C/000406,no,Authorised,L01EA01,yes,no,no,no,no,no,07/11/2001,,Novartis Europharm Limited,Antineoplastic agents,26/07/2001,31/08/2023,46,"Glivec is indicated for the treatment of, , , 	adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, 	adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, 	adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, 	adult patients with relapsed or refractory Ph+ ALL as monotherapy;, 	adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, 	adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , 	the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, 	the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, 	the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., ",25/06/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/glivec,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",493.61500000000024
304,Human,Imatinib Teva,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Myelodysplastic-Myeloproliferative Diseases;  Hypereosinophilic Syndrome;  Dermatofibrosarcoma",imatinib,IMATINIB,EMEA/H/C/002585,no,Authorised,L01EA01,no,yes,no,no,no,no,07/01/2013,,Teva B.V.,"Antineoplastic agents, Protein kinase inhibitors",18/10/2012,26/09/2022,19,"Imatinib Teva is indicated for the treatment ofAdult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr?abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon?alpha therapy, or in accelerated phase or blast crisis.Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.Adult patients with relapsed or refractory Ph+ ALL as monotherapy.Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.The effect of imatinib on the outcome of bone marrow transplantation has not been determined.Imatinib Teva is indicated forthe treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases. ",25/04/2018,28/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",493.61500000000024
1040,Human,Imatinib Accord,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Dermatofibrosarcoma;  Myelodysplastic-Myeloproliferative Diseases;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Hypereosinophilic Syndrome",imatinib,IMATINIB,EMEA/H/C/002681,no,Authorised,L01EA01,no,yes,no,no,no,no,30/06/2013,,Accord Healthcare S.L.U.,imatinib,,12/12/2022,20,"Imatinib Accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.- adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.- adult patients with relapsed or refractory Ph+ ALL as monotherapy.- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.- adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.- the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).- the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatmentThe effect of imatinib on the outcome of bone marrow transplantation has not been determined.In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.  ",16/05/2017,14/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",493.61500000000024
1207,Human,Imatinib Actavis,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Myelodysplastic-Myeloproliferative Diseases;  Hypereosinophilic Syndrome;  Dermatofibrosarcoma",imatinib,IMATINIB,EMEA/H/C/002594,no,Withdrawn,L01EA01,no,yes,no,no,no,no,17/04/2013,,Actavis Group PTC ehf,"Protein kinase inhibitors, Antineoplastic agents",21/02/2013,16/12/2021,13,"Imatinib Actavis is indicated for the treatment of:, , , 	paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;, 	paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, 	adult patients with Ph+ CML in blast crisis;, 	adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, 	adult patients with relapsed or refractory Ph+ ALL as monotherapy;, 	adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, 	adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement;, 	the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery., , , The effect of imatinib on the outcome of bone marrow transplantation has not been determined., , Imatinib Actavis is indicated for:, , , 	In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., , ",08/01/2018,05/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-actavis,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",493.61500000000024
1680,Human,Imatinib medac,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Dermatofibrosarcoma;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Myelodysplastic-Myeloproliferative Diseases;  Hypereosinophilic Syndrome",imatinib,IMATINIB,EMEA/H/C/002692,no,Withdrawn,L01XE01,no,yes,no,no,no,no,25/09/2013,,Medac,Protein kinase inhibitors,,11/04/2018,5,"Imatinib medac is indicated for the treatment of:paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;paediatric patients with Ph+CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase;adult and paediatric patients with Ph+CML in blast crisis;adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) integrated with chemotherapy;adult patients with relapsed or refractory Ph+ALL as monotherapy;adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement;adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.The effect of imatinib on the outcome of bone marrow transplantation has not been determined.In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.",11/04/2018,16/10/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-medac,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",493.61500000000024
1289,Human,Latuda,Schizophrenia,lurasidone,LURASIDONE,EMEA/H/C/002713,no,Authorised,N05AE05,no,no,no,no,no,no,21/03/2014,,Aziende Chimiche Riunite Angelini Francesco S.p.A.,Psycholeptics,22/01/2014,10/03/2022,25,Treatment of schizophrenia in adults aged 18 years and over.,12/03/2018,17/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/latuda,PQXKDMSYBGKCJA-CVTJIBDQSA-N,"InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1",492.68900000000014
941,Human,Rasagiline Mylan,Parkinson Disease,rasagiline,RASAGILINE TARTRATE,EMEA/H/C/004064,no,Authorised,N04BD02,no,yes,no,no,no,no,04/04/2016,,Mylan Pharmaceuticals Limited,Anti-Parkinson drugs,28/01/2016,22/02/2023,7,Rasagiline Mylan is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.,18/05/2016,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-mylan,YGKHOZXCTLKSLJ-KHAGDFGNSA-N,"InChI=1S/2C12H13N.C4H6O6/c2*1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;5-1(3(7)8)2(6)4(9)10/h2*1,3-6,12-13H,7-9H2;1-2,5-6H,(H,7,8)(H,9,10)/t2*12-;1-,2-/m111/s1",492.57200000000034
1511,Human,Daurismo,"Leukemia, Myeloid, Acute",glasdegib,GLASDEGIB MALEATE,EMEA/H/C/004878,no,Authorised,L01XX63,yes,no,no,no,no,yes,26/06/2020,,Pfizer Europe MA EEIG,Antineoplastic agents,30/04/2020,05/07/2022,4,"Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.",10/07/2020,07/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo,VJCVKWFBWAVYOC-UIXXXISESA-N,"InChI=1S/C21H22N6O.C4H4O4/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20;5-3(6)1-2-4(7)8/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28);1-2H,(H,5,6)(H,7,8)/b;2-1-/t16-,19-;/m1./s1",490.5200000000001
565,Human,Zelboraf,Melanoma,vemurafenib,VEMURAFENIB,EMEA/H/C/002409,no,Authorised,L01EC01,no,no,no,no,no,no,17/02/2012,,Roche Registration GmbH,Antineoplastic agents,15/12/2011,26/06/2023,24,"Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma., ",14/08/2018,18/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf,GPXBXXGIAQBQNI-UHFFFAOYSA-N,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",489.9310000000001
7,Human,Levitra,Erectile Dysfunction,vardenafil,VARDENAFIL,EMEA/H/C/000475,no,Authorised,G04BE09,no,no,no,no,no,no,06/03/2003,,Bayer AG ,Urologicals,,30/11/2023,33,"Treatment of erectile dysfunction in adult men.Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Levitra to be effective, sexual stimulation is required.Levitra is not indicated for use by women.",19/04/2018,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levitra,SECKRCOLJRRGGV-UHFFFAOYSA-N,"InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)",488.6140000000002
1304,Human,Vivanza,Erectile Dysfunction,vardenafil,VARDENAFIL,EMEA/H/C/000488,no,Withdrawn,G04BE09,no,no,no,no,no,no,04/03/2003,,Bayer AG ,Urologicals,,20/10/2021,28,"Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Vivanza to be effective, sexual stimulation is required.Vivanza is not indicated for use by women.",19/04/2018,28/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/vivanza,SECKRCOLJRRGGV-UHFFFAOYSA-N,"InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)",488.6140000000002
188,Human,Sprycel,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive",dasatinib (anhydrous),DASATINIB,EMEA/H/C/000709,no,Authorised,L01EA02,no,no,no,no,no,no,20/11/2006,,Bristol-Myers Squibb Pharma EEIG,Antineoplastic agents,21/09/2006,16/06/2022,41,"Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.",03/08/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",488.01700000000005
862,Human,Dasatinib Accord,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive",dasatinib (anhydrous),DASATINIB,EMEA/H/C/005446,no,Withdrawn,L01EA02,no,yes,no,no,no,no,24/03/2022,,Accord Healthcare S.L.U.,Antineoplastic agents,27/01/2022,08/06/2022,1,Dasatinib Accord is indicated for the treatment of adult patients with:• Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy.Dasatinib Accord is indicated for the treatment of paediatric patients with:• newly diagnosed Ph+ ALL in combination with chemotherapy.,24/01/2022,30/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accord,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",488.01700000000005
863,Human,Dasatinib Accordpharma,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive",dasatinib (anhydrous),DASATINIB,EMEA/H/C/005317,no,Withdrawn,L01EA02,no,yes,no,no,no,no,24/03/2022,,Accord Healthcare S.L.U.,Antineoplastic agents,27/01/2022,22/06/2022,1,"Dasatinib Accordpharma is indicated for the treatment of adult patients with:? newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.? chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.? Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Dasatinib Accordpharma is indicated for the treatment of paediatric patients with:? newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.? newly diagnosed Ph+ ALL in combination with chemotherapy.",24/01/2022,30/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",488.01700000000005
1498,Human,Vizimpro,"Carcinoma, Non-Small-Cell Lung",dacomitinib,DACOMITINIB MONOHYDRATE,EMEA/H/C/004779,no,Authorised,L01EB07,yes,no,no,no,no,no,02/04/2019,,Pfizer Europe MA EEIG,Antineoplastic agents,31/01/2019,02/07/2021,2,"Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.",05/06/2019,21/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro,BSPLGGCPNTZPIH-IPZCTEOASA-N,"InChI=1S/C24H25ClFN5O2.H2O/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31;/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29);1H2/b6-5+;",487.96300000000014
397,Human,Pemazyre,Cholangiocarcinoma,pemigatinib,PEMIGATINIB,EMEA/H/C/005266,no,Authorised,L01EN02,yes,no,yes,no,no,yes,26/03/2021,,Incyte Biosciences Distribution B.V.,Antineoplastic agents,28/01/2021,26/07/2023,6,Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.,04/05/2021,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre,HCDMJFOHIXMBOV-UHFFFAOYSA-N,"InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)",487.5070000000002
659,Human,Quviviq,Sleep Initiation and Maintenance Disorders,daridorexant,DARIDOREXANT HYDROCHLORIDE,EMEA/H/C/005634,no,Authorised,N05,yes,no,no,no,no,no,29/04/2022,,Idorsia Pharmaceuticals Deutschland GmbH,Psycholeptics,24/02/2022,12/05/2023,5,Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.,03/05/2022,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq,HJVGDXBEMFHGKI-BQAIUKQQSA-N,"InChI=1S/C23H23ClN6O2.ClH/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30;/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28);1H/t23-;/m0./s1",487.39100000000013
157,Human,Relvar Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, vilanterol",VILANTEROL,EMEA/H/C/002673,no,Authorised,R03AK10,no,no,no,no,no,no,13/11/2013,,GlaxoSmithKline (Ireland) Limited,Adrenergics and other drugs for obstructive airway diseases,19/09/2013,06/07/2023,25,"Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 ",26/07/2018,08/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta,DAFYYTQWSAWIGS-DEOSSOPVSA-N,"InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1",486.436
1075,Human,Laventair Ellipta (previously Laventair),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol",VILANTEROL,EMEA/H/C/003754,no,Authorised,R03AL03,yes,no,no,no,no,no,08/05/2014,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases, ",20/02/2014,09/11/2022,17,Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,21/04/2017,21/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/laventair-ellipta,DAFYYTQWSAWIGS-DEOSSOPVSA-N,"InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1",486.436
343,Human,Scemblix,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",asciminib,ASCIMINIB HYDROCHLORIDE,EMEA/H/C/005605,no,Authorised,L01EA06,yes,no,no,no,no,yes,25/08/2022,,Novartis Europharm Limited,Antineoplastic agents,23/06/2022,24/07/2023,3,Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.1).,20/06/2022,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix,HGCOOPLEWPBLOY-PFEQFJNWSA-N,"InChI=1S/C20H18ClF2N5O3.ClH/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28;/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30);1H/t14-;/m1./s1",486.306
1035,Human,Resolor,Constipation,prucalopride,PRUCALOPRIDE SUCCINATE,EMEA/H/C/001012,no,Authorised,A06AX05,no,no,no,no,no,no,14/10/2009,,Takeda Pharmaceuticals International AG Ireland,Other drugs for constipation,,14/12/2022,29,Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.,05/02/2018,15/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/resolor,QZRSNVSQLGRAID-UHFFFAOYSA-N,"InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)",485.96500000000026
672,Human,Giotrif,"Carcinoma, Non-Small-Cell Lung",afatinib,AFATINIB,EMEA/H/C/002280,no,Authorised,L01XE13,no,no,no,no,no,no,25/09/2013,,Boehringer Ingelheim International GmbH,Antineoplastic agents,25/07/2013,19/06/2023,15,Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.,28/06/2018,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif,ULXXDDBFHOBEHA-CWDCEQMOSA-N,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",485.9470000000001
1397,Human,Spedra,Erectile Dysfunction,avanafil,AVANAFIL,EMEA/H/C/002581,no,Authorised,G04BE10,no,no,no,no,no,no,21/06/2013,26/04/2013,Menarini International Operations Luxembourg S.A.,Drugs used in erectile dysfunction,,04/11/2021,13,"Treatment of erectile dysfunction in adult men.In order for Spedra to be effective, sexual stimulation is required.",23/04/2018,24/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/spedra,WEAJZXNPAWBCOA-INIZCTEOSA-N,"InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1",483.96000000000004
915,Human,Stivarga,Colorectal Neoplasms,regorafenib,REGORAFENIB,EMEA/H/C/002573,no,Authorised,L01EX05,no,no,no,no,no,no,26/08/2013,,Bayer Pharma AG,"Antineoplastic agents, Protein kinase inhibitors",,07/03/2023,20,"Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",25/06/2018,08/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga,FNHKPVJBJVTLMP-UHFFFAOYSA-N,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",482.82099999999997
1799,Human,Dutrebis,HIV Infections,"lamivudine, raltegravir potassium",RALTEGRAVIR POTASSIUM,EMEA/H/C/003823,no,Withdrawn,J05AR16,no,no,no,no,no,no,26/03/2015,,Merck Sharp  Dohme Limited,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,26/03/2015,0,"Dutrebis is indicated in combination with other anti?retroviral medicinal products for the treatment of human immunodeficiency virus (HIV?1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).",26/03/2015,27/04/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/dutrebis,IFUKBHBISRAZTF-UHFFFAOYSA-M,"InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1",482.51300000000003
454,Human,Tukysa,Breast Neoplasms;  Neoplasm Metastasis,tucatinib,TUCATINIB,EMEA/H/C/005263,no,Authorised,L01EH03,yes,no,no,no,no,no,11/02/2021,,Seagen B.V.,Antineoplastic agents,10/12/2020,20/07/2023,5,Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti?HER2 treatment regimens.,18/02/2021,21/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa,SDEAXTCZPQIFQM-UHFFFAOYSA-N,"InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)",480.53200000000015
550,Human,Nulibry,"Metal Metabolism, Inborn Errors",fosdenopterin,FOSDENOPTERIN HYDROBROMIDE DIHYDRATE,EMEA/H/C/005378,no,Authorised,A16AX19,yes,no,no,no,no,yes,15/09/2022,,TMC Pharma (EU) Limited,"Other alimentary tract and metabolism products, ",21/07/2022,17/07/2023,2,NULIBRY is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.,18/07/2022,21/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nulibry,GGLKTKQOHMCQHF-UNHNTEMGSA-N,"InChI=1S/C10H14N5O8P.BrH.2H2O/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18;;;/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16);1H;2*1H2/t2-,4-,5+,8-;;;/m1.../s1",480.1650000000002
1175,Human,Clopidogrel Viatris (previously Clopidogrel Taw Pharma),Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction,clopidogrel,CLOPIDOGREL BESILATE,EMEA/H/C/001189,no,Authorised,B01AC04,no,yes,no,no,no,no,16/10/2009,,Viatris Limited,Antithrombotic agents,23/07/2009,03/08/2022,26,"Secondary prevention of atherothrombotic events Clopidogrel is indicated in:Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.Adult patients suffering from acute coronary syndrome.Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS) Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ?4) or minor IS (NIHSS ?3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillation:In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.For further information please refer to section 5.1.",23/04/2018,03/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-viatris-previously-clopidogrel-taw-pharma,CUZIJKLLBDXNFV-RSAXXLAASA-N,"InChI=1S/C16H16ClNO2S.C6H6O3S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;7-10(8,9)6-4-2-1-3-5-6/h2-5,7,9,15H,6,8,10H2,1H3;1-5H,(H,7,8,9)/t15-;/m0./s1",480.0070000000001
119,Human,Jaypirca,"Lymphoma, Mantle-Cell",pirtobrutinib,PIRTOBRUTINIB,EMEA/H/C/005863,no,Authorised,L01E,yes,no,yes,no,no,no,30/10/2023,,Eli Lilly Nederland B.V.,Protein kinase inhibitors,26/04/2023,,,Treatment of mantle cell lymphoma (MCL),24/04/2023,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca,FWZAWAUZXYCBKZ-NSHDSACASA-N,"InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1",479.434
309,Human,Erleada,Prostatic Neoplasms,apalutamide,APALUTAMIDE,EMEA/H/C/004452,no,Authorised,L02BB05,no,no,no,no,no,no,14/01/2019,,Janssen-Cilag International NV,Endocrine therapy,15/11/2018,22/09/2023,11,Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).,19/03/2019,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/erleada,HJBWBFZLDZWPHF-UHFFFAOYSA-N,"InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)",477.443
1940,Human,Thelin,"Hypertension, Pulmonary",sitaxentan sodium,SITAXENTAN SODIUM,EMEA/H/C/000679,no,Withdrawn,C02KX03,no,no,no,no,no,no,10/08/2006,,Pfizer Ltd.,"Antihypertensives, ",,06/01/2011,13,"Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.",06/01/2011,03/03/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/thelin,MDTNUYUCUYPIHE-UHFFFAOYSA-N,"InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1",476.89500000000015
897,Human,Symtuza,HIV Infections,"darunavir, cobicistat, emtricitabine, tenofovir alafenamide",TENOFOVIR ALAFENAMIDE,EMEA/H/C/004391,no,Authorised,J05,no,no,no,no,no,no,21/09/2017,,Janssen-Cilag International NV,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",19/07/2017,07/03/2023,17,Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).Genotypic testing should guide the use of Symtuza.,06/07/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza,LDEKQSIMHVQZJK-CAQYMETFSA-N,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1",476.4740000000001
957,Human,Odefsey,HIV Infections,"emtricitabine, rilpivirine, tenofovir alafenamide",TENOFOVIR ALAFENAMIDE,EMEA/H/C/004156,no,Authorised,J05AR19,no,no,no,no,no,no,21/06/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,28/04/2016,16/02/2023,20,"Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ? 100,000 HIV 1 RNA copies/mL., ",16/05/2018,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey,LDEKQSIMHVQZJK-CAQYMETFSA-N,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1",476.4740000000001
962,Human,Descovy,HIV Infections,"emtricitabine, tenofovir alafenamide",TENOFOVIR ALAFENAMIDE,EMEA/H/C/004094,no,Authorised,J05AR17,no,no,no,no,no,no,21/04/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,25/02/2016,16/02/2023,20,Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).,28/05/2018,17/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/descovy,LDEKQSIMHVQZJK-CAQYMETFSA-N,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1",476.4740000000001
1066,Human,Genvoya,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",TENOFOVIR ALAFENAMIDE,EMEA/H/C/004042,no,Authorised,J05AR,no,no,no,no,no,no,19/11/2015,,Gilead Sciences Ireland UC,Antivirals for systemic use,24/09/2015,03/10/2022,27,"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.",26/07/2018,28/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya,LDEKQSIMHVQZJK-CAQYMETFSA-N,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1",476.4740000000001
1505,Human,Ulipristal Acetate Gedeon Richter,Leiomyoma,ulipristal acetate,ULIPRISTAL ACETATE,EMEA/H/C/005017,no,Withdrawn,G03XB02,no,no,no,no,no,no,27/08/2018,,Gedeon Richter Plc.,"Sex hormones and modulators of the genital system, ",28/06/2018,14/06/2021,1,Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.,27/08/2018,09/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ulipristal-acetate-gedeon-richter,OOLLAFOLCSJHRE-ZHAKMVSLSA-N,"InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1",475.62900000000025
1573,Human,Esmya,Leiomyoma,ulipristal,ULIPRISTAL ACETATE,EMEA/H/C/002041,no,Authorised,G03XB02,no,no,no,no,no,no,22/02/2012,,Gedeon Richter Ltd ,"Sex hormones and modulators of the genital system, ",15/12/2011,11/01/2021,16,Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.,26/07/2018,03/02/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/esmya,OOLLAFOLCSJHRE-ZHAKMVSLSA-N,"InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1",475.62900000000025
467,Human,Caprelsa,Thyroid Neoplasms,vandetanib,VANDETANIB,EMEA/H/C/002315,no,Authorised,L01XE,no,no,yes,no,no,no,16/02/2012,,Sanofi B.V.,Antineoplastic and immunomodulating agents,17/11/2011,11/08/2023,52,"Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.Caprelsa is indicated in adults, children and adolescents aged 5 years and older.For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.",31/05/2018,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa,UHTHHESEBZOYNR-UHFFFAOYSA-N,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",475.3620000000001
117,Human,Revatio,"Hypertension, Pulmonary",sildenafil,SILDENAFIL,EMEA/H/C/000638,no,Authorised,G04BE03,no,no,no,no,no,no,28/10/2005,,Upjohn EESV,Urologicals,27/07/2005,26/09/2023,50,"Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. ",30/07/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/revatio,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
140,Human,Sildenafil Actavis,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/001090,no,Authorised,G04BE03,no,yes,no,no,no,no,10/12/2009,,Actavis Group PTC ehf,Urologicals,24/09/2009,10/11/2023,17,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Sildenafil Actavis to be effective, sexual stimulation is required.",06/04/2018,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sildenafil-actavis,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
377,Human,Viagra,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/000202,no,Authorised,G04BE03,no,no,no,no,no,no,13/09/1998,,Upjohn EESV,Urologicals,27/05/1998,14/09/2023,45,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Viagra to be effective, sexual stimulation is required.",17/06/2016,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viagra,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
939,Human,Vizarsin,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/001076,no,Authorised,G04BE03,no,yes,no,no,no,no,21/09/2009,,"Krka, d.d., Novo mesto",Urologicals,25/06/2009,22/02/2023,19,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Vizarsin to be effective, sexual stimulation is required.",06/12/2017,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vizarsin,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
1208,Human,Sildenafil Teva,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/001073,no,Authorised,G04BE03,no,yes,no,no,no,no,30/11/2009,,Teva B.V. ,Drugs used in erectile dysfunction,24/09/2009,01/07/2022,17,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance., , In order for Sildenafil Teva to be effective, sexual stimulation is required., ",25/04/2016,04/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sildenafil-teva,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
1224,Human,Sildenafil ratiopharm,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/001080,no,Authorised,G04BE03,no,yes,no,no,no,no,23/12/2009,,Ratiopharm GmbH,Urologicals,,21/06/2022,19,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for sildenafil to be effective, sexual stimulation is required.",20/03/2018,24/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sildenafil-ratiopharm,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
2014,Human,Patrex,Erectile Dysfunction,sildenafil,SILDENAFIL,EMEA/H/C/000204,no,Withdrawn,G04BE03,no,no,no,no,no,no,15/09/1998,,Pfizer Limited,Urologicals,,15/09/2003,4,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penileerection sufficient for satisfactory sexual performance.In order for Patrex to be effective, sexual stimulation is required.PATREX is not indicated for use by women.",15/09/2003,18/08/2005,https://www.ema.europa.eu/en/medicines/human/EPAR/patrex,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",474.5870000000001
308,Human,Glyxambi,"Diabetes Mellitus, Type 2","empagliflozin, linagliptin",LINAGLIPTIN,EMEA/H/C/003833,no,Authorised,A10BD19,no,no,no,no,no,no,11/11/2016,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,15/09/2016,30/08/2023,16,"Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.",03/08/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi,LTXREWYXXSTFRX-QGZVFWFLSA-N,"InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1",472.55300000000017
699,Human,Jentadueto,"Diabetes Mellitus, Type 2","linagliptin, metformin hydrochloride",LINAGLIPTIN,EMEA/H/C/002279,no,Authorised,A10BD11,no,no,no,no,no,no,19/07/2012,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,,02/03/2023,21,"Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.",20/07/2018,07/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto,LTXREWYXXSTFRX-QGZVFWFLSA-N,"InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1",472.55300000000017
763,Human,Trajenta,"Diabetes Mellitus, Type 2",linagliptin,LINAGLIPTIN,EMEA/H/C/002110,no,Authorised,A10BH05,no,no,no,no,no,no,23/08/2011,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,,30/03/2023,19,"Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.",26/06/2018,17/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta,LTXREWYXXSTFRX-QGZVFWFLSA-N,"InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1",472.55300000000017
297,Human,Brukinsa,Waldenstrom Macroglobulinemia,zanubrutinib,ZANUBRUTINIB,EMEA/H/C/004978,no,Authorised,L01EL03,yes,no,no,no,no,no,22/11/2021,,BeiGene Ireland Ltd,Antineoplastic agents,22/07/2021,28/09/2023,7,"Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).",15/12/2021,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa,RNOAOAWBMHREKO-QFIPXVFZSA-N,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",471.56100000000015
946,Human,Pemetrexed Krka,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM,EMEA/H/C/003958,no,Authorised,L01BA04,no,yes,no,no,no,no,22/05/2018,,KRKA d.d.,Antineoplastic agents,22/03/2018,15/02/2023,6,Malignant pleural mesotheliomaPemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,22/05/2018,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-krka,NYDXNILOWQXUOF-GXKRWWSZSA-L,"InChI=1S/C20H21N5O6.2Na/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;/q;2*+1/p-2/t13-;;/m0../s1",471.38100000000003
1135,Human,Pemetrexed Pfizer (previously Pemetrexed Hospira),"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DISODIUM,EMEA/H/C/003970,no,Authorised,L01BA04,no,yes,no,no,no,no,19/11/2015,,Pfizer Europe MA EEIG,Antineoplastic agents,23/09/2015,29/08/2022,14,Malignant pleural mesotheliomaPemetrexed Pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,24/04/2018,21/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-pemetrexed-hospira,NYDXNILOWQXUOF-GXKRWWSZSA-L,"InChI=1S/C20H21N5O6.2Na/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;/q;2*+1/p-2/t13-;;/m0../s1",471.38100000000003
1546,Human,Conbriza,"Osteoporosis, Postmenopausal",bazedoxifene,BAZEDOXIFENE,EMEA/H/C/000913,no,Authorised,G03XC02,no,no,no,no,no,no,17/04/2009,,Pfizer Europe MA EEIG,"Sex hormones and modulators of the genital system, ",19/02/2009,09/03/2021,15,"Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.",02/08/2018,23/03/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza,UCJGJABZCDBEDK-UHFFFAOYSA-N,"InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3",470.6130000000003
927,Human,Ivabradine Anpharm,Angina Pectoris;  Heart Failure,ivabradine,IVABRADINE,EMEA/H/C/004187,no,Authorised,C01EB17,no,no,no,no,no,no,08/09/2015,,"""Anpharm"" Przedsi?biorstwo Farmaceutyczne S.A.",Other cardiac preparations,,20/10/2021,9,"Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.",11/01/2018,28/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-anpharm,ACRHBAYQBXXRTO-OAQYLSRUSA-N,"InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1",468.5940000000003
120,Human,Suboxone,Opioid-Related Disorders,"buprenorphine, naloxone",BUPRENORPHINE,EMEA/H/C/000697,no,Authorised,N07BC51,no,no,no,no,no,no,26/09/2006,,Indivior Europe Limited,Other nervous system drugs,27/07/2006,09/10/2023,22,"Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.",31/05/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone,RMRJXGBAOAMLHD-IHFGGWKQSA-N,"InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",467.65000000000015
469,Human,Buvidal,Opioid-Related Disorders,buprenorphine,BUPRENORPHINE,EMEA/H/C/004651,no,Authorised,N07BC01,no,no,no,no,no,no,20/11/2018,,Camurus AB,Other nervous system drugs,20/09/2018,26/07/2021,8,"Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.",18/12/2018,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/buvidal,RMRJXGBAOAMLHD-IHFGGWKQSA-N,"InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",467.65000000000015
339,Human,Vantobra (previously Tobramycin PARI),Respiratory Tract Infections;  Cystic Fibrosis,tobramycin,TOBRAMYCIN,EMEA/H/C/005086,no,Authorised,J01GB01,no,no,no,no,no,no,18/02/2019,,Pari Pharma GmbH,"Antibacterials for systemic use, ",,15/09/2023,5,Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.,17/04/2019,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari,NLVFBUXFDBBNBW-PBSUHMDJSA-N,"InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",467.5200000000002
465,Human,Tobi Podhaler,Cystic Fibrosis;  Respiratory Tract Infections,tobramycin,TOBRAMYCIN,EMEA/H/C/002155,no,Authorised,J01GB01,no,no,no,no,no,no,20/07/2011,,Viatris Healthcare Limited,"Antibacterials for systemic use, ",23/09/2010,21/07/2023,21,Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,23/04/2018,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tobi-podhaler,NLVFBUXFDBBNBW-PBSUHMDJSA-N,"InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",467.5200000000002
1712,Human,Vantobra,Cystic Fibrosis;  Respiratory Tract Infections,tobramycin,TOBRAMYCIN,EMEA/H/C/002633,no,Withdrawn,J01GB01,no,no,no,no,no,no,18/03/2015,,Pari Pharma GmbH,"Antibacterials for systemic use, , Aminoglycoside antibacterials",,21/09/2017,3,Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.,21/09/2017,29/03/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra,NLVFBUXFDBBNBW-PBSUHMDJSA-N,"InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",467.5200000000002
177,Human,Calquence,"Leukemia, Lymphocytic, Chronic, B-Cell",acalabrutinib,ACALABRUTINIB,EMEA/H/C/005299,no,Authorised,L01EL02,yes,no,no,no,no,no,05/11/2020,,AstraZeneca AB,"Antineoplastic agents, protein kinase inhibitors, ",05/11/2020,16/08/2023,7,Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.,11/11/2020,03/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/calquence,WDENQIQQYWYTPO-IBGZPJMESA-N,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",465.5170000000003
1494,Human,Ifirmasta (previously Irbesartan Krka),Hypertension,irbesartan,IRBESARTAN HYDROCHLORIDE,EMEA/H/C/000962,no,Authorised,C09CA04,no,yes,no,no,no,no,01/12/2008,,"Krka, d.d., Novo mesto",Agents acting on the renin-angiotensin system,25/09/2008,30/06/2021,14,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,05/10/2016,03/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ifirmasta,ZUYFSRQJPNUOQU-UHFFFAOYSA-N,"InChI=1S/C25H28N6O.ClH/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23;/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30);1H",465.00100000000015
605,Human,Nexavar,"Carcinoma, Hepatocellular;  Carcinoma, Renal Cell",sorafenib,SORAFENIB,EMEA/H/C/000690,no,Authorised,L01EX02,no,no,no,no,no,yes,19/07/2006,,Bayer AG,Antineoplastic agents,,06/07/2023,33,"Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.",25/06/2018,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar,MLDQJTXFUGDVEO-UHFFFAOYSA-N,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",464.831
1226,Human,Xtandi,Prostatic Neoplasms,enzalutamide,ENZALUTAMIDE,EMEA/H/C/002639,no,Authorised,L02BB04,no,no,no,no,no,no,21/06/2013,26/04/2013,Astellas Pharma Europe B.V.,Endocrine therapy,25/04/2013,24/05/2022,21,Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.,08/02/2018,17/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi,WXCXUHSOUPDCQV-UHFFFAOYSA-N,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",464.44399999999996
1983,Human,Zimulti,Obesity,rimonabant,RIMONABANT,EMEA/H/C/000691,no,Withdrawn,A08AX01,no,no,no,no,no,no,19/06/2006,,sanofi-aventis,"Antiobesity preparations, excl. diet products",,17/07/2008,8,"As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).",17/07/2008,30/01/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/zimulti,JZCPYUJPEARBJL-UHFFFAOYSA-N,"InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)",463.796
1984,Human,Acomplia,Obesity,rimonabant,RIMONABANT,EMEA/H/C/000666,no,Withdrawn,A08AX01,no,no,no,no,no,no,19/06/2006,,sanofi-aventis,"Antiobesity preparations, excl. diet products",,17/07/2008,8,"As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).",17/07/2008,30/01/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia,JZCPYUJPEARBJL-UHFFFAOYSA-N,"InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)",463.796
732,Human,Sitagliptin / Metformin hydrochloride Mylan,"Diabetes Mellitus, Type 2","sitagliptin hydrochloride monohydrate, metformin hydrochloride",SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE,EMEA/H/C/005678,no,Authorised,A10BD07,no,yes,no,no,no,no,16/02/2022,,Mylan Ireland Limited,Drugs used in diabetes,16/12/2021,29/05/2023,2,"For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride Mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride Mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride Mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARg agonist.Sitagliptin/Metformin hydrochloride Mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",14/12/2021,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-mylan,YPULIQLVSSZRST-KLQYNRQASA-N,"InChI=1S/C16H15F6N5O.ClH.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;;/h4,6,9H,1-3,5,7,23H2;1H;1H2/t9-;;/m1../s1",461.794
1147,Human,Sitagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE,EMEA/H/C/005850,no,Authorised,A10BD07,no,yes,no,no,no,no,22/07/2022,,Accord Healthcare S.L.U.,Drugs used in diabetes,19/05/2022,31/08/2022,1,"For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",03/08/2022,01/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-accord,YPULIQLVSSZRST-KLQYNRQASA-N,"InChI=1S/C16H15F6N5O.ClH.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;;/h4,6,9H,1-3,5,7,23H2;1H;1H2/t9-;;/m1../s1",461.794
592,Human,Vipdomet,"Diabetes Mellitus, Type 2","alogliptin, metformin",ALOGLIPTIN BENZOATE,EMEA/H/C/002654,no,Authorised,A10BD13,no,no,no,no,no,no,18/09/2013,,Takeda Pharma A/S,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/07/2013,07/09/2022,11,"Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.",16/10/2017,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet,KEJICOXJTRHYAK-XFULWGLBSA-N,"InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1",461.5220000000001
20,Human,Otezla,"Arthritis, Psoriatic;  Psoriasis",apremilast,APREMILAST,EMEA/H/C/003746,no,Authorised,L04AA32,no,no,no,no,no,no,15/01/2015,,Amgen Europe BV,Immunosuppressants,,13/07/2022,21,"Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).",02/08/2018,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/otezla,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,"InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1",460.50800000000015
658,Human,Eliquis,Arthroplasty;  Venous Thromboembolism,apixaban,APIXABAN,EMEA/H/C/002148,no,Authorised,B01AF02,no,no,no,no,no,no,18/05/2011,,Bristol-Myers Squibb / Pfizer EEIG,Antithrombotic agents,17/03/2011,25/05/2023,32,"For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ? II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ? II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).",03/08/2018,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis,QNZCBYKSOIHPEH-UHFFFAOYSA-N,"InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)",459.50600000000014
1244,Human,Apixaban Accord,Venous Thromboembolism;  Stroke;  Arthroplasty,apixaban,APIXABAN,EMEA/H/C/005358,no,Authorised,B01AF02,no,yes,no,no,no,no,23/07/2020,,Accord Healthcare S.L.U.,Antithrombotic agents,28/05/2020,18/05/2022,2,"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ? II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ? II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).",06/08/2020,19/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/apixaban-accord,QNZCBYKSOIHPEH-UHFFFAOYSA-N,"InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)",459.50600000000014
63,Human,Orserdu,Breast Neoplasms,elacestrant,ELACESTRANT,EMEA/H/C/005898,no,Authorised,L02BA,yes,no,no,no,no,no,15/09/2023,,Stemline Therapeutics B.V.,Endocrine therapy,20/07/2023,,,"Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",18/07/2023,27/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu,SIFNOOUKXBRGGB-AREMUKBSSA-N,"InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1",458.6460000000002
372,Human,Litfulo,Alopecia Areata,ritlecitinib,RITLECITINIB TOSILATE,EMEA/H/C/006025,no,Authorised,L04AF08,yes,no,no,no,no,no,15/09/2023,,Pfizer Europe MA EEIG,Immunosuppressants,20/07/2023,,,Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.,17/07/2023,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo,YOZLVAFWYLSRRN-VZXYPILPSA-N,"InChI=1S/C15H19N5O.C7H8O3S/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;1-6-2-4-7(5-3-6)11(8,9)10/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);2-5H,1H3,(H,8,9,10)/t10-,11+;/m0./s1",457.5560000000002
568,Human,Fotivda,"Carcinoma, Renal Cell",tivozanib hydrochloride monohydrate,TIVOZANIB,EMEA/H/C/004131,no,Authorised,L01EK03,yes,no,no,no,no,no,24/08/2017,,Recordati Netherlands B.V.,Antineoplastic agents,22/06/2017,17/07/2023,9,"Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC., , Treatment of advanced renal cell carcinoma., ",08/02/2018,17/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda,SPMVMDHWKHCIDT-UHFFFAOYSA-N,"InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",454.8700000000001
108,Human,Nordimet,"Arthritis, Psoriatic;  Psoriasis;  Arthritis, Juvenile Rheumatoid;  Arthritis, Rheumatoid",methotrexate,METHOTREXATE,EMEA/H/C/003983,no,Authorised,L04AX03,no,no,no,no,no,no,18/08/2016,,Nordic Group B.V.,Antineoplastic agents,23/06/2016,18/10/2023,22,"Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.",16/05/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet,FBOZXECLQNJBKD-ZDUSSCGKSA-N,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",454.44700000000006
850,Human,Jylamvo,"Arthritis, Psoriatic;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Psoriasis;  Arthritis, Rheumatoid;  Arthritis",methotrexate,METHOTREXATE,EMEA/H/C/003756,no,Authorised,L04AX03,no,no,no,no,no,no,29/03/2017,,Therakind (Europe) Limited,Antineoplastic agents,26/01/2017,30/03/2023,12,"In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.",22/05/2018,03/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jylamvo,FBOZXECLQNJBKD-ZDUSSCGKSA-N,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",454.44700000000006
1180,Human,Rhokiinsa,"Glaucoma, Open-Angle;  Ocular Hypertension",netarsudil,NETARSUDIL,EMEA/H/C/004583,no,Authorised,S01EX05,yes,no,no,no,no,no,19/11/2019,,Santen Oy,Ophthalmologicals,19/09/2019,26/07/2022,2,Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension.,03/12/2019,26/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa,OURRXQUGYQRVML-AREMUKBSSA-N,"InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1",453.54200000000026
1041,Human,Repaglinide Krka,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/001066,no,Authorised,A10BX02,no,yes,no,no,no,no,03/11/2009,,"Krka, d.d., Novo mesto",Drugs used in diabetes,23/07/2009,13/12/2022,8,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",27/10/2017,14/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
1042,Human,Enyglid,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/001065,no,Authorised,A10BX02,no,yes,no,no,no,no,13/10/2009,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,13/12/2022,9,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",24/06/2016,14/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/enyglid,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
1337,Human,Repaglinide Accord,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/002318,no,Authorised,A10BX02,no,yes,no,no,no,no,22/12/2011,,Accord Healthcare S.L.U.,Drugs used in diabetes,20/10/2011,21/01/2022,7,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",19/09/2016,21/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-accord,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
1372,Human,Repaglinide Teva,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/001067,no,Authorised,A10BX02,no,yes,no,no,no,no,28/06/2009,,Teva Pharma B.V.,Drugs used in diabetes,23/04/2009,13/12/2021,9,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2-diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",25/05/2016,17/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-teva,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
1761,Human,Prandin,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/000362,no,Authorised,A10BX02,no,no,no,no,no,no,29/01/2001,,Novo Nordisk A/S,Drugs used in diabetes,,06/09/2017,16,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",06/09/2017,14/05/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/prandin,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
1786,Human,NovoNorm,"Diabetes Mellitus, Type 2",repaglinide,REPAGLINIDE,EMEA/H/C/000187,no,Authorised,A10BX02,no,no,no,no,no,no,16/08/1998,,Novo Nordisk A/S,Drugs used in diabetes,,05/09/2017,16,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",06/09/2017,28/09/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/novonorm,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",452.5950000000002
241,Human,Atectura Breezhaler,Asthma,"indacaterol, mometasone",INDACATEROL ACETATE,EMEA/H/C/005067,no,Authorised,R03AK,no,no,no,no,no,no,30/05/2020,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",26/03/2020,07/09/2023,9,Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.,23/06/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/atectura-breezhaler,HZHXFIDENGBQFQ-FTBISJDPSA-N,"InChI=1S/C24H28N2O3.C2H4O2/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-2(3)4/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1H3,(H,3,4)/t22-;/m0./s1",452.5510000000001
520,Human,Orkambi,Cystic Fibrosis,"lumacaftor, ivacaftor",LUMACAFTOR,EMEA/H/C/003954,no,Authorised,R07AX30,no,no,no,no,no,no,19/11/2015,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,23/09/2015,04/07/2023,32,Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene.,09/03/2023,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi,UFSKUSARDNFIRC-UHFFFAOYSA-N,"InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)",452.4130000000001
307,Human,Synjardy,"Diabetes Mellitus, Type 2","empagliflozin, metformin",EMPAGLIFLOZIN,EMEA/H/C/003770,no,Authorised,A10BD20,no,no,no,no,no,no,27/05/2015,,Boehringer Ingelheim,Drugs used in diabetes,26/03/2015,30/08/2023,26,"Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets. ",31/05/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/synjardy,OBWASQILIWPZMG-QZMOQZSNSA-N,"InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1",450.9150000000001
308,Human,Glyxambi,"Diabetes Mellitus, Type 2","empagliflozin, linagliptin",EMPAGLIFLOZIN,EMEA/H/C/003833,no,Authorised,A10BD19,no,no,no,no,no,no,11/11/2016,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,15/09/2016,30/08/2023,16,"Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.",03/08/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi,OBWASQILIWPZMG-QZMOQZSNSA-N,"InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1",450.9150000000001
387,Human,Jardiance,"Diabetes Mellitus, Type 2;  Heart Failure;  Renal Insufficiency, Chronic",empagliflozin,EMPAGLIFLOZIN,EMEA/H/C/002677,no,Authorised,A10BK03,no,no,no,no,no,no,22/05/2014,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,20/03/2014,24/07/2023,28,"Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease. ",31/05/2018,14/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance,OBWASQILIWPZMG-QZMOQZSNSA-N,"InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1",450.9150000000001
1058,Human,Xalkori,"Carcinoma, Non-Small-Cell Lung",crizotinib,CRIZOTINIB,EMEA/H/C/002489,no,Authorised,L01ED01,no,no,no,no,no,no,23/10/2012,,Pfizer Europe MA EEIG,Antineoplastic agents,19/07/2012,28/10/2022,33,XALKORI as monotherapy is indicated for:The first?line treatment of adults with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC)The treatment of adults with ROS1?positive advanced non?small cell lung cancer (NSCLC)The treatment of paediatric patients (age ?6 to ,31/08/2018,02/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori,KTEIFNKAUNYNJU-GFCCVEGCSA-N,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",450.345
871,Human,Sivextro,"Soft Tissue Infections;  Skin Diseases, Bacterial",tedizolid phosphate,TEDIZOLID PHOSPHATE,EMEA/H/C/002846,no,Authorised,J01XX11,no,no,no,no,no,no,23/03/2015,,Merck Sharp & Dohme B.V.,"Antibacterials for systemic use, , Other antibacterials",22/01/2015,27/03/2023,21,Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.,08/08/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro,QCGUSIANLFXSGE-GFCCVEGCSA-N,"InChI=1S/C17H16FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H2,26,27,28)/t12-/m1/s1",450.3230000000001
376,Human,Jinarc,"Polycystic Kidney, Autosomal Dominant",tolvaptan,TOLVAPTAN,EMEA/H/C/002788,no,Authorised,C03XA01,yes,no,no,no,no,no,27/05/2015,,Otsuka Pharmaceutical Netherlands B.V.,"Diuretics, ",26/02/2015,01/09/2022,20,Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.,26/07/2018,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc,GYHCTFXIZSNGJT-UHFFFAOYSA-N,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",448.95000000000016
475,Human,Tolvaptan Accord,Inappropriate ADH Syndrome,tolvaptan,TOLVAPTAN,EMEA/H/C/005961,no,Authorised,C03XA01,no,yes,no,no,no,no,,,Accord Healthcare S.L.U.,"Diuretics, ",26/01/2023,24/03/2023,,Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).,24/01/2023,14/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tolvaptan-accord,GYHCTFXIZSNGJT-UHFFFAOYSA-N,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",448.95000000000016
1213,Human,Samsca,Inappropriate ADH Syndrome,tolvaptan,TOLVAPTAN,EMEA/H/C/000980,no,Authorised,C03XA01,no,no,no,no,no,no,02/08/2009,,Otsuka Pharmaceutical Netherlands B.V.,"Diuretics, ",28/05/2009,12/05/2022,15,"Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH)., ",29/06/2018,01/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/samsca,GYHCTFXIZSNGJT-UHFFFAOYSA-N,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",448.95000000000016
406,Human,Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen),Schizophrenia;  Bipolar Disorder,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/003803,no,Authorised,N05AX12,no,yes,no,no,no,no,30/06/2015,,Mylan Pharmaceuticals Limited,Psycholeptics,23/04/2015,06/09/2023,16,Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,02/02/2018,08/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
551,Human,Abilify Maintena,Schizophrenia,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/002755,no,Authorised,N05AX12,no,no,no,no,no,no,14/11/2013,,Otsuka Pharmaceutical Netherlands B.V.,Psycholeptics,18/09/2013,20/07/2023,20,Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.,27/08/2018,20/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
1148,Human,Aripiprazole Sandoz,Schizophrenia;  Bipolar Disorder,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/004008,no,Authorised,N05AX12,no,yes,no,no,no,no,20/08/2015,,Sandoz GmbH,Psycholeptics,25/06/2015,01/09/2022,9,"Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older., ",15/02/2018,01/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-sandoz,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
1154,Human,Aripiprazole Zentiva,Schizophrenia;  Bipolar Disorder,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/003899,no,Authorised,N05AX12,no,yes,no,no,no,no,25/06/2015,,"Zentiva, k.s.",Psycholeptics,23/04/2015,10/08/2022,9,Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,06/02/2018,26/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-zentiva,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
1198,Human,Aripiprazole Accord,Schizophrenia;  Bipolar Disorder,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/004021,no,Authorised,N05AX12,no,yes,no,no,no,no,15/11/2015,,Accord Healthcare S.L.U.,Psycholeptics,23/09/2015,11/07/2022,15,"Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older., ",15/02/2018,13/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-accord,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
1261,Human,Abilify,Schizophrenia;  Bipolar Disorder,aripiprazole,ARIPIPRAZOLE,EMEA/H/C/000471,no,Authorised,N05AX12,no,no,no,no,no,no,04/06/2004,,Otsuka Pharmaceutical Netherlands B.V.,Psycholeptics,26/02/2004,28/03/2022,49,Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,26/03/2018,08/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/abilify,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",448.394
978,Human,Stribild,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil",ELVITEGRAVIR,EMEA/H/C/002574,no,Authorised,J05AR09,no,no,no,no,no,no,24/05/2013,,Gilead Sciences Ireland UC,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,12/01/2023,25,Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.,19/07/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stribild,JUZYLCPPVHEVSV-LJQANCHMSA-N,"InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1",447.8900000000001
1066,Human,Genvoya,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",ELVITEGRAVIR,EMEA/H/C/004042,no,Authorised,J05AR,no,no,no,no,no,no,19/11/2015,,Gilead Sciences Ireland UC,Antivirals for systemic use,24/09/2015,03/10/2022,27,"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.",26/07/2018,28/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya,JUZYLCPPVHEVSV-LJQANCHMSA-N,"InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1",447.8900000000001
1795,Human,Vitekta,HIV Infections,elvitegravir,ELVITEGRAVIR,EMEA/H/C/002577,no,Withdrawn,J05AX11,yes,no,no,no,no,no,13/11/2013,,Gilead Sciences International Ltd,Antivirals for systemic use,19/09/2013,03/11/2016,4,"Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.",03/11/2016,29/05/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/vitekta,JUZYLCPPVHEVSV-LJQANCHMSA-N,"InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1",447.8900000000001
704,Human,Ibrance,Breast Neoplasms,palbociclib,PALBOCICLIB,EMEA/H/C/003853,no,Authorised,L01XE33,yes,no,no,no,no,no,09/11/2016,,Pfizer Europe MA EEIG ,Antineoplastic agents,15/09/2016,26/05/2023,16,"Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.",30/07/2018,06/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance,AHJRHEGDXFFMBM-UHFFFAOYSA-N,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",447.5430000000001
522,Human,Gefitinib Mylan,"Carcinoma, Non-Small-Cell Lung",gefitinib,GEFITINIB,EMEA/H/C/004826,no,Authorised,L01XE02,no,yes,no,no,no,no,27/09/2018,,Mylan Pharmaceuticals Limited,"Antineoplastic agents, Protein kinase inhibitors",,23/06/2023,6,Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non?small cell lung cancer (NSCLC) with activating mutations of EGFR?TK.,10/10/2018,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/gefitinib-mylan,XGALLCVXEZPNRQ-UHFFFAOYSA-N,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",446.9100000000001
570,Human,Iressa,"Carcinoma, Non-Small-Cell Lung",gefitinib,GEFITINIB,EMEA/H/C/001016,no,Authorised,L01XE02,no,no,no,no,no,no,24/06/2009,,AstraZeneca AB,Antineoplastic agents,,14/07/2023,16,Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.,23/04/2018,17/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/iressa,XGALLCVXEZPNRQ-UHFFFAOYSA-N,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",446.9100000000001
237,Human,Armisarte (previously Pemetrexed Actavis),"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED DIACID MONOHYDRATE,EMEA/H/C/004109,no,Authorised,L01BA04,no,no,no,no,no,no,18/01/2016,,Actavis Group PTC ehf,Antineoplastic agents,19/11/2015,16/10/2023,14,Malignant pleural mesotheliomaPemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,10/04/2018,17/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/armisarte,NBNBOZLBWLNZHB-ZOWNYOTGSA-N,"InChI=1S/C20H21N5O6.H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);1H2/t13-;/m0./s1",445.432
518,Human,Vokanamet,"Diabetes Mellitus, Type 2","canagliflozin, metformin",CANAGLIFLOZIN,EMEA/H/C/002656,no,Authorised,A10BD16,no,no,no,no,no,no,23/04/2014,,Janssen-Cilag International NV,Drugs used in diabetes,,15/06/2023,22,"Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated doses of metformin alonein patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.in patients already being treated with the combination of canagliflozin and metformin as separate tabletsFor study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",15/03/2018,28/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet,XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,"InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1",444.524
524,Human,Invokana,"Diabetes Mellitus, Type 2",canagliflozin,CANAGLIFLOZIN,EMEA/H/C/002649,no,Authorised,A10BK02,no,no,no,no,no,no,15/11/2013,,Janssen-Cilag International NV,Drugs used in diabetes,19/09/2013,15/06/2023,23,"Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.",26/07/2018,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/invokana,XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,"InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1",444.524
1107,Human,Isentress,HIV Infections,raltegravir,RALTEGRAVIR,EMEA/H/C/000860,no,Authorised,J05AJ01,no,no,no,no,yes,no,19/12/2007,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,15/11/2007,17/10/2022,42,Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.,07/06/2018,20/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/isentress,CZFFBEXEKNGXKS-UHFFFAOYSA-N,"InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)",444.423
1187,Human,Sitagliptin Accord,"Diabetes Mellitus, Type 2",sitagliptin,SITAGLIPTIN HYDROCHLORIDE,EMEA/H/C/005598,no,Authorised,A10BH01,no,yes,no,no,no,no,25/04/2022,,Accord Healthcare S.L.U.,Drugs used in diabetes,24/02/2022,25/04/2022,,"For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPARy) agonist (i.e. a thiazolidinedione) when use of a PPARy agonist is appropriate and when diet and exercise plus the PPARy agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPARy agonist and metformin when use of a PPARy agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",22/02/2022,21/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-accord,PNXSHNOORJKXDW-SBSPUUFOSA-N,"InChI=1S/C16H15F6N5O.ClH/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;/h4,6,9H,1-3,5,7,23H2;1H/t9-;/m1./s1",443.77899999999994
459,Human,Nexpovio,Multiple Myeloma,selinexor,SELINEXOR,EMEA/H/C/005127,no,Authorised,L01XX66,yes,no,no,no,no,no,26/03/2021,,Stemline Therapeutics B.V.,Antineoplastic agents,28/01/2021,14/08/2023,8,"NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.",27/05/2021,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio,DEVSOMFAQLZNKR-RJRFIUFISA-N,"InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-",443.3109999999999
825,Human,Mirvaso,Skin Diseases,brimonidine,BRIMONIDINE TARTRATE,EMEA/H/C/002642,no,Authorised,D11AX21,no,no,no,no,no,no,20/02/2014,,Galderma International,Other dermatological preparations,,18/04/2023,13,Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.,26/04/2018,19/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso,QZHBYNSSDLTCRG-LREBCSMRSA-N,"InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1",442.2260000000001
1028,Human,Simbrinza,"Ocular Hypertension;  Glaucoma, Open-Angle","brinzolamide, brimonidine tartrate",BRIMONIDINE TARTRATE,EMEA/H/C/003698,no,Authorised,S01EC54,no,no,no,no,no,no,18/07/2014,,Novartis Europharm Limited,Ophthalmologicals,22/05/2014,10/12/2022,10,Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.,23/08/2018,19/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza,QZHBYNSSDLTCRG-LREBCSMRSA-N,"InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1",442.2260000000001
1968,Human,Tikosyn,Atrial Fibrillation;  Atrial Flutter,dofetilide,DOFETILIDE,EMEA/H/C/000238,no,Withdrawn,C01BD04,no,no,no,no,no,no,29/11/1999,,Pfizer Limited,Cardiac therapy,,31/12/2009,0,"Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5.1).Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).",31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn,IXTMWRCNAAVVAI-UHFFFAOYSA-N,"InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3",441.575
205,Human,Piqray,Breast Neoplasms,alpelisib,ALPELISIB,EMEA/H/C/004804,no,Authorised,L01XE,yes,no,no,no,no,no,27/07/2020,,Novartis Europharm Limited ,Antineoplastic agents,28/05/2020,14/09/2023,10,"Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1).",30/07/2020,26/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/piqray,STUWGJZDJHPWGZ-LBPRGKRZSA-N,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",441.479
38,Human,Pylclari,Prostatic Neoplasms,piflufolastat (18F),PIFLUFOLASTAT (18F),EMEA/H/C/005520,no,Authorised,V09,yes,no,no,no,no,no,24/07/2023,,Curium Pet France,Diagnostic radiopharmaceuticals,25/05/2023,27/11/2023,1,"This medicinal product is for diagnostic use only.Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high-risk PCa prior to initial curative therapy,To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.Pylclari is indicated for use with positron emission tomography (PET).",28/07/2023,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pylclari,OLWVRJUNLXQDSP-MVBOSPHXSA-N,"InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1",441.40293800000006
398,Human,Dovato,HIV Infections,"dolutegravir, lamivudine",DOLUTEGRAVIR SODIUM,EMEA/H/C/004909,no,Authorised,J05AR,no,no,no,no,no,no,10/06/2022,,ViiV Healthcare B.V.,Antivirals for systemic use,26/04/2019,06/09/2023,14,"Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.",04/09/2019,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dovato,UGWJRRXTMKRYNK-VSLILLSYSA-M,"InChI=1S/C20H19F2N3O5.Na/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22;/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28);/q;+1/p-1/t10-,15+;/m1./s1",441.3660000000001
979,Human,Juluca,HIV Infections,"dolutegravir, rilpivirine",DOLUTEGRAVIR SODIUM,EMEA/H/C/004427,no,Authorised,J05AR,no,no,no,no,no,no,16/05/2018,,ViiV Healthcare B.V.,Antivirals for systemic use,22/03/2018,12/01/2023,14,Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA ,16/05/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/juluca,UGWJRRXTMKRYNK-VSLILLSYSA-M,"InChI=1S/C20H19F2N3O5.Na/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22;/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28);/q;+1/p-1/t10-,15+;/m1./s1",441.3660000000001
394,Human,Mektovi,Melanoma,binimetinib,BINIMETINIB,EMEA/H/C/004579,no,Authorised,L01EE03,yes,no,no,no,no,no,20/09/2018,,Pierre Fabre Medicament,Antineoplastic agents,,23/06/2023,7,Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,27/07/2018,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi,ACWZRVQXLIRSDF-UHFFFAOYSA-N,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",441.23199999999997
834,Human,Zeposia,"Multiple Sclerosis, Relapsing-Remitting;  Colitis, Ulcerative",ozanimod,OZANIMOD HYDROCHLORIDE,EMEA/H/C/004835,no,Authorised,L04AA38,yes,no,no,no,no,no,20/05/2020,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,26/03/2020,24/03/2023,5,"Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.",27/05/2020,13/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia,HAOOCAKHSFYDBU-BDQAORGHSA-N,"InChI=1S/C23H24N4O3.ClH/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28;/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3;1H/t20-;/m0./s1",440.9310000000001
334,Human,Imbruvica,"Lymphoma, Mantle-Cell;  Leukemia, Lymphocytic, Chronic, B-Cell",ibrutinib,IBRUTINIB,EMEA/H/C/003791,no,Authorised,L01EL01,no,no,no,no,no,no,21/10/2014,,Janssen-Cilag International NV,"Antineoplastic agents, Protein kinase inhibitors",25/07/2014,15/09/2023,31,"IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.",29/07/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica,XYFPWWZEPKGCCK-GOSISDBHSA-N,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",440.50700000000023
772,Human,Votrient,"Carcinoma, Renal Cell",pazopanib,PAZOPANIB,EMEA/H/C/001141,no,Authorised,L01XE11,no,no,no,no,no,no,14/06/2010,,Novartis Europharm Limited ,Antineoplastic agents,14/06/2010,20/04/2023,31,Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.,08/05/2018,16/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/votrient,CUIHSIWYWATEQL-UHFFFAOYSA-N,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",437.52900000000005
532,Human,Vaborem,"Urinary Tract Infections;  Bacteremia;  Bacterial Infections;  Respiratory Tract Infections;  Pneumonia;  Pneumonia, Ventilator-Associated","meropenem, vaborbactam",MEROPENEM TRIHYDRATE,EMEA/H/C/004669,no,Authorised,J01DH,no,no,no,no,no,no,20/11/2018,,Menarini International Operations Luxembourg S.A.,"Antibacterials for systemic use, ",20/09/2018,24/07/2023,7,"Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.",18/12/2018,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem,CTUAQTBUVLKNDJ-OBZXMJSBSA-N,"InChI=1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1",437.5150000000002
141,Human,Cresemba,Aspergillosis,isavuconazole,ISAVUCONAZOLE,EMEA/H/C/002734,no,Authorised,J02AC,no,no,no,no,no,yes,15/10/2015,,Basilea Pharmaceutica Deutschland GmbH,,23/07/2005,19/12/2022,17,Cresemba is indicated in adults for the treatment of:invasive aspergillosismucormycosis in patients for whom amphotericin B is inappropriateConsideration should be given to official guidance on the appropriate use of antifungal agents.,24/08/2017,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba,DDFOUSQFMYRUQK-RCDICMHDSA-N,"InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1",437.475
1101,Human,Relistor,Opioid-Related Disorders;  Constipation,methylnaltrexone bromide,METHYLNALTREXONE BROMIDE,EMEA/H/C/000870,no,Authorised,A06AH01,no,no,no,no,no,no,01/07/2008,,Bausch Health Ireland Limited,Peripheral opioid receptor antagonists,24/04/2008,28/10/2022,18,Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.,09/01/2017,31/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/relistor,IFGIYSGOEZJNBE-NQMNLMSRSA-N,"InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22-;/m1./s1",436.34600000000006
1886,Human,Trevaclyn,Dyslipidemias,"laropiprant, nicotinic acid",LAROPIPRANT,EMEA/H/C/000897,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd,Lipid modifying agents,,10/04/2013,11,"Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/trevaclyn,NXFFJDQHYLNEJK-CYBMUJFWSA-N,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",435.90400000000005
1887,Human,Pelzont,Dyslipidemias,"laropiprant, nicotinic acid",LAROPIPRANT,EMEA/H/C/000903,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd,Lipid modifying agents,,10/04/2013,11,"Pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Pelzont.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/pelzont,NXFFJDQHYLNEJK-CYBMUJFWSA-N,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",435.90400000000005
1888,Human,Tredaptive,Dyslipidemias,"laropiprant, nicotinic acid",LAROPIPRANT,EMEA/H/C/000889,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd.,Lipid modifying agents,,10/04/2013,11,"Tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Tredaptive.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/tredaptive,NXFFJDQHYLNEJK-CYBMUJFWSA-N,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",435.90400000000005
256,Human,Rivaroxaban Accord,Acute Coronary Syndrome;  Coronary Artery Disease;  Peripheral Arterial Disease;  Venous Thromboembolism;  Stroke;  Atrial Fibrillation;  Pulmonary Embolism,rivaroxaban,RIVAROXABAN,EMEA/H/C/005279,no,Authorised,B01AF01,no,yes,no,no,no,no,16/11/2020,,Accord Healthcare S.L.U.,Antithrombotic agents,17/09/2020,27/09/2023,5,"Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.",24/11/2020,12/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",435.88900000000007
504,Human,Xarelto,"Arthroplasty, Replacement;  Venous Thromboembolism",rivaroxaban,RIVAROXABAN,EMEA/H/C/000944,no,Authorised,B01AF01,no,no,no,no,no,no,30/09/2008,,Bayer AG,Antithrombotic agents,24/07/2008,26/07/2023,40,"Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.",02/07/2018,02/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",435.88900000000007
657,Human,Rivaroxaban Viatris (previously Rivaroxaban Mylan),Venous Thromboembolism;  Pulmonary Embolism;  Acute Coronary Syndrome;  Stroke;  Coronary Artery Disease;  Peripheral Arterial Disease;  Atrial Fibrillation,rivaroxaban,RIVAROXABAN,EMEA/H/C/005600,no,Authorised,B01AF01,no,yes,no,no,no,no,12/11/2021,,Mylan Ireland Limited,Antithrombotic agents,16/09/2021,22/06/2023,4,"Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.-------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. ",14/09/2021,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-viatris,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",435.88900000000007
300,Human,Exforge HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",VALSARTAN,EMEA/H/C/001068,no,Authorised,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",07/06/2018,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
312,Human,Dafiro HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",VALSARTAN,EMEA/H/C/001160,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,15/12/2022,26,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",25/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro-hct,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
314,Human,Copalia HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",VALSARTAN,EMEA/H/C/001159,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,"Angiotensin II antagonists, combinations, Agents acting on the renin-angiotensin system, Angiotensin II antagonists and calcium channel blockers",,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",17/04/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
390,Human,Neparvis,Heart Failure,"sacubitril, valsartan",VALSARTAN,EMEA/H/C/004343,no,Authorised,C09DX04,yes,no,no,no,no,no,26/05/2016,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,31/03/2016,11/09/2023,18,Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).,22/06/2018,13/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
395,Human,Entresto,Heart Failure,"sacubitril, valsartan",VALSARTAN,EMEA/H/C/004062,no,Authorised,C09DX04,no,no,no,no,no,no,19/11/2015,,Novartis Europharm Limited,"Angiotensin II antagonists, other combinations, Agents acting on the renin-angiotensin system",24/09/2015,11/09/2023,18,Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.,22/06/2018,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/entresto,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
464,Human,Amlodipine  / Valsartan Mylan ,Hypertension,"amlodipine, valsartan",VALSARTAN,EMEA/H/C/004037,no,Authorised,C09DB01,no,yes,no,no,no,no,22/03/2016,,Mylan Pharmaceuticals Limited,Agents acting on the renin-angiotensin system,28/01/2016,14/08/2023,11,Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,26/02/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
1087,Human,Dafiro,Hypertension,"amlodipine, valsartan",VALSARTAN,EMEA/H/C/000776,no,Authorised,C09DB01,no,no,no,no,no,no,15/01/2007,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,10/11/2022,30,"Treatment of essential hypertension., , Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy., ",07/06/2018,11/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
1900,Human,Imprida HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",VALSARTAN,EMEA/H/C/001161,no,Withdrawn,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Ltd.,"Angiotensin II antagonists, plain, Angiotensin II antagonists, combinations",,20/10/2012,3,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",20/10/2012,22/10/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/imprida-hct,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",435.52800000000013
1065,Human,Intelence,HIV Infections,etravirine,ETRAVIRINE,EMEA/H/C/000900,no,Authorised,J05AG04,no,no,no,no,no,no,28/08/2008,,Janssen-Cilag International NV,"Non-nucleoside reverse transcriptase inhibitors, Antivirals for systemic use",,07/10/2022,30,"Intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age.This indication is based on week-48 analyses from two phase-III trials in highly pretreated patients where Intelence was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, phase-II trial in antiretroviral-treatment-experienced paediatric patients.",13/07/2017,28/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/intelence,PYGWGZALEOIKDF-UHFFFAOYSA-N,"InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)",435.28499999999997
355,Human,Lynparza,Ovarian Neoplasms,olaparib,OLAPARIB,EMEA/H/C/003726,no,Authorised,L01XK01,no,no,no,no,no,no,16/12/2014,,AstraZeneca AB,Antineoplastic agents,,15/09/2023,23,"Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).",08/05/2018,21/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza,FDLYAMZZIXQODN-UHFFFAOYSA-N,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",434.4710000000001
328,Human,ellaOne,"Contraception, Postcoital",ulipristal acetate,ULIPRISTAL,EMEA/H/C/001027,no,Authorised,G03AD02,no,no,no,no,no,no,15/05/2009,,Laboratoire HRA Pharma,"Sex hormones and modulators of the genital system, , Emergency contraceptives",,07/09/2023,30,Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.,22/08/2018,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone,HKDLNTKNLJPAIY-WKWWZUSTSA-N,"InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1",433.5920000000001
690,Human,Rxulti,Schizophrenia,brexpiprazole,BREXPIPRAZOLE,EMEA/H/C/003841,no,Authorised,N05AX16,no,no,no,no,no,no,26/07/2018,,Otsuka Pharmaceutical Netherlands B.V.,Psycholeptics,30/05/2018,26/05/2023,5,Treatment of schizophrenia.,26/11/2018,14/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti,ZKIAIYBUSXZPLP-UHFFFAOYSA-N,"InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)",433.5770000000001
290,Human,CellCept,Graft Rejection,mycophenolate mofetil,MYCOPHENOLATE MOFETIL,EMEA/H/C/000082,no,Authorised,L04AA06,no,no,no,no,no,no,14/02/1996,,Roche Registration GmbH,Immunosuppressants,,15/03/2023,38,"CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.",09/08/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cellcept,RTGDFNSFWBGLEC-SYZQJQIISA-N,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",433.5010000000002
322,Human,Myfenax,Graft Rejection,mycophenolate mofetil,MYCOPHENOLATE MOFETIL,EMEA/H/C/000884,no,Authorised,L04AA06,no,yes,no,no,no,no,21/02/2008,,Teva B.V.,Immunosuppressants,13/12/2007,22/09/2023,27,"Myfenax is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.",19/03/2018,26/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/myfenax,RTGDFNSFWBGLEC-SYZQJQIISA-N,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",433.5010000000002
1173,Human,Myclausen,Graft Rejection,mycophenolate mofetil,MYCOPHENOLATE MOFETIL,EMEA/H/C/001218,no,Authorised,L04AA06,no,yes,no,no,no,no,07/10/2010,,Passauer Pharma GmbH,Immunosuppressants,,01/08/2022,15,"Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants., ",05/03/2018,04/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/myclausen,RTGDFNSFWBGLEC-SYZQJQIISA-N,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",433.5010000000002
1222,Human,Mycophenolate mofetil Teva,Graft Rejection,mycophenolate mofetil,MYCOPHENOLATE MOFETIL,EMEA/H/C/000882,no,Authorised,L04AA06,no,yes,no,no,no,no,21/02/2008,,Teva Pharma B.V.,Immunosuppressants,13/12/2007,24/06/2022,25,"Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.",19/03/2018,24/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/mycophenolate-mofetil-teva,RTGDFNSFWBGLEC-SYZQJQIISA-N,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",433.5010000000002
963,Human,Roclanda,"Glaucoma, Open-Angle;  Ocular Hypertension",latanoprost / netarsudil,LATANOPROST,EMEA/H/C/005107,no,Authorised,S01EE,yes,no,no,no,no,no,07/01/2021,,Santen Oy,Ophthalmologicals,12/11/2020,12/12/2022,4,Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.,21/01/2021,16/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/roclanda,GGXICVAJURFBLW-CEYXHVGTSA-N,"InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1",432.60100000000006
1117,Human,Azarga,"Glaucoma, Open-Angle;  Ocular Hypertension","brinzolamide, timolol",TIMOLOL MALEATE,EMEA/H/C/000960,no,Authorised,S01ED51,no,no,no,no,no,no,25/11/2008,,Novartis Europharm Limited,Ophthalmologicals,,11/10/2022,16,Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.,22/06/2018,11/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/azarga,WLRMANUAADYWEA-NWASOUNVSA-N,"InChI=1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1",432.4990000000002
1344,Human,Klisyri,"Keratosis, Actinic",tirbanibulin,TIRBANIBULIN,EMEA/H/C/005183,no,Authorised,D06BX03,yes,no,no,no,no,no,16/07/2021,,"Almirall, S.A.",Antibiotics and chemotherapeutics for dermatological use,20/05/2021,18/01/2022,1,"Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.",20/04/2021,19/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri,HUNGUWOZPQBXGX-UHFFFAOYSA-N,"InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)",431.53600000000006
1047,Human,Feraccru,"Anemia, Iron-Deficiency",ferric maltol,FERRIC MALTOL,EMEA/H/C/002733,no,Authorised,B03AB,no,no,no,no,no,no,18/02/2016,,Norgine B.V.,Antianemic preparations,17/12/2015,08/12/2022,17,Feraccru is indicated in adults for the treatment of iron deficiency.,15/06/2018,12/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru,AHPWLYJHTFAWKI-UHFFFAOYSA-K,"InChI=1S/3C6H6O3.Fe/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3",431.1540000000001
1633,Human,Picato,"Keratosis, Actinic",ingenol mebutate,INGENOL MEBUTATE,EMEA/H/C/002275,no,Withdrawn,D06BX02,yes,no,no,no,no,no,15/11/2012,,LEO Laboratories Ltd.,"Antibiotics and chemotherapeutics for dermatological use, Other chemotherapeutics",,02/07/2020,10,"Picato is indicated for the cutaneous treatment of non?hyperkeratotic, non?hypertrophic actinic keratosis in adults.",13/07/2017,31/07/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/picato,VDJHFHXMUKFKET-WDUFCVPESA-N,"InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1",430.5410000000002
178,Human,CoAprovel,Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/000222,no,Authorised,C09DA04,no,no,no,no,no,no,14/10/1998,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,22/07/1998,27/10/2023,49,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,22/08/2017,31/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/coaprovel,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
186,Human,Karvezide,Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/000221,no,Authorised,C09DA04,no,no,no,no,no,no,16/10/1998,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,27/10/2023,47,Treatment of essential hypertension.This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,24/08/2017,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/karvezide,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
414,Human,Irbesartan Teva,Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/001093,no,Authorised,C09CA04,no,yes,no,no,no,no,30/10/2009,,Teva B.V.,Agents acting on the renin-angiotensin system,23/07/2009,01/09/2023,16,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,31/08/2016,05/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
590,Human,Ifirmacombi,Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/002302,no,Authorised,C09DA04,no,yes,no,no,no,no,04/03/2011,,"Krka, d.d., Novo mesto",Agents acting on the renin-angiotensin system,,07/07/2023,15,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,20/12/2017,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ifirmacombi,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
598,Human,Karvea,Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/000142,no,Authorised,C09CA04,no,no,no,no,no,no,26/08/1997,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,06/07/2023,46,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,02/08/2017,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/karvea,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
609,Human,Aprovel,Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/000141,no,Authorised,C09CA04,no,no,no,no,no,no,26/08/1997,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,06/07/2023,48,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.,02/08/2017,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aprovel,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
684,Human,Irbesartan/Hydrochlorothiazide Teva,Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/001112,no,Authorised,C09DA04,no,yes,no,no,no,no,26/11/2009,,Teva B.V. ,Agents acting on the renin-angiotensin system,24/09/2009,15/06/2023,22,Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,07/11/2017,16/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-teva,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
837,Human,Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop),Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/000783,no,Authorised,C09DA04,no,no,no,no,no,no,18/01/2007,,sanofi-aventis groupe ,Agents acting on the renin-angiotensin system,,12/04/2023,34,Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,28/08/2017,13/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
1129,Human,Irbesartan Zentiva (previously Irbesartan Winthrop),Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/000785,no,Authorised,C09CA04,no,no,no,no,no,no,19/01/2007,,Zentiva k.s.,Agents acting on the renin-angiotensin system,19/01/2007,27/09/2022,28,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.,02/08/2017,28/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-zentiva,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
1792,Human,Sabervel,Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/002510,no,Withdrawn,C09CA04,no,yes,no,no,no,no,13/04/2012,,Pharmathen S.A.,Agents acting on the renin-angiotensin system,,04/09/2014,2,Sabervel is indicated in adults for the treatment of essential hypertension.It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,04/09/2014,29/06/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/sabervel,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
1971,Human,Irbesartan BMS,Hypertension,irbesartan,IRBESARTAN,EMEA/H/C/000786,no,Withdrawn,C09CA04,no,no,no,no,no,no,19/01/2007,,Bristol-Myers Squibb Pharma EEIG,Agents acting on the renin-angiotensin system,,07/04/2009,7,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).,07/04/2009,26/11/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-bms,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
1972,Human,Irbesartan Hydrochlorothiazide BMS,Hypertension,"irbesartan, hydrochlorothiazide",IRBESARTAN,EMEA/H/C/000784,no,Withdrawn,C09DA04,no,no,no,no,no,no,19/01/2007,,Bristol-Myers Squibb Pharma EEIG,Agents acting on the renin-angiotensin system,,09/10/2009,8,Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).,09/10/2009,24/11/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-bms,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",428.54000000000013
1167,Human,Ranexa (previously Latixa),Angina Pectoris,ranolazine,RANOLAZINE,EMEA/H/C/000805,no,Authorised,C01EB18,no,no,no,no,no,no,08/07/2008,,Menarini International Operations Luxembourg S.A. (MIOL),Cardiac therapy,,10/08/2022,22,"Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists)., ",03/08/2017,11/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa,XKLMZUWKNUAPSZ-UHFFFAOYSA-N,"InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)",427.5450000000001
1168,Human,Pemetrexed medac,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED,EMEA/H/C/003905,no,Authorised,L01BA04,no,yes,no,no,no,no,26/11/2015,,medac Gesellschaft für klinische Spezialpräparate mbH,"Folic acid analogues, Antineoplastic agents",23/09/2015,08/08/2022,8,"Malignant pleural mesothelioma Pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer Pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., ",18/05/2018,09/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-medac,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",427.417
1178,Human,Pemetrexed Fresenius Kabi,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED,EMEA/H/C/003895,no,Authorised,L01BA04,no,yes,no,no,no,no,22/07/2016,,Fresenius Kabi Deutschland GmbH,Antineoplastic agents,26/05/2016,26/07/2022,13,Malignant pleural mesotheliomaPemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Fresenius Kabi is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Fresenius Kabi is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,06/07/2018,27/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-fresenius-kabi,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",427.417
1255,Human,Alimta,"Mesothelioma;  Carcinoma, Non-Small-Cell Lung",pemetrexed,PEMETREXED,EMEA/H/C/000564,no,Authorised,L01BA04,no,no,no,no,no,no,20/09/2004,,Eli Lilly Nederland B.V.,Antineoplastic agents,,22/04/2022,27,Malignant pleural mesotheliomaAlimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.Non-small-cell lung cancerAlimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.,23/03/2018,03/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/alimta,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",427.417
1394,Human,Pemetrexed Lilly,"Carcinoma, Non-Small-Cell Lung;  Mesothelioma",pemetrexed,PEMETREXED,EMEA/H/C/004114,no,Withdrawn,L01BA04,no,yes,no,no,no,no,14/09/2015,,Eli Lilly Netherlands,Antineoplastic agents,,18/06/2021,7,Malignant pleural mesotheliomaPemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.,26/04/2017,26/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-lilly,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",427.417
244,Human,Enerzair Breezhaler,Asthma,"indacaterol, glycopyrronium bromide, mometasone",MOMETASONE,EMEA/H/C/005061,no,Authorised,R03AL,no,no,no,no,no,no,03/07/2020,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",07/09/2023,16/06/2023,6,Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.,21/07/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/enerzair-breezhaler,QLIIKPVHVRXHRI-CXSFZGCWSA-N,"InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",427.36800000000005
1513,Human,Celsunax,Radionuclide Imaging;  Dementia;  Movement Disorders,ioflupane (123I),IOFLUPANE (123I),EMEA/H/C/005135,no,Authorised,V09AB03,no,yes,no,no,no,no,17/06/2021,,Pinax Pharma GmbH,Diagnostic radiopharmaceuticals,22/04/2021,17/06/2021,,"This medicinal product is for diagnostic use only.Celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Celsunax is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Celsunax is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.",01/07/2021,02/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/celsunax,HXWLAJVUJSVENX-HFIFKADTSA-N,"InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4",427.29058900000007
1643,Human,Invega,Schizophrenia;  Psychotic Disorders,paliperidone,PALIPERIDONE,EMEA/H/C/000746,no,Authorised,N05AX13,no,no,no,no,no,no,24/06/2007,,Janssen-Cilag International NV,Psycholeptics,,09/04/2021,18,Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.Invega is indicated for the treatment of schizoaffective disorder in adults.,31/05/2018,19/05/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/invega,PMXMIIMHBWHSKN-UHFFFAOYSA-N,"InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3",426.49200000000013
1497,Human,Verquvo,Heart Failure,vericiguat,VERICIGUAT,EMEA/H/C/005319,no,Authorised,C01,yes,no,no,no,no,no,16/07/2021,,Bayer AG,Cardiac therapy,20/05/2021,16/07/2021,,Treatment of symptomatic chronic heart failure,19/05/2021,27/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo,QZFHIXARHDBPBY-UHFFFAOYSA-N,"InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)",426.387
492,Human,Pifeltro,HIV Infections,doravirine,DORAVIRINE,EMEA/H/C/004747,no,Authorised,J05AG06,no,no,no,no,no,no,22/11/2018,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,20/09/2018,07/07/2023,9,"Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class.",21/09/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro,ZIAOVIPSKUPPQW-UHFFFAOYSA-N,"InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)",425.754
493,Human,Delstrigo,HIV Infections,"doravirine, lamivudine, tenofovir disoproxil",DORAVIRINE,EMEA/H/C/004746,no,Authorised,J05AR,no,no,no,no,no,no,22/11/2018,,Merck Sharp & Dohme B.V.,"Antivirals for treatment of HIV infections, combinations",20/09/2018,23/06/2023,11,"Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir.Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.",21/09/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo,ZIAOVIPSKUPPQW-UHFFFAOYSA-N,"InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)",425.754
854,Human,Sotyktu,Psoriasis,deucravacitinib,DEUCRAVACITINIB,EMEA/H/C/005755,no,Authorised,L04AA,yes,no,no,no,no,no,24/03/2023,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,26/01/2023,24/03/2023,,Treatment of moderate-to-severe plaque psoriasis in adults.,24/01/2023,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sotyktu,BZZKEPGENYLQSC-FIBGUPNXSA-N,"InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3",425.4673053
1164,Human,Zynquista,"Diabetes Mellitus, Type 1",sotagliflozin,SOTAGLIFLOZIN,EMEA/H/C/004889,no,Withdrawn,A10,yes,no,no,no,no,no,26/04/2019,,Guidehouse Germany GmbH,Drugs used in diabetes,27/02/2019,22/03/2022,3,"Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy., ",27/02/2019,16/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista,QKDRXGFQVGOQKS-CRSSMBPESA-N,"InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1",424.9460000000001
61,Human,Pravafenix,Dyslipidemias,"fenofibrate, pravastatin",PRAVASTATIN,EMEA/H/C/001243,no,Authorised,C10BA03,no,no,no,no,no,no,14/04/2011,,Laboratoires SMB S.A.,Lipid modifying agents,,27/11/2023,8,Pravafenix is indicated for the treatment of high-coronary-heart-disease (CHD)-risk adult patients with mixed dyslipidaemia characterised by high triglycerides and low HDL-cholesterol (C) levels whose LDL-C levels are adequately controlled while on a treatment with pravastatin-40-mg monotherapy.,14/01/2016,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pravafenix,TUZYXOIXSAXUGO-PZAWKZKUSA-N,"InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1",424.5340000000001
423,Human,Adempas,"Hypertension, Pulmonary",riociguat,RIOCIGUAT,EMEA/H/C/002737,no,Authorised,C02KX05,no,no,no,no,no,no,27/03/2014,,Bayer AG,Antihypertensives for pulmonary arterial hypertension,23/01/2014,31/05/2023,13,"Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ? 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists. ",07/03/2018,31/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/adempas,WXXSNCNJFUAIDG-UHFFFAOYSA-N,"InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)",422.424
10,Human,Hycamtin,Ovarian Neoplasms;  Uterine Cervical Neoplasms;  Small Cell Lung Carcinoma,topotecan,TOPOTECAN,EMEA/H/C/000123,no,Authorised,L01CE01,no,no,no,no,no,no,12/11/1996,,Sandoz Pharmaceuticals d.d.,Antineoplastic agents,17/07/1996,01/12/2023,39,Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.,23/04/2018,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
722,Human,Potactasol,Uterine Cervical Neoplasms;  Small Cell Lung Carcinoma,topotecan,TOPOTECAN,EMEA/H/C/002282,no,Authorised,L01CE01,no,yes,no,no,no,no,06/01/2011,,Actavis Group PTC ehf,Antineoplastic agents,21/10/2010,31/05/2023,11,Topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1).,20/03/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/potactasol,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
1174,Human,Topotecan Hospira,Uterine Cervical Neoplasms;  Small Cell Lung Carcinoma,topotecan,TOPOTECAN,EMEA/H/C/001192,no,Authorised,L01CE01,no,no,no,no,no,no,09/06/2010,,Pfizer Europe MA EEIG,Other antineoplastic agents,18/03/2010,01/08/2022,19,"Topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate., , Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination., ",13/04/2018,04/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/topotecan-hospira,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
1716,Human,Topotecan Actavis,Uterine Cervical Neoplasms;  Small Cell Lung Carcinoma,topotecan,TOPOTECAN,EMEA/H/C/001031,no,Withdrawn,L01CE01,no,yes,no,no,no,no,24/07/2009,,Actavis Group PTC ehf,Antineoplastic agents,,15/01/2019,6,"Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first-line regimen is not considered appropriate., , Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination., ",19/01/2014,07/03/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/topotecan-actavis,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
1754,Human,Topotecan Teva,Ovarian Neoplasms;  Uterine Cervical Neoplasms;  Small Cell Lung Carcinoma,topotecan,TOPOTECAN,EMEA/H/C/001071,no,Withdrawn,L01CE01,no,yes,no,no,no,no,21/09/2009,,Teva B.V.,Antineoplastic agents,,22/06/2018,8,"Topotecan monotherapy is indicated for the treatment of:, , , 	patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;, 	patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first-line regimen is not considered appropriate., , , Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination., ",22/06/2018,13/07/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/topotecan-teva,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
1967,Human,Evotopin,Ovarian Neoplasms,topotecan,TOPOTECAN,EMEA/H/C/000124,no,Withdrawn,L01CE01,no,no,no,no,no,no,15/04/1997,,Beecham Group plc,Antineoplastic agents,,31/12/2009,0,Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/evotopin,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",421.4530000000001
901,Human,Erivedge,"Carcinoma, Basal Cell",vismodegib,VISMODEGIB,EMEA/H/C/002602,no,Authorised,L01XX43,no,no,no,no,no,no,12/07/2013,26/04/2013,Roche Registration GmbH,Antineoplastic agents,25/04/2013,15/03/2023,15,Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy,15/03/2018,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge,BPQMGSKTAYIVFO-UHFFFAOYSA-N,"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",421.305
25,Human,Ocaliva,"Liver Cirrhosis, Biliary",obeticholic acid,OBETICHOLIC ACID,EMEA/H/C/004093,no,Authorised,A05AA04,yes,no,yes,no,no,yes,12/12/2016,,ADVANZ PHARMA Limited,Bile and liver therapy,13/10/2016,08/06/2023,17,Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.,21/03/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva,ZXERDUOLZKYMJM-ZWECCWDJSA-N,"InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1",420.63400000000007
1854,Human,Doribax,"Pneumonia, Ventilator-Associated;  Pneumonia, Bacterial;  Urinary Tract Infections;  Bacterial Infections;  Cross Infection",doripenem,DORIPENEM,EMEA/H/C/000891,no,Withdrawn,J01DH04,no,no,no,no,no,no,25/07/2008,,Janssen-Cilag International NV,"Antibacterials for systemic use, ",,21/02/2012,10,Doribax is indicated for the treatment of the following infections in adults:nosocomial pneumonia (including ventilator-associated pneumonia);complicated intra-abdominal infections;complicated urinary tract infections.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,21/02/2012,17/10/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/doribax,AVAACINZEOAHHE-VFZPANTDSA-N,"InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1",420.5130000000001
22,Human,Plavix,Stroke;  Peripheral Vascular Diseases;  Atrial Fibrillation;  Myocardial Infarction;  Acute Coronary Syndrome,clopidogrel,CLOPIDOGREL HYDROGEN SULFATE,EMEA/H/C/000174,no,Authorised,B01AC04,no,no,no,no,no,no,15/07/1998,,Sanofi Winthrop Industrie,Antithrombotic agents,25/03/1998,05/07/2023,50,"Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2  score ?4) or minor IS (NIHSS  ?3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.",22/03/2018,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/plavix,FDEODCTUSIWGLK-RSAXXLAASA-N,"InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1",419.9080000000001
310,Human,Clopidogrel / Acetylsalicylic acid Mylan,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",CLOPIDOGREL HYDROGEN SULFATE,EMEA/H/C/004996,no,Authorised,B01AC30,no,yes,no,no,no,no,09/01/2020,,Mylan Pharmaceuticals Limited,Antithrombotic agents,14/11/2019,22/09/2023,5,Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).Clopidogrel/Acetylsalicylic acid Mylan is a fixed-dose combination medicinal product for continuation of therapy in:Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy,24/01/2020,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acetylsalicylic-acid-mylan,FDEODCTUSIWGLK-RSAXXLAASA-N,"InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1",419.9080000000001
470,Human,Tivicay,HIV Infections,dolutegravir,DOLUTEGRAVIR,EMEA/H/C/002753,no,Authorised,J05AX12,no,no,no,no,no,no,16/01/2014,,ViiV Healthcare BV,Antivirals for systemic use,21/11/2013,20/07/2023,34,"Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.",01/03/2018,14/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay,RHWKPHLQXYSBKR-BMIGLBTASA-N,"InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1",419.38400000000007
286,Human,Cholib,Dyslipidemias,"fenofibrate, simvastatin",SIMVASTATIN,EMEA/H/C/002559,no,Authorised,C10BA04,no,no,no,no,no,no,26/08/2013,,Viatris Healthcare Limited,Lipid modifying agents,27/06/2013,23/08/2023,16,Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.,20/08/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cholib,RYMZZMVNJRMUDD-HGQWONQESA-N,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",418.5740000000001
228,Human,Lytgobi,Cholangiocarcinoma,futibatinib,FUTIBATINIB,EMEA/H/C/005627,no,Authorised,L01XE51,yes,no,yes,no,no,no,04/07/2023,,Taiho Pharma Netherlands B.V.,antineoplastic agents,26/04/2023,10/10/2023,1,Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,18/07/2023,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi,KEIPNCCJPRMIAX-HNNXBMFYSA-N,"InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1",418.45700000000016
1197,Human,Copiktra,"Leukemia, Lymphocytic, Chronic, B-Cell;  Lymphoma, Follicular",duvelisib,DUVELISIB,EMEA/H/C/005381,no,Authorised,L01EM04,yes,no,no,no,no,no,19/05/2021,,Secura Bio Limited,Antineoplastic agents,25/03/2021,27/01/2022,2,Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies.,31/05/2021,13/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra,SJVQHLPISAIATJ-ZDUSSCGKSA-N,"InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1",416.87200000000007
544,Human,Qaialdo,Edema;  Heart Failure;  Liver Cirrhosis;  Ascites;  Nephrotic Syndrome;  Hyperaldosteronism;  Essential Hypertension,spironolactone,SPIRONOLACTONE,EMEA/H/C/005535,no,Authorised,C03DA01,no,no,no,no,no,no,26/05/2023,,Nova Laboratories Ireland Limited,Antihypertensives and diuretics in combination,,26/05/2023,,"In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). ",25/07/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo,LXMSZDCAJNLERA-ZHYRCANASA-N,"InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1",416.58300000000014
1189,Human,Ganfort,"Glaucoma, Open-Angle;  Ocular Hypertension","bimatoprost, timolol",BIMATOPROST,EMEA/H/C/000668,no,Authorised,S01ED51,no,no,no,no,no,no,19/05/2006,,AbbVie Deutschland GmbH & Co. KG,Ophthalmologicals,,20/07/2022,23,"Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues., ",06/04/2017,20/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort,AQOKCDNYWBIDND-FTOWTWDKSA-N,"InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1",415.574
1190,Human,Lumigan,"Glaucoma, Open-Angle;  Ocular Hypertension",bimatoprost,BIMATOPROST,EMEA/H/C/000391,no,Authorised,S01EE03,no,no,no,no,no,no,08/03/2002,,AbbVie Deutschland GmbH & Co. KG,"Prostaglandin analogues, Ophthalmologicals",,20/07/2022,37,"Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., ",18/05/2017,20/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan,AQOKCDNYWBIDND-FTOWTWDKSA-N,"InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1",415.574
1693,Human,Airexar Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","salmeterol xinafoate, fluticasone propionate",SALMETEROL,EMEA/H/C/004267,no,Withdrawn,R03AK06,no,no,no,no,no,no,18/08/2016,,Teva B.V.,"Drugs for obstructive airway diseases, ",23/06/2016,19/02/2018,2,"Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting ?2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting ?2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 ",09/03/2017,02/07/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/airexar-spiromax,GIIZNNXWQWCKIB-UHFFFAOYSA-N,"InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2",415.5740000000002
654,Human,Zydelig,"Lymphoma, Non-Hodgkin;  Leukemia, Lymphocytic, Chronic, B-Cell",idelalisib,IDELALISIB,EMEA/H/C/003843,no,Authorised,L01XX47,yes,no,no,no,no,no,18/09/2014,,Gilead Sciences Ireland UC,"Antineoplastic agents, Other antineoplastic agents",25/07/2014,23/06/2023,20,"Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.",07/06/2018,23/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig,IFSDAJWBUCMOAH-HNNXBMFYSA-N,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",415.432
1155,Human,Ontilyv,Parkinson Disease,opicapone,OPICAPONE,EMEA/H/C/005782,no,Authorised,"N04, N04BX04",no,no,no,no,no,no,21/02/2022,,Bial Portela & Companhia S.A.,Anti-Parkinson drugs,16/12/2021,24/08/2022,1,Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.,14/12/2021,25/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv,ASOADIZOVZTJSR-UHFFFAOYSA-N,"InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3",413.1730000000001
1248,Human,Ongentys,Parkinson Disease,opicapone,OPICAPONE,EMEA/H/C/002790,no,Authorised,N04,no,no,no,no,no,no,24/06/2016,,"Bial - Portela  Cª, S.A.",Anti-Parkinson drugs,28/04/2016,13/05/2022,8,Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.,17/01/2017,13/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys,ASOADIZOVZTJSR-UHFFFAOYSA-N,"InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3",413.1730000000001
315,Human,Trepulmix,"Hypertension, Pulmonary",treprostinil,TREPROSTINIL SODIUM,EMEA/H/C/005207,no,Authorised,B01AC21,no,no,no,no,no,yes,03/04/2020,,SciPharm Sàrl,Antithrombotic agents,30/01/2020,13/09/2023,4,"Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.",08/04/2020,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trepulmix,IQKAWAUTOKVMLE-ZSESPEEFSA-M,"InChI=1S/C23H34O5.Na/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);/q;+1/p-1/t16-,17-,18+,19-,21+;/m0./s1",412.50200000000007
1245,Human,Selincro,Alcohol-Related Disorders,nalmefene,NALMEFENE HYDROCHLORIDE DIHYDRATE,EMEA/H/C/002583,no,Authorised,N07BB05,no,no,no,no,no,no,24/02/2013,,H. Lundbeck A/S,Drugs used in alcohol dependence,,16/05/2022,13,"Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.Selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.",08/12/2017,17/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/selincro,XOBQQQVDLSMXCE-JVRGSUDVSA-N,"InChI=1S/C21H25NO3.ClH.2H2O/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;;;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H;2*1H2/t16-,19+,20+,21-;;;/m1.../s1",411.9260000000001
390,Human,Neparvis,Heart Failure,"sacubitril, valsartan",SACUBITRIL,EMEA/H/C/004343,no,Authorised,C09DX04,yes,no,no,no,no,no,26/05/2016,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,31/03/2016,11/09/2023,18,Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).,22/06/2018,13/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis,PYNXFZCZUAOOQC-UTKZUKDTSA-N,"InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1",411.4980000000001
395,Human,Entresto,Heart Failure,"sacubitril, valsartan",SACUBITRIL,EMEA/H/C/004062,no,Authorised,C09DX04,no,no,no,no,no,no,19/11/2015,,Novartis Europharm Limited,"Angiotensin II antagonists, other combinations, Agents acting on the renin-angiotensin system",24/09/2015,11/09/2023,18,Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.,22/06/2018,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/entresto,PYNXFZCZUAOOQC-UTKZUKDTSA-N,"InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1",411.4980000000001
733,Human,Okedi,Schizophrenia,risperidone,RISPERIDONE,EMEA/H/C/005406,no,Authorised,N05AX08,no,no,no,no,no,no,14/02/2022,,"Laboratorios Farmacéuticos Rovi, S.A.",Psycholeptics,16/12/2021,26/05/2023,2,Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.,15/12/2021,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/okedi,RAPZEAPATHNIPO-UHFFFAOYSA-N,"InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3",410.49300000000005
1258,Human,Nustendi,Hypercholesterolemia;  Dyslipidemias,"bempedoic acid, ezetimibe",EZETIMIBE,EMEA/H/C/004959,no,Authorised,C10B,yes,no,no,no,no,no,27/03/2020,,Daiichi Sankyo Europe GmbH,Lipid modifying agents,30/01/2020,19/04/2022,5,"Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibealone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin",24/04/2020,21/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi,OLNTVTPDXPETLC-XPWALMASSA-N,"InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1",409.432
314,Human,Copalia HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",AMLODIPINE,EMEA/H/C/001159,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,"Angiotensin II antagonists, combinations, Agents acting on the renin-angiotensin system, Angiotensin II antagonists and calcium channel blockers",,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",17/04/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
588,Human,Twynsta,Hypertension,"telmisartan, amlodipine",AMLODIPINE,EMEA/H/C/001224,no,Authorised,C09DB04,no,no,no,no,no,no,07/10/2010,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,11/07/2023,13,Treatment of essential hypertension in adults:Add-on therapyTwynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.,22/05/2018,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/twynsta,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
1087,Human,Dafiro,Hypertension,"amlodipine, valsartan",AMLODIPINE,EMEA/H/C/000776,no,Authorised,C09DB01,no,no,no,no,no,no,15/01/2007,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,10/11/2022,30,"Treatment of essential hypertension., , Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy., ",07/06/2018,11/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
1801,Human,Rasilamlo,Hypertension,"aliskiren hemifumarate, amlodipine besilate",AMLODIPINE,EMEA/H/C/002073,no,Withdrawn,C09XA53,no,no,no,no,no,no,14/04/2011,,Novartis Europharm Ltd,Agents acting on the renin-angiotensin system,,25/06/2015,7,Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.,25/06/2015,28/03/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilamlo,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
1900,Human,Imprida HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",AMLODIPINE,EMEA/H/C/001161,no,Withdrawn,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Ltd.,"Angiotensin II antagonists, plain, Angiotensin II antagonists, combinations",,20/10/2012,3,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",20/10/2012,22/10/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/imprida-hct,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
1903,Human,Rasitrio,Hypertension,"aliskiren, amlodipine, hydrochlorothiazide",AMLODIPINE,EMEA/H/C/002017,no,Withdrawn,C09XA54,no,no,no,no,no,no,22/11/2011,,Novartis Europharm Ltd.,Cardiovascular system,,03/10/2013,1,"Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.",03/10/2013,20/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/rasitrio,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",408.88200000000006
845,Human,Dapagliflozin Viatris,"Diabetes Mellitus, Type 2;  Heart Failure, Systolic;  Heart Failure;  Renal Insufficiency, Chronic",dapagliflozin,DAPAGLIFLOZIN,EMEA/H/C/006006,no,Authorised,A10BK01,no,yes,no,no,no,no,24/03/2023,,Viatris Limited,Drugs used in diabetes,26/01/2023,,,"Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.",24/01/2023,04/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dapagliflozin-viatris,JVHXJTBJCFBINQ-ADAARDCZSA-N,"InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1",408.87800000000004
1618,Human,Qtrilmet,"Diabetes Mellitus, Type 2","metformin hydrochloride, saxagliptin, dapagliflozin",DAPAGLIFLOZIN,EMEA/H/C/004910,no,Withdrawn,A10BD,no,no,no,no,no,no,11/11/2019,,AstraZeneca AB,Drugs used in diabetes,19/09/2019,14/08/2020,2,Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.when already being treated with metformin and saxagliptin and dapagliflozin.,10/12/2019,09/10/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet,JVHXJTBJCFBINQ-ADAARDCZSA-N,"InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1",408.87800000000004
331,Human,Orphacol,"Digestive System Diseases;  Metabolism, Inborn Errors",cholic acid,CHOLIC ACID,EMEA/H/C/001250,no,Authorised,A05AA03,yes,no,no,yes,no,no,12/09/2013,25/05/2012,Theravia,Bile acids and derivatives,16/12/2010,15/05/2023,13,"Orphacol is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3?-hydroxy-?5-C27-steroid oxidoreductase deficiency or ?4-3-oxosteroid-5?-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.",04/08/2017,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orphacol,BHQCQFFYRZLCQQ-OELDTZBJSA-N,"InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",408.5790000000001
1635,Human,Kolbam ,"Metabolism, Inborn Errors",cholic acid,CHOLIC ACID,EMEA/H/C/002081,no,Withdrawn,A05AA03,no,no,no,yes,no,no,20/11/2015,,Retrophin Europe Ltd,Bile and liver therapy,21/11/2013,27/03/2020,14,"Cholic Acid FGK is indicated for the treatment of inborn errors of primary bile acid synthesis, in infants from one month of age for continuous lifelong treatment through adulthood, encompassing the following single enzyme defects:sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency;2- (or alpha-) methylacyl-CoA racemase (AMACR) deficiency;cholesterol 7 alpha-hydroxylase (CYP7A1) deficiency.",07/12/2016,15/07/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/kolbam,BHQCQFFYRZLCQQ-OELDTZBJSA-N,"InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",408.5790000000001
27,Human,Xelevia,"Diabetes Mellitus, Type 2",sitagliptin,SITAGLIPTIN,EMEA/H/C/000762,no,Authorised,A10BH01,no,no,no,no,no,no,21/03/2007,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,24/01/2007,14/11/2023,39,"For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",20/08/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
150,Human,Velmetia,"Diabetes Mellitus, Type 2","sitagliptin, metformin",SITAGLIPTIN,EMEA/H/C/000862,no,Authorised,A10BD07,no,no,no,no,no,no,16/07/2008,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,24/04/2008,09/11/2023,37,For patients with type-2 diabetes mellitus:Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.,29/06/2018,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/velmetia,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
358,Human,Ristaben,"Diabetes Mellitus, Type 2",sitagliptin,SITAGLIPTIN,EMEA/H/C/001234,no,Authorised,A10BH01,no,no,no,no,no,no,15/03/2010,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,17/12/2009,14/09/2023,27,"For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",22/05/2018,21/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ristaben,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
368,Human,Tesavel,"Diabetes Mellitus, Type 2",sitagliptin,SITAGLIPTIN,EMEA/H/C/000910,no,Authorised,A10BH01,no,no,no,no,no,no,10/01/2008,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,15/11/2007,14/09/2023,28,"For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPAR? agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPAR?) agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.",08/08/2018,19/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tesavel,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
371,Human,Januvia,"Diabetes Mellitus, Type 2",sitagliptin,SITAGLIPTIN,EMEA/H/C/000722,no,Authorised,A10BH01,no,no,no,no,no,no,20/03/2007,,Merck Sharp and Dohme B.V,Drugs used in diabetes,,14/09/2023,32,"For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;a PPAR? agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",16/05/2018,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/januvia,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
494,Human,Ristfor,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",SITAGLIPTIN,EMEA/H/C/001235,no,Authorised,A10BD07,no,no,no,no,no,no,15/03/2010,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,17/12/2009,01/08/2023,27,For patients with type-2 diabetes mellitus:Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPAR?) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.,29/06/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ristfor,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
495,Human,Efficib,"Diabetes Mellitus, Type 2","sitagliptin, metformin",SITAGLIPTIN,EMEA/H/C/000896,no,Authorised,A10BD07,no,no,no,no,no,no,15/07/2008,,Merck Sharp and Dohme B.V,Drugs used in diabetes,24/04/2008,01/08/2023,33,"For patients with type-2 diabetes mellitus:Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",22/05/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efficib,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
496,Human,Janumet,"Diabetes Mellitus, Type 2","sitagliptin, metformin",SITAGLIPTIN,EMEA/H/C/000861,no,Authorised,A10BD07,no,no,no,no,no,no,16/07/2008,18/02/2009,Merck Sharp & Dohme B.V.,Drugs used in diabetes,24/04/2008,01/08/2023,30,"For patients with type 2 diabetes mellitus:Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Janumet is indicated as triple combination therapy with a PPAR  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR  agonist.Janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",29/06/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/janumet,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",407.318
827,Human,Lorviqua,"Carcinoma, Non-Small-Cell Lung",lorlatinib,LORLATINIB,EMEA/H/C/004646,no,Authorised,L01ED05,yes,no,yes,no,no,no,06/05/2019,,Pfizer Europe MA EEIG,"Antineoplastic agents, Protein kinase inhibitors",28/02/2019,04/04/2023,11,Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK?positive advanced NSCLC whose disease has progressed after:alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; orcrizotinib and at least one other ALK TKI.,17/06/2019,18/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua,IIXWYSCJSQVBQM-LLVKDONJSA-N,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1",406.42100000000005
575,Human,Fareston,Breast Neoplasms,toremifene,TOREMIFENE,EMEA/H/C/000091,no,Authorised,L02BA02,no,no,no,no,no,no,14/02/1996,,Orion Corporation,Endocrine therapy,17/10/1995,24/11/2021,25,First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.,26/07/2018,17/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fareston,XFCLJVABOIYOMF-QPLCGJKRSA-N,"InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-",405.9690000000002
360,Human,Apretude,HIV Infections,cabotegravir,CABOTEGRAVIR,EMEA/H/C/005756,no,Authorised,J05AJ04,no,no,no,no,no,no,15/09/2023,,ViiV Healthcare B.V.,Antivirals for systemic use,20/07/2023,,,"Apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).",17/07/2023,20/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/apretude,WCWSTNLSLKSJPK-LKFCYVNXSA-N,"InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1",405.3570000000001
435,Human,Cerdelga,Gaucher Disease,eliglustat,ELIGLUSTAT,EMEA/H/C/003724,no,Authorised,A16AX10,yes,no,no,no,no,yes,19/01/2015,,Sanofi B.V.,"Other alimentary tract and metabolism products, ",20/11/2014,29/06/2023,16,"Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs).",07/06/2018,28/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga,FJZZPCZKBUKGGU-AUSIDOKSSA-N,"InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1",404.5510000000001
4,Human,Opzelura,Vitiligo,ruxolitinib,RUXOLITINIB PHOSPHATE,EMEA/H/C/005843,no,Authorised,D11AH,no,no,no,no,no,no,19/04/2023,,Incyte Biosciences Distribution B.V.,Other dermatological preparations,23/02/2023,19/10/2023,2,Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.,22/02/2023,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura,JFMWPOCYMYGEDM-XFULWGLBSA-N,"InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1",404.367
1630,Human,Duzallo,Gout,"allopurinol, lesinurad",LESINURAD,EMEA/H/C/004412,no,Withdrawn,M04AA51,yes,no,no,no,no,no,23/08/2018,,Grunenthal GmbH,Antigout preparations,28/06/2019,31/07/2019,2,Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.,06/08/2020,,https://www.ema.europa.eu/en/medicines/human/EPAR/duzallo,FGQFOYHRJSUHMR-UHFFFAOYSA-N,"InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)",404.289
1632,Human,Zurampic,Hyperuricemia,lesinurad,LESINURAD,EMEA/H/C/003932,no,Withdrawn,M04AB05,yes,no,no,no,no,no,18/02/2016,,Grünenthal GmbH,Antigout preparations,,15/06/2017,4,"Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone., ",15/06/2017,31/07/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic,FGQFOYHRJSUHMR-UHFFFAOYSA-N,"InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)",404.289
1156,Human,Daxas,"Pulmonary Disease, Chronic Obstructive",roflumilast,ROFLUMILAST,EMEA/H/C/001179,no,Authorised,R03DX07,yes,no,no,no,no,no,05/07/2010,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",22/04/2010,25/08/2022,19,"Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment., ",23/04/2018,25/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/daxas,MNDBXUUTURYVHR-UHFFFAOYSA-N,"InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",403.21200000000005
1774,Human,Libertek,"Pulmonary Disease, Chronic Obstructive",roflumilast,ROFLUMILAST,EMEA/H/C/002399,no,Withdrawn,R03DX08,no,no,no,no,no,no,28/02/2011,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",,11/01/2018,11,Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,11/01/2018,08/02/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/libertek,MNDBXUUTURYVHR-UHFFFAOYSA-N,"InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",403.21200000000005
1775,Human,Daliresp,"Pulmonary Disease, Chronic Obstructive",roflumilast,ROFLUMILAST,EMEA/H/C/002398,no,Withdrawn,R03DX07,no,no,no,no,no,no,28/02/2011,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",,03/11/2016,9,Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,03/11/2016,06/02/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/daliresp,MNDBXUUTURYVHR-UHFFFAOYSA-N,"InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",403.21200000000005
957,Human,Odefsey,HIV Infections,"emtricitabine, rilpivirine, tenofovir alafenamide",RILPIVIRINE HYDROCHLORIDE,EMEA/H/C/004156,no,Authorised,J05AR19,no,no,no,no,no,no,21/06/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,28/04/2016,16/02/2023,20,"Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ? 100,000 HIV 1 RNA copies/mL., ",16/05/2018,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey,KZVVGZKAVZUACK-BJILWQEISA-N,"InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;",402.88899999999995
979,Human,Juluca,HIV Infections,"dolutegravir, rilpivirine",RILPIVIRINE HYDROCHLORIDE,EMEA/H/C/004427,no,Authorised,J05AR,no,no,no,no,no,no,16/05/2018,,ViiV Healthcare B.V.,Antivirals for systemic use,22/03/2018,12/01/2023,14,Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA ,16/05/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/juluca,KZVVGZKAVZUACK-BJILWQEISA-N,"InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;",402.88899999999995
1043,Human,Eviplera,HIV Infections,"emtricitabine, rilpivirine, tenofovir disoproxil",RILPIVIRINE HYDROCHLORIDE,EMEA/H/C/002312,no,Authorised,J05AR08,no,no,no,no,no,no,27/11/2011,,Gilead Sciences International Ltd ,Antivirals for systemic use,,12/12/2022,25,"Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.",19/07/2018,13/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera,KZVVGZKAVZUACK-BJILWQEISA-N,"InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;",402.88899999999995
1102,Human,Edurant,HIV Infections,rilpivirine,RILPIVIRINE HYDROCHLORIDE,EMEA/H/C/002264,no,Authorised,J05AG05,no,no,no,no,no,no,28/11/2011,,Janssen-Cilag International N.V.   ,Antivirals for systemic use,,28/10/2022,20,"Edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in antiretroviral treatment?naïve patients 12 years of age and older with a viral load ? 100,000 HIV?1 RNA copies/ml., , As with other antiretroviral medicinal products, genotypic resistance testing should guide the use of Edurant., ",08/05/2018,28/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/edurant,KZVVGZKAVZUACK-BJILWQEISA-N,"InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;",402.88899999999995
336,Human,Evrysdi,"Muscular Atrophy, Spinal",risdiplam,RISDIPLAM,EMEA/H/C/005145,no,Authorised,M09AX10,no,no,no,no,yes,no,26/03/2021,,Roche Registration GmbH ,Other drugs for disorders of the musculo-skeletal system,25/02/2021,16/08/2023,5,"Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. ",04/05/2021,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi,ASKZRYGFUPSJPN-UHFFFAOYSA-N,"InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3",401.4740000000001
621,Human,Rivastigmine Actavis,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE HYDROGEN TARTRATE,EMEA/H/C/002036,no,Authorised,N06DA03,no,yes,no,no,no,no,16/06/2011,,Actavis Group PTC ehf,"Psychoanaleptics, ",,31/05/2023,17,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,04/04/2018,05/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-actavis,GWHQHAUAXRMMOT-MBANBULQSA-N,"InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m01/s1",400.4280000000001
267,Human,Zubsolv,Opioid-Related Disorders,"buprenorphine, naloxone",NALOXONE HYDROCHLORIDE DIHYDRATE,EMEA/H/C/004407,no,Authorised,N07BC51,no,no,no,no,no,no,10/11/2017,,Accord Healthcare S.L.U.,Other nervous system drugs,,05/10/2023,10,"Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.",02/02/2018,10/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zubsolv,TXMZWEASFRBVKY-IOQDSZRYSA-N,"InChI=1S/C19H21NO4.ClH.2H2O/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;;;/h2-4,14,17,21,23H,1,5-10H2;1H;2*1H2/t14-,17+,18+,19-;;;/m1.../s1",399.87100000000015
935,Human,Nyxoid,Opioid-Related Disorders,naloxone,NALOXONE HYDROCHLORIDE DIHYDRATE,EMEA/H/C/004325,no,Authorised,V03AB15,no,no,no,no,no,no,09/11/2017,,Mundipharma Corporation (Ireland) Limited,All other therapeutic products,,24/02/2023,8,Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.Nyxoid is indicated in adults and adolescents aged 14 years and over.Nyxoid is not a substitute for emergency medical care.,10/01/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid,TXMZWEASFRBVKY-IOQDSZRYSA-N,"InChI=1S/C19H21NO4.ClH.2H2O/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;;;/h2-4,14,17,21,23H,1,5-10H2;1H;2*1H2/t14-,17+,18+,19-;;;/m1.../s1",399.87100000000015
902,Human,Nubeqa,"Prostatic Neoplasms, Castration-Resistant",darolutamide,DAROLUTAMIDE,EMEA/H/C/004790,no,Authorised,L02BB,yes,no,no,no,no,no,27/03/2020,,Bayer AG,Endocrine therapy,30/01/2020,27/02/2023,4,NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).,01/04/2020,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa,BLIJXOOIHRSQRB-PXYINDEMSA-N,"InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1",398.854
1376,Human,Sunitinib Accord,"Gastrointestinal Stromal Tumors;  Carcinoma, Renal Cell;  Neuroendocrine Tumors",sunitinib,SUNITINIB,EMEA/H/C/005419,no,Authorised,L01EX01,yes,yes,no,no,no,no,11/02/2021,,Accord Healthcare S.L.U.,Antineoplastic agents,10/12/2020,14/12/2021,1,"Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.",06/04/2021,14/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord,WINHZLLDWRZWRT-ATVHPVEESA-N,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",398.482
1490,Human,Sutent,"Gastrointestinal Stromal Tumors;  Carcinoma, Renal Cell;  Neuroendocrine Tumors",sunitinib,SUNITINIB,EMEA/H/C/000687,no,Authorised,L01EX01,no,no,no,no,no,no,19/07/2006,,Pfizer Limited,Antineoplastic agents,,04/08/2021,39,"Gastrointestinal stromal tumour (GIST)Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.Experience with Sutent as first-line treatment is limited (see section 5.1).",22/02/2018,13/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/sutent,WINHZLLDWRZWRT-ATVHPVEESA-N,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",398.482
203,Human,Xadago,Parkinson Disease,safinamide,SAFINAMIDE METHANESULFONATE,EMEA/H/C/002396,no,Authorised,N04B,no,no,no,no,no,no,23/02/2015,,Zambon SpA,Anti-Parkinson drugs,,19/10/2023,13,Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.,20/12/2017,26/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xadago,YKOCHIUQOBQIAC-YDALLXLXSA-N,"InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1",398.456
50,Human,Trixeo Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol, glycopyrronium bromide, budesonide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/004983,no,Authorised,R03AL,no,no,no,no,no,no,09/12/2020,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",15/10/2020,23/11/2023,5,Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.,05/01/2021,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
57,Human,Riltrava Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol fumarate dihydrate, glycopyrronium, budesonide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/005311,no,Authorised,R03AL11,no,no,no,no,no,no,06/01/2022,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",11/11/2021,23/11/2023,3,Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,10/11/2021,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riltrava-aerosphere,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
244,Human,Enerzair Breezhaler,Asthma,"indacaterol, glycopyrronium bromide, mometasone",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/005061,no,Authorised,R03AL,no,no,no,no,no,no,03/07/2020,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",07/09/2023,16/06/2023,6,Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.,21/07/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/enerzair-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
630,Human,Trimbow,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/004257,no,Authorised,R03AL09,no,no,no,no,no,no,17/07/2017,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",18/05/2017,24/03/2022,7,"Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. ",17/07/2017,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
682,Human,Sialanar,Sialorrhea,glycopyrronium,GLYCOPYRRONIUM BROMIDE,EMEA/H/C/003883,no,Authorised,A03AB02,no,no,no,no,no,no,15/09/2016,,Proveca Pharma Limited,Drugs for functional gastrointestinal disorders,,08/06/2023,10,Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.,11/05/2017,19/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
937,Human,Ulunar Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/003875,no,Authorised,R03AL04,no,no,no,no,no,no,23/04/2014,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",,15/11/2021,14,Ulunar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,08/05/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ulunar-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1374,Human,Seebri Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,GLYCOPYRRONIUM BROMIDE,EMEA/H/C/002430,no,Authorised,R03BB06,no,no,no,no,no,no,28/09/2012,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",,28/10/2021,12,Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,09/07/2018,15/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1407,Human,Enurev Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,GLYCOPYRRONIUM BROMIDE,EMEA/H/C/002691            ,no,Authorised,R03BB06,no,no,no,no,no,no,28/09/2012,,Novartis Europharm Ltd,"Drugs for obstructive airway diseases, ",,28/10/2021,10,Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,13/07/2017,10/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/enurev-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1410,Human,Tovanor Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,GLYCOPYRRONIUM BROMIDE,EMEA/H/C/002690,no,Authorised,R03BB06,no,no,no,no,no,no,28/09/2012,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",,28/10/2021,15,Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,09/07/2018,09/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/tovanor-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1471,Human,Xoterna Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/003755,no,Authorised,R03AL04,no,no,no,no,no,no,18/09/2013,,Novartis Europharm Limited,Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids,25/07/2013,06/08/2021,16,Xoterna Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,23/07/2018,07/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/xoterna-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1479,Human,Ultibro Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",GLYCOPYRRONIUM BROMIDE,EMEA/H/C/002679,no,Authorised,R03AL04,no,no,no,no,no,no,19/09/2013,,Novartis Europharm Limited,"Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids, Drugs for obstructive airway diseases, ",,06/08/2021,13,Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,23/07/2018,01/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ultibro-breezhaler,VPNYRYCIDCJBOM-QQTWVUFVSA-M,"InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1/t17-,19-;/m0./s1",398.34099999999995
1412,Human,Betmiga,"Urinary Bladder, Overactive",mirabegron,MIRABEGRON,EMEA/H/C/002388,no,Authorised,G04BD12,no,no,no,no,no,no,20/12/2012,,Astellas Pharma Europe B.V.,Urologicals,,26/10/2021,13,Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome.,18/09/2017,05/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga,PBAPPPCECJKMCM-IBGZPJMESA-N,"InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1",396.5159999999999
768,Human,Cinacalcet Accordpharma,Hyperparathyroidism,cinacalcet,CINACALCET HYDROCHLORIDE,EMEA/H/C/005236,no,Authorised,H05BX01,no,yes,no,no,no,no,03/04/2020,,Accord Healthcare S.L.U.,Calcium homeostasis,30/01/2020,15/05/2023,3,"Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.",15/04/2020,16/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-accordpharma,QANQWUQOEJZMLL-PKLMIRHRSA-N,"InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1",393.88000000000005
804,Human,Cinacalcet Mylan,"Hyperparathyroidism, Secondary;  Hypercalcemia",cinacalcet,CINACALCET HYDROCHLORIDE,EMEA/H/C/004014,no,Authorised,H05BX01,no,yes,no,no,no,no,19/11/2015,,Mylan Pharmaceuticals Limited,Calcium homeostasis,24/09/2015,17/04/2023,15,"Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.Reduction of hypercalcaemia in patients with:parathyroid carcinomaprimary HPT for whom parathyroidectomywould be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated. ",11/01/2017,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-mylan,QANQWUQOEJZMLL-PKLMIRHRSA-N,"InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1",393.88000000000005
875,Human,Mimpara,Hypercalcemia;  Parathyroid Neoplasms;  Hyperparathyroidism,cinacalcet,CINACALCET HYDROCHLORIDE,EMEA/H/C/000570,no,Authorised,H05BX01,no,no,no,no,no,no,22/10/2004,,Amgen Europe B.V.,Calcium homeostasis,,29/12/2022,25,"Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate.Parathyroid carcinoma and primary hyperparathyroidism in adults.Reduction of hypercalcaemia in adult patients with:parathyroid carcinoma;primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.",04/06/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara,QANQWUQOEJZMLL-PKLMIRHRSA-N,"InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1",393.88000000000005
770,Human,Tarceva,"Carcinoma, Non-Small-Cell Lung;  Pancreatic Neoplasms",erlotinib,ERLOTINIB,EMEA/H/C/000618,no,Authorised,L01EB02,no,no,no,no,no,no,19/09/2005,,Roche Registration GmbH,Antineoplastic agents,,16/03/2023,32,"Non-small cell lung cancer (NSCLC)Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.Pancreatic cancerTarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.",09/08/2018,16/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva,AAKJLRGGTJKAMG-UHFFFAOYSA-N,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",393.4430000000001
434,Human,Actos,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/000285,no,Authorised,A10BG03,no,no,no,no,no,no,13/10/2000,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,11/08/2023,30,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.",26/05/2016,28/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/actos,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
717,Human,Pioglitazone Actavis,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002324,no,Authorised,A10BG03,no,yes,no,no,no,no,15/03/2012,,Actavis Group PTC ehf  ,Drugs used in diabetes,19/01/2012,31/05/2023,9,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).",20/03/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-actavis,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
787,Human,Pioglitazone Teva,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002297,no,Withdrawn,A10BG03,no,yes,no,no,no,no,26/03/2012,,Teva B.V.,Alimentary tract and metabolism,19/01/2012,04/11/2021,12,"Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylureaas triple oral therapy in combination with- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",11/12/2017,04/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1108,Human,Glubrava,"Diabetes Mellitus, Type 2","pioglitazone, metformin",PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/000893,no,Withdrawn,A10BD05,no,no,no,no,no,no,11/12/2007,,Takeda Pharma A/S,Drugs used in diabetes,,04/02/2021,19,"Glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",10/11/2017,18/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1111,Human,Glidipion (previously Pioglitazone Actavis Group),"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002558,no,Withdrawn,A10BG03,no,yes,no,no,no,no,15/03/2012,,Actavis Group PTC ehf   ,Drugs used in diabetes,,11/06/2020,8,"Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",28/07/2017,17/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1112,Human,Glustin,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/000286,no,Withdrawn,A10BG03,no,no,no,no,no,no,11/10/2000,,Takeda Pharma A/S,Drugs used in diabetes,,04/02/2021,28,"Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",26/05/2016,17/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/glustin,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1150,Human,Pioglitazone Teva Pharma,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002410,no,Withdrawn,A10BG03,no,yes,no,no,no,no,26/03/2012,,Teva Pharma B.V.,Drugs used in diabetes,19/01/2012,21/06/2021,13,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy:, , , 	in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance., , , Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance., , After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained., ",31/01/2018,30/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva-pharma,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1351,Human,Pioglitazone Accord,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002277,no,Authorised,A10BG03,no,yes,no,no,no,no,21/03/2012,,Accord Healthcare S.L.U.,Drugs used in diabetes,19/01/2012,11/01/2022,7,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",28/06/2016,13/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-accord,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1826,Human,Paglitaz,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002309,no,Withdrawn,A10BG03,no,yes,no,no,no,no,21/03/2012,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,15/01/2014,1,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained. ",15/01/2014,10/03/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/paglitaz,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1855,Human,Pioglitazone Krka,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002453,no,Withdrawn,A10BG03,no,yes,no,no,no,no,21/03/2012,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,16/09/2014,2,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea; Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",16/09/2014,26/09/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-krka,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
1880,Human,Sepioglin,"Diabetes Mellitus, Type 2",pioglitazone,PIOGLITAZONE HYDROCHLORIDE,EMEA/H/C/002021,no,Withdrawn,A10BG03,no,yes,no,no,no,no,09/03/2012,,Vaia S.A.,Drugs used in diabetes,,06/06/2013,1,"Pioglitazone is indicated as second- or third-line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. Pioglitazone is also indicated for combination with insulin in type-2-diabetes-mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).",06/06/2013,18/07/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/sepioglin,GHUUBYQTCDQWRA-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H",392.90799999999996
375,Human,Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau),"Xanthomatosis, Cerebrotendinous;  Metabolism, Inborn Errors",chenodeoxycholic acid,CHENODEOXYCHOLIC ACID,EMEA/H/C/004061,no,Authorised,A05AA01,yes,no,no,yes,no,yes,10/04/2017,,Leadiant GmbH,Bile and liver therapy,21/07/2016,20/07/2023,6,"Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.",28/09/2017,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant,RUDATBOHQWOJDD-BSWAIDMHSA-N,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1",392.5800000000001
29,Human,Kalydeco,Cystic Fibrosis,ivacaftor,IVACAFTOR,EMEA/H/C/002494,no,Authorised,R07AX02,no,no,no,no,yes,no,23/07/2012,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,24/05/2012,20/11/2023,38,"Kalydeco tablets are indicated:As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F, R1070W, D1152H, 2789+5G?A, 3272 26A?G, and 3849+10kbC?T.In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5.1).Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene.",08/09/2017,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco,PURKAOJPTOLRMP-UHFFFAOYSA-N,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",392.49900000000014
80,Human,Symkevi,Cystic Fibrosis,"tezacaftor, ivacaftor",IVACAFTOR,EMEA/H/C/004682,no,Authorised,R07AX31,no,no,no,no,no,yes,31/10/2018,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,27/06/2018,23/08/2023,12,"Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F, R1070W, D1152H, 2789+5G?A, 3272 26A?G, and 3849+10kbC?T.",22/11/2018,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi,PURKAOJPTOLRMP-UHFFFAOYSA-N,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",392.49900000000014
244,Human,Enerzair Breezhaler,Asthma,"indacaterol, glycopyrronium bromide, mometasone",INDACATEROL,EMEA/H/C/005061,no,Authorised,R03AL,no,no,no,no,no,no,03/07/2020,,Novartis Europharm Limited,"Drugs for obstructive airway diseases, ",07/09/2023,16/06/2023,6,Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.,21/07/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/enerzair-breezhaler,QZZUEBNBZAPZLX-QFIPXVFZSA-N,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",392.499
245,Human,Bemrist Breezhaler,Asthma,"indacaterol, mometasone",INDACATEROL,EMEA/H/C/005516,no,Authorised,R03AK,no,no,no,no,no,no,30/05/2020,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases, ",26/03/2020,07/09/2023,6,Bemrist Breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.,24/06/2020,16/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bemrist-breezhaler,QZZUEBNBZAPZLX-QFIPXVFZSA-N,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",392.499
520,Human,Orkambi,Cystic Fibrosis,"lumacaftor, ivacaftor",IVACAFTOR,EMEA/H/C/003954,no,Authorised,R07AX30,no,no,no,no,no,no,19/11/2015,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,23/09/2015,04/07/2023,32,Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene.,09/03/2023,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi,PURKAOJPTOLRMP-UHFFFAOYSA-N,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",392.49900000000014
534,Human,Kaftrio,Cystic Fibrosis,"ivacaftor, tezacaftor, elexacaftor",IVACAFTOR,EMEA/H/C/005269,no,Authorised,R07AX32,yes,no,no,no,no,yes,21/08/2020,,Vertex Pharmaceuticals (Ireland) Limited,Other respiratory system products,25/06/2020,07/07/2023,15,Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,21/08/2020,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio,PURKAOJPTOLRMP-UHFFFAOYSA-N,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",392.49900000000014
1471,Human,Xoterna Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",INDACATEROL,EMEA/H/C/003755,no,Authorised,R03AL04,no,no,no,no,no,no,18/09/2013,,Novartis Europharm Limited,Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids,25/07/2013,06/08/2021,16,Xoterna Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,23/07/2018,07/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/xoterna-breezhaler,QZZUEBNBZAPZLX-QFIPXVFZSA-N,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",392.499
1479,Human,Ultibro Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide",INDACATEROL,EMEA/H/C/002679,no,Authorised,R03AL04,no,no,no,no,no,no,19/09/2013,,Novartis Europharm Limited,"Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids, Drugs for obstructive airway diseases, ",,06/08/2021,13,Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,23/07/2018,01/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ultibro-breezhaler,QZZUEBNBZAPZLX-QFIPXVFZSA-N,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",392.499
110,Human,Ozurdex,Macular Edema;  Uveitis,dexamethasone,DEXAMETHASONE,EMEA/H/C/001140,no,Authorised,S01BA01,no,no,no,no,no,no,26/07/2010,,AbbVie Deutschland GmbH & Co. KG,"Ophthalmologicals, Other ophthalmologicals",20/05/2010,20/07/2022,19,"Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.",06/04/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex,UREBDLICKHMUKA-CXSFZGCWSA-N,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",392.4670000000001
762,Human,Neofordex,Multiple Myeloma,dexamethasone,DEXAMETHASONE,EMEA/H/C/004071,no,Authorised,H02AB02,no,no,no,no,no,no,16/03/2016,,THERAVIA,Corticosteroids for systemic use,17/12/2015,15/05/2023,11,Treatment of multiple myeloma.,28/05/2018,17/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/neofordex-0,UREBDLICKHMUKA-CXSFZGCWSA-N,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",392.4670000000001
1161,Human,Dynastat,"Pain, Postoperative",parecoxib,PARECOXIB SODIUM,EMEA/H/C/000381,no,Authorised,M01AH04,no,no,no,no,no,no,22/03/2002,,Pfizer Europe MA EEIG,"Coxibs, Antiinflammatory and antirheumatic products",,16/06/2022,32,"For the short-term treatment of postoperative pain in adults., ",21/06/2018,17/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dynastat,HQPVVKXJNZEAFW-UHFFFAOYSA-M,"InChI=1S/C19H18N2O4S.Na/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15;/h4-12H,3H2,1-2H3,(H,21,22);/q;+1/p-1",392.4120000000001
325,Human,Abiraterone Accord,Prostatic Neoplasms,abiraterone,ABIRATERONE ACETATE,EMEA/H/C/005408,no,Authorised,L02BX03,no,yes,no,no,no,no,26/04/2021,,Accord Healthcare S.L.U.,Endocrine therapy,25/02/2021,25/09/2023,1,Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.,05/05/2021,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-accord,UVIQSJCZCSLXRZ-UBUQANBQSA-N,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1",391.55500000000006
402,Human,Abiraterone Mylan,Prostatic Neoplasms,abiraterone acetate,ABIRATERONE ACETATE,EMEA/H/C/005368,no,Authorised,L02BX03,no,yes,no,no,no,no,20/08/2021,,Mylan Ireland Limited,"Endocrine therapy, Other hormone antagonists and related agents",24/06/2021,05/09/2023,4,Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.,26/08/2021,11/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-mylan,UVIQSJCZCSLXRZ-UBUQANBQSA-N,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1",391.55500000000006
710,Human,Akeega,"Prostatic Neoplasms, Castration-Resistant","niraparib, abiraterone acetate",ABIRATERONE ACETATE,EMEA/H/C/005932,no,Authorised,L01,no,no,no,no,no,no,19/04/2023,,Janssen-Cilag International N.V.,Antineoplastic agents,23/02/2023,19/04/2023,,Treatment of adult patients with prostate cancer.,02/06/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/akeega,UVIQSJCZCSLXRZ-UBUQANBQSA-N,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1",391.55500000000006
916,Human,Abiraterone Krka ,Prostatic Neoplasms,abiraterone acetate,ABIRATERONE ACETATE,EMEA/H/C/005649,no,Authorised,L02BX03,no,yes,no,no,no,no,24/06/2021,,"Krka, d.d., Novo mesto",Endocrine therapy,22/04/2021,23/11/2022,2,Abiraterone Krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.,23/11/2021,08/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-krka,UVIQSJCZCSLXRZ-UBUQANBQSA-N,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1",391.55500000000006
1053,Human,Zytiga,Prostatic Neoplasms,abiraterone,ABIRATERONE ACETATE,EMEA/H/C/002321,no,Authorised,L02BX03,no,no,no,no,yes,no,05/09/2011,,Janssen-Cilag International N.V.,Endocrine therapy,21/07/2011,28/06/2022,26,Zytiga is indicated with prednisone or prednisolone for:the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.,12/06/2018,06/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga,UVIQSJCZCSLXRZ-UBUQANBQSA-N,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1",391.55500000000006
749,Human,Rapiscan,Myocardial Perfusion Imaging,regadenoson,REGADENOSON,EMEA/H/C/001176,no,Authorised,C01EB21,no,no,no,no,no,no,06/09/2010,,GE Healthcare AS ,Cardiac therapy,,30/03/2023,15,This medicinal product is for diagnostic use only.Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.,07/12/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan,LZPZPHGJDAGEJZ-AKAIJSEGSA-N,"InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1",390.36
23,Human,Cialis,Erectile Dysfunction,tadalafil,TADALAFIL,EMEA/H/C/000436,no,Authorised,G04BE08,no,no,no,no,no,no,12/11/2002,,Eli Lilly Nederland B.V.,Urologicals,25/07/2002,25/08/2023,32,"Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.",23/03/2017,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cialis,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",389.41100000000006
152,Human,Talmanco (previously Tadalafil Generics),"Hypertension, Pulmonary",tadalafil,TADALAFIL,EMEA/H/C/004297,no,Authorised,G04BE08,no,yes,no,no,no,no,09/01/2017,,Viatris Limited,Urologicals,10/11/2016,06/11/2023,8,"Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.",04/06/2017,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/talmanco-previously-tadalafil-generics,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",389.41100000000006
348,Human,Adcirca (previously Tadalafil Lilly),"Hypertension, Pulmonary",tadalafil,TADALAFIL,EMEA/H/C/001021,no,Authorised,G04BE08,no,no,no,no,no,no,01/10/2008,,Eli Lilly Nederland B.V.,Urologicals,24/07/2008,01/09/2023,17,"AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.",23/03/2017,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",389.41100000000006
354,Human,Tadalafil Lilly,Erectile Dysfunction,tadalafil,TADALAFIL,EMEA/H/C/004666,no,Authorised,G04BE08,no,no,no,no,no,no,22/03/2017,,Eli Lilly Nederland B.V.,Urologicals,26/01/2017,23/08/2023,6,"Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.",12/06/2017,21/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tadalafil-lilly,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",389.41100000000006
712,Human,Tadalafil Mylan,Erectile Dysfunction,tadalafil,TADALAFIL,EMEA/H/C/003787,no,Authorised,G04BE08,no,yes,no,no,no,no,21/11/2014,,Mylan Pharmaceuticals Limited,Urologicals,,15/06/2022,15,"Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Mylan is not indicated for use by women.",03/08/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tadalafil-mylan,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",389.41100000000006
1131,Human,Zalviso,"Pain, Postoperative",sufentanil,SUFENTANIL,EMEA/H/C/002784,no,Withdrawn,N01AH03,no,no,no,no,no,no,18/09/2015,,FGK Representative Service GmbH,Anesthetics,23/07/2015,05/08/2022,7,"Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients., ",22/05/2017,27/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso,GGCSSNBKKAUURC-UHFFFAOYSA-N,"InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3",386.56100000000004
1449,Human,Inlyta,"Carcinoma, Renal Cell",axitinib,AXITINIB,EMEA/H/C/002406,no,Authorised,L01EK01,no,no,no,no,no,no,03/09/2012,,Pfizer Europe MA EEIG ,Protein kinase inhibitors,24/05/2012,20/08/2021,14,Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.,03/08/2018,28/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta,RITAVMQDGBJQJZ-FMIVXFBMSA-N,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",386.4800000000001
1306,Human,Gencebok,Apnea,caffeine citrate,CAFFEINE CITRATE,EMEA/H/C/005435,no,Authorised,N06BC01,no,no,no,no,no,no,19/08/2020,,Gennisium Pharma,"Psychoanaleptics, ",25/06/2020,22/02/2022,6,Treatment of primary apnoea of premature newborns.,27/08/2020,22/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/gencebok,RCQXSQPPHJPGOF-UHFFFAOYSA-N,"InChI=1S/C8H10N4O2.C6H8O7/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2;7-3(8)1-6(13,5(11)12)2-4(9)10/h4H,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",386.31700000000006
1365,Human,Peyona (previously Nymusa),Apnea,caffeine,CAFFEINE CITRATE,EMEA/H/C/001014,no,Authorised,N06BC01,no,no,no,no,no,no,02/07/2009,,Chiesi Farmaceutici SpA,"Psychoanaleptics, ",23/04/2009,14/12/2021,13,Treatment of primary apnoea of premature newborns.,21/09/2017,22/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/peyona-previously-nymusa,RCQXSQPPHJPGOF-UHFFFAOYSA-N,"InChI=1S/C8H10N4O2.C6H8O7/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2;7-3(8)1-6(13,5(11)12)2-4(9)10/h4H,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",386.31700000000006
1299,Human,Brinavess,Atrial Fibrillation,vernakalant hydrochloride,VERNAKALANT HYDROCHLORIDE,EMEA/H/C/001215,no,Authorised,C01BG11,no,no,no,no,no,no,01/09/2010,,Correvio,Cardiac therapy,,02/03/2022,16,Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:for non-surgery patients: atrial fibrillation ,09/01/2018,03/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess,JMHYCBFEEFHTMK-IIUXMCBISA-N,"InChI=1S/C20H31NO4.ClH/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21;/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3;1H/t16-,17-,18-;/m1./s1",385.9320000000001
284,Human,"Vantavo (previously Alendronate sodium and colecalciferol, MSD)","Osteoporosis, Postmenopausal","alendronic acid, colecalciferol",COLECALCIFEROL,EMEA/H/C/001180,no,Authorised,M05BB03,no,no,no,no,no,no,16/10/2009,,N.V. Organon,Drugs for treatment of bone diseases,23/07/2009,04/10/2023,18,Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.,09/07/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo,QYSXJUFSXHHAJI-YHJXBONMSA-N,"InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24-,25-,26+,27-/m1/s1",384.648
285,Human,Fosavance,"Osteoporosis, Postmenopausal","alendronic acid, colecalciferol",COLECALCIFEROL,EMEA/H/C/000619,no,Authorised,M05BB03,no,no,no,no,no,no,24/08/2005,,N.V. Organon,Drugs for treatment of bone diseases,26/05/2005,04/10/2023,27,Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Fosavance reduces the risk of vertebral and hip fractures.,09/07/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fosavance,QYSXJUFSXHHAJI-YHJXBONMSA-N,"InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24-,25-,26+,27-/m1/s1",384.648
134,Human,Artesunate Amivas,Malaria,artesunate,ARTESUNATE,EMEA/H/C/005550,no,Authorised,P01BE03,yes,no,no,no,no,yes,22/11/2021,,Amivas Ireland Ltd,Antiprotozoals,16/08/2023,08/11/2023,4,Artesunate Amivas is indicated for the initial treatment of severe malaria in adults and children.Consideration should be given to official guidance on the appropriate use of antimalarial agents.,04/01/2022,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/artesunate-amivas,FIHJKUPKCHIPAT-AHIGJZGOSA-N,"InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1",384.4250000000002
271,Human,Bortezomib Hospira,Multiple Myeloma,bortezomib,BORTEZOMIB,EMEA/H/C/004207,no,Authorised,L01XG01,no,yes,no,no,no,no,22/07/2016,,Pfizer Europe MA EEIG,Other antineoplastic agents,26/05/2016,06/10/2023,13,"Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",08/08/2018,09/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",384.245
1281,Human,Bortezomib Accord,Multiple Myeloma,bortezomib,BORTEZOMIB,EMEA/H/C/003984,no,Authorised,L01XX32,no,yes,no,no,no,no,20/07/2015,,Accord Healthcare S.L.U.,Antineoplastic agents,21/05/2015,25/03/2022,13,"Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high?dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high?dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",28/05/2018,25/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",384.245
1467,Human,Bortezomib Sun,Multiple Myeloma,bortezomib,BORTEZOMIB,EMEA/H/C/004076,no,Authorised,L01XG01,no,yes,no,no,no,no,22/07/2016,,SUN Pharmaceutical Industries (Europe) B.V.,Antineoplastic agents,26/03/2016,31/08/2021,12,"Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",07/09/2017,09/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-sun,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",384.245
1480,Human,Bortezomib Fresenius Kabi,Multiple Myeloma,bortezomib,BORTEZOMIB,EMEA/H/C/005074,no,Authorised,L01XG01,no,yes,no,no,no,no,14/11/2019,,Fresenius Kabi Deutschland GmbH,Antineoplastic agents,19/09/2019,28/07/2021,5,"Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",25/11/2019,01/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-fresenius-kabi,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",384.245
1523,Human,Velcade,Multiple Myeloma,bortezomib,BORTEZOMIB,EMEA/H/C/000539,no,Authorised,L01XG01,no,no,no,no,no,no,26/04/2004,,Janssen-Cilag International NV,Antineoplastic agents,,13/05/2021,45,"Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",21/02/2017,04/06/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/velcade,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",384.245
870,Human,Azopt,"Glaucoma, Open-Angle;  Ocular Hypertension",brinzolamide,BRINZOLAMIDE,EMEA/H/C/000267,no,Authorised,S01EC04,no,no,no,no,no,no,09/03/2000,,Novartis Europharm Limited,Ophthalmologicals,,16/03/2023,28,"Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.",22/06/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azopt,HCRKCZRJWPKOAR-JTQLQIEISA-N,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",383.51700000000005
1028,Human,Simbrinza,"Ocular Hypertension;  Glaucoma, Open-Angle","brinzolamide, brimonidine tartrate",BRINZOLAMIDE,EMEA/H/C/003698,no,Authorised,S01EC54,no,no,no,no,no,no,18/07/2014,,Novartis Europharm Limited,Ophthalmologicals,22/05/2014,10/12/2022,10,Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.,23/08/2018,19/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza,HCRKCZRJWPKOAR-JTQLQIEISA-N,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",383.51700000000005
1117,Human,Azarga,"Glaucoma, Open-Angle;  Ocular Hypertension","brinzolamide, timolol",BRINZOLAMIDE,EMEA/H/C/000960,no,Authorised,S01ED51,no,no,no,no,no,no,25/11/2008,,Novartis Europharm Limited,Ophthalmologicals,,11/10/2022,16,Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.,22/06/2018,11/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/azarga,HCRKCZRJWPKOAR-JTQLQIEISA-N,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",383.51700000000005
742,Human,Pantozol Control,Gastroesophageal Reflux,pantoprazole,PANTOPRAZOLE,EMEA/H/C/001013,no,Authorised,A02BC02,no,no,no,no,no,no,11/06/2009,,Takeda GmbH,Proton pump inhibitors,19/02/2009,26/04/2023,17,"Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.",02/07/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pantozol-control,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",383.37600000000003
748,Human,Controloc Control,Gastroesophageal Reflux,pantoprazole,PANTOPRAZOLE,EMEA/H/C/001097,no,Authorised,A02BC02,no,no,no,no,no,no,11/06/2009,,Takeda GmbH,Proton pump inhibitors,,26/04/2023,15,"Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.",02/07/2018,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/controloc-control,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",383.37600000000003
750,Human,Somac Control,Gastroesophageal Reflux,pantoprazole,PANTOPRAZOLE,EMEA/H/C/001098,no,Authorised,A02BC02,no,no,no,no,no,no,12/06/2009,,Takeda GmbH,Proton pump inhibitors,19/02/2009,26/04/2023,16,"Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.",02/07/2018,24/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/somac-control,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",383.37600000000003
1346,Human,Pantoloc Control,Gastroesophageal Reflux,pantoprazole,PANTOPRAZOLE,EMEA/H/C/001100,no,Withdrawn,A02BC02,no,no,no,no,no,no,11/06/2009,,Takeda GmbH,Proton pump inhibitors,19/02/2009,14/01/2021,18,"Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.",25/06/2018,18/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pantoloc-control,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",383.37600000000003
1809,Human,Pantecta Control,Gastroesophageal Reflux,pantoprazole,PANTOPRAZOLE,EMEA/H/C/001099,no,Withdrawn,A02BC02,no,no,no,no,no,no,12/06/2009,,Takeda GmbH,Proton pump inhibitors,,19/09/2016,7,"Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.",19/09/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/pantecta-control,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",383.37600000000003
1939,Human,Onsenal,Adenomatous Polyposis Coli,celecoxib,CELECOXIB,EMEA/H/C/000466,no,Withdrawn,L01XX33,no,no,no,yes,no,no,17/10/2003,,Pfizer Limited,Antineoplastic agents,,28/03/2011,13,"Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)",28/03/2011,06/04/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal,RZEKVGVHFLEQIL-UHFFFAOYSA-N,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",381.379
1064,Human,Recarbrio,Gram-Negative Bacterial Infections,"imipenem, cilastatin, relebactam",CILASTATIN SODIUM,EMEA/H/C/004808,no,Authorised,J01DH56,yes,no,no,no,no,no,13/02/2020,,Merck Sharp & Dohme B.V. ,"Carbapenems, Antibacterials for systemic use, ",12/12/2019,28/11/2022,5,"Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",26/02/2020,29/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio,QXPBTTUOVWMPJN-QBNHLFMHSA-M,"InChI=1S/C16H26N2O5S.Na/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21;/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23);/q;+1/p-1/b12-6-;/t10-,11+;/m1./s1",380.44200000000006
429,Human,Rinvoq,"Arthritis, Rheumatoid",upadacitinib,UPADACITINIB,EMEA/H/C/004760,yes,Authorised,L04AA44,yes,no,no,no,no,no,16/12/2019,,AbbVie Deutschland GmbH & Co. KG,Immunosuppressants,17/10/2019,20/07/2023,17,"Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.",18/10/2019,29/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq,WYQFJHHDOKWSHR-MNOVXSKESA-N,"InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1",380.37399999999997
1385,Human,Talzenna,Breast Neoplasms,talazoparib,TALAZOPARIB,EMEA/H/C/004674,no,Authorised,L01XK04,yes,no,no,no,no,no,20/06/2019,,Pfizer Europe MA EEIG,Antineoplastic agents,26/04/2019,06/12/2021,6,"Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",08/07/2019,07/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna,HWGQMRYQVZSGDQ-HZPDHXFCSA-N,"InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1",380.35799999999995
917,Human,Senshio,Postmenopause,ospemifene,OSPEMIFENE,EMEA/H/C/002780,no,Authorised,G03XC05,no,no,no,no,no,no,14/01/2015,,Shionogi B.V.,"Sex hormones and modulators of the genital system, ",,07/03/2023,13,Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.,13/09/2017,08/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/senshio,LUMKNAVTFCDUIE-VHXPQNKSSA-N,"InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-",378.89900000000006
961,Human,Kerendia,"Renal Insufficiency, Chronic;  Diabetes Mellitus, Type 2",finerenone,FINERENONE,EMEA/H/C/005200,no,Authorised,C09,yes,no,no,no,no,no,16/02/2022,,Bayer AG,Agents acting on the renin-angiotensin system,16/12/2021,06/02/2023,1,Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.,14/12/2021,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia,BTBHLEZXCOBLCY-QGZVFWFLSA-N,"InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1",378.432
755,Human,Volibris,"Hypertension, Pulmonary",ambrisentan,AMBRISENTAN,EMEA/H/C/000839,no,Authorised,C02KX02,no,no,no,no,no,no,20/04/2008,,GlaxoSmithKline (Ireland) Limited,"Antihypertensives, ",,22/09/2021,23,"Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1).  Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1).",26/04/2017,24/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/volibris,OUJTZYPIHDYQMC-LJQANCHMSA-N,"InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1",378.4280000000001
806,Human,Ambrisentan Mylan,"Hypertension, Pulmonary",ambrisentan,AMBRISENTAN,EMEA/H/C/004985,no,Authorised,C02KX02,no,yes,no,no,no,no,20/06/2019,,Mylan S.A.S,"Antihypertensives, ",,25/04/2023,4,"Ambrisentan Mylan is indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Ambrisentan Mylan is indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.",15/07/2019,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-mylan,OUJTZYPIHDYQMC-LJQANCHMSA-N,"InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1",378.4280000000001
549,Human,Mysimba,Obesity;  Overweight,"naltrexone, bupropion",NALTREXONE HYDROCHLORIDE,EMEA/H/C/003687,no,Authorised,A08AA,yes,no,no,no,no,no,26/03/2015,,Orexigen Therapeutics Ireland Limited,"Antiobesity preparations, excl. diet products",18/12/2014,04/07/2023,25,"Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (?18 years) with an initial Body Mass Index (BMI) of? 30 kg/m2 (obese), or? 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.",02/07/2018,21/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba,RHBRMCOKKKZVRY-ITLPAZOVSA-N,"InChI=1S/C20H23NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,15,18,22,24H,1-2,5-10H2;1H/t15-,18+,19+,20-;/m1./s1",377.8680000000001
451,Human,Tecovirimat SIGA,Poxviridae Infections;  Cowpox;  Monkeypox;  Vaccinia;  Smallpox,tecovirimat monohydrate,TECOVIRIMAT,EMEA/H/C/005248,no,Authorised,J05AX24,yes,no,no,no,no,no,06/01/2022,,SIGA Technologies Netherlands B.V.,Antivirals for systemic use,11/11/2021,31/05/2023,2,Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations.,10/11/2021,23/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga,CSKDFZIMJXRJGH-VWLPUNTISA-N,"InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+",376.33400000000006
622,Human,Livtencity,Cytomegalovirus Infections,maribavir,MARIBAVIR,EMEA/H/C/005787,no,Authorised,J05AX10,yes,no,no,no,no,yes,09/11/2022,,Takeda Pharmaceuticals International AG Ireland Branch,Antivirals for systemic use,15/09/2022,04/07/2023,4,"LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents.",14/09/2022,05/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/livtencity,KJFBVJALEQWJBS-XUXIUFHCSA-N,"InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1",376.24000000000007
1157,Human,Opatanol,"Conjunctivitis, Allergic",olopatadine,OLOPATADINE HYDROCHLORIDE,EMEA/H/C/000407,no,Authorised,S01GX09,no,no,no,no,no,no,16/05/2002,,Novartis Europharm Limited,Ophthalmologicals,,23/08/2022,23,"Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis., ",19/04/2018,24/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/opatanol,HVRLZEKDTUEKQH-NOILCQHBSA-N,"InChI=1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;",373.88000000000005
593,Human,Efient,"Acute Coronary Syndrome;  Angina, Unstable;  Myocardial Infarction",prasugrel,PRASUGREL,EMEA/H/C/000984,no,Authorised,B01AC22,no,no,no,no,no,no,24/02/2009,,Substipharm,Antithrombotic agents,18/12/2008,29/09/2022,25,"Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).",16/03/2017,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efient,DTGLZDAWLRGWQN-UHFFFAOYSA-N,"InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3",373.44900000000007
100,Human,Exjade,beta-Thalassemia;  Iron Overload,deferasirox,DEFERASIROX,EMEA/H/C/000670,no,Authorised,V03AC03,yes,no,no,no,no,no,28/08/2006,,Novartis Europharm Limited,All other therapeutic products,28/06/2006,28/09/2023,52,Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (? 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (? 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.,23/07/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exjade,BOFQWVMAQOTZIW-UHFFFAOYSA-N,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",373.368
384,Human,Deferasirox Accord,Iron Overload;  beta-Thalassemia,deferasirox,DEFERASIROX,EMEA/H/C/005156,no,Authorised,V03AC03,no,yes,no,no,no,no,09/01/2020,,Accord Healthcare S.L.U.,"All other therapeutic products, Iron chelating agents",,13/09/2023,5,"Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (",04/03/2020,14/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/deferasirox-accord,BOFQWVMAQOTZIW-UHFFFAOYSA-N,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",373.368
877,Human,Deferasirox Mylan,Iron Overload;  beta-Thalassemia,deferasirox,DEFERASIROX,EMEA/H/C/005014,no,Authorised,V03AC03,no,yes,no,no,no,no,26/09/2019,,Mylan Pharmaceuticals Limited,Iron chelating agents,25/07/2019,17/03/2023,9,"Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (",10/10/2019,28/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/deferasirox-mylan,BOFQWVMAQOTZIW-UHFFFAOYSA-N,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",373.368
1734,Human,Ionsys,"Pain, Postoperative",fentanyl,FENTANYL HYDROCHLORIDE,EMEA/H/C/002715,no,Withdrawn,N02AB03,no,no,no,no,no,no,18/11/2015,,Incline Therapeutics Europe Ltd,Analgesics,23/09/2015,26/10/2018,2,Ionsys is indicated for the management of acute moderate to severe post-operative pain in adult patients.,19/11/2015,06/11/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/ionsys,LHCBOXPPRUIAQT-UHFFFAOYSA-N,"InChI=1S/C22H28N2O.ClH/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19;/h3-12,21H,2,13-18H2,1H3;1H",372.94
1942,Human,Ionsys,"Pain, Postoperative",fentanyl,FENTANYL HYDROCHLORIDE,EMEA/H/C/000612,no,Withdrawn,N02AB03,no,no,no,no,no,no,24/01/2006,25/07/2008,Janssen-Cilag International NV,Analgesics,,24/01/2011,3,Management of acute moderate to severe post-operative pain for use in a hospital setting only,24/01/2011,28/01/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/ionsys-0,LHCBOXPPRUIAQT-UHFFFAOYSA-N,"InChI=1S/C22H28N2O.ClH/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19;/h3-12,21H,2,13-18H2,1H3;1H",372.94
96,Human,Olumiant,"Arthritis, Rheumatoid",baricitinib,BARICITINIB,EMEA/H/C/004085,yes,Authorised,L04AA37,no,no,no,no,no,no,13/02/2017,,Eli Lilly Nederland B.V.,Immunosuppressants,14/12/2016,18/10/2023,17,"Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.",25/01/2018,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant,XUZMWHLSFXCVMG-UHFFFAOYSA-N,"InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)",371.426
965,Human,Zoely,Contraception,"nomegestrol, estradiol",NOMEGESTROL ACETATE,EMEA/H/C/001213,no,Authorised,G03AA14,no,no,no,no,no,no,26/07/2011,,Theramex Ireland Limited,"Sex hormones and modulators of the genital system, ",,28/11/2022,23,"Oral contraception, ",12/07/2018,16/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zoely,IIVBFTNIGYRNQY-YQLZSBIMSA-N,"InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1",370.48900000000015
1860,Human,Ioa,Contraception,"nomegestrol acetate, estradiol",NOMEGESTROL ACETATE,EMEA/H/C/002068,no,Withdrawn,G03AA14,no,no,no,no,no,no,16/11/2011,,N.V. Organon,"Sex hormones and modulators of the genital system, ",,16/01/2014,4,Oral contraception.,16/01/2014,26/08/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/ioa,IIVBFTNIGYRNQY-YQLZSBIMSA-N,"InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1",370.48900000000015
2013,Human,Rayzon,"Pain, Postoperative",parecoxib,PARECOXIB,EMEA/H/C/000382,no,Withdrawn,M01AH04,no,no,no,no,no,no,22/03/2002,,Pharmacia Europe EEIG,Antiinflammatory and antirheumatic products,,24/06/2005,4,"For the short-term treatment of postoperative pain.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of theindividual patient's overall risks (see sections 4.3, 4.4).",24/06/2005,23/08/2005,https://www.ema.europa.eu/en/medicines/human/EPAR/rayzon,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,"InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)",370.43000000000006
2022,Human,Xapit,"Pain, Postoperative",parecoxib,PARECOXIB,EMEA/H/C/000380,no,Withdrawn,M01AH04,no,no,no,no,no,no,22/03/2002,,Pharmacia Europe EEIG,Antiinflammatory and antirheumatic products,,02/03/2004,0,For the short-term treatment of postoperative pain.,02/03/2004,23/08/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/xapit,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,"InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)",370.43000000000006
856,Human,Lydisilka,"Contraceptives, Oral","estetrol, drospirenone",DROSPIRENONE,EMEA/H/C/005382,no,Authorised,G03,no,no,no,no,no,no,19/05/2021,,Estetra SPRL,"Sex hormones and modulators of the genital system, ",25/03/2021,30/03/2023,3,"Oral contraception.The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).",24/03/2021,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lydisilka,METQSPRSQINEEU-HXCATZOESA-N,"InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1",366.50100000000015
858,Human,Drovelis,"Contraceptives, Oral","estetrol, drospirenone",DROSPIRENONE,EMEA/H/C/005336,no,Authorised,G03,no,no,no,no,no,no,19/05/2021,,Gedeon Richter Plc.,"Sex hormones and modulators of the genital system, ",25/03/2021,30/03/2023,4,oral contraceptive,24/03/2021,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/drovelis,METQSPRSQINEEU-HXCATZOESA-N,"InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1",366.50100000000015
249,Human,Rekambys,HIV Infections,rilpivirine,RILPIVIRINE,EMEA/H/C/005060,no,Authorised,J05AG05,yes,no,no,no,no,no,17/12/2020,,Janssen-Cilag International NV,Antivirals for systemic use,15/10/2020,28/09/2023,9,"Rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.",04/01/2021,13/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys,YIBOMRUWOWDFLG-ONEGZZNKSA-N,"InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+",366.428
1064,Human,Recarbrio,Gram-Negative Bacterial Infections,"imipenem, cilastatin, relebactam",RELEBACTAM MONOHYDRATE,EMEA/H/C/004808,no,Authorised,J01DH56,yes,no,no,no,no,no,13/02/2020,,Merck Sharp & Dohme B.V. ,"Carbapenems, Antibacterials for systemic use, ",12/12/2019,28/11/2022,5,"Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",26/02/2020,29/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio,TWFRCSHLWKJBQH-UXQCFNEQSA-N,"InChI=1S/C12H20N4O6S.H2O/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21;/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21);1H2/t9-,10+;/m1./s1",366.39600000000013
805,Human,Lokelma,Hyperkalemia,sodium zirconium cyclosilicate,SODIUM ZIRCONIUM CYCLOSILICATE,EMEA/H/C/004029,no,Authorised,V03AE10,no,no,no,no,no,no,22/03/2018,,AstraZeneca AB,All other therapeutic products,26/01/2017,26/04/2023,9,Lokelma is indicated for the treatment of hyperkalaemia in adult patients.,27/04/2018,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lokelma,QMLIRKACNOVYNW-UHFFFAOYSA-N,"InChI=1S/2Na.O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/q2*+1;-6;+4",365.453
252,Human,Plenadren,Adrenal Insufficiency,hydrocortisone,HYDROCORTISONE,EMEA/H/C/002185,no,Authorised,H02AB09,no,no,no,no,no,no,03/11/2011,,Takeda Pharmaceuticals International AG Ireland Branch,Corticosteroids for systemic use,,28/09/2023,14,Treatment of adrenal insufficiency in adults.,15/05/2018,13/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren,JYGXADMDTFJGBT-VWUMJDOOSA-N,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",362.46600000000007
443,Human,Efmody,"Adrenal Hyperplasia, Congenital",hydrocortisone,HYDROCORTISONE,EMEA/H/C/005105,no,Authorised,H02AB09,no,no,no,no,no,no,27/05/2021,,Diurnal Europe B.V.,Corticosteroids for systemic use,25/03/2021,23/08/2023,3,Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.,24/03/2021,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efmody,JYGXADMDTFJGBT-VWUMJDOOSA-N,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",362.46600000000007
899,Human,Alkindi,Adrenal Insufficiency,hydrocortisone,HYDROCORTISONE,EMEA/H/C/004416,no,Authorised,H02AB09,no,no,no,no,no,no,09/02/2018,,Diurnal Europe B.V.,Corticosteroids for systemic use,14/12/2017,09/11/2022,8,"Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).",29/06/2018,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/alkindi,JYGXADMDTFJGBT-VWUMJDOOSA-N,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",362.46600000000007
1019,Human,Quinsair,Cystic Fibrosis;  Respiratory Tract Infections,levofloxacin,LEVOFLOXACIN,EMEA/H/C/002789,no,Authorised,J01MA12,yes,no,no,no,no,no,25/03/2015,,Chiesi Farmaceutici S.p.A,"Antibacterials for systemic use, ",18/12/2014,23/11/2022,15,Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,07/06/2018,22/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair,GSDSWSVVBLHKDQ-JTQLQIEISA-N,"InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1",361.37300000000005
61,Human,Pravafenix,Dyslipidemias,"fenofibrate, pravastatin",FENOFIBRATE,EMEA/H/C/001243,no,Authorised,C10BA03,no,no,no,no,no,no,14/04/2011,,Laboratoires SMB S.A.,Lipid modifying agents,,27/11/2023,8,Pravafenix is indicated for the treatment of high-coronary-heart-disease (CHD)-risk adult patients with mixed dyslipidaemia characterised by high triglycerides and low HDL-cholesterol (C) levels whose LDL-C levels are adequately controlled while on a treatment with pravastatin-40-mg monotherapy.,14/01/2016,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pravafenix,YMTINGFKWWXKFG-UHFFFAOYSA-N,"InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",360.8370000000001
286,Human,Cholib,Dyslipidemias,"fenofibrate, simvastatin",FENOFIBRATE,EMEA/H/C/002559,no,Authorised,C10BA04,no,no,no,no,no,no,26/08/2013,,Viatris Healthcare Limited,Lipid modifying agents,27/06/2013,23/08/2023,16,Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.,20/08/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cholib,YMTINGFKWWXKFG-UHFFFAOYSA-N,"InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",360.8370000000001
32,Human,Ventavis,"Hypertension, Pulmonary",iloprost,ILOPROST,EMEA/H/C/000474,no,Authorised,B01AC11,no,no,no,no,no,no,15/09/2003,,Bayer AG,Antithrombotic agents,22/05/2003,27/11/2023,30,"Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.",09/02/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ventavis,HIFJCPQKFCZDDL-ACWOEMLNSA-N,"InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1",360.494
1538,Human,Amyvid,Radionuclide Imaging,florbetapir (18F),FLORBETAPIR (18F),EMEA/H/C/002422,no,Authorised,V09AX05,no,no,no,no,no,no,14/01/2013,,Eli Lilly Nederland B.V.,Diagnostic radiopharmaceuticals,18/10/2012,10/03/2021,14,"This medicinal product is for diagnostic use only.Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ?-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.",04/06/2018,31/03/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/amyvid,YNDIAUKFXKEXSV-CRYLGTRXSA-N,"InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1",359.431938
444,Human,Ecansya (previously Capecitabine Krka),Colonic Neoplasms;  Breast Neoplasms;  Colorectal Neoplasms;  Stomach Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/002605,no,Authorised,L01BC06,no,yes,no,no,no,no,20/04/2012,,"Krka, d.d., Novo mesto",Antineoplastic agents,,24/08/2023,15,Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.,09/12/2016,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
500,Human,Capecitabine Accord,Colonic Neoplasms;  Breast Neoplasms;  Colorectal Neoplasms;  Stomach Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/002386,no,Authorised,L01BC06,no,yes,no,no,no,no,20/04/2012,,Accord Healthcare S.L.U.,Antineoplastic agents,,07/12/2021,16,Capecitabine Accord is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Accord is indicated for the treatment of metastatic colorectal cancer.Capecitabine Accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. ,09/01/2017,03/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-accord,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
857,Human,Capecitabine Medac,Colorectal Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/002568,no,Authorised,L01BC06,no,yes,no,no,no,no,19/11/2012,,medac Gesellschaft für klinische Spezialpräparate mbH,Antineoplastic agents,,30/03/2023,13,Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.,16/06/2017,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
1104,Human,Xeloda,Colonic Neoplasms;  Breast Neoplasms;  Colorectal Neoplasms;  Stomach Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/000316,no,Authorised,L01BC06,no,no,no,no,no,no,02/02/2001,,CHEPLAPHARM Arzneimittel GmbH,Antineoplastic agents,19/10/2000,25/10/2022,30,Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.Xeloda is indicated for the treatment of metastatic colorectal cancer.Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.,22/03/2018,26/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
1468,Human,Capecitabine Teva,Colonic Neoplasms;  Breast Neoplasms;  Colorectal Neoplasms;  Stomach Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/002362,no,Authorised,L01BC06,no,yes,no,no,no,no,20/04/2012,,Teva Pharma B.V.,Antineoplastic agents,,23/07/2021,15,Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer.Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer.Capecitabine Teva is indicated for first?line treatment of advanced gastric cancer in combination with a platinum?based regimen.Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.,01/02/2018,08/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-teva,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
1807,Human,Capecitabine SUN,Stomach Neoplasms;  Breast Neoplasms;  Colonic Neoplasms;  Colorectal Neoplasms,capecitabine,CAPECITABINE,EMEA/H/C/002050,no,Withdrawn,L01BC06,no,yes,no,no,no,no,21/06/2013,,Sun Pharmaceutical Industries Europe B.V.,capecitabine,,21/06/2016,3,Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine is indicated for the treatment of metastatic colorectal cancer.Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.,21/06/2016,22/12/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-sun,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",359.3540000000001
18,Human,Dovprela (previously Pretomanid FGK),"Tuberculosis, Multidrug-Resistant",pretomanid,PRETOMANID,EMEA/H/C/005167,no,Authorised,J04,yes,no,no,no,no,yes,31/07/2020,,Mylan IRE Healthcare Limited,Antimycobacterials,26/03/2020,15/11/2023,9,"Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",11/08/2020,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk,ZLHZLMOSPGACSZ-NSHDSACASA-N,"InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1",359.2600000000001
37,Human,Neuraceq,Radionuclide Imaging;  Alzheimer Disease,florbetaben (18F),FLORBETABEN (18F),EMEA/H/C/002553,no,Authorised,V09AX06,no,no,no,no,no,no,20/02/2014,,Life Molecular Imaging GmbH,Diagnostic radiopharmaceuticals,,18/10/2023,20,"This medicinal product is for diagnostic use only.Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.",12/03/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq,NCWZOASIUQVOFA-FWZJPQCDSA-N,"InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1",358.443938
1212,Human,Clopidogrel Taw Pharma (previously Clopidogrel Mylan),Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction;  Acute Coronary Syndrome,clopidogrel,CLOPIDOGREL HYDROCHLORIDE,EMEA/H/C/001134,no,Authorised,B01AC04,no,yes,no,no,no,no,21/09/2009,,Taw Pharma (Ireland) Limited,Antithrombotic agents,25/06/2009,29/06/2022,20,", 	, 		, 			, 			Secondary prevention of atherothrombotic events, 			, 			Clopidogrel is indicated in: , 			- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease., 			- Adult patients suffering from acute coronary syndrome:, 			   - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA)., 			    - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy., 			, 			In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS), 			Clopidogrel in combination with ASA is indicated in:, 			- Adult patients with moderate to high-risk TIA (ABCD2  score ?4) or minor IS (NIHSS  ?3) within 24 hours of either the TIA or IS event. , 			, 			Prevention of atherothrombotic and thromboembolic events in atrial fibrillation, 			In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke., 			, 			For further information please refer to section 5.1., , 			, 			, 		, 	, , ",13/04/2018,01/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-taw-pharma-previously-clopidogrel-mylan,XIHVAFJSGWDBGA-RSAXXLAASA-N,"InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1",358.29
715,Human,Kentera (previously Oxybutynin Nicobrand),"Urinary Incontinence, Urge",oxybutynin,OXYBUTYNIN,EMEA/H/C/000532,no,Authorised,G04BD04,no,no,no,no,no,no,15/06/2004,,Teva B.V. ,Urologicals,,26/05/2023,21,Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.,03/05/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand,XIQVNETUBQGFHX-UHFFFAOYSA-N,"InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3",357.494
1817,Human,Avandamet,"Diabetes Mellitus, Type 2","rosiglitazone, metformin",ROSIGLITAZONE,EMEA/H/C/000522,no,Withdrawn,A10BD03,no,no,no,no,no,no,20/10/2003,,SmithKline Beecham Plc,Drugs used in diabetes,,03/12/2010,16,"AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).",03/12/2010,08/06/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/avandamet,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",357.435
1818,Human,Avandia,"Diabetes Mellitus, Type 2",rosiglitazone,ROSIGLITAZONE,EMEA/H/C/000268,no,Withdrawn,A10BG02,no,no,no,no,no,no,11/07/2000,,SmithKline Beecham Plc,Drugs used in diabetes,,03/12/2010,23,"Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).",03/12/2010,08/06/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/avandia,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",357.435
1934,Human,Avaglim,"Diabetes Mellitus, Type 2","rosiglitazone, glimepiride",ROSIGLITAZONE,EMEA/H/C/000675,no,Withdrawn,A10BD04,no,no,no,no,no,no,27/06/2006,,SmithKline Beecham Ltd,Drugs used in diabetes,,26/07/2011,11,"AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.",26/07/2011,12/08/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/avaglim,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",357.435
2017,Human,Venvia,"Diabetes Mellitus, Type 2",rosiglitazone,ROSIGLITAZONE,EMEA/H/C/000270,no,Withdrawn,A10BG02,no,no,no,no,no,no,11/07/2000,,SmithKline Beecham Plc,Drugs used in diabetes,,25/11/2004,6,"Rosiglitazone is indicated as oral monotherapy in type 2 diabetes mellitus patients, particularly overweight patients, inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.Rosiglitazone is also indicated for oral combination treatment in type 2 diabetes mellitus patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea:in combination with metformin particularly in overweight patients.in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated.",25/11/2004,18/04/2005,https://www.ema.europa.eu/en/medicines/human/EPAR/venvia,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",357.435
2018,Human,Nyracta,"Diabetes Mellitus, Type 2",rosiglitazone,ROSIGLITAZONE,EMEA/H/C/000269,no,Withdrawn,A10BG02,no,no,no,no,no,no,11/07/2000,,SmithKline Beecham Plc,Drugs used in diabetes,,08/12/2004,6,"Rosiglitazone is indicated as oral monotherapy in type 2 diabetes mellitus patients, particularly overweight patients, inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.Rosiglitazone is also indicated for oral combination treatment in type 2 diabetes mellitus patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea:- in combination with metformin particularly in overweight patients.­- in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated.",08/12/2004,18/04/2005,https://www.ema.europa.eu/en/medicines/human/EPAR/nyracta,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",357.435
1979,Human,Parareg,Hypercalcemia;  Parathyroid Neoplasms;  Hyperparathyroidism,cinacalcet,CINACALCET,EMEA/H/C/000575,no,Withdrawn,H05BX01,no,no,no,no,no,no,22/10/2004,,Dompé Biotec S.p.A.,Calcium homeostasis,,29/10/2008,6,"Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Reduction of hypercalcaemia in patients with:-parathyroid carcinoma.- primary HPT for whom parathyroidectomy would be indicated on the basis of serum calciumlevels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.",29/10/2008,14/05/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/parareg,VDHAWDNDOKGFTD-MRXNPFEDSA-N,"InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1",357.41900000000004
393,Human,Tandemact,"Diabetes Mellitus, Type 2","pioglitazone, glimepiride",PIOGLITAZONE,EMEA/H/C/000680,no,Authorised,A10BD06,no,no,no,no,no,no,08/01/2007,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,07/09/2023,22,Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.,30/11/2016,13/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact,HYAFETHFCAUJAY-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",356.447
466,Human,Competact,"Diabetes Mellitus, Type 2","pioglitazone, metformin",PIOGLITAZONE,EMEA/H/C/000655,no,Authorised,A10BD05,no,no,no,no,no,no,28/07/2006,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,11/08/2023,21,"Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.",12/12/2016,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/competact,HYAFETHFCAUJAY-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",356.447
1144,Human,Incresync,"Diabetes Mellitus, Type 2","alogliptin, pioglitazone",PIOGLITAZONE,EMEA/H/C/002178,no,Authorised,A10BD09,no,no,no,no,no,no,19/09/2013,,Takeda Pharma A/S,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/07/2013,07/09/2022,13,"Incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus:, , , 	as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, 	in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone., , , In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination., , After initiation of therapy with Incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4)., ",25/05/2018,09/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/incresync,HYAFETHFCAUJAY-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",356.447
2034,Human,Orlaam,Opioid-Related Disorders,levacetylmethadol,LEVACETYLMETHADOL,EMEA/H/C/000077,no,Withdrawn,N02AC,no,no,no,no,no,no,01/07/1997,,Sipaco Internacional Lda.,Analgesics,,11/06/2002,0,"ORLAAM is indicated for the substitution maintenance treatment of opiate addiction in adults previously treated with methadone, as part of a comprehensive treatment plan including medical, social and psychological care.ORLAAM should be administered under the supervision of physicians with experience in addiction treatment and whenever practicable, in centres specialising in the treatment of drug addiction.ORLAAM is not intended for take home use.",11/06/2002,30/06/2002,https://www.ema.europa.eu/en/medicines/human/EPAR/orlaam,XBMIVRRWGCYBTQ-AVRDEDQJSA-N,"InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1",353.50600000000014
263,Human,Lyfnua,Cough,gefapixant,GEFAPIXANT,EMEA/H/C/005476,no,Authorised,R05DB29,yes,no,no,no,no,no,15/09/2023,,Merck Sharp & Dohme B.V.,Cough and cold preparations,20/07/2023,,,Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.,17/07/2023,10/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lyfnua,HLWURFKMDLAKOD-UHFFFAOYSA-N,"InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)",353.40400000000005
696,Human,Evrenzo,"Anemia;  Kidney Failure, Chronic",roxadustat,ROXADUSTAT,EMEA/H/C/004871,no,Authorised,B03XA05,yes,no,no,no,no,no,18/08/2021,,Astellas Pharma Europe B.V.,Antianemic preparations,24/06/2021,02/06/2023,3,Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).,24/08/2021,08/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo,YOZBGTLTNGAVFU-UHFFFAOYSA-N,"InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)",352.346
731,Human,Komboglyze,"Diabetes Mellitus, Type 2","saxagliptin, metformin hydrochloride",SAXAGLIPTIN HYDROCHLORIDE,EMEA/H/C/002059,no,Authorised,A10BD10,no,no,no,no,no,no,24/11/2011,,AstraZeneca AB ,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,30/05/2023,20,Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.,26/06/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze,TUAZNHHHYVBVBR-NHKADLRUSA-N,"InChI=1S/C18H25N3O2.ClH/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;/h10-15,23H,1-7,9,20H2;1H/t10?,11?,12-,13+,14+,15-,17?,18?;/m1./s1",351.8780000000001
87,Human,Zynrelef,"Pain, Postoperative","bupivacaine, meloxicam",MELOXICAM,EMEA/H/C/005205,no,Withdrawn,N01B,no,no,no,no,no,no,24/09/2020,,"Heron Therapeutics, B.V.",Anesthetics,23/07/2020,05/10/2023,3,Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).,06/10/2020,22/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zynrelef,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,"InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)",351.40900000000005
183,Human,Fycompa,"Epilepsies, Partial",perampanel,PERAMPANEL,EMEA/H/C/002434,no,Authorised,N03AX22,no,no,no,no,no,no,23/07/2012,,Eisai GmbH,"Antiepileptics, , Other antiepileptics",24/05/2012,27/04/2023,32,Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.,23/04/2018,31/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa,PRMWGUBFXWROHD-UHFFFAOYSA-N,"InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H",349.3930000000001
154,Human,Vfend,Candidiasis;  Mycoses;  Aspergillosis,voriconazole,VORICONAZOLE,EMEA/H/C/000387,no,Authorised,J02AC03,no,no,no,no,no,no,19/03/2002,,Pfizer Europe MA EEIG,Antimycotics for systemic use,13/12/2001,28/09/2023,55,"Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.",06/06/2018,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vfend,BCEHBSKCWLPMDN-MGPLVRAMSA-N,"InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1",349.316
683,Human,Voriconazole Hikma (previously Voriconazole Hospira),Bacterial Infections and Mycoses;  Aspergillosis;  Candidiasis,voriconazole,VORICONAZOLE,EMEA/H/C/003737,no,Authorised,J02AC03,no,yes,no,no,no,no,27/05/2015,,Hikma Farmaceutica (Portugal) S.A.,Antimycotics for systemic use,26/03/2015,16/06/2023,12,"Voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT)recipients.",20/09/2017,16/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-hikma-previously-voriconazole-hospira,BCEHBSKCWLPMDN-MGPLVRAMSA-N,"InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1",349.316
691,Human,Voriconazole Accord,Aspergillosis;  Candidiasis;  Mycoses,voriconazole,VORICONAZOLE,EMEA/H/C/002669,no,Authorised,J02AC03,no,yes,no,no,no,no,16/05/2013,,Accord Healthcare S.L.U.,"Antimycotics for systemic use, Triazole derivatives",,13/06/2023,17,"Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections.",08/02/2018,14/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-accord,BCEHBSKCWLPMDN-MGPLVRAMSA-N,"InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1",349.316
1332,Human,Targretin,"Lymphoma, T-Cell, Cutaneous",bexarotene,BEXAROTENE,EMEA/H/C/000326,no,Authorised,L01XF03,no,no,no,no,no,no,29/03/2001,,Eisai GmbH,Antineoplastic agents,16/11/2000,21/06/2021,23,Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.,21/06/2018,26/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/targretin,NAVMQTYZDKMPEU-UHFFFAOYSA-N,"InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)",348.48600000000005
814,Human,Nexium Control,Gastroesophageal Reflux,esomeprazole,ESOMEPRAZOLE,EMEA/H/C/002618,no,Authorised,A02BC05,no,no,no,no,no,no,26/08/2013,,GlaxoSmithKline Dungarvan Limited,Proton pump inhibitors,27/06/2013,24/04/2023,17,Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.,29/08/2017,24/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control,SUBDBMMJDZJVOS-DEOSSOPVSA-N,"InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1",345.424
1258,Human,Nustendi,Hypercholesterolemia;  Dyslipidemias,"bempedoic acid, ezetimibe",BEMPEDOIC ACID,EMEA/H/C/004959,no,Authorised,C10B,yes,no,no,no,no,no,27/03/2020,,Daiichi Sankyo Europe GmbH,Lipid modifying agents,30/01/2020,19/04/2022,5,"Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibealone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin",24/04/2020,21/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi,HYHMLYSLQUKXKP-UHFFFAOYSA-N,"InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)",344.492
1262,Human,Nilemdo,Hypercholesterolemia;  Dyslipidemias,bempedoic acid,BEMPEDOIC ACID,EMEA/H/C/004958,no,Authorised,C10AX,yes,no,no,no,no,no,01/04/2020,,Daiichi Sankyo Europe GmbH,Lipid modifying agents,30/01/2020,01/04/2022,6,"Nilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.",24/04/2020,08/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/nilemdo,HYHMLYSLQUKXKP-UHFFFAOYSA-N,"InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)",344.492
1803,Human,Budesonide/Formoterol Teva Pharma B.V.,Asthma,"budesonide, formoterol fumarate dihydrate",FORMOTEROL,EMEA/H/C/003953,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,16/12/2016,1,"Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists. ",16/12/2016,30/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonideformoterol-teva-pharma-bv,BPZSYCZIITTYBL-YJYMSZOUSA-N,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1",344.411
116,Human,Fingolimod Mylan,"Multiple Sclerosis, Relapsing-Remitting",fingolimod,FINGOLIMOD HYDROCHLORIDE,EMEA/H/C/005661,no,Authorised,L04AA27,no,yes,no,no,no,no,18/08/2021,,Mylan Ireland Limited,Immunosuppressants,25/06/2020,09/11/2023,5,"Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:, , Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, , Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI., ",31/08/2021,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fingolimod-mylan,SWZTYAVBMYWFGS-UHFFFAOYSA-N,"InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H",343.939
381,Human,Gilenya,Multiple Sclerosis,fingolimod,FINGOLIMOD HYDROCHLORIDE,EMEA/H/C/002202,no,Authorised,L04AA27,no,no,no,no,no,no,17/03/2011,,Novartis Europharm Limited,Immunosuppressants,20/01/2011,14/09/2023,36,"Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).orPatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.",02/07/2018,15/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya,SWZTYAVBMYWFGS-UHFFFAOYSA-N,"InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H",343.939
456,Human,Fingolimod Accord,"Multiple Sclerosis, Relapsing-Remitting",fingolimod,FINGOLIMOD HYDROCHLORIDE,EMEA/H/C/005191,no,Authorised,L04AA27,no,yes,no,no,no,no,25/06/2020,,Accord Healthcare S.L.U.,"Immunosuppressants, Selective immunosuppressants",30/04/2020,18/08/2023,4,"Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapyorPatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.",03/07/2020,18/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fingolimod-accord,SWZTYAVBMYWFGS-UHFFFAOYSA-N,"InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H",343.939
1396,Human,Phelinun,"Multiple Myeloma;  Hodgkin Disease;  Lymphoma, Non-Hodgkin;  Precursor Cell Lymphoblastic Leukemia-Lymphoma;  Leukemia, Myeloid, Acute;  Neuroblastoma;  Ovarian Neoplasms;  Hematopoietic Stem Cell Transplantation",melphalan,MELPHALAN HYDROCHLORIDE,EMEA/H/C/005173,no,Authorised,L01AA03,no,no,no,no,no,no,16/11/2020,,ADIENNE S.r.l. S.U.,Antineoplastic agents,17/09/2020,06/10/2021,1,"High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases.",25/11/2020,24/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/phelinun,OUUYBRCCFUEMLH-YDALLXLXSA-N,"InChI=1S/C13H18Cl2N2O2.ClH/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;/h1-4,12H,5-9,16H2,(H,18,19);1H/t12-;/m0./s1",341.666
0,Human,Ryeqo,Leiomyoma,"relugolix, estradiol, norethisterone acetate",NORETHISTERONE ACETATE,EMEA/H/C/005267,no,Authorised,H01CC54,yes,no,no,no,no,no,16/07/2021,,Gedeon Richter Plc.,Pituitary and hypothalamic hormones and analogues,16/07/2021,30/10/2023,6,"Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.",19/05/2021,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo,IMONTRJLAWHYGT-ZCPXKWAGSA-N,"InChI=1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1",340.4630000000001
548,Human,Vipidia,"Diabetes Mellitus, Type 2",alogliptin benzoate,ALOGLIPTIN,EMEA/H/C/002182,no,Authorised,A10BH04,no,no,no,no,no,no,18/09/2013,,Takeda Pharma A/S,"Drugs used in diabetes, Dipeptidyl peptidase 4 (DPP-4) inhibitors",,25/05/2023,10,"Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",15/01/2015,21/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,"InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1",339.399
1144,Human,Incresync,"Diabetes Mellitus, Type 2","alogliptin, pioglitazone",ALOGLIPTIN,EMEA/H/C/002178,no,Authorised,A10BD09,no,no,no,no,no,no,19/09/2013,,Takeda Pharma A/S,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/07/2013,07/09/2022,13,"Incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus:, , , 	as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, 	in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone., , , In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination., , After initiation of therapy with Incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4)., ",25/05/2018,09/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/incresync,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,"InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1",339.399
192,Human,Raxone,"Optic Atrophy, Hereditary, Leber",idebenone,IDEBENONE,EMEA/H/C/003834,no,Authorised,N06BX13,yes,no,no,yes,no,yes,08/09/2015,,Chiesi Farmaceutici S.p.A,"Other psychostimulants and nootropics, Psychoanaleptics, ",25/06/2015,19/10/2023,9,Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).,08/03/2018,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/raxone,JGPMMRGNQUBGND-UHFFFAOYSA-N,"InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3",338.444
617,Human,Oxbryta,"Anemia;  Anemia, Hemolytic;  Anemia, Sickle Cell",Voxelotor,VOXELOTOR,EMEA/H/C/004869,no,Authorised,B06AX03,yes,no,no,no,no,yes,14/02/2022,,Pfizer Europe MA EEIG ,Other hematological agents,16/12/2021,08/06/2023,4,Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.,14/12/2021,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta,FWCVZAQENIZVMY-UHFFFAOYSA-N,"InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3",337.379
1089,Human,Effentora,Pain;  Cancer,fentanyl,FENTANYL,EMEA/H/C/000833,no,Authorised,N02AB03,no,no,no,no,no,no,04/04/2008,,Teva B.V.,Analgesics,,29/09/2022,28,"Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain., , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain., , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. , ",31/05/2018,11/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/effentora,PJMPHNIQZUBGLI-UHFFFAOYSA-N,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",336.479
1097,Human,PecFent,Pain;  Cancer,fentanyl,FENTANYL,EMEA/H/C/001164,no,Authorised,N02AB03,no,no,no,no,no,no,31/08/2010,,Kyowa Kirin Holdings B.V.,Analgesics,,29/09/2022,23,"PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer.",19/07/2018,08/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pecfent,PJMPHNIQZUBGLI-UHFFFAOYSA-N,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",336.479
1366,Human,Yentreve,"Urinary Incontinence, Stress",duloxetine,DULOXETINE HYDROCHLORIDE,EMEA/H/C/000545,no,Authorised,N06AX21,no,no,no,no,no,no,11/08/2004,,Eli Lilly Nederland B.V.,"Psychoanaleptics, ",,15/12/2021,28,Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).,19/12/2016,21/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/yentreve,BFFSMCNJSOPUAY-LMOVPXPDSA-N,"InChI=1S/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/m0./s1",333.88399999999996
409,Human,Akynzeo,Vomiting;  Neoplasms;  Nausea;  Cancer,"netupitant, palonosetron",PALONOSETRON HYDROCHLORIDE,EMEA/H/C/003728,no,Authorised,A04AA,no,no,no,no,no,no,27/05/2015,,Helsinn Birex Pharmaceuticals Ltd,"Antiemetics and antinauseants, ",26/03/2015,05/09/2023,16,Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.,12/04/2018,08/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo,OLDRWYVIKMSFFB-SSPJITILSA-N,"InChI=1S/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/m1./s1",332.87499999999994
936,Human,Aloxi,Vomiting;  Cancer,palonosetron,PALONOSETRON HYDROCHLORIDE,EMEA/H/C/000563,no,Authorised,A04AA05,no,no,no,no,no,no,22/03/2005,,Helsinn Birex Pharmaceuticals Ltd.,"Antiemetics and antinauseants, , Serotonin (5HT3) antagonists",,26/04/2018,22,"Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.",26/04/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi,OLDRWYVIKMSFFB-SSPJITILSA-N,"InChI=1S/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/m1./s1",332.87499999999994
1263,Human,Palonosetron Hospira,Nausea;  Vomiting;  Cancer,palonosetron,PALONOSETRON HYDROCHLORIDE,EMEA/H/C/004069,no,Withdrawn,A04AA05,no,yes,no,no,no,no,08/04/2016,,Pfizer Europe MA EEIG,"Antiemetics and antinauseants, ",,12/12/2018,4,Palonosetron Hospira is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy;the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Palonosetron Hospira is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.,01/02/2018,08/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-hospira,OLDRWYVIKMSFFB-SSPJITILSA-N,"InChI=1S/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/m1./s1",332.87499999999994
511,Human,Ztalmy,"Epileptic Syndromes;  Spasms, Infantile",ganaxolone,GANAXOLONE,EMEA/H/C/005825,no,Authorised,N03AX,yes,no,no,no,no,yes,26/07/2023,,Marinus Pharmaceuticals Emerald Limited,Other antiepileptics,25/05/2023,,,Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.,24/04/2023,31/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ztalmy,PGTVWKLGGCQMBR-FLBATMFCSA-N,"InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1",332.5280000000001
1439,Human,Dectova,"Influenza, Human",Zanamivir,ZANAMIVIR,EMEA/H/C/004102,no,Authorised,J05AH01,yes,no,no,yes,no,no,26/04/2019,,GlaxoSmithKline Trading Services Limited,Antivirals for systemic use,26/04/2019,21/09/2021,4,"Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.",07/06/2019,08/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/dectova,ARAIBEBZBOPLMB-UFGQHTETSA-N,"InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1",332.31300000000005
595,Human,Vazkepa,Dyslipidemias,icosapent ethyl,ICOSAPENT ETHYL,EMEA/H/C/005398,no,Authorised,C10AX,yes,no,no,no,no,no,26/03/2021,,Amarin Pharmaceuticals Ireland Limited,Lipid modifying agents,28/01/2021,27/06/2023,5,Indicated to reduce cardiovascular risk as an adjunct to statin therapy.,14/04/2021,10/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa,SSQPWTVBQMWLSZ-AAQCHOMXSA-N,"InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-",330.51200000000017
689,Human,Nitisinone MDK (previously Nitisinone MendeliKABS),Tyrosinemias,nitisinone,NITISINONE,EMEA/H/C/004281,no,Withdrawn,A16AX04,no,yes,no,no,no,no,24/08/2017,,MendeliKABS Europe Ltd,"Other alimentary tract and metabolism products, ",22/06/2017,15/07/2022,6,Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.,21/04/2018,14/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nitisinone-mdk,OUBCNLGXQFSTLU-UHFFFAOYSA-N,"InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",329.2300000000001
707,Human,Nityr,Tyrosinemias,nitisinone,NITISINONE,EMEA/H/C/004582,no,Authorised,A16AX04,no,yes,no,no,no,no,26/07/2018,,Cycle Pharmaceuticals (Europe) Ltd,"Other alimentary tract and metabolism products, ",31/05/2018,04/05/2023,5,Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.,26/07/2018,05/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nityr,OUBCNLGXQFSTLU-UHFFFAOYSA-N,"InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",329.2300000000001
833,Human,Orfadin,Tyrosinemias,nitisinone,NITISINONE,EMEA/H/C/000555,no,Authorised,A16AX04,no,no,no,no,no,no,21/02/2005,,Swedish Orphan Biovitrum International AB,"Other alimentary tract and metabolism products, ",18/11/2004,13/04/2023,21,Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).,26/01/2017,14/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/orfadin,OUBCNLGXQFSTLU-UHFFFAOYSA-N,"InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",329.2300000000001
1595,Human,Alpivab,"Influenza, Human",peramivir,PERAMIVIR,EMEA/H/C/004299,no,Withdrawn,J05AH03,yes,no,no,no,no,no,13/04/2018,,Biocryst,Antivirals for systemic use,,20/11/2020,2,Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.,13/04/2018,09/12/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/alpivab,XRQDFNLINLXZLB-CKIKVBCHSA-N,"InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1",328.413
1083,Human,Adasuve,Schizophrenia;  Bipolar Disorder,loxapine,LOXAPINE,EMEA/H/C/002400,no,Authorised,N05AH01,no,no,no,no,no,no,20/02/2013,,Ferrer Internacional S.A.,Nervous system,,31/10/2022,14,Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.,15/01/2018,14/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve,XJGVXQDUIWGIRW-UHFFFAOYSA-N,"InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",327.815
120,Human,Suboxone,Opioid-Related Disorders,"buprenorphine, naloxone",NALOXONE,EMEA/H/C/000697,no,Authorised,N07BC51,no,no,no,no,no,no,26/09/2006,,Indivior Europe Limited,Other nervous system drugs,27/07/2006,09/10/2023,22,"Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.",31/05/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone,UZHSEJADLWPNLE-GRGSLBFTSA-N,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",327.38000000000005
513,Human,Buccolam,Epilepsy,midazolam,MIDAZOLAM,EMEA/H/C/002267,no,Authorised,N05CD08,no,no,no,no,no,no,04/09/2011,,Neuraxpharm Pharmaceuticals S.L.,Psycholeptics,23/06/2011,07/07/2023,18,"Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.",25/07/2018,31/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam,DDLIGBOFAVUZHB-UHFFFAOYSA-N,"InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3",325.77399999999994
612,Human,Isturisa,Cushing Syndrome,osilodrostat,OSILODROSTAT PHOSPHATE,EMEA/H/C/004821,no,Authorised,H02CA02,yes,no,no,no,no,yes,09/01/2020,,Recordati Rare Diseases,Corticosteroids for systemic use,14/11/2019,27/06/2023,5,Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.,18/02/2020,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/isturisa,FMCPYRDGUZBOJZ-BTQNPOSSSA-N,"InChI=1S/C13H10FN3.H3O4P/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13;1-5(2,3)4/h1,3,5,7-8,13H,2,4H2;(H3,1,2,3,4)/t13-;/m1./s1",325.236
1825,Human,Nuedexta,Neurobehavioral Manifestations,"dextromethorphan hydrobromide, quinidine sulfate",QUINIDINE,EMEA/H/C/002560,no,Withdrawn,N07XX59,no,no,no,no,no,no,24/06/2013,,Jenson Pharmaceutical Services Limited,Other nervous system drugs,,24/10/2014,2,Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.,24/10/2014,11/03/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta,LOUPRKONTZGTKE-LHHVKLHASA-N,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1",324.424
856,Human,Lydisilka,"Contraceptives, Oral","estetrol, drospirenone",ESTETROL MONOHYDRATE,EMEA/H/C/005382,no,Authorised,G03,no,no,no,no,no,no,19/05/2021,,Estetra SPRL,"Sex hormones and modulators of the genital system, ",25/03/2021,30/03/2023,3,"Oral contraception.The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).",24/03/2021,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lydisilka,XRJNAPXFAXBPAM-BVTDNVAGSA-N,"InChI=1S/C18H24O4.H2O/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22;/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3;1H2/t12-,13-,14-,15-,16-,17+,18+;/m1./s1",322.40100000000007
858,Human,Drovelis,"Contraceptives, Oral","estetrol, drospirenone",ESTETROL MONOHYDRATE,EMEA/H/C/005336,no,Authorised,G03,no,no,no,no,no,no,19/05/2021,,Gedeon Richter Plc.,"Sex hormones and modulators of the genital system, ",25/03/2021,30/03/2023,4,oral contraceptive,24/03/2021,31/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/drovelis,XRJNAPXFAXBPAM-BVTDNVAGSA-N,"InChI=1S/C18H24O4.H2O/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22;/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3;1H2/t12-,13-,14-,15-,16-,17+,18+;/m1./s1",322.40100000000007
832,Human,Zerbaxa,Bacterial Infections,"ceftolozane, tazobactam",TAZOBACTAM SODIUM,EMEA/H/C/003772,no,Authorised,J01,no,no,no,no,no,no,18/09/2015,,Merck Sharp & Dohme B.V. ,"Antibacterials for systemic use, ",23/07/2015,25/07/2022,15,"Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",08/05/2018,14/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa,RFMIKMMOLPNEDG-QVUDESDKSA-M,"InChI=1S/C10H12N4O5S.Na/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19;/h2-3,7-8H,4-5H2,1H3,(H,16,17);/q;+1/p-1/t7-,8+,10+;/m1./s1",322.278
600,Human,DuoPlavin,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",CLOPIDOGREL,EMEA/H/C/001143,no,Authorised,B01AC30,no,no,no,no,no,no,14/03/2010,,Sanofi Winthrop Industrie,Antithrombotic agents,17/12/2009,30/06/2023,30,DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI);ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.For further information please refer to section 5.1.,18/01/2018,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duoplavin-0,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
607,Human,Iscover,Stroke;  Peripheral Vascular Diseases;  Atrial Fibrillation;  Myocardial Infarction;  Acute Coronary Syndrome,clopidogrel,CLOPIDOGREL,EMEA/H/C/000175,no,Authorised,B01AC04,no,no,no,no,no,no,14/07/1998,,Sanofi Winthrop Industrie,Antithrombotic agents,25/03/1998,06/07/2022,50,"Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.Adult patients suffering from acute coronary syndrome:Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).ST segment elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2  score ?4) or minor IS (NIHSS  ?3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.",18/01/2018,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/iscover,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
647,Human,Clopidogrel Zentiva (previously Clopidogrel Winthrop),Stroke;  Peripheral Vascular Diseases;  Myocardial Infarction;  Acute Coronary Syndrome,clopidogrel,CLOPIDOGREL,EMEA/H/C/000975,no,Authorised,B01AC04,no,no,no,no,no,no,15/07/2008,,Zentiva k.s.,Antithrombotic agents,24/04/2008,23/06/2023,32,"Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.For further information please refer to section 5.1.",30/04/2018,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-zentiva,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1578,Human,Clopidogrel ratiopharm GmbH,Peripheral Vascular Diseases;  Acute Coronary Syndrome;  Myocardial Infarction;  Stroke,clopidogrel,CLOPIDOGREL,EMEA/H/C/001165,no,Withdrawn,B01AC04,no,yes,no,no,no,no,28/07/2009,,Archie Samiel s.r.o.,Antithrombotic agents,,22/08/2019,12,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q wave-myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.",13/04/2018,25/01/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-ratiopharm-gmbh,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1676,Human,Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover),Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",CLOPIDOGREL,EMEA/H/C/001144,no,Authorised,B01AC30,no,no,no,no,no,no,14/03/2010,,Sanofi-Aventis Groupe,Antithrombotic agents,,19/09/2019,22,Acute Coronary SyndromeMyocardial Infarction,18/01/2018,13/11/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acetylsalicylic-acid-zentiva-previously-duocover,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1778,Human,Clopidogrel Acino,Peripheral Vascular Diseases;  Acute Coronary Syndrome;  Myocardial Infarction;  Stroke,clopidogrel,CLOPIDOGREL,EMEA/H/C/001166,no,Withdrawn,B01AC04,no,yes,no,no,no,no,28/07/2009,,Acino AG,Antithrombotic agents,,28/01/2016,6,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:, , , 	, 		, 			Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, 			Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA), 			ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy, 			Patients suffering from acute coronary syndrome., 		, 	, , ",28/01/2016,04/01/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acino,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1797,Human,Clopidogrel/Acetylsalicylic acid Teva,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",CLOPIDOGREL,EMEA/H/C/002272,no,Withdrawn,B01AC30,no,no,no,no,no,no,01/09/2014,,Teva Pharma B.V.,combinations,26/06/2014,03/06/2016,1,Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed?dose combination medicinal product for continuation of therapy in:Non?ST segment elevation acute coronary syndrome (unstable angina or non?Q?wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy,03/06/2016,28/04/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrelacetylsalicylic-acid-teva,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1876,Human,Clopidogrel ratiopharm,Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction,clopidogrel,CLOPIDOGREL,EMEA/H/C/001173,no,Withdrawn,B01AC04,no,yes,no,no,no,no,23/09/2009,,Archie Samuel s.r.o.,Antithrombotic agents,,25/10/2013,5,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For further information please refer to section 5.1.",25/10/2013,12/12/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-ratiopharm-0,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1914,Human,Clopidogrel Acino Pharma GmbH,Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction,clopidogrel,CLOPIDOGREL,EMEA/H/C/001175,no,Withdrawn,B01AC04,no,yes,no,no,no,no,21/09/2009,,Acino Pharma GmbH,Antithrombotic agents,,13/02/2012,1,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.For further information please refer to section 5.1.",13/02/2012,26/07/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acino-pharma-gmbh,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1915,Human,Clopidogrel Acino Pharma,Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction,clopidogrel,CLOPIDOGREL,EMEA/H/C/001172,no,Withdrawn,B01AC04,no,yes,no,no,no,no,21/09/2009,,Acino Pharma GmbH,Antithrombotic agents,,09/02/2012,1,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.For further information please refer to section 5.1.",09/02/2012,26/07/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acino-pharma,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1916,Human,Clopidogrel Hexal,Peripheral Vascular Diseases;  Acute Coronary Syndrome;  Myocardial Infarction;  Stroke,clopidogrel,CLOPIDOGREL,EMEA/H/C/001139,no,Withdrawn,B01AC04,no,yes,no,no,no,no,28/07/2009,,Acino Pharma GmbH,Antithrombotic agents,,09/02/2012,2,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:-          Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);-          ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.For further information please refer to section 5.1.",09/02/2012,26/07/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-hexal,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1930,Human,Clopidogrel Sandoz,Peripheral Vascular Diseases;  Stroke;  Myocardial Infarction,clopidogrel,CLOPIDOGREL,EMEA/H/C/001174,no,Withdrawn,B01AC04,no,yes,no,no,no,no,21/09/2009,,Acino Pharma GmbH,Antithrombotic agents,,16/09/2010,2,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:* Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.For further information please refer to section 5.1.",16/09/2010,26/10/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-sandoz,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
1941,Human,Clopidogrel 1A Pharma,Peripheral Vascular Diseases,clopidogrel,CLOPIDOGREL,EMEA/H/C/001054,no,Withdrawn,B01AC04,no,yes,no,no,no,no,28/07/2009,,Acino Pharma GmbH ,Antithrombotic agents,,01/02/2011,1,"Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.Patients suffering from acute coronary syndrome:- Non ST segment elevation acute coronary syndrome (unstable angina or non Q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.For further information please refer to section 5.1.",01/02/2011,28/02/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-1a-pharma,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",321.829
993,Human,Lysodren,Adrenal Cortex Neoplasms,mitotane,MITOTANE,EMEA/H/C/000521,no,Authorised,L01XX23,no,no,no,no,no,no,28/04/2004,,HRA Pharma Rare Diseases,Antineoplastic agents,,01/12/2022,18,"Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.",25/04/2016,18/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren,JWBOIMRXGHLCPP-UHFFFAOYSA-N,"InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H",320.04599999999994
373,Human,Lumeblue (previously known as Methylthioninium chloride Cosmo),Colorectal Neoplasms;  Colonoscopy,methylthioninium chloride,METHYLTHIONINIUM CHLORIDE,EMEA/H/C/002776,no,Authorised,V04CX,no,no,no,no,no,no,19/08/2020,,Alfasigma S.p.A.,Other diagnostic agents,25/06/2020,11/09/2023,3,Lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.,26/08/2020,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue,CXKWCBBOMKCUKX-UHFFFAOYSA-M,"InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1",319.861
594,Human,Methylthioninium chloride Proveblue,Methemoglobinemia,methylthioninium chloride,METHYLTHIONINIUM CHLORIDE,EMEA/H/C/002108,no,Authorised,V03AB17,no,no,no,no,no,no,06/05/2011,,Provepharm SAS,All other therapeutic products,,12/05/2023,26,"Acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia.Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old).",06/04/2018,10/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue,CXKWCBBOMKCUKX-UHFFFAOYSA-M,"InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1",319.861
477,Human,Bonviva,"Osteoporosis, Postmenopausal",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/000501,no,Authorised,M05BA06,no,no,no,no,no,no,23/02/2004,,Atnahs Pharma Netherlands B.V.,Drugs for treatment of bone diseases,23/10/2003,25/07/2022,29,"Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.",10/07/2018,11/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
579,Human,Bondronat,"Hypercalcemia;  Breast Neoplasms;  Neoplasm Metastasis;  Fractures, Bone",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/000101,no,Authorised,M05BA06,no,no,no,no,no,no,25/06/1996,,Atnahs Pharma Netherlands B.V.,Drugs for treatment of bone diseases,14/02/1996,19/05/2023,32,"Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases.",10/07/2018,14/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bondronat,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1016,Human,Ibandronic acid Accord,Wounds and Injuries;  Breast Diseases;  Neoplastic Processes;  Calcium Metabolism Disorders;  Water-Electrolyte Imbalance,ibandronic acid,IBANDRONIC ACID,EMEA/H/C/002638,no,Authorised,M05BA06,no,yes,no,no,no,no,18/11/2012,,Accord Healthcare S.L.U.,Drugs for treatment of bone diseases,,05/01/2023,14,"Ibandronic acid is indicated in adults forPrevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.Treatment of tumour induced hypercalcaemia with or without metastases.Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.",18/09/2017,05/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-accord,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1071,Human,Ibandronic Acid Teva,"Breast Neoplasms;  Neoplasm Metastasis;  Fractures, Bone;  Osteoporosis, Postmenopausal",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/001195,no,Authorised,M05BA06,no,yes,no,no,no,no,17/09/2010,,Teva Pharma B.V.,Drugs for treatment of bone diseases,24/06/2010,22/11/2022,12,"Ibandronic acid 50mgIbandronic Acid Teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.Ibandronic acid 150mgTreatment of osteoporosis in postmenopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.",10/11/2016,22/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-teva,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1081,Human,Iasibon,"Hypercalcemia;  Fractures, Bone;  Neoplasm Metastasis;  Breast Neoplasms",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/002025,no,Authorised,M05BA06,no,yes,no,no,no,no,21/01/2011,,Pharmathen S.A.,Drugs for treatment of bone diseases,21/10/2010,03/10/2022,11,"Concentrate for solution for infusion, , Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases., , Treatment of tumour-induced hypercalcaemia with or without metastases., , Film-coated Tablets, , Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases., ",18/10/2016,14/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/iasibon,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1203,Human,Ibandronic Acid Sandoz,"Breast Neoplasms;  Neoplasm Metastasis;  Fractures, Bone",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/002367,no,Authorised,M05BA06,no,yes,no,no,no,no,26/07/2011,,Sandoz GmbH,"Drugs for treatment of bone diseases, Bisphosphonates",17/02/2011,06/07/2022,9,"Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases., ",21/07/2016,06/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-sandoz,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1889,Human,Bondenza (previously Ibandronic Acid Roche),"Osteoporosis, Postmenopausal",ibandronic acid,IBANDRONIC ACID,EMEA/H/C/000502,no,Withdrawn,M05BA06,no,no,no,no,no,no,23/02/2004,,Roche Registration Ltd.,Drugs for treatment of bone diseases,,15/11/2012,16,Treatment of osteoporosis in post-menopausal women at increased risk of fracture.A reduction in the risk of vertebral fractures has been demonstrated. Efficacy on femoral-neck fractures has not been established.,15/11/2012,13/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/bondenza-previously-ibandronic-acid-roche,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
1962,Human,Destara,Hypercalcemia;  Cancer,ibandronic acid,IBANDRONIC ACID,EMEA/H/C/000103,no,Withdrawn,M05BA06,no,no,no,no,no,no,25/06/1996,,Roche Registration Ltd.,Drugs for treatment of bone diseases,,31/12/2009,0,Treatment of tumour-induced hypercalcaemia with or without metastases.,31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/destara,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",319.231
324,Human,Bevespi Aerosphere,"Pulmonary Disease, Chronic Obstructive","glycopyrronium, formoterol fumarate dihydrate",GLYCOPYRRONIUM,EMEA/H/C/004245,no,Authorised,R03AL07,no,no,no,no,no,no,18/12/2018,,AstraZeneca AB,formoterol and glycopyrronium bromide,18/10/2018,15/09/2023,6,Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,05/02/2019,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere,ANGKOCUUWGHLCE-HKUYNNGSSA-N,"InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1/t17-,19-/m0/s1",318.43699999999995
623,Human,Trydonis,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide",GLYCOPYRRONIUM,EMEA/H/C/004702,no,Authorised,R03AL09,no,no,no,no,no,no,26/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,02/12/2022,5,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,26/04/2018,04/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis,ANGKOCUUWGHLCE-HKUYNNGSSA-N,"InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1/t17-,19-/m0/s1",318.43699999999995
631,Human,Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol",GLYCOPYRRONIUM,EMEA/H/C/004836,no,Authorised,R03AL09,no,no,no,no,no,no,23/04/2018,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases, ",,09/12/2022,4,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,23/04/2018,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riarify,ANGKOCUUWGHLCE-HKUYNNGSSA-N,"InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1/t17-,19-/m0/s1",318.43699999999995
1064,Human,Recarbrio,Gram-Negative Bacterial Infections,"imipenem, cilastatin, relebactam",IMIPENEM MONOHYDRATE,EMEA/H/C/004808,no,Authorised,J01DH56,yes,no,no,no,no,no,13/02/2020,,Merck Sharp & Dohme B.V. ,"Carbapenems, Antibacterials for systemic use, ",12/12/2019,28/11/2022,5,"Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",26/02/2020,29/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio,GSOSVVULSKVSLQ-JJVRHELESA-N,"InChI=1S/C12H17N3O4S.H2O/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17;/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19);1H2/t6-,7-,9-;/m1./s1",317.367
1189,Human,Ganfort,"Glaucoma, Open-Angle;  Ocular Hypertension","bimatoprost, timolol",TIMOLOL,EMEA/H/C/000668,no,Authorised,S01ED51,no,no,no,no,no,no,19/05/2006,,AbbVie Deutschland GmbH & Co. KG,Ophthalmologicals,,20/07/2022,23,"Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues., ",06/04/2017,20/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort,BLJRIMJGRPQVNF-JTQLQIEISA-N,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",316.4270000000001
1438,Human,DuoTrav,"Glaucoma, Open-Angle;  Ocular Hypertension","travoprost, timolol",TIMOLOL,EMEA/H/C/000665,no,Authorised,S01ED51,no,no,no,no,no,no,23/04/2006,,Novartis Europharm Limited,Ophthalmologicals,23/02/2006,24/09/2021,18,Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.,15/02/2018,08/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/duotrav,BLJRIMJGRPQVNF-JTQLQIEISA-N,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",316.4270000000001
769,Human,Febuxostat Mylan,"Hyperuricemia;  Arthritis, Gouty;  Gout",febuxostat,FEBUXOSTAT,EMEA/H/C/004374,no,Authorised,M04AA03,no,yes,no,no,no,no,15/06/2017,,Mylan Pharmaceuticals Limited,Antigout preparations,21/04/2017,15/05/2023,11,"Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults.",15/06/2017,16/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan,BQSJTQLCZDPROO-UHFFFAOYSA-N,"InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",316.382
779,Human,Febuxostat Krka,Hyperuricemia;  Gout,febuxostat,FEBUXOSTAT,EMEA/H/C/004773,no,Authorised,M04AA03,no,yes,no,no,no,no,28/03/2019,,"Krka, d.d., Novo mesto",Antigout preparations,31/01/2019,11/05/2023,4,"Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Krka is indicated in adults.",29/03/2019,11/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-krka,BQSJTQLCZDPROO-UHFFFAOYSA-N,"InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",316.382
823,Human,Adenuric,Gout,febuxostat,FEBUXOSTAT,EMEA/H/C/000777,no,Authorised,M04AA03,no,no,no,no,no,no,21/04/2008,,Menarini International Operations Luxembourg S.A. (MIOL),Antigout preparations,,08/08/2022,23,"80 mg strength:Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated in adults.120 mg strength:Adenuric is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Adenuric is indicated in adults.",31/05/2018,20/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric,BQSJTQLCZDPROO-UHFFFAOYSA-N,"InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",316.382
112,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EFAVIRENZ,EMEA/H/C/004240,no,Authorised,J05AR06,no,yes,no,no,no,no,05/09/2017,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,22/06/2017,03/11/2023,16,"Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",15/08/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
677,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EFAVIRENZ,EMEA/H/C/004274,no,Authorised,J05AR06,no,yes,no,no,no,no,08/02/2018,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,14/12/2017,15/06/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",08/02/2018,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-krka,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
720,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EFAVIRENZ,EMEA/H/C/004250,no,Authorised,J05AR06,no,yes,no,no,no,no,17/07/2017,,Zentiva k.s.,Antivirals for systemic use,18/05/2017,30/05/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with combination efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",09/01/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-zentiva,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
741,Human,Sustiva,HIV Infections,efavirenz,EFAVIRENZ,EMEA/H/C/000249,no,Authorised,J05AG03,no,no,no,no,no,no,28/05/1999,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,23/05/2023,48,"Sustiva is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Sustiva has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Sustiva.",15/12/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sustiva,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
811,Human,Stocrin,HIV Infections,efavirenz,EFAVIRENZ,EMEA/H/C/000250,no,Authorised,J05AG03,no,no,no,no,no,no,28/05/1999,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,24/02/1999,14/04/2023,49,"Stocrin is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Stocrin has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Stocrin.",30/07/2018,25/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stocrin,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
924,Human,Efavirenz Teva,HIV Infections,efavirenz,EFAVIRENZ,EMEA/H/C/002352,no,Authorised,J05AG03,no,yes,no,no,no,no,09/01/2012,,Teva B.V.,Antivirals for systemic use,,27/02/2023,12,"Efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children 3 years of age and older.Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with protease inhibitors (PIs) has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz.",09/09/2016,03/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-teva,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
1338,Human,Atripla,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EFAVIRENZ,EMEA/H/C/000797,no,Withdrawn,J05AR06,no,no,no,no,no,no,13/12/2007,,Gilead Sciences Ireland UC,Antivirals for systemic use,,17/08/2021,36,"Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla.No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients.No data are available to support the combination of Atripla and other antiretroviral agents.",25/07/2018,21/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/atripla,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",315.678
1310,Human,Leganto,Restless Legs Syndrome;  Parkinson Disease,rotigotine,ROTIGOTINE,EMEA/H/C/002380,no,Withdrawn,N04BC09,no,no,no,no,no,no,16/06/2011,,UCB Pharma S.A.  ,Anti-Parkinson drugs,14/04/2011,14/12/2021,19,"Leganto is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.Leganto is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).",24/04/2018,18/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/leganto,KFQYTPMOWPVWEJ-INIZCTEOSA-N,"InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1",315.4819999999999
1379,Human,Neupro,Restless Legs Syndrome;  Parkinson Disease,rotigotine,ROTIGOTINE,EMEA/H/C/000626,no,Authorised,N04BC09,no,no,no,no,no,no,15/02/2006,,UCB Pharma S.A.,Anti-Parkinson drugs,15/12/2005,08/11/2021,31,"Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.",09/11/2017,10/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/neupro,KFQYTPMOWPVWEJ-INIZCTEOSA-N,"InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1",315.4819999999999
730,Human,Qtern,"Diabetes Mellitus, Type 2;  Diabetes Mellitus;  Nutritional and Metabolic Diseases;  Metabolic Diseases;  Glucose Metabolism Disorders","saxagliptin, dapagliflozin",SAXAGLIPTIN,EMEA/H/C/004057,no,Authorised,A10BD21,no,no,no,no,no,no,15/07/2016,,Astra Zeneca AB,Drugs used in diabetes,,30/05/2023,11,"Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,when already being treated with the free combination of dapagliflozin and saxagliptin.(See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.)",20/12/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/qtern,QGJUIPDUBHWZPV-SGTAVMJGSA-N,"InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1",315.4170000000001
817,Human,Onglyza,"Diabetes Mellitus, Type 2",saxagliptin,SAXAGLIPTIN,EMEA/H/C/001039,no,Authorised,A10BH03,no,no,no,no,no,no,30/09/2009,,AstraZeneca AB,Drugs used in diabetes,,19/04/2023,22,"Add-on combination therapyOnglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.",17/08/2017,21/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza,QGJUIPDUBHWZPV-SGTAVMJGSA-N,"InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1",315.4170000000001
1618,Human,Qtrilmet,"Diabetes Mellitus, Type 2","metformin hydrochloride, saxagliptin, dapagliflozin",SAXAGLIPTIN,EMEA/H/C/004910,no,Withdrawn,A10BD,no,no,no,no,no,no,11/11/2019,,AstraZeneca AB,Drugs used in diabetes,19/09/2019,14/08/2020,2,Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.when already being treated with metformin and saxagliptin and dapagliflozin.,10/12/2019,09/10/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet,QGJUIPDUBHWZPV-SGTAVMJGSA-N,"InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1",315.4170000000001
626,Human,Epidyolex,"Lennox Gastaut Syndrome;  Epilepsies, Myoclonic",cannabidiol,CANNABIDIOL,EMEA/H/C/004675,no,Authorised,N03AX,no,no,no,no,no,yes,19/09/2019,,Jazz Pharmaceuticals Ireland Limited,"Antiepileptics, ",25/07/2019,31/05/2023,15,"Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.",04/10/2019,04/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,"InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1",314.46900000000005
1954,Human,Bextra,"Arthritis, Rheumatoid;  Osteoarthritis;  Dysmenorrhea",valdecoxib,VALDECOXIB,EMEA/H/C/000431,no,Withdrawn,M01AH03,no,no,no,no,no,no,27/03/2003,,Pharmacia - Pfizer EEIG,Antiinflammatory and antirheumatic products,,03/02/2010,2,"Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).",03/02/2010,03/02/2010,https://www.ema.europa.eu/en/medicines/human/EPAR/bextra,LNPDTQAFDNKSHK-UHFFFAOYSA-N,"InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",314.366
2015,Human,Valdyn (previously Kudeq),"Arthritis, Rheumatoid;  Osteoarthritis;  Dysmenorrhea",valdecoxib,VALDECOXIB,EMEA/H/C/000437,no,Withdrawn,M01AH03,no,no,no,no,no,no,27/03/2003,,Pfizer Limited,Antiinflammatory and antirheumatic products,,24/06/2005,0,Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.,24/06/2005,11/08/2005,https://www.ema.europa.eu/en/medicines/human/EPAR/valdyn-previously-kudeq,LNPDTQAFDNKSHK-UHFFFAOYSA-N,"InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",314.366
2023,Human,Valdyn,"Osteoarthritis;  Arthritis, Rheumatoid;  Dysmenorrhea",valdecoxib,VALDECOXIB,EMEA/H/C/000432,no,Withdrawn,M01AH03,no,no,no,no,no,no,27/03/2003,,Pharmacia Europe EEIG,Antiinflammatory and antirheumatic products,,02/03/2004,0,Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.,02/03/2004,23/08/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/valdyn,LNPDTQAFDNKSHK-UHFFFAOYSA-N,"InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",314.366
955,Human,Sapropterin Dipharma,Phenylketonurias,sapropterin,SAPROPTERIN DIHYDROCHLORIDE,EMEA/H/C/005646,no,Authorised,A16AX07,no,yes,no,no,no,no,16/02/2022,,Dipharma Arzneimittel GmbH,"Other alimentary tract and metabolism products, ",16/12/2021,30/01/2023,3,Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.,14/12/2021,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma,RKSUYBCOVNCALL-NTVURLEBSA-N,"InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1",314.17300000000006
1662,Human,Kuvan,Phenylketonurias,sapropterin,SAPROPTERIN DIHYDROCHLORIDE,EMEA/H/C/000943,no,Authorised,A16AX07,no,no,no,no,no,no,02/12/2008,,BioMarin International Limited,"Other alimentary tract and metabolism products, ",,16/01/2020,20,Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.,12/04/2018,04/03/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan,RKSUYBCOVNCALL-NTVURLEBSA-N,"InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1",314.17300000000006
596,Human,Lenalidomide Krka d.d.,"Multiple Myeloma;  Lymphoma, Follicular;  Myelodysplastic Syndromes",lenalidomide,LENALIDOMIDE HYDROCHLORIDE HYDRATE,EMEA/H/C/005729,no,Withdrawn,L04AX04,no,yes,no,no,no,no,11/02/2021,,"Krka, d.d., Novo mesto ",Immunosuppressants,10/12/2020,13/12/2021,2,"Multiple myelomaLenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka d.d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka d.d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka d.d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Follicular lymphomaLenalidomide Krka d.d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).",18/02/2021,10/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-krka-dd,NEUSAGZHGGOOIV-UHFFFAOYSA-N,"InChI=1S/C13H13N3O3.ClH.H2O/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;;/h1-3,10H,4-6,14H2,(H,15,17,18);1H;1H2",313.741
329,Human,Olanzapine Teva,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000810,no,Authorised,N05AH03,no,yes,no,no,no,no,12/12/2007,,Teva B.V. ,Psycholeptics,,22/09/2023,30,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",19/02/2018,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
578,Human,Olanzapine Mylan,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000961,no,Authorised,N05AH03,no,yes,no,no,no,no,06/10/2008,,Mylan Pharmaceuticals Limited,Psycholeptics,,19/05/2023,19,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",12/12/2017,14/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-mylan,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
914,Human,Olanzapine Apotex,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/001178,no,Authorised,N05AH03,no,yes,no,no,no,no,10/06/2010,,Apotex Europe BV,Psycholeptics,,08/03/2023,13,"Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",07/02/2017,09/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-apotex,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
945,Human,Zalasta,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000792,no,Authorised,N05AH03,no,yes,no,no,no,no,27/09/2007,,Krka,Psycholeptics,,03/02/2023,20,"Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",19/01/2018,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zalasta,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1024,Human,Olanzapine Glenmark Europe,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/001086,no,Authorised,N05AH03,no,yes,no,no,no,no,03/12/2009,,Glenmark Arzneimittel GmbH,Psycholeptics,,20/12/2022,14,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",23/10/2017,20/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-glenmark-europe,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1025,Human,Olanzapine Glenmark,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/001085,no,Authorised,N05AH03,no,yes,no,no,no,no,03/12/2009,,Glenmark Arzneimittel GmbH,Psycholeptics,,20/12/2022,15,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",23/02/2017,20/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-glenmark,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1316,Human,Zyprexa Velotab,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000287,no,Authorised,N05AH03,no,no,no,no,no,no,03/02/2000,,Eli Lilly Nederland B.V.,Psycholeptics,21/10/1999,22/12/2021,31,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",23/02/2017,11/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zyprexa-velotab,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1358,Human,Zyprexa,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000115,no,Authorised,N05AH03,no,no,no,no,no,no,27/09/1996,,Eli Lilly Nederland B.V.,Psycholeptics,,22/12/2021,42,"Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.",23/02/2017,10/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zyprexa,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1631,Human,Olazax,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/001087,no,Authorised,N05AH03,no,yes,no,no,no,no,11/12/2009,,Glenmark Pharmaceuticals s.r.o. ,Psycholeptics,,25/06/2020,12,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",23/02/2017,31/07/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/olazax,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1641,Human,Olazax Disperzi,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/001088,no,Authorised,N05AH03,no,yes,no,no,no,no,10/12/2009,,Glenmark Pharmaceuticals s.r.o. ,Psycholeptics,,16/03/2020,12,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",23/02/2017,16/06/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/olazax-disperzi,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
1862,Human,Olanzapine Cipla (previously Olanzapine Neopharma),Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000793,no,Withdrawn,N05AH03,no,yes,no,no,no,no,14/11/2007,,Cipla (EU) Limited,Psycholeptics,,28/11/2013,12,"AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.",28/11/2013,24/07/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-cipla-previously-olanzapine-neopharma,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
2029,Human,Olansek,Schizophrenia;  Bipolar Disorder,olanzapine,OLANZAPINE,EMEA/H/C/000114,no,Withdrawn,N05AH03,no,no,no,no,no,no,07/10/1996,,Eli Lilly  Co. Ltd.,Psycholeptics,,17/03/2003,0,Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode. Olanzapine has not been demonstrated to prevent recurrence of manic or depressive episodes (see Section 5.1).,17/03/2003,12/06/2003,https://www.ema.europa.eu/en/medicines/human/EPAR/olansek,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",312.442
718,Human,Ebilfumin,"Influenza, Human",oseltamivir,OSELTAMIVIR,EMEA/H/C/003717,no,Authorised,J05AH02,no,yes,no,no,no,no,22/05/2014,,Actavis Group PTC ehf,"Antivirals for systemic use, Neuraminidase inhibitors",20/03/2014,31/05/2023,15,"Treatment of influenzaIn patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community.Ebilfumin is indicated for the treatment of infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC). The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child.Prevention of influenzaPost-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.The appropriate use of Ebilfumin for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.Ebilfumin is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC).Ebilfumin is not a substitute for influenza vaccination. ",29/05/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ebilfumin,VSZGPKBBMSAYNT-RRFJBIMHSA-N,"InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1",312.4100000000001
885,Human,Tamiflu,"Influenza, Human",oseltamivir,OSELTAMIVIR,EMEA/H/C/000402,no,Authorised,J05AH02,no,no,no,no,no,no,20/06/2002,,Roche Registration GmbH,Antivirals for systemic use,21/03/2002,13/03/2023,42,"Treatment of influenzaTamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.Prevention of influenzaPost-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.The appropriate use of Tamiflu for prevention of influenza should be determined on a case-by-case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.Tamiflu is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic-influenza outbreak.Tamiflu is not a substitute for influenza vaccination.The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of oseltamivir for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses, available information on influenza drug susceptibility patterns for each season and the impact of the disease in different geographical areas and patient populations.",09/08/2018,24/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu,VSZGPKBBMSAYNT-RRFJBIMHSA-N,"InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1",312.4100000000001
142,Human,Xeljanz,"Arthritis, Rheumatoid",tofacitinib,TOFACITINIB,EMEA/H/C/004214,yes,Authorised,L04AA29,no,no,no,no,no,no,22/03/2017,25/04/2013,Pfizer Europe MA EEIG,Immunosuppressants,24/07/2013,13/10/2023,28,"Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.",25/06/2018,13/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz,UJLAWZDWDVHWOW-YPMHNXCESA-N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",312.37700000000007
501,Human,Neoclarityn,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/000314,no,Authorised,R06AX27,no,no,no,no,no,no,15/01/2001,,N.V. Organon,"Antihistamines for systemic use, ",21/09/2000,08/06/2023,46,Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria,15/06/2018,02/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
502,Human,Aerius,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/000313,no,Authorised,R06AX27,no,no,no,no,no,no,15/01/2001,,N.V. Organon,"Antihistamines for systemic use, ",21/09/2000,08/06/2023,50,Aerius is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.,29/06/2018,02/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aerius,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
503,Human,Azomyr,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/000310,no,Authorised,R06AX27,no,no,no,no,no,no,15/01/2001,,N.V. Organon,"Antihistamines for systemic use, ",22/09/2022,08/06/2023,52,Azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5.1)urticaria (see section 5.1),29/06/2018,02/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azomyr,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
713,Human,Desloratadine Actavis,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/002435,no,Authorised,R06AX27,no,yes,no,no,no,no,13/01/2012,,Actavis Group PTC ehf,"Antihistamines for systemic use, ",,31/05/2023,16,Treatment of allergic rhinitis and urticaria.,21/03/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-actavis,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
1223,Human,Desloratadine ratiopharm,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/002404,no,Authorised,R06AX27,no,yes,no,no,no,no,13/01/2012,,Ratiopharm GmbH,"Antihistamines for systemic use, ",17/11/2011,22/06/2022,12,Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician,29/11/2017,24/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-ratiopharm,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
1232,Human,Desloratadine Teva,"Rhinitis, Allergic, Perennial;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/002419,no,Authorised,R06AX27,no,yes,no,no,no,no,24/11/2011,,Teva B.V,"Antihistamines for systemic use, ",22/09/2011,30/05/2022,18,Desloratadine Teva is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.,13/03/2018,09/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-teva,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
1233,Human,Dasselta,"Rhinitis, Allergic, Perennial;  Rhinitis, Allergic, Seasonal;  Urticaria",desloratadine,DESLORATADINE,EMEA/H/C/002310,no,Authorised,R06AX27,no,yes,no,no,no,no,28/11/2011,,"Krka, d.d., Novo mesto","Antihistamines for systemic use, ",,30/05/2022,13,Dasselta is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.,12/03/2018,09/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dasselta,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
1960,Human,Allex,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/000312,no,Withdrawn,R06AX27,no,no,no,no,no,no,15/01/2001,,Schering-Plough Europe,"Antihistamines for systemic use, ",,31/12/2009,0,Aerius is indicated for the relief of symptoms associated with:- allergic rhinitis (see section 5.1)- urticaria (see section 5.1),31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/allex,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
2025,Human,Opulis,"Rhinitis, Allergic, Perennial;  Urticaria;  Rhinitis, Allergic, Seasonal",desloratadine,DESLORATADINE,EMEA/H/C/000311,no,Withdrawn,R06AX27,no,no,no,no,no,no,15/01/2001,,Schering-Plough Europe,"Antihistamines for systemic use, ",,10/03/2004,0,Opulis is indicated for the relief of symptoms associated with:- allergic rhinitis (see section 5.1)- urticaria (see section 5.1),10/03/2004,19/05/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/opulis,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",310.8279999999999
341,Human,Vyndaqel,Amyloidosis,tafamidis,TAFAMIDIS,EMEA/H/C/002294,no,Authorised,N07XX08,yes,no,no,yes,no,yes,16/11/2011,,Pfizer Europe MA EEIG,Other nervous system drugs,21/07/2011,31/08/2023,27,Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.,12/10/2017,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel,TXEIIPDJKFWEEC-UHFFFAOYSA-N,"InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)",308.12
725,Human,Vafseo,"Renal Insufficiency, Chronic;  Anemia",vadadustat,VADADUSTAT,EMEA/H/C/005131,no,Authorised,,yes,no,no,no,no,no,24/04/2023,,Akebia Europe Limited,Antianemic preparations,23/02/2023,24/04/2023,,Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.,31/05/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/vafseo,JGRXMPYUTJLTKT-UHFFFAOYSA-N,"InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)",306.705
6,Human,Qutenza,Neuralgia,capsaicin,CAPSAICIN,EMEA/H/C/000909,no,Authorised,N01BX04,no,no,no,no,no,no,15/05/2009,,Grunenthal GmbH,Anesthetics,19/03/2009,01/12/2023,19,Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.,24/08/2017,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza,YKPUWZUDDOIDPM-SOFGYWHQSA-N,"InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+",305.418
1833,Human,Sonata,Sleep Initiation and Maintenance Disorders,zaleplon,ZALEPLON,EMEA/H/C/000227,no,Withdrawn,N05CF03,no,no,no,no,no,no,12/03/1999,,Meda AB,Psycholeptics,,03/07/2015,19,"Sonata is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.",03/07/2015,21/10/2015,https://www.ema.europa.eu/en/medicines/human/EPAR/sonata,HUNXMJYCHXQEGX-UHFFFAOYSA-N,"InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3",305.341
1901,Human,Zerene,Sleep Initiation and Maintenance Disorders,zaleplon,ZALEPLON,EMEA/H/C/000228,no,Withdrawn,N05CF03,no,no,no,no,no,no,12/03/1999,,Meda AB,Psycholeptics,,23/08/2012,13,"Zerene is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.",23/08/2012,15/10/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/zerene,HUNXMJYCHXQEGX-UHFFFAOYSA-N,"InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3",305.341
943,Human,Stalevo,Parkinson Disease,"levodopa, carbidopa, entacapone",ENTACAPONE,EMEA/H/C/000511,no,Authorised,N04BA03,no,no,no,no,no,no,17/10/2003,,Orion Corporation,Anti-Parkinson drugs,,12/01/2023,29,Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
998,Human,Levodopa/Carbidopa/Entacapone Orion,Parkinson Disease,"levodopa, carbidopa, entacapone",ENTACAPONE,EMEA/H/C/002441,no,Authorised,N04BA03,no,no,no,no,no,no,23/08/2011,,Orion Corporation,Nervous system,,12/01/2023,13,Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levodopa-carbidopa-entacapone-orion,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1002,Human,Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz),Parkinson Disease,"levodopa, carbidopa, entacapone",ENTACAPONE,EMEA/H/C/002785,no,Authorised,N04BA03,no,no,no,no,no,no,11/11/2013,,Orion Corporation,Anti-Parkinson drugs,19/09/2013,12/01/2023,10,Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.,06/07/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/corbilta,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1408,Human,Entacapone Orion,Parkinson Disease,entacapone,ENTACAPONE,EMEA/H/C/002440,no,Authorised,N04BX02,no,no,no,no,no,no,18/08/2011,,Orion Corporation,Anti-Parkinson drugs,23/06/2011,21/10/2021,10,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",15/12/2016,10/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1411,Human,Comtess,Parkinson Disease,entacapone,ENTACAPONE,EMEA/H/C/000170,no,Authorised,N04BX02,no,no,no,no,no,no,16/09/1998,,Orion Corporation,Anti-Parkinson drugs,27/05/1998,21/10/2021,28,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",15/12/2016,05/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/comtess,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1424,Human,Comtan,Parkinson Disease,entacapone,ENTACAPONE,EMEA/H/C/000171,no,Authorised,N04BX02,no,no,no,no,no,no,22/09/1998,,Orion Corporation,Anti-Parkinson drugs,,11/10/2021,26,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",27/06/2018,26/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/comtan,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1448,Human,Entacapone Teva,Parkinson Disease,entacapone,ENTACAPONE,EMEA/H/C/002075,no,Authorised,N04BX02,no,yes,no,no,no,no,18/02/2011,,Teva Pharma B.V.,Anti-Parkinson drugs,18/11/2010,10/09/2021,10,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",30/03/2016,28/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-teva,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",305.29
1682,Human,Savene,Extravasation of Diagnostic and Therapeutic Materials,dexrazoxane,DEXRAZOXANE HYDROCHLORIDE,EMEA/H/C/000682,no,Authorised,V03AF02,no,no,no,no,no,no,27/07/2006,,Clinigen Healthcare B.V.,All other therapeutic products,,11/01/2019,14,Savene is indicated for the treatment of anthracycline extravasation.,08/02/2018,08/10/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/savene,BIFMNMPSIYHKDN-FJXQXJEOSA-N,"InChI=1S/C11H16N4O4.ClH/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14;/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19);1H/t7-;/m0./s1",304.734
2008,Human,Uprima,Erectile Dysfunction,apomorphine,APOMORPHINE HYDROCHLORIDE,EMEA/H/C/000327,no,Withdrawn,G04BE,no,no,no,no,no,no,28/05/2001,,Abbott Laboratories Ltd.,Urologicals,,29/05/2006,4,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Uprima to be effective, sexual stimulation is required.",29/05/2006,29/05/2006,https://www.ema.europa.eu/en/medicines/human/EPAR/uprima,SKYZYDSNJIOXRL-BTQNPOSSSA-N,"InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m1./s1",303.78899999999993
2019,Human,Taluvian,Erectile Dysfunction,apomorphine,APOMORPHINE HYDROCHLORIDE,EMEA/H/C/000386,no,Withdrawn,G04BE,no,no,no,no,no,no,28/05/2001,,Abbott S.r.l.,Urologicals,,13/07/2004,0,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Taluvian to be effective, sexual stimulation is required.",13/07/2004,10/11/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/taluvian,SKYZYDSNJIOXRL-BTQNPOSSSA-N,"InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m1./s1",303.78899999999993
2020,Human,Ixense,Erectile Dysfunction,apomorphine,APOMORPHINE HYDROCHLORIDE,EMEA/H/C/000328,no,Withdrawn,G04BE,no,no,no,no,no,no,28/05/2001,,Takeda Europe R Centre Ltd.,Urologicals,,28/09/2004,0,"Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Ixense to be effective, sexual stimulation is required.",28/09/2004,10/11/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/ixense,SKYZYDSNJIOXRL-BTQNPOSSSA-N,"InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m1./s1",303.78899999999993
745,Human,Evoltra,Precursor Cell Lymphoblastic Leukemia-Lymphoma,clofarabine,CLOFARABINE,EMEA/H/C/000613,no,Authorised,L01BB06,yes,no,no,yes,no,no,29/05/2006,,Sanofi B.V.,Antineoplastic agents,23/02/2006,09/03/2023,33,Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.,14/11/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra,WDDPHFBMKLOVOX-AYQXTPAHSA-N,"InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1",303.681
911,Human,Ivozall,Precursor Cell Lymphoblastic Leukemia-Lymphoma,clofarabine,CLOFARABINE,EMEA/H/C/005039,no,Authorised,L01BB06,no,yes,no,no,no,no,14/11/2019,,ORPHELIA Pharma SAS,Antineoplastic agents,19/09/2019,06/03/2023,4,Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.,22/11/2019,13/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ivozall,WDDPHFBMKLOVOX-AYQXTPAHSA-N,"InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1",303.681
460,Human,Jalra,"Diabetes Mellitus, Type 2",vildagliptin,VILDAGLIPTIN,EMEA/H/C/001048,no,Authorised,A10BH02,no,no,no,no,no,no,19/11/2008,,Novartis Europharm Limited,"Dipeptidyl peptidase 4 (DPP-4) inhibitors, Drugs used in diabetes",25/09/2008,14/08/2023,24,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",26/04/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jalra,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
461,Human,Galvus,"Diabetes Mellitus, Type 2",vildagliptin,VILDAGLIPTIN,EMEA/H/C/000771,no,Authorised,A10BH02,no,no,no,no,no,no,25/09/2007,,Novartis Europharm Limited,Drugs used in diabetes,19/07/2007,14/08/2023,23,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control",26/04/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/galvus,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
462,Human,Xiliarx,"Diabetes Mellitus, Type 2",vildagliptin,VILDAGLIPTIN,EMEA/H/C/001051,no,Authorised,A10BH02,no,no,no,no,no,no,19/11/2008,,Novartis Europharm Limited,Drugs used in diabetes,,14/08/2023,23,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",26/04/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xiliarx,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
714,Human,Vildagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2",vildagliptin / metformin hydrochloride,VILDAGLIPTIN,EMEA/H/C/005738,no,Authorised,A10BD08,yes,yes,no,no,no,no,24/03/2022,,Accord Healthcare S.L.U.,Drugs used in diabetes,16/12/2021,01/06/2023,2,"Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone.- in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",14/12/2021,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
873,Human,Eucreas,"Diabetes Mellitus, Type 2","vildagliptin, metformin",VILDAGLIPTIN,EMEA/H/C/000807,no,Authorised,A10BD08,no,no,no,no,no,no,14/11/2007,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,07/07/2022,23,"Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control",23/04/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eucreas,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
900,Human,Zomarist,"Diabetes Mellitus, Type 2","vildagliptin, metformin",VILDAGLIPTIN,EMEA/H/C/001049,no,Authorised,A10BD08,no,no,no,no,no,no,30/11/2008,,Novartis Europharm Limited ,Drugs used in diabetes,,14/10/2022,23,"Zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.",21/04/2017,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zomarist,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
1091,Human,Icandra (previously Vildagliptin / metformin hydrochloride Novartis),"Diabetes Mellitus, Type 2","vildagliptin, metformin",VILDAGLIPTIN,EMEA/H/C/001050,no,Authorised,A10BD08,no,no,no,no,no,no,30/11/2008,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,14/10/2022,25,"Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",12/04/2018,09/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/icandra-previously-vildagliptin-metformin-hydrochloride-novartis,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",303.406
1732,Human,Trobalt,Epilepsy,retigabine,RETIGABINE,EMEA/H/C/001245,no,Withdrawn,N03AX21,no,no,no,no,no,no,27/03/2011,,Glaxo Group Limited ,"Antiepileptics, ",,19/07/2018,12,"Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.",11/05/2016,19/11/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt,PCOBBVZJEWWZFR-UHFFFAOYSA-N,"InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)",303.33699999999993
514,Human,Oprymea,Parkinson Disease,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/000941,no,Authorised,N04BC05,no,yes,no,no,no,no,12/09/2008,,"Krka, d.d., Novo mesto",Anti-Parkinson drugs,,10/01/2023,22,"Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).",12/03/2018,31/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/oprymea,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
545,Human,Sifrol,Restless Legs Syndrome;  Parkinson Disease,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/000133,no,Authorised,N04BC05,no,no,no,no,no,no,13/10/1997,,Boehringer Ingelheim International GmbH,Anti-Parkinson drugs,18/06/1997,08/06/2023,37,"Sifrol is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt). ",08/02/2018,25/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sifrol,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
546,Human,Mirapexin,Restless Legs Syndrome;  Parkinson Disease,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/000134,no,Authorised,N04BC05,no,no,no,no,no,no,23/02/1998,,Boehringer Ingelheim International GmbH,Anti-Parkinson drugs,,08/06/2023,40,"Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).",20/06/2018,25/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mirapexin,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
1398,Human,Pramipexole Teva,Parkinson Disease,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/000940,no,Authorised,N04BC05,no,yes,no,no,no,no,18/12/2008,,Teva Pharma B.V.,Anti-Parkinson drugs,23/10/2008,05/11/2021,22,"Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).",14/12/2017,23/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/pramipexole-teva,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
1592,Human,Pramipexole Accord,Parkinson Disease;  Restless Legs Syndrome,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/002291,no,Authorised,N04BC05,no,yes,no,no,no,no,29/09/2011,,Accord Healthcare S.L.U.,Anti-Parkinson drugs,21/07/2011,20/11/2020,10,"Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).",24/10/2017,11/12/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/pramipexole-accord,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
2009,Human,Daquiran,Parkinson Disease,pramipexole,PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE,EMEA/H/C/000135,no,Withdrawn,N04BC05,no,no,no,no,no,no,27/10/1997,,Dr. Karl Thomae GmbH,Anti-Parkinson drugs,,02/02/2006,5,"DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).",02/02/2006,23/05/2006,https://www.ema.europa.eu/en/medicines/human/EPAR/daquiran,APVQOOKHDZVJEX-QTPLPEIMSA-N,"InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1",302.2710000000001
1586,Human,Panretin,"Sarcoma, Kaposi",alitretinoin,ALITRETINOIN,EMEA/H/C/000279,no,Withdrawn,L01XX22,no,no,no,no,no,no,11/10/2000,,Eisai GmbH,Antineoplastic agents,,24/01/2019,17,"Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral KS is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.",21/06/2018,11/01/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/panretin,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+",300.442
215,Human,Brintellix,"Depressive Disorder, Major",vortioxetine,VORTIOXETINE,EMEA/H/C/002717,no,Authorised,N06AX26,no,no,no,no,no,no,18/12/2013,,H. Lundbeck A/S,"Psychoanaleptics, ",24/10/2013,18/10/2023,23,Treatment of major depressive episodes in adults.,18/07/2018,24/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix,YQNWZWMKLDQSAC-UHFFFAOYSA-N,"InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3",298.4549999999999
178,Human,CoAprovel,Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000222,no,Authorised,C09DA04,no,no,no,no,no,no,14/10/1998,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,22/07/1998,27/10/2023,49,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,22/08/2017,31/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/coaprovel,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
186,Human,Karvezide,Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000221,no,Authorised,C09DA04,no,no,no,no,no,no,16/10/1998,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,27/10/2023,47,Treatment of essential hypertension.This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,24/08/2017,30/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/karvezide,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
210,Human,Actelsar HCT,Essential Hypertension,"telmisartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002676,no,Authorised,C09DA07,no,yes,no,no,no,no,13/03/2013,,Actavis Group hf,"Agents acting on the renin-angiotensin system, Angiotensin II antagonists and diuretics",17/01/2013,23/10/2023,17,Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. ,19/06/2018,24/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
300,Human,Exforge HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/001068,no,Authorised,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",07/06/2018,29/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
312,Human,Dafiro HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/001160,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,15/12/2022,26,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",25/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
314,Human,Copalia HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/001159,no,Authorised,C09DX01,no,no,no,no,no,no,03/11/2009,,Novartis Europharm Limited,"Angiotensin II antagonists, combinations, Agents acting on the renin-angiotensin system, Angiotensin II antagonists and calcium channel blockers",,14/09/2023,24,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",17/04/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
448,Human,Tolucombi,Hypertension,"telmisartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002549,no,Authorised,C09DA07,no,yes,no,no,no,no,13/03/2013,,"Krka, d.d., Novo mesto",telmisartan and diuretics,17/01/2013,14/08/2023,11,Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.,14/02/2018,24/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tolucombi,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
590,Human,Ifirmacombi,Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002302,no,Authorised,C09DA04,no,yes,no,no,no,no,04/03/2011,,"Krka, d.d., Novo mesto",Agents acting on the renin-angiotensin system,,07/07/2023,15,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,20/12/2017,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ifirmacombi,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
684,Human,Irbesartan/Hydrochlorothiazide Teva,Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/001112,no,Authorised,C09DA04,no,yes,no,no,no,no,26/11/2009,,Teva B.V. ,Agents acting on the renin-angiotensin system,24/09/2009,15/06/2023,22,Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,07/11/2017,16/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-teva,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
837,Human,Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop),Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000783,no,Authorised,C09DA04,no,no,no,no,no,no,18/01/2007,,sanofi-aventis groupe ,Agents acting on the renin-angiotensin system,,12/04/2023,34,Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,28/08/2017,13/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
891,Human,MicardisPlus,Hypertension,,HYDROCHLOROTHIAZIDE,EMEA/H/C/000413,no,Authorised,C09DA07,no,no,no,no,no,no,19/04/2002,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,31/10/2022,33,"Treatment of essential hypertension.MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",06/04/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/micardisplus,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1141,Human,PritorPlus,Hypertension,"telmisartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000414,no,Authorised,C09DA07,no,no,no,no,no,no,22/04/2002,,Bayer AG,Agents acting on the renin-angiotensin system,,24/08/2022,37,"Treatment of essential hypertension.PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",13/04/2018,14/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pritorplus,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1142,Human,Kinzalkomb,Hypertension,"telmisartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000415,no,Authorised,C09DA07,no,no,no,no,no,no,19/04/2002,,Bayer AG,Agents acting on the renin-angiotensin system,,24/08/2022,39,"Treatment of essential hypertension.Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",12/04/2018,14/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalkomb,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1242,Human,Rasilez HCT,Hypertension,"aliskiren, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000964,no,Withdrawn,C09XA52,no,no,no,no,no,no,16/01/2009,,Noden Pharma DAC,Agents acting on the renin-angiotensin system,,20/12/2021,17,"Treatment of essential hypertension in adults.Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",27/08/2018,20/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1900,Human,Imprida HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/001161,no,Withdrawn,C09DX01,no,no,no,no,no,no,15/10/2009,,Novartis Europharm Ltd.,"Angiotensin II antagonists, plain, Angiotensin II antagonists, combinations",,20/10/2012,3,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",20/10/2012,22/10/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/imprida-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1903,Human,Rasitrio,Hypertension,"aliskiren, amlodipine, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002017,no,Withdrawn,C09XA54,no,no,no,no,no,no,22/11/2011,,Novartis Europharm Ltd.,Cardiovascular system,,03/10/2013,1,"Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.",03/10/2013,20/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/rasitrio,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1904,Human,Riprazo HCT ,Hypertension,"aliskiren, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002420,no,Withdrawn,C09XA52,no,no,no,no,no,no,13/04/2011,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,30/08/2012,0,"Treatment of essential hypertension in adults.Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",30/08/2012,20/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/riprazo-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1905,Human,Sprimeo HCT,Hypertension,"aliskiren, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/002421,no,Withdrawn,C09XA52,no,no,no,no,no,no,23/06/2011,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,06/07/2012,0,"Treatment of essential hypertension in adults.Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",06/07/2012,28/08/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/sprimeo-hct,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
1972,Human,Irbesartan Hydrochlorothiazide BMS,Hypertension,"irbesartan, hydrochlorothiazide",HYDROCHLOROTHIAZIDE,EMEA/H/C/000784,no,Withdrawn,C09DA04,no,no,no,no,no,no,19/01/2007,,Bristol-Myers Squibb Pharma EEIG,Agents acting on the renin-angiotensin system,,09/10/2009,8,Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).,09/10/2009,24/11/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-bms,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",297.745
442,Human,Duloxetine Mylan,"Neuralgia;  Diabetic Neuropathies;  Depressive Disorder, Major;  Anxiety Disorders",duloxetine,DULOXETINE,EMEA/H/C/003981,no,Authorised,N06AX21,no,yes,no,no,no,no,19/06/2015,,Mylan Pharmaceuticals Limited,"Psychoanaleptics, ",23/04/2015,24/08/2023,18,Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults.,03/08/2018,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
648,Human,Cymbalta,"Anxiety Disorders;  Diabetic Neuropathies;  Depressive Disorder, Major",duloxetine,DULOXETINE,EMEA/H/C/000572,no,Authorised,N06AX21,no,no,no,no,no,no,17/12/2004,,Eli Lilly Nederland B.V.,"Psychoanaleptics, ",16/09/2004,14/12/2021,32,Treatment of major depressive disorder.Treatment of diabetic peripheral neuropathic pain.Treatment of generalised anxiety disorder.Cymbalta is indicated in adults.,26/01/2017,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cymbalta,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
1163,Human,Duloxetine Zentiva,"Neuralgia;  Depressive Disorder, Major;  Anxiety Disorders;  Diabetes Mellitus",duloxetine,DULOXETINE,EMEA/H/C/003935,no,Authorised,N06AX21,no,yes,no,no,no,no,20/08/2015,,"Zentiva, k.s.",Other antidepressants,25/06/2015,12/08/2022,11,"Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder., , Duloxetine Zentiva is indicated in adults., ",17/05/2017,16/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-zentiva,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
1367,Human,Duloxetine Lilly,"Neuralgia;  Diabetic Neuropathies;  Depressive Disorder, Major",duloxetine,DULOXETINE,EMEA/H/C/004000,no,Authorised,N06AX21,no,no,no,no,no,no,08/12/2014,,Eli Lilly Nederland B.V.,"Psychoanaleptics, ",23/10/2014,15/12/2021,9,Duloxetine Lilly is indicated in adults for:Treatment of major depressive disorderTreatment of diabetic peripheral neuropathic painTreatment of generalised anxiety disorderDuloxetine Lilly is indicated in adults.,26/01/2017,21/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-lilly,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
1516,Human,Nodetrip (previously Xeristar),"Anxiety Disorders;  Depressive Disorder, Major;  Diabetic Neuropathies",duloxetine,DULOXETINE,EMEA/H/C/000573,no,Withdrawn,N06AX21,no,no,no,no,no,no,17/12/2004,,"Esteve Pharmaceuticals, S.A.","Psychoanaleptics, ",16/09/2004,12/05/2021,32,Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Xeristar is indicated in adults.,09/12/2016,22/06/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/nodetrip-previously-xeristar,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
1747,Human,Ariclaim,Diabetic Neuropathies,duloxetine,DULOXETINE,EMEA/H/C/000552,no,Withdrawn,N06AX21,no,no,no,no,no,no,11/08/2004,,Eli Lilly Nederland B.V.,"Psychoanaleptics, ",,09/12/2016,26,Treatment of diabetic peripheral neuropathic pain.Ariclaim is indicated in adults.,09/12/2016,07/08/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/ariclaim,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
1897,Human,Duloxetine Boehringer Ingelheim,Diabetic Neuropathies,duloxetine,DULOXETINE,EMEA/H/C/001007,no,Withdrawn,N06AX21,no,no,no,no,no,no,08/10/2008,,Boehringer Ingelheim International GmbH,"Psychoanaleptics, ",,07/12/2009,2,Treatment of diabetic peripheral neuropathic pain in adults.,07/12/2009,17/01/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-boehringer-ingelheim,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",297.423
996,Human,Atriance,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,nelarabine,NELARABINE,EMEA/H/C/000752,no,Authorised,L01BB07,yes,no,no,yes,no,no,22/08/2007,,Sandoz Pharmaceuticals d.d.,Antineoplastic agents,,16/01/2023,26,"Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data., ",30/04/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/atriance,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,"InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1",297.2710000000001
532,Human,Vaborem,"Urinary Tract Infections;  Bacteremia;  Bacterial Infections;  Respiratory Tract Infections;  Pneumonia;  Pneumonia, Ventilator-Associated","meropenem, vaborbactam",VABORBACTAM,EMEA/H/C/004669,no,Authorised,J01DH,no,no,no,no,no,no,20/11/2018,,Menarini International Operations Luxembourg S.A.,"Antibacterials for systemic use, ",20/09/2018,24/07/2023,7,"Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.",18/12/2018,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem,IOOWNWLVCOUUEX-WPRPVWTQSA-N,"InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1",297.141
1352,Human,Palonosetron Accord,Vomiting;  Nausea;  Cancer,palonosetron,PALONOSETRON,EMEA/H/C/004129,no,Authorised,A04AA05,no,yes,no,no,no,no,26/05/2016,,Accord Healthcare S.L.U.,"Antiemetics and antinauseants, ",31/03/2016,10/01/2022,5,"Palonosetron Accord is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Palonosetron Accord is indicated in paediatric patients 1 month of age and older for:The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.",26/05/2016,13/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-accord,CPZBLNMUGSZIPR-NVXWUHKLSA-N,"InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1",296.414
1090,Human,Evra,Contraception,"norelgestromin, ethinyl estradiol",ETHINYL ESTRADIOL,EMEA/H/C/000410,no,Authorised,G03AA13,no,no,no,no,no,no,22/08/2002,,Gedeon Richter Plc.,"Sex hormones and modulators of the genital system, ",,09/11/2022,25,Female contraception.Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.,23/06/2017,09/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/evra,BFPYWIDHMRZLRN-SLHNCBLASA-N,"InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1",296.40999999999997
1295,Human,Zebinix,Epilepsy,eslicarbazepine acetate,ESLICARBAZEPINE ACETATE,EMEA/H/C/000988,no,Authorised,N03AF04,no,no,no,no,no,no,21/04/2009,,"BIAL - Portela & Ca, S.A.","Antiepileptics, ",19/02/2009,04/03/2022,31,"Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.",17/05/2018,14/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix,QIALRBLEEWJACW-INIZCTEOSA-N,"InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1",296.326
1906,Human,Exalief,Epilepsy,eslicarbazepine acetate,ESLICARBAZEPINE ACETATE,EMEA/H/C/000987,no,Withdrawn,N03AF04,no,no,no,no,no,no,21/04/2009,,"BIAL - Portela  Ca, S.A.","Antiepileptics, ",,21/04/2012,5,Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.,21/04/2012,16/08/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/exalief,QIALRBLEEWJACW-INIZCTEOSA-N,"InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1",296.326
403,Human,Lonsurf,Colorectal Neoplasms,"trifluridine, tipiracil",TRIFLURIDINE,EMEA/H/C/003897,no,Authorised,L01BC59,no,no,no,no,no,no,25/04/2016,,Les Laboratoires Servier,Antineoplastic agents,25/02/2016,26/07/2023,9,"Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.",14/08/2017,11/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf,VSQQQLOSPVPRAZ-RRKCRQDMSA-N,"InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1",296.20099999999996
24,Human,Ozawade,"Sleep Apnea, Obstructive",pitolisant,PITOLISANT,EMEA/H/C/005117,no,Authorised,N07XX11,no,no,no,no,no,no,01/09/2021,,Bioprojet Pharma,Other nervous system drugs,20/05/2021,27/11/2023,3,Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA),20/05/2021,01/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade,NNACHAUCXXVJSP-UHFFFAOYSA-N,"InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2",295.854
125,Human,Wakix,Narcolepsy,pitolisant,PITOLISANT,EMEA/H/C/002616,no,Authorised,N07XX11,yes,no,no,no,no,yes,31/03/2016,,Bioprojet Pharma,Other nervous system drugs,19/11/2015,13/11/2023,15,"Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).",22/02/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/wakix,NNACHAUCXXVJSP-UHFFFAOYSA-N,"InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2",295.854
972,Human,Hemangiol,Hemangioma,propranolol,PROPRANOLOL HYDROCHLORIDE,EMEA/H/C/002621,no,Authorised,C07AA05,no,no,no,no,no,no,23/04/2014,,Pierre Fabre Medicament,Beta blocking agents,20/02/2014,10/01/2023,6,"Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:, , , 	Life- or function-threatening haemangioma,, 	Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, 	Haemangioma with a risk of permanent scars or disfigurement., , , It is to be initiated in infants aged 5 weeks to 5 months., ",14/03/2018,09/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol,ZMRUPTIKESYGQW-UHFFFAOYSA-N,"InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H",295.81
824,Human,Entecavir Mylan,Hepatitis B,entecavir,ENTECAVIR MONOHYDRATE,EMEA/H/C/004377,no,Authorised,J05AF10,no,yes,no,no,no,no,18/09/2017,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,18/05/2017,18/04/2023,6,"Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to ",18/09/2017,19/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/entecavir-mylan,YXPVEXCTPGULBZ-WQYNNSOESA-N,"InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7-,8-;/m0./s1",295.29900000000004
781,Human,Anagrelide Mylan,"Thrombocythemia, Essential",anagrelide,ANAGRELIDE HYDROCHLORIDE,EMEA/H/C/004585,no,Authorised,L01XX35,no,yes,no,no,no,no,15/02/2018,,Mylan Pharmaceuticals Limited,Antineoplastic agents,14/12/2017,28/04/2023,8,"Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10?/l ora history of thrombo-haemorrhagic events. ",15/02/2018,11/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/anagrelide-mylan,TVWRQCIPWUCNMI-UHFFFAOYSA-N,"InChI=1S/C10H7Cl2N3O.ClH/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7;/h1-2H,3-4H2,(H,13,14,16);1H",292.55299999999994
954,Human,Cuprior,Hepatolenticular Degeneration,trientine,TRIENTINE TETRAHYDROCHLORIDE,EMEA/H/C/004005,no,Authorised,A16AX,no,no,no,no,no,no,05/09/2017,,GMP-Orphan SA,"Other alimentary tract and metabolism products, ",21/04/2017,17/08/2022,6,"Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ? 5 years intolerant to D-penicillamine therapy., ",05/09/2017,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cuprior,OKHMDSCYUWAQPT-UHFFFAOYSA-N,"InChI=1S/C6H18N4.4ClH/c7-1-3-9-5-6-10-4-2-8;;;;/h9-10H,1-8H2;4*1H",292.08200000000005
711,Human,Zoledronic acid Actavis,"Fractures, Bone",zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/002488,no,Authorised,M05BA08,no,yes,no,no,no,no,20/04/2012,,Actavis Group PTC ehf  ,Drugs for treatment of bone diseases,16/02/2012,31/05/2023,15,"Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. ",03/10/2017,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-actavis,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
1333,Human,Zoledronic Acid Accord,"Hypercalcemia;  Fractures, Bone;  Cancer",zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/002667,no,Authorised,M05BA08,no,yes,no,no,no,no,16/01/2014,,Accord Healthcare S.L.U.,Bisphosphonates,21/11/2013,24/01/2022,9,"Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).",04/08/2017,24/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-accord,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
1409,Human,Zoledronic Acid Hospira,Hypercalcemia,zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/002365,no,Authorised,M05BA08,no,yes,no,no,no,no,19/11/2012,,Pfizer Europe MA EEIG,Drugs for treatment of bone diseases,,01/10/2021,18,"4 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.",12/02/2018,09/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-hospira,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
1508,Human,Zometa,"Cancer;  Fractures, Bone",zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/000336,no,Authorised,M05BA08,no,no,no,no,no,no,20/03/2001,,Phoenix Labs Unlimited Company,Drugs for treatment of bone diseases,14/12/2000,04/06/2021,36,"Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).",13/07/2018,09/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/zometa,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
1603,Human,Zoledronic acid medac,"Fractures, Bone;  Cancer",zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/002359,no,Authorised,M05BA08,no,yes,no,no,no,no,03/08/2012,,medac Gesellschaft für klinische Spezialpräparate mbH,Drugs for treatment of bone diseases,24/05/2012,23/09/2020,13,"Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).",16/06/2017,20/11/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-medac,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
1811,Human,Zoledronic acid Teva Generics,Osteoporosis;  Osteitis Deformans,zoledronic acid,ZOLEDRONIC ACID MONOHYDRATE,EMEA/H/C/002805,no,Withdrawn,M05BA08,no,yes,no,no,no,no,27/03/2014,,Teva Generics B.V,Bisphosphonates,23/01/2014,13/07/2015,2,"Treatment of osteoporosisin post-menopausal womenin adult menat increased risk of fracture, including those with recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapyin post-menopausal womenin adult menat increased risk of fracture.Treatment of Paget's disease of the bone in adults.",13/07/2015,08/08/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-teva-generics,FUXFIVRTGHOMSO-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2",290.105
87,Human,Zynrelef,"Pain, Postoperative","bupivacaine, meloxicam",BUPIVACAINE,EMEA/H/C/005205,no,Withdrawn,N01B,no,no,no,no,no,no,24/09/2020,,"Heron Therapeutics, B.V.",Anesthetics,23/07/2020,05/10/2023,3,Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).,06/10/2020,22/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zynrelef,LEBVLXFERQHONN-UHFFFAOYSA-N,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",288.43499999999995
1084,Human,Exparel liposomal,Acute Pain,bupivacaine,BUPIVACAINE,EMEA/H/C/004586,no,Authorised,N01BB01,no,no,no,no,no,no,16/11/2020,,Pacira Ireland Limited,"Amides, Anesthetics, local",17/09/2020,07/11/2022,1,Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.,10/12/2020,14/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal,LEBVLXFERQHONN-UHFFFAOYSA-N,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",288.43499999999995
1099,Human,Intrarosa,Postmenopause,prasterone,PRASTERONE,EMEA/H/C/004138,no,Authorised,G03XX01,yes,no,no,no,no,no,08/01/2018,,Endoceutics S.A.,Other sex hormones and modulators of the genital system,09/11/2017,15/09/2022,6,"Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms., ",08/01/2018,03/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/intrarosa,FMGSKLZLMKYGDP-USOAJAOKSA-N,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1",288.43100000000004
1920,Human,Intrinsa,"Sexual Dysfunctions, Psychological",testosterone,TESTOSTERONE,EMEA/H/C/000634,no,Withdrawn,G03BA03,no,no,no,no,no,no,28/07/2006,,Warner Chilcott UK Ltd.,"Sex hormones and modulators of the genital system, ",,25/05/2012,6,Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.,25/05/2012,18/06/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/intrinsa,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",288.43100000000004
1925,Human,Livensa,"Sexual Dysfunctions, Psychological",testosterone,TESTOSTERONE,EMEA/H/C/000630,no,Withdrawn,G03BA03,no,no,no,no,no,no,28/07/2006,,Warner Chilcott  Deutschland GmbH,"Sex hormones and modulators of the genital system, ",,18/07/2011,6,Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.,18/07/2011,16/04/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/livensa,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",288.43100000000004
2037,Human,EchoGen,Echocardiography,dodecafluoropentane,DODECAFLUOROPENTANE,EMEA/H/C/000149,no,Withdrawn,V08DA,no,no,no,no,no,no,17/07/1998,,Sonus Pharmaceuticals Ltd.,Contrast media,,22/01/2001,0,"EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.",22/01/2001,22/05/2001,https://www.ema.europa.eu/en/medicines/human/EPAR/echogen,NJCBUSHGCBERSK-UHFFFAOYSA-N,"InChI=1S/C5F12/c6-1(7,2(8,9)4(12,13)14)3(10,11)5(15,16)17",288.03099999999995
306,Human,Zavicefta,"Pneumonia, Bacterial;  Soft Tissue Infections;  Pneumonia;  Urinary Tract Infections;  Gram-Negative Bacterial Infections","ceftazidime, avibactam",AVIBACTAM SODIUM,EMEA/H/C/004027,no,Authorised,J01,no,no,no,no,no,no,23/06/2016,,Pfizer Ireland Pharmaceuticals,"Antibacterials for systemic use, ",28/04/2016,22/04/2022,15,"Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.",14/06/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta,RTCIKUMODPANKX-JBUOLDKXSA-M,"InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1",287.229
67,Human,Kivexa,HIV Infections,"abacavir, lamivudine",ABACAVIR,EMEA/H/C/000581,no,Authorised,J05AR02,no,no,no,no,no,no,16/12/2004,,ViiV Healthcare BV,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,15/11/2023,37,"Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.",25/01/2018,27/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa,MCGSCOLBFJQGHM-SCZZXKLOSA-N,"InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1",286.33900000000006
305,Human,Ziagen,HIV Infections,abacavir,ABACAVIR,EMEA/H/C/000252,no,Authorised,J05AF06,no,no,no,no,no,no,08/07/1999,,ViiV Healthcare B.V.,Antivirals for systemic use,25/03/1999,27/09/2023,47,"Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children.The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy.Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.",01/03/2018,28/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen,MCGSCOLBFJQGHM-SCZZXKLOSA-N,"InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1",286.33900000000006
223,Human,Mavenclad,Multiple Sclerosis,cladribine,CLADRIBINE,EMEA/H/C/004230,no,Authorised,L04AA40,no,no,no,no,no,no,22/08/2017,,Merck Europe B.V.,Immunosuppressants,22/06/2017,04/10/2023,9,Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.,09/07/2018,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad,PTOAARAWEBMLNO-KVQBGUIXSA-N,"InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1",285.69100000000003
1765,Human,Litak,"Leukemia, Hairy Cell",cladribine,CLADRIBINE,EMEA/H/C/000504,no,Authorised,L01BB04,no,no,no,no,no,no,14/04/2004,,Lipomed GmbH,Antineoplastic agents,,07/03/2018,7,Litak is indicated for the treatment of hairy-cell leukaemia.,07/03/2018,04/04/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/litak,PTOAARAWEBMLNO-KVQBGUIXSA-N,"InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1",285.69100000000003
424,Human,Eurartesim,Malaria,"piperaquine tetraphosphate, artenimol",ARTENIMOL,EMEA/H/C/001199,no,Authorised,P01BF05,no,no,no,no,no,no,27/10/2011,,Alfasigma S.p.A.,Antiprotozoals,,25/08/2023,13,"Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more.Consideration should be given to official guidance on the appropriate use of antimalarial agents.",14/09/2017,30/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim,BJDCWCLMFKKGEE-ISOSDAIHSA-N,"InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1",284.35200000000003
812,Human,Translarna,"Muscular Dystrophy, Duchenne",ataluren,ATALUREN,EMEA/H/C/002720,no,Authorised,M09AX03,yes,no,yes,no,no,yes,31/07/2014,,PTC Therapeutics International Limited,Other drugs for disorders of the musculo-skeletal system,23/01/2014,16/03/2023,22,"Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients.The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.",23/07/2018,25/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/translarna,OOUGLTULBSNHNF-UHFFFAOYSA-N,"InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)",284.246
700,Human,Lutetium (177Lu) chloride Billev (previously Illuzyce),Radionuclide Imaging,lutetium (177Lu) chloride,LUTETIUM (177LU) CHLORIDE,EMEA/H/C/005859,no,Authorised,V10X,no,no,no,no,no,no,15/09/2022,,Billev Pharma Aps,Therapeutic radiopharmaceuticals,21/07/2022,14/11/2022,2,"Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.",18/07/2022,07/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lutetium-177lu-chloride-billev-previously-illuzyce,AEDROEGYZIARPU-SUNKFXMWSA-K,InChI=1S/3ClH.Lu/h3*1H;/q;;;+3/p-3/i;;;1+2,283.3027581
1563,Human,EndolucinBeta,Radionuclide Imaging,lutetium (177 Lu) chloride,LUTETIUM (177LU) CHLORIDE,EMEA/H/C/003999,no,Authorised,V10X,no,no,no,no,no,no,06/07/2016,,ITM Medical Isotopes GmbH,Therapeutic radiopharmaceuticals,,08/02/2021,8,"EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.",27/03/2018,16/02/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/endolucinbeta,AEDROEGYZIARPU-SUNKFXMWSA-K,InChI=1S/3ClH.Lu/h3*1H;/q;;;+3/p-3/i;;;1+2,283.3027581
1619,Human,Lumark,Radionuclide Imaging,lutetium (177 Lu) chloride,LUTETIUM (177LU) CHLORIDE,EMEA/H/C/002749,no,Authorised,V10,no,no,no,no,no,no,18/06/2015,,I.D.B. Radiopharmacy B.V.,Therapeutic radiopharmaceuticals,22/04/2015,17/09/2020,9,"Lumark is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.",04/04/2018,29/09/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/lumark,AEDROEGYZIARPU-SUNKFXMWSA-K,InChI=1S/3ClH.Lu/h3*1H;/q;;;+3/p-3/i;;;1+2,283.3027581
964,Human,Intuniv,Attention Deficit Disorder with Hyperactivity,guanfacine,GUANFACINE HYDROCHLORIDE,EMEA/H/C/003759,no,Authorised,C02AC02,yes,no,no,no,no,no,17/09/2015,,Takeda Pharmaceuticals International AG Ireland Branch,"Antiadrenergic agents, centrally acting, Antihypertensives, ",,03/02/2023,12,"Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective., , Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures., ",16/10/2017,16/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv,DGFYECXYGUIODH-UHFFFAOYSA-N,"InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H",282.558
403,Human,Lonsurf,Colorectal Neoplasms,"trifluridine, tipiracil",TIPIRACIL HYDROCHLORIDE,EMEA/H/C/003897,no,Authorised,L01BC59,no,no,no,no,no,no,25/04/2016,,Les Laboratoires Servier,Antineoplastic agents,25/02/2016,26/07/2023,9,"Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.",14/08/2017,11/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf,KGHYQYACJRXCAT-UHFFFAOYSA-N,"InChI=1S/C9H11ClN4O2.ClH/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11;/h11H,1-4H2,(H2,12,13,15,16);1H",279.127
481,Human,Trecondi,Hematopoietic Stem Cell Transplantation,treosulfan,TREOSULFAN,EMEA/H/C/004751,no,Authorised,L01AB02,no,no,no,no,no,no,20/06/2019,,medac Gesellschaft für klinische Spezialpräparate mbH,Antineoplastic agents,,06/03/2023,4,Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.,22/07/2019,08/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trecondi,YCPOZVAOBBQLRI-WDSKDSINSA-N,"InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1",278.304
1176,Human,Entecavir Accord,"Hepatitis B, Chronic",entecavir,ENTECAVIR,EMEA/H/C/004458,no,Authorised,J05AF10,no,yes,no,no,no,no,25/09/2017,,Accord Healthcare S.L.U.,Antivirals for systemic use,19/07/2017,01/07/2022,5,"Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:, , , 	compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis., 	decompensated liver disease., , , For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B., , Entecavir Accord is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to ",26/09/2017,29/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/entecavir-accord,QDGZDCVAUDNJFG-FXQIFTODSA-N,"InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1",277.284
1318,Human,Baraclude,"Hepatitis B, Chronic",entecavir,ENTECAVIR,EMEA/H/C/000623,no,Authorised,J05AF10,no,no,no,no,no,no,26/06/2006,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,31/01/2022,27,"Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis;decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.",26/06/2018,11/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/baraclude,QDGZDCVAUDNJFG-FXQIFTODSA-N,"InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1",277.284
1298,Human,Jayempi,Graft Rejection,azathioprine,AZATHIOPRINE,EMEA/H/C/005055,no,Authorised,L04AX01,no,no,no,no,no,no,21/06/2021,,Nova Laboratories Ireland Limited,Immunosuppressants,22/04/2021,01/03/2022,1,"Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.",20/04/2021,04/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi,LMEKQMALGUDUQG-UHFFFAOYSA-N,"InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)",277.269
549,Human,Mysimba,Obesity;  Overweight,"naltrexone, bupropion",BUPROPION HYDROCHLORIDE,EMEA/H/C/003687,no,Authorised,A08AA,yes,no,no,no,no,no,26/03/2015,,Orexigen Therapeutics Ireland Limited,"Antiobesity preparations, excl. diet products",18/12/2014,04/07/2023,25,"Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (?18 years) with an initial Body Mass Index (BMI) of? 30 kg/m2 (obese), or? 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.",02/07/2018,21/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba,HEYVINCGKDONRU-UHFFFAOYSA-N,"InChI=1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H",276.20699999999994
577,Human,Spravato,Depressive Disorder,esketamine,ESKETAMINE HYDROCHLORIDE,EMEA/H/C/004535,no,Authorised,N06AX27,yes,no,no,no,no,no,18/12/2019,,Janssen-Cilag International NV,Other antidepressants,17/10/2019,04/07/2023,8,"Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.",19/12/2019,14/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/spravato,VCMGMSHEPQENPE-ZOWNYOTGSA-N,"InChI=1S/C13H16ClNO.ClH/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14;/h2-3,6-7,15H,4-5,8-9H2,1H3;1H/t13-;/m0./s1",274.191
485,Human,Camzyos,"Cardiomyopathy, Hypertrophic",mavacamten,MAVACAMTEN,EMEA/H/C/005457,no,Authorised,C01EB,yes,no,no,no,no,no,26/06/2023,,Bristol-Myers Squibb Pharma EEIG,Other cardiac preparations,,04/08/2023,1,Treatment of symptomatic obstructive hypertrophic cardiomyopathy.,24/07/2023,07/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos,RLCLASQCAPXVLM-NSHDSACASA-N,"InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1",273.336
361,Human,Vizamyl,Radionuclide Imaging;  Alzheimer Disease,flutemetamol (18F),FLUTEMETAMOL (18F),EMEA/H/C/002557,no,Authorised,V09AX04,no,no,no,no,no,no,22/08/2014,,GE Healthcare AS,Diagnostic radiopharmaceuticals,26/06/2014,20/09/2023,16,"This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.",31/07/2017,20/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vizamyl,VVECGOCJFKTUAX-HUYCHCPVSA-N,"InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1",273.32293799999997
171,Human,Imnovid (previously Pomalidomide Celgene),Multiple Myeloma,pomalidomide,POMALIDOMIDE,EMEA/H/C/002682,no,Authorised,L04AX06,yes,no,no,no,no,no,05/08/2013,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,30/05/2013,25/08/2023,24,"Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.",11/07/2018,06/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid,UVSMNLNDYGZFPF-UHFFFAOYSA-N,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",273.248
1067,Human,Tasmar,Parkinson Disease,tolcapone,TOLCAPONE,EMEA/H/C/000132,no,Authorised,N04BX01,no,no,no,no,no,no,27/08/1997,,Viatris Healthcare Limited,"Anti-Parkinson drugs, Other dopaminergic agents",,21/11/2022,24,"Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.",08/08/2018,25/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar,MIQPIUSUKVNLNT-UHFFFAOYSA-N,"InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3",273.244
965,Human,Zoely,Contraception,"nomegestrol, estradiol",ESTRADIOL,EMEA/H/C/001213,no,Authorised,G03AA14,no,no,no,no,no,no,26/07/2011,,Theramex Ireland Limited,"Sex hormones and modulators of the genital system, ",,28/11/2022,23,"Oral contraception, ",12/07/2018,16/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zoely,VOXZDWNPVJITMN-ZBRFXRBCSA-N,"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",272.38800000000003
1860,Human,Ioa,Contraception,"nomegestrol acetate, estradiol",ESTRADIOL,EMEA/H/C/002068,no,Withdrawn,G03AA14,no,no,no,no,no,no,16/11/2011,,N.V. Organon,"Sex hormones and modulators of the genital system, ",,16/01/2014,4,Oral contraception.,16/01/2014,26/08/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/ioa,VOXZDWNPVJITMN-ZBRFXRBCSA-N,"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",272.38800000000003
822,Human,Zoledronic acid Mylan,"Fractures, Bone",zoledronic acid,ZOLEDRONIC ACID,EMEA/H/C/002482,no,Authorised,M05BA08,no,yes,no,no,no,no,23/08/2012,,Mylan Pharmaceuticals Limited,Drugs for treatment of bone diseases,,19/04/2023,14,"Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).",11/09/2017,20/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-mylan,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",272.09
997,Human,Aclasta,"Osteoporosis;  Osteitis Deformans;  Osteoporosis, Postmenopausal",zoledronic acid,ZOLEDRONIC ACID,EMEA/H/C/000595,no,Authorised,M05BA08,no,no,no,no,no,no,15/04/2005,,Sandoz Pharmaceuticals d.d.,Drugs for treatment of bone diseases,,16/01/2023,31,"Treatment of osteoporosis:, , , 	in post-menopausal women;, 	in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone., ",23/03/2017,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",272.09
1437,Human,Zoledronic acid Teva,"Fractures, Bone;  Cancer",zoledronic acid,ZOLEDRONIC ACID,EMEA/H/C/002439,no,Authorised,M05BA08,no,yes,no,no,no,no,16/08/2012,,Teva B.V.,Drugs for treatment of bone diseases,15/03/2012,17/09/2021,14,Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.,27/02/2018,11/10/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-teva,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",272.09
1508,Human,Zometa,"Cancer;  Fractures, Bone",zoledronic acid,ZOLEDRONIC ACID,EMEA/H/C/000336,no,Authorised,M05BA08,no,no,no,no,no,no,20/03/2001,,Phoenix Labs Unlimited Company,Drugs for treatment of bone diseases,14/12/2000,04/06/2021,36,"Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).",13/07/2018,09/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/zometa,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",272.09
1730,Human,Zoledronic acid Teva Pharma,"Osteoporosis;  Osteitis Deformans;  Osteoporosis, Postmenopausal",zoledronic acid,ZOLEDRONIC ACID,EMEA/H/C/002437,no,Withdrawn,M05BA08,no,yes,no,no,no,no,15/08/2012,,Teva B.V.,Drugs for treatment of bone diseases,,18/01/2018,11,"Treatment of osteoporosis:, , , 	in post-menopausal women;, 	in men;, , , at increased risk of fracture including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:, , , 	in post-menopausal women;, 	in men;, , , at increased risk of fracture., , Treatment of Paget’s disease of the bone in adults., ",22/05/2017,12/12/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-teva-pharma,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",272.09
1825,Human,Nuedexta,Neurobehavioral Manifestations,"dextromethorphan hydrobromide, quinidine sulfate",DEXTROMETHORPHAN,EMEA/H/C/002560,no,Withdrawn,N07XX59,no,no,no,no,no,no,24/06/2013,,Jenson Pharmaceutical Services Limited,Other nervous system drugs,,24/10/2014,2,Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.,24/10/2014,11/03/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta,MKXZASYAUGDDCJ-NJAFHUGGSA-N,"InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1",271.404
2,Human,Leflunomide medac,"Arthritis, Rheumatoid",leflunomide,LEFLUNOMIDE,EMEA/H/C/001227,no,Authorised,L04AA13,no,yes,no,no,no,no,27/07/2010,,medac Gesellschaft für klinische Spezialpräparate mbH,Selective immunosuppressants,,31/10/2023,19,"Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.",30/01/2018,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
440,Human,Arava,"Arthritis, Rheumatoid;  Arthritis, Psoriatic",leflunomide,LEFLUNOMIDE,EMEA/H/C/000235,no,Authorised,L04AA13,no,no,no,no,no,no,02/09/1999,,Sanofi-aventis Deutschland GmbH,Immunosuppressants,20/05/1999,26/06/2023,41,"Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.",09/04/2018,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/arava,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
452,Human,Aubagio,Multiple Sclerosis,teriflunomide,TERIFLUNOMIDE,EMEA/H/C/002514,no,Authorised,L04AA31,no,no,no,no,no,no,26/08/2013,,Sanofi Winthrop Industrie,Selective immunosuppressants,21/03/2013,13/07/2023,26,AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).,28/05/2018,22/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio,UTNUDOFZCWSZMS-YFHOEESVSA-N,"InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-",270.21
1000,Human,Teriflunomide Mylan,"Multiple Sclerosis, Relapsing-Remitting",teriflunomide,TERIFLUNOMIDE,EMEA/H/C/005962,no,Authorised,L04AA31,no,yes,no,no,no,no,09/11/2022,,Mylan Pharmaceuticals Limited,Immunosuppressants,15/09/2022,10/01/2023,1,Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established). ,14/09/2022,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-mylan,UTNUDOFZCWSZMS-YFHOEESVSA-N,"InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-",270.21
1082,Human,Teriflunomide Accord,"Multiple Sclerosis, Relapsing-Remitting",teriflunomide,TERIFLUNOMIDE,EMEA/H/C/005960,no,Authorised,L04AA31,no,yes,no,no,no,no,09/11/2022,,Accord Healthcare S.L.U.,"Immunosuppressants, Selective immunosuppressants",15/09/2022,,,Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).,14/09/2022,14/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-accord,UTNUDOFZCWSZMS-YFHOEESVSA-N,"InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-",270.21
1246,Human,Leflunomide Zentiva (previously Leflunomide Winthrop),"Arthritis, Rheumatoid;  Arthritis, Psoriatic",leflunomide,LEFLUNOMIDE,EMEA/H/C/001129,no,Authorised,L04AA13,no,no,no,no,no,no,08/01/2010,,Zentiva k.s.,Immunosuppressants,,13/05/2022,18,"Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.",09/04/2018,17/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-zentiva,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
1247,Human,Leflunomide ratiopharm,"Arthritis, Rheumatoid",leflunomide,LEFLUNOMIDE,EMEA/H/C/002035,no,Authorised,L04AA13,no,yes,no,no,no,no,28/11/2010,,Ratiopharm GmbH,Immunosuppressants,23/09/2010,13/05/2022,16,"Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.",21/12/2017,17/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-ratiopharm,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
1821,Human,Repso,"Arthritis, Rheumatoid;  Arthritis, Psoriatic",leflunomide,LEFLUNOMIDE,EMEA/H/C/001222,no,Withdrawn,L04AA13,no,yes,no,no,no,no,14/03/2011,,Teva B.V.,Immunosuppressants,,30/03/2016,11,"Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.",30/03/2016,21/04/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/repso,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
1873,Human,Leflunomide Teva,"Arthritis, Rheumatoid",leflunomide,LEFLUNOMIDE,EMEA/H/C/002356,no,Withdrawn,L04AA13,no,yes,no,no,no,no,10/03/2011,,Teva Pharma B.V.,Immunosuppressants,,15/01/2014,6,"Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching. ",15/01/2014,18/03/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-teva,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",270.21
30,Human,Inaqovi,"Leukemia, Myeloid","cedazuridine, decitabine",CEDAZURIDINE,EMEA/H/C/005823,no,Authorised,L01BC58,yes,no,no,no,no,no,15/09/2023,,Otsuka Pharmaceutical Netherlands B.V.,Antineoplastic agents,20/07/2023,,,Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.,17/07/2023,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inaqovi,VUDZSIYXZUYWSC-DBRKOABJSA-N,"InChI=1S/C9H14F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4-7,14-16H,1-3H2,(H,12,17)/t4-,5-,6-,7-/m1/s1",268.216
222,Human,Fintepla,"Epilepsies, Myoclonic",fenfluramine,FENFLURAMINE HYDROCHLORIDE,EMEA/H/C/003933,no,Authorised,N03,yes,no,no,no,no,yes,18/12/2020,,UCB Pharma S.A.  ,"Antiepileptics, ",15/10/2020,31/08/2023,7,Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.,08/01/2021,20/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla,ZXKXJHAOUFHNAS-UHFFFAOYSA-N,"InChI=1S/C12H16F3N.ClH/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15;/h4-6,8-9,16H,3,7H2,1-2H3;1H",267.7219999999999
639,Human,Ontozry,Epilepsy,cenobamate,CENOBAMATE,EMEA/H/C/005377,no,Authorised,N03AX,yes,no,no,no,no,no,26/03/2021,,Angelini Pharma S.p.A,"Antiepileptics, ",,27/06/2023,5,Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.,13/04/2021,28/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry,GFHAXPJGXSQLPT-VIFPVBQESA-N,"InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1",267.67600000000004
892,Human,Lamivudine/Zidovudine Teva,HIV Infections,"lamivudine, zidovudine",ZIDOVUDINE,EMEA/H/C/001236,no,Withdrawn,J05AR01,no,yes,no,no,no,no,28/02/2011,,Teva Pharma B.V. ,Antivirals for systemic use,18/11/2010,21/03/2022,16,Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.,20/04/2018,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva,HBOMLICNUCNMMY-XLPZGREQSA-N,"InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1",267.245
1152,Human,Combivir,HIV Infections,"lamivudine, zidovudine",ZIDOVUDINE,EMEA/H/C/000190,no,Authorised,J05AR01,no,no,no,no,no,no,18/03/1998,,ViiV Healthcare BV,Antivirals for systemic use,19/11/1997,11/08/2022,37,"Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection., ",25/01/2018,29/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/combivir,HBOMLICNUCNMMY-XLPZGREQSA-N,"InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1",267.245
818,Human,Viramune,HIV Infections,nevirapine,NEVIRAPINE,EMEA/H/C/000183,no,Authorised,J05AG01,no,no,no,no,no,no,04/02/1998,,Boehringer Ingelheim International GmbH,Antivirals for systemic use,22/10/1997,20/04/2023,44,"Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.",01/05/2018,21/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/viramune,NQDJXKOVJZTUJA-UHFFFAOYSA-N,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",266.304
898,Human,Nevirapine Teva,HIV Infections,nevirapine,NEVIRAPINE,EMEA/H/C/001119,no,Withdrawn,J05AG01,no,yes,no,no,no,no,30/11/2009,,Teva B.V. ,Antivirals for systemic use,24/09/2009,08/12/2021,11,"Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.",28/08/2016,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nevirapine-teva,NQDJXKOVJZTUJA-UHFFFAOYSA-N,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",266.304
221,Human,Revlimid,"Multiple Myeloma;  Lymphoma, Mantle-Cell;  Myelodysplastic Syndromes",lenalidomide,LENALIDOMIDE,EMEA/H/C/000717,no,Authorised,L04AX04,yes,no,no,no,no,no,14/06/2007,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,,28/09/2023,51,"Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).",29/06/2018,20/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid,GOTYRUGSSMKFNF-UHFFFAOYSA-N,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",259.265
335,Human,Lenalidomide Accord,Multiple Myeloma,lenalidomide,LENALIDOMIDE,EMEA/H/C/004857,no,Authorised,L04AX04,no,yes,no,no,no,no,20/09/2018,,Accord Healthcare S.L.U.,Immunosuppressants,26/07/2018,09/08/2023,11,"Multiple myelomaLenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).",27/07/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-accord,GOTYRUGSSMKFNF-UHFFFAOYSA-N,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",259.265
587,Human,Lenalidomide Mylan,Multiple Myeloma,lenalidomide,LENALIDOMIDE,EMEA/H/C/005306,no,Authorised,L04AX07,no,yes,no,no,no,no,18/12/2020,,Mylan Ireland Limited,Immunosuppressants,15/10/2020,29/06/2023,8,"Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).",07/01/2021,12/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-mylan,GOTYRUGSSMKFNF-UHFFFAOYSA-N,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",259.265
34,Human,Thalidomide BMS (previously Thalidomide Celgene),Multiple Myeloma,thalidomide,THALIDOMIDE,EMEA/H/C/000823,no,Authorised,L04AX02,no,no,no,no,no,no,16/04/2008,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,,26/11/2023,31,"Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy.Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).",08/08/2018,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene,UEJJHQNACJXSKW-UHFFFAOYSA-N,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",258.233
1106,Human,Thalidomide Lipomed,Multiple Myeloma,thalidomide,THALIDOMIDE,EMEA/H/C/005715,no,Authorised,L04AX02,no,no,no,no,no,no,19/09/2022,,Lipomed GmbH,Immunosuppressants,21/07/2022,,,"Thalidomide Lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ? 65 years or ineligible for high dose chemotherapy.Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme (see section 4.4).",18/07/2022,20/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed,UEJJHQNACJXSKW-UHFFFAOYSA-N,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",258.233
960,Human,Xagrid,"Thrombocythemia, Essential",anagrelide,ANAGRELIDE,EMEA/H/C/000480,no,Authorised,L01XX35,no,no,no,no,no,no,15/11/2004,,Takeda Pharmaceuticals International AG Ireland Branch,Antineoplastic agents,,16/02/2023,40,Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk ET is defined by one or more of the following features:>60 years of age or;a platelet count >1000 x 109/l or;a history of thrombohaemorrhagic events.,11/07/2018,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xagrid,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,"InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)",256.092
40,Human,Omidria,"Lens Implantation, Intraocular;  Pain, Postoperative","phenylephrine, ketorolac",KETOROLAC,EMEA/H/C/003702,no,Authorised,S01,no,no,no,no,no,no,28/07/2015,,Rayner Surgical (Ireland) Limited,Ophthalmologicals,21/05/2015,24/11/2023,9,"Omidria is indicated in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.",31/01/2018,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/omidria,OZWKMVRBQXNZKK-UHFFFAOYSA-N,"InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)",255.27299999999997
2035,Human,Vitrasert Implant,Cytomegalovirus Retinitis;  HIV Infections,ganciclovir,GANCICLOVIR,EMEA/H/C/000120,no,Withdrawn,J05AB06,no,no,no,no,no,no,18/03/1997,,"Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..",Antivirals for systemic use,,02/04/2002,0,The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).,02/04/2002,13/05/2002,https://www.ema.europa.eu/en/medicines/human/EPAR/vitrasert-implant,IRSCQMHQWWYFCW-UHFFFAOYSA-N,"InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)",255.23400000000004
1404,Human,Nevanac,"Pain, Postoperative;  Ophthalmologic Surgical Procedures",nepafenac,NEPAFENAC,EMEA/H/C/000818,no,Authorised,S01BC10,no,no,no,no,no,no,11/12/2007,,Novartis Europharm Limited,Ophthalmologicals,,18/10/2021,17,"Nevanac is indicated for:, , , 	prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, 	reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., , ",23/08/2018,16/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac,QEFAQIPZVLVERP-UHFFFAOYSA-N,"InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)",254.28899999999996
1325,Human,Staquis,"Dermatitis, Atopic",crisaborole,CRISABOROLE,EMEA/H/C/004863,no,Withdrawn,D11AH06,yes,no,no,no,no,no,27/03/2020,,Pfizer Europe MA EEIG ,Other dermatological preparations,30/01/2020,01/10/2021,6,Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ? 40% body surface area (BSA) affected.,22/04/2020,08/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/staquis,USZAGAREISWJDP-UHFFFAOYSA-N,"InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2",251.04999999999998
93,Human,Prometax,Alzheimer Disease;  Parkinson Disease;  Dementia,rivastigmine,RIVASTIGMINE,EMEA/H/C/000255,no,Authorised,N06DA03,no,no,no,no,no,no,03/12/1998,,Novartis Europharm Limited,"Psychoanaleptics, ",16/09/1998,21/11/2023,46,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,08/05/2018,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/prometax,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
333,Human,Rivastigmine Sandoz,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/001183,no,Authorised,N06DA03,no,no,no,no,no,no,10/12/2009,,Sandoz GmbH,"Psychoanaleptics, ",,05/06/2023,14,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,16/08/2016,25/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-sandoz,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
667,Human,Rivastigmine Hexal,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/001182,no,Authorised,N06DA03,no,no,no,no,no,no,11/12/2009,,Hexal AG ,"Psychoanaleptics, ",,05/06/2023,15,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,08/08/2016,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-hexal,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
669,Human,Rivastigmine 1 A Pharma,Alzheimer Disease;  Dementia;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/001181,no,Authorised,N06DA03,no,no,no,no,no,no,11/12/2009,,1 A Pharma GmbH,"Psychoanaleptics, ",,05/06/2023,15,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,16/08/2016,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-1-pharma,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
695,Human,Exelon,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/000169,no,Authorised,N06DA03,no,no,no,no,no,no,11/05/1998,,Novartis Europharm Limited,"Psychoanaleptics, ",28/01/1998,14/04/2023,46,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,25/01/2018,08/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/exelon,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
949,Human,Nimvastid,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/001029,no,Authorised,N06DA03,no,yes,no,no,no,no,11/05/2009,,"Krka, d.d., Novo mesto","Psychoanaleptics, ",,26/01/2023,10,"Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease., ",18/01/2018,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nimvastid,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
1856,Human,Rivastigmine 3M Health Care Ltd,Alzheimer Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/003824,no,Withdrawn,N06DA03,no,yes,no,no,no,no,03/04/2014,,3M Health Care Limited,"Psychoanaleptics, , Anticholinesterases",23/01/2014,19/08/2014,1,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.,19/08/2014,18/09/2014,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-3m-health-care-ltd,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
1902,Human,Rivastigmine Teva,Dementia;  Alzheimer Disease;  Parkinson Disease,rivastigmine,RIVASTIGMINE,EMEA/H/C/001044,no,Withdrawn,N06DA03,no,yes,no,no,no,no,17/04/2009,,Teva Pharma B.V.,Anticholinesterases,,10/09/2012,4,Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,10/09/2012,27/09/2012,https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-teva,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",250.34199999999998
161,Human,Vimpat,Epilepsy,lacosamide,LACOSAMIDE,EMEA/H/C/000863,no,Authorised,N03AX18,no,no,no,no,no,no,29/08/2008,,UCB Pharma SA,"Antiepileptics, ",26/06/2008,26/10/2023,46,"Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.",26/07/2018,07/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat,VPPJLAIAVCUEMN-GFCCVEGCSA-N,"InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",250.298
165,Human,Lacosamide UCB,"Epilepsies, Partial",lacosamide,LACOSAMIDE,EMEA/H/C/005243,no,Authorised,N03AX18,no,no,no,no,no,no,26/08/2019,,UCB Pharma S.A.,"Antiepileptics, ",27/06/2019,26/10/2023,6,"Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy., ",12/09/2019,07/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-ucb,VPPJLAIAVCUEMN-GFCCVEGCSA-N,"InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",250.298
251,Human,Lacosamide Adroiq,Epilepsy,lacosamide,LACOSAMIDE,EMEA/H/C/006047,no,Authorised,N03AX18,no,yes,no,no,no,no,31/05/2023,,Extrovis EU Ltd.,"Antiepileptics, ",30/03/2023,09/10/2023,2,"Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Lacosamide Adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.",27/03/2023,13/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-adroiq,VPPJLAIAVCUEMN-GFCCVEGCSA-N,"InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",250.298
468,Human,Lacosamide Accord,Epilepsy,lacosamide,LACOSAMIDE,EMEA/H/C/004443,no,Authorised,N03AX18,no,yes,no,no,no,no,18/09/2017,,Accord Healthcare S.L.U.,"Antiepileptics, ",20/07/2017,04/08/2023,12,"Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.Lacosamide Accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.",04/04/2018,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-accord,VPPJLAIAVCUEMN-GFCCVEGCSA-N,"InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",250.298
284,Human,"Vantavo (previously Alendronate sodium and colecalciferol, MSD)","Osteoporosis, Postmenopausal","alendronic acid, colecalciferol",ALENDRONIC ACID,EMEA/H/C/001180,no,Authorised,M05BB03,no,no,no,no,no,no,16/10/2009,,N.V. Organon,Drugs for treatment of bone diseases,23/07/2009,04/10/2023,18,Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.,09/07/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo,OGSPWJRAVKPPFI-UHFFFAOYSA-N,"InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)",249.09599999999998
285,Human,Fosavance,"Osteoporosis, Postmenopausal","alendronic acid, colecalciferol",ALENDRONIC ACID,EMEA/H/C/000619,no,Authorised,M05BB03,no,no,no,no,no,no,24/08/2005,,N.V. Organon,Drugs for treatment of bone diseases,26/05/2005,04/10/2023,27,Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Fosavance reduces the risk of vertebral and hip fractures.,09/07/2018,04/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fosavance,OGSPWJRAVKPPFI-UHFFFAOYSA-N,"InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)",249.09599999999998
73,Human,Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004137,no,Authorised,J05AR03,no,yes,no,no,no,no,09/11/2016,,Zentiva k.s.,Antivirals for systemic use,15/09/2016,23/05/2023,8,"Treatment of HIV-1 infectionEmtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.",13/10/2017,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-zentiva,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
112,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004240,no,Authorised,J05AR06,no,yes,no,no,no,no,05/09/2017,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,22/06/2017,03/11/2023,16,"Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",15/08/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
527,Human,Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004050,no,Authorised,J05AR03,no,yes,no,no,no,no,16/12/2016,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,13/10/2016,05/07/2023,14,"Treatment of HIV-1 infection:Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1).Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1).Pre-exposure prophylaxis (PrEP):Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).",02/06/2017,27/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-mylan,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
665,Human,Emtricitabine/Tenofovir disoproxil Krka d.d.,HIV Infections,"emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004686,no,Authorised,J05AR03,no,yes,no,no,no,no,28/04/2017,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,23/02/2017,21/06/2023,10,"Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.",25/07/2018,22/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka-dd,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
668,Human,Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004215,no,Authorised,J05AR03,no,yes,no,no,no,no,09/12/2016,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,13/10/2016,21/06/2023,12,"Treatment of HIV-1 infectionEmtricitabine/tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.",25/07/2018,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
677,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004274,no,Authorised,J05AR06,no,yes,no,no,no,no,08/02/2018,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,14/12/2017,15/06/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",08/02/2018,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-krka,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
720,Human,Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/004250,no,Authorised,J05AR06,no,yes,no,no,no,no,17/07/2017,,Zentiva k.s.,Antivirals for systemic use,18/05/2017,30/05/2023,10,"Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with combination efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",09/01/2018,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-zentiva,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
828,Human,Emtriva,HIV Infections,emtricitabine,EMTRICITABINE,EMEA/H/C/000533,no,Authorised,J05AF09,no,no,no,no,no,no,24/10/2003,,Gilead Sciences Ireland UC,Antivirals for systemic use,,18/04/2023,33,"Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.This indication is based on studies in treatment-naive patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens.When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.",24/07/2018,18/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
897,Human,Symtuza,HIV Infections,"darunavir, cobicistat, emtricitabine, tenofovir alafenamide",EMTRICITABINE,EMEA/H/C/004391,no,Authorised,J05,no,no,no,no,no,no,21/09/2017,,Janssen-Cilag International NV,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",19/07/2017,07/03/2023,17,Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).Genotypic testing should guide the use of Symtuza.,06/07/2017,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
957,Human,Odefsey,HIV Infections,"emtricitabine, rilpivirine, tenofovir alafenamide",EMTRICITABINE,EMEA/H/C/004156,no,Authorised,J05AR19,no,no,no,no,no,no,21/06/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,28/04/2016,16/02/2023,20,"Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ? 100,000 HIV 1 RNA copies/mL., ",16/05/2018,20/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
962,Human,Descovy,HIV Infections,"emtricitabine, tenofovir alafenamide",EMTRICITABINE,EMEA/H/C/004094,no,Authorised,J05AR17,no,no,no,no,no,no,21/04/2016,,Gilead Sciences Ireland UC,Antivirals for systemic use,25/02/2016,16/02/2023,20,Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).,28/05/2018,17/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/descovy,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
977,Human,Truvada,HIV Infections,"emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/000594,no,Authorised,J05AR03,no,no,no,no,no,no,20/02/2005,,Gilead Sciences Ireland UC,Antivirals for systemic use,18/11/2004,12/01/2023,46,"Treatment of HIV-1 infection:, , , 	Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults., 	Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years., , , Pre-exposure prophylaxis (PrEP):, , , 	Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk., , ",19/07/2017,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/truvada,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
978,Human,Stribild,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/002574,no,Authorised,J05AR09,no,no,no,no,no,no,24/05/2013,,Gilead Sciences Ireland UC,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,12/01/2023,25,Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.,19/07/2018,02/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stribild,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
1043,Human,Eviplera,HIV Infections,"emtricitabine, rilpivirine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/002312,no,Authorised,J05AR08,no,no,no,no,no,no,27/11/2011,,Gilead Sciences International Ltd ,Antivirals for systemic use,,12/12/2022,25,"Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.",19/07/2018,13/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
1066,Human,Genvoya,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",EMTRICITABINE,EMEA/H/C/004042,no,Authorised,J05AR,no,no,no,no,no,no,19/11/2015,,Gilead Sciences Ireland UC,Antivirals for systemic use,24/09/2015,03/10/2022,27,"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.",26/07/2018,28/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
1338,Human,Atripla,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil",EMTRICITABINE,EMEA/H/C/000797,no,Withdrawn,J05AR06,no,no,no,no,no,no,13/12/2007,,Gilead Sciences Ireland UC,Antivirals for systemic use,,17/08/2021,36,"Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla.No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients.No data are available to support the combination of Atripla and other antiretroviral agents.",25/07/2018,21/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/atripla,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",247.251
490,Human,Busilvex,Hematopoietic Stem Cell Transplantation,busulfan,BUSULFAN,EMEA/H/C/000472,no,Withdrawn,L01AB01,no,no,no,no,no,no,09/07/2003,,Pierre Fabre Medicament,Antineoplastic agents,19/03/2003,01/02/2022,19,Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busilvex following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.,24/05/2017,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/busilvex,COVZYZSDYWQREU-UHFFFAOYSA-N,"InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3",246.306
1529,Human,Busulfan Fresenius Kabi,Hematopoietic Stem Cell Transplantation,busulfan,BUSULFAN,EMEA/H/C/002806,no,Authorised,L01AB01,no,yes,no,no,no,no,22/09/2014,,Fresenius Kabi Deutschland GmbH,Alkyl sulfonates,25/07/2014,26/04/2021,9,Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.,08/05/2018,18/05/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/busulfan-fresenius-kabi,COVZYZSDYWQREU-UHFFFAOYSA-N,"InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3",246.306
1120,Human,Hetlioz,"Sleep Disorders, Circadian Rhythm",tasimelteon,TASIMELTEON,EMEA/H/C/003870,no,Authorised,N05CH,no,no,no,no,no,yes,03/07/2015,,Vanda Pharmaceuticals Netherlands B.V.,Psycholeptics,23/04/2015,10/10/2022,9,"Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults., ",06/07/2017,11/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/hetlioz,PTOIAAWZLUQTIO-GXFFZTMASA-N,"InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1",245.322
162,Human,Rebetol,"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/000246,no,Withdrawn,J05AP01,no,no,no,no,no,no,06/05/1999,,Merck Sharp and Dohme B.V,"Antivirals for systemic use, Antivirals for treatment of HCV infections",,24/11/2022,39,Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.,03/02/2017,07/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rebetol,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
278,Human,Azacitidine Mylan,"Myelodysplastic Syndromes;  Leukemia, Myelomonocytic, Chronic;  Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/004984,no,Authorised,L01BC07,no,yes,no,no,no,no,27/03/2020,,Mylan Ireland Limited,Antineoplastic agents,30/01/2020,05/10/2023,7,"Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification.",06/04/2020,05/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
685,Human,Vidaza,"Myelodysplastic Syndromes;  Leukemia, Myelomonocytic, Chronic;  Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/000978,no,Authorised,L01BC07,no,no,no,no,yes,no,17/12/2008,,Bristol-Myers Squibb Pharma EEIG,Antineoplastic agents,23/10/2008,28/04/2022,26,"Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification.",18/05/2017,15/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
865,Human,Azacitidine Accord,"Myelodysplastic Syndromes;  Leukemia, Myelomonocytic, Chronic;  Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/005147,no,Authorised,L01BC07,no,yes,no,no,no,no,13/02/2020,,Accord Healthcare S.L.U.,Antineoplastic agents,12/12/2019,15/03/2023,6,"Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),- chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,- acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,- AML with >30% marrow blasts according to the WHO classification.",21/02/2020,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
969,Human,Azacitidine betapharm,"Myelodysplastic Syndromes;  Leukemia, Myelomonocytic, Chronic;  Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/005075,no,Authorised,L01BC07,no,yes,no,no,no,no,24/03/2020,,betapharm Arzneimittel GmbH,Antineoplastic agents,30/01/2020,10/02/2023,5,"Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 % to 30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification,AML with > 30 % marrow blasts according to the WHO classification.",20/11/2020,13/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-betapharm,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
1475,Human,Onureg,"Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/004761,no,Authorised,L01BC07,no,no,no,no,no,no,17/06/2021,,Bristol-Myers Squibb Pharma EEIG,Antineoplastic agents,22/04/2021,23/07/2021,1,"Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).",20/04/2021,06/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/onureg,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
1492,Human,Azacitidine Celgene,"Myelodysplastic Syndromes;  Leukemia, Myelomonocytic, Chronic;  Leukemia, Myeloid, Acute",azacitidine,AZACITIDINE,EMEA/H/C/005300,no,Withdrawn,L01BC07,no,no,no,no,no,no,02/08/2019,,Celgene Europe BV,Antineoplastic agents,27/06/2019,21/05/2021,2,"Azacitidine Celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,AML with >30% marrow blasts according to the WHO classification.",14/08/2019,04/08/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-celgene,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",244.207
1506,Human,Ribavirin Teva Pharma B.V.,"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/001064,no,Withdrawn,J05AP01,no,yes,no,no,no,no,01/07/2009,,Teva B.V.,Antivirals for systemic use,23/04/2009,22/06/2021,14,"Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).",04/11/2016,09/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva-pharma-bv,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
1507,Human,Ribavirin Teva,"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/001018,no,Withdrawn,J05AB04,no,yes,no,no,no,no,31/03/2009,,Teva B.V.,Antivirals for systemic use,,22/06/2021,15,"Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.",14/11/2016,09/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
1601,Human,Ribavirin Mylan (previously Ribavirin Three Rivers),"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/001185,no,Withdrawn,J05AB04,no,yes,no,no,no,no,10/06/2010,,Mylan S.A.S,Antivirals for systemic use,,13/03/2019,10,"Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.  ",29/07/2016,23/11/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-mylan,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
1890,Human,Ribavirin BioPartners,"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/001184,no,Withdrawn,J05AB04,no,yes,no,no,no,no,06/04/2010,,BioPartners GmbH,Antivirals for systemic use,,21/11/2012,2,"Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)Children three years of age and older and adolescentsRibavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).Previous-treatment-failure patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).",21/11/2012,06/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-biopartners,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
2026,Human,Cotronak,"Hepatitis C, Chronic",ribavirin,RIBAVIRIN,EMEA/H/C/000247,no,Withdrawn,J05AB04,no,no,no,no,no,no,07/05/1999,,Schering-Plough Europe,Antivirals for systemic use,,01/03/2004,4,"Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.",01/03/2004,01/03/2004,https://www.ema.europa.eu/en/medicines/human/EPAR/cotronak,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",244.207
1170,Human,Thymanax,"Depressive Disorder, Major",Agomelatine,AGOMELATINE,EMEA/H/C/000916,no,Withdrawn,N06AX22,no,no,no,no,no,no,19/02/2009,18/11/2006,Servier (Ireland) Industries Ltd,"Psychoanaleptics, ",27/07/2006,31/07/2022,24,Treatment of major depressive episodes in adults.,11/09/2017,08/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax,YJYPHIXNFHFHND-UHFFFAOYSA-N,"InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)",243.30599999999998
1171,Human,Valdoxan,"Depressive Disorder, Major",Agomelatine,AGOMELATINE,EMEA/H/C/000915,no,Authorised,N06AX22,no,no,no,no,no,no,19/02/2009,,Les Laboratoires Servier,"Psychoanaleptics, ",20/11/2008,09/11/2021,24,"Treatment of major depressive episodes in adults., ",11/09/2017,08/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan,YJYPHIXNFHFHND-UHFFFAOYSA-N,"InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)",243.30599999999998
103,Human,Vyxeos liposomal (previously known as Vyxeos),"Leukemia, Myeloid, Acute","daunorubicin, cytarabine",CYTARABINE,EMEA/H/C/004282,no,Authorised,L01XY01,no,no,no,no,no,yes,23/08/2018,,Jazz Pharmaceuticals Ireland Limited,Antineoplastic agents,26/04/2018,05/06/2023,9,"Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).",29/06/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,"InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1",243.219
849,Human,DepoCyte,Meningeal Neoplasms,cytarabine,CYTARABINE,EMEA/H/C/000317,no,Withdrawn,L01BC01,no,no,no,no,no,no,11/07/2001,,Pacira Limited,Antineoplastic agents,10/07/2018,26/06/2017,15,Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.,26/06/2017,03/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/depocyte,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,"InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1",243.219
1584,Human,Sebivo,"Hepatitis B, Chronic",telbivudine,TELBIVUDINE,EMEA/H/C/000713,no,Withdrawn,J05AF11,no,no,no,no,no,no,24/04/2007,,Novartis Europharm Limited,Nucleoside and nucleotide reverse transcriptase inhibitors,22/02/2007,12/04/2018,20,"Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.",12/04/2018,14/01/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/sebivo,IQFYYKKMVGJFEH-CSMHCCOUSA-N,"InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1",242.231
614,Human,Zyclara,"Keratosis;  Keratosis, Actinic",imiquimod,IMIQUIMOD,EMEA/H/C/002387,no,Authorised,D06BB10,no,no,no,no,no,no,23/08/2012,,Viatris Healthcare Limited,Antibiotics and chemotherapeutics for dermatological use,21/06/2012,05/07/2023,15,"Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.",16/02/2018,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara,DOUYETYNHWVLEO-UHFFFAOYSA-N,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",240.31
615,Human,Aldara,"Condylomata Acuminata;  Keratosis;  Keratosis, Actinic;  Carcinoma, Basal Cell",imiquimod,IMIQUIMOD,EMEA/H/C/000179,no,Authorised,D06BB10,no,no,no,no,no,no,18/09/1998,,Viatris Healthcare Limited,Antibiotics and chemotherapeutics for dermatological use,27/05/1998,05/07/2023,31,"Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.",29/06/2018,06/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/aldara,DOUYETYNHWVLEO-UHFFFAOYSA-N,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",240.31
2032,Human,Zartra,Condylomata Acuminata,imiquimod,IMIQUIMOD,EMEA/H/C/000180,no,Withdrawn,L03AX,no,no,no,no,no,no,18/09/1998,,Laboratoires 3M Santé,"Immunostimulants, ",,11/06/2002,0,Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.,11/06/2002,31/07/2002,https://www.ema.europa.eu/en/medicines/human/EPAR/zartra,DOUYETYNHWVLEO-UHFFFAOYSA-N,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",240.31
944,Human,Inovelon,Epilepsy,rufinamide,RUFINAMIDE,EMEA/H/C/000660,no,Authorised,N03AF03,no,no,no,no,no,no,16/01/2007,,Eisai GmbH,"Antiepileptics, ",,16/02/2023,23,Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.,03/08/2018,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon,POGQSBRIGCQNEG-UHFFFAOYSA-N,"InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)",238.197
679,Human,Dexdor,Conscious Sedation,dexmedetomidine,DEXMEDETOMIDINE HYDROCHLORIDE,EMEA/H/C/002268,no,Authorised,N05CM18,no,no,no,no,no,no,15/09/2011,,Orion Corporation,Psycholeptics,,08/07/2022,16,For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).,08/12/2017,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor,VPNGEIHDPSLNMU-MERQFXBCSA-N,"InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1",236.746
351,Human,Fortacin,"Sexual Dysfunction, Physiological","lidocaine, prilocaine",LIDOCAINE,EMEA/H/C/002693,no,Authorised,N01BB20,no,no,no,no,no,no,15/11/2013,,Recordati Ireland Ltd.,Anesthetics,19/09/2013,15/09/2023,12,Treatment of primary premature ejaculation in adult men.,25/11/2013,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fortacin,NNJVILVZKWQKPM-UHFFFAOYSA-N,"InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",234.34299999999996
1206,Human,Senstend,Premature Ejaculation,"lidocaine, prilocaine",LIDOCAINE,EMEA/H/C/005298,no,Withdrawn,N01BB20,no,no,no,no,no,no,14/11/2019,,Plethora Pharma Solutions Limited,Anesthetics,19/09/2019,14/11/2019,,Senstend is indicated for the treatment of primary premature ejaculation in adult men.,29/11/2019,05/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/senstend,NNJVILVZKWQKPM-UHFFFAOYSA-N,"InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",234.34299999999996
445,Human,Diacomit,"Myoclonic Epilepsy, Juvenile",stiripentol,STIRIPENTOL,EMEA/H/C/000664,no,Authorised,N03AX17,no,no,no,no,no,no,03/01/2007,11/02/2009,Biocodex,"Antiepileptics, ",,25/04/2023,18,"Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.",23/06/2014,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit,IBLNKMRFIPWSOY-FNORWQNLSA-N,"InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+",234.29499999999996
8,Human,Rilutek,Amyotrophic Lateral Sclerosis,riluzole,RILUZOLE,EMEA/H/C/000109,no,Authorised,N07XX02,no,no,no,no,no,no,10/06/1996,,Sanofi Winthrop Industrie,Other nervous system drugs,14/02/1996,15/11/2023,32,"Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease.",13/11/2017,04/12/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/rilutek,FTALBRSUTCGOEG-UHFFFAOYSA-N,"InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)",234.202
1073,Human,Riluzole Zentiva,Amyotrophic Lateral Sclerosis,riluzole,RILUZOLE,EMEA/H/C/002622,no,Authorised,N07XX02,no,no,no,no,no,no,07/05/2012,,Zentiva k.s.,Other nervous system drugs,,15/11/2022,13,"Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease. ",08/05/2018,22/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/riluzole-zentiva,FTALBRSUTCGOEG-UHFFFAOYSA-N,"InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)",234.202
51,Human,Slenyto,Sleep Initiation and Maintenance Disorders;  Autistic Disorder,melatonin,MELATONIN,EMEA/H/C/004425,no,Authorised,N05CH01,no,no,no,no,no,no,20/09/2018,,RAD Neurim Pharmaceuticals EEC SARL,Psycholeptics,26/07/2018,24/11/2023,10,"Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.",10/10/2018,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/slenyto,DRLFMBDRBRZALE-UHFFFAOYSA-N,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",232.28300000000002
380,Human,Melatonin Neurim,Sleep Initiation and Maintenance Disorders,melatonin,MELATONIN,EMEA/H/C/005603,no,Authorised,N05CH01,no,no,no,no,no,no,07/11/2022,,RAD Neurim Pharmaceuticals EEC SARL,Psycholeptics,15/09/2022,14/09/2023,1,Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.,14/09/2022,15/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/melatonin-neurim,DRLFMBDRBRZALE-UHFFFAOYSA-N,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",232.28300000000002
761,Human,Circadin,Sleep Initiation and Maintenance Disorders,melatonin,MELATONIN,EMEA/H/C/000695,no,Authorised,N05CH01,no,no,no,no,no,no,29/06/2007,,RAD Neurim Pharmaceuticals EEC SARL,Psycholeptics,,16/05/2023,34,Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.,26/07/2018,17/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/circadin,DRLFMBDRBRZALE-UHFFFAOYSA-N,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",232.28300000000002
1837,Human,Rienso,"Anemia;  Kidney Failure, Chronic",ferumoxytol,FERUMOXYTOL,EMEA/H/C/002215,no,Withdrawn,B03,yes,no,no,no,no,no,15/06/2012,,Takeda Pharma A/S,Other antianemic preparations,,13/04/2015,7,Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).,13/04/2015,13/07/2015,https://www.ema.europa.eu/en/medicines/human/EPAR/rienso,WTFXARWRTYJXII-UHFFFAOYSA-N,InChI=1S/3Fe.4O/q+2;2*+3;4*-2,231.53099999999998
224,Human,Sunosi,"Narcolepsy;  Sleep Apnea, Obstructive",solriamfetol,SOLRIAMFETOL HYDROCHLORIDE,EMEA/H/C/004893,no,Authorised,N06BA14,yes,no,no,no,no,no,16/01/2020,,Atnahs Pharma Netherlands B.V.,"Psychoanaleptics, ",14/11/2019,22/09/2023,8,"Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). ",12/02/2020,19/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi,KAOVAAHCFNYXNJ-SBSPUUFOSA-N,"InChI=1S/C10H14N2O2.ClH/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H2,12,13);1H/t9-;/m1./s1",230.69500000000002
67,Human,Kivexa,HIV Infections,"abacavir, lamivudine",LAMIVUDINE,EMEA/H/C/000581,no,Authorised,J05AR02,no,no,no,no,no,no,16/12/2004,,ViiV Healthcare BV,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,15/11/2023,37,"Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.",25/01/2018,27/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
398,Human,Dovato,HIV Infections,"dolutegravir, lamivudine",LAMIVUDINE,EMEA/H/C/004909,no,Authorised,J05AR,no,no,no,no,no,no,10/06/2022,,ViiV Healthcare B.V.,Antivirals for systemic use,26/04/2019,06/09/2023,14,"Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.",04/09/2019,12/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dovato,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
493,Human,Delstrigo,HIV Infections,"doravirine, lamivudine, tenofovir disoproxil",LAMIVUDINE,EMEA/H/C/004746,no,Authorised,J05AR,no,no,no,no,no,no,22/11/2018,,Merck Sharp & Dohme B.V.,"Antivirals for treatment of HIV infections, combinations",20/09/2018,23/06/2023,11,"Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir.Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.",21/09/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
815,Human,Lamivudine Teva Pharma B.V.,HIV Infections,lamivudine,LAMIVUDINE,EMEA/H/C/001111,no,Authorised,J05AF05,no,yes,no,no,no,no,10/12/2009,,Teva B.V. ,Antivirals for systemic use,,21/04/2023,19,Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.,20/04/2018,21/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
892,Human,Lamivudine/Zidovudine Teva,HIV Infections,"lamivudine, zidovudine",LAMIVUDINE,EMEA/H/C/001236,no,Withdrawn,J05AR01,no,yes,no,no,no,no,28/02/2011,,Teva Pharma B.V. ,Antivirals for systemic use,18/11/2010,21/03/2022,16,Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.,20/04/2018,21/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
1078,Human,Lamivudine Teva,"Hepatitis B, Chronic",lamivudine,LAMIVUDINE,EMEA/H/C/001113,no,Authorised,J05AF05,no,yes,no,no,no,no,23/10/2009,,Teva B.V.,Antivirals for systemic use,,15/11/2022,13,"Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).",18/05/2018,17/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
1151,Human,Epivir,HIV Infections,lamivudine,LAMIVUDINE,EMEA/H/C/000107,no,Authorised,J05AF05,no,no,no,no,no,no,08/08/1996,,ViiV Healthcare BV,Antivirals for systemic use,,11/08/2022,50,"Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children., ",05/03/2018,29/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/epivir,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
1152,Human,Combivir,HIV Infections,"lamivudine, zidovudine",LAMIVUDINE,EMEA/H/C/000190,no,Authorised,J05AR01,no,no,no,no,no,no,18/03/1998,,ViiV Healthcare BV,Antivirals for systemic use,19/11/1997,11/08/2022,37,"Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection., ",25/01/2018,29/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/combivir,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
1192,Human,Zeffix,"Hepatitis B, Chronic",lamivudine,LAMIVUDINE,EMEA/H/C/000242,no,Authorised,J05AF05,no,no,no,no,no,no,29/07/1999,,GlaxoSmithKline (Ireland) Limited,Antivirals for systemic use,22/04/1999,18/07/2022,29,"Zeffix is indicated for the treatment of chronic hepatitis B in adults with:, , , 	compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;, 	decompensated liver disease in combination with a second agent without cross-resistance to lamivudine., , ",25/01/2018,19/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zeffix,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
1799,Human,Dutrebis,HIV Infections,"lamivudine, raltegravir potassium",LAMIVUDINE,EMEA/H/C/003823,no,Withdrawn,J05AR16,no,no,no,no,no,no,26/03/2015,,Merck Sharp  Dohme Limited,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,26/03/2015,0,"Dutrebis is indicated in combination with other anti?retroviral medicinal products for the treatment of human immunodeficiency virus (HIV?1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).",26/03/2015,27/04/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/dutrebis,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",229.261
30,Human,Inaqovi,"Leukemia, Myeloid","cedazuridine, decitabine",DECITABINE,EMEA/H/C/005823,no,Authorised,L01BC58,yes,no,no,no,no,no,15/09/2023,,Otsuka Pharmaceutical Netherlands B.V.,Antineoplastic agents,20/07/2023,,,Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.,17/07/2023,30/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inaqovi,XAUDJQYHKZQPEU-KVQBGUIXSA-N,"InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1",228.208
1499,Human,Dacogen,"Leukemia, Myeloid",decitabine,DECITABINE,EMEA/H/C/002221,no,Authorised,L01BC08,no,no,no,no,no,yes,20/09/2012,,Janssen-Cilag International N.V.  ,Antineoplastic agents,,10/06/2021,16,"Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.",24/08/2017,20/07/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen,XAUDJQYHKZQPEU-KVQBGUIXSA-N,"InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1",228.208
349,Human,Procysbi,Cystinosis,mercaptamine,MERCAPTAMINE BITARTRATE,EMEA/H/C/002465,no,Authorised,A16AA04,no,no,no,no,no,no,05/09/2013,,Chiesi Farmaceutici S.p.A,"Other alimentary tract and metabolism products, ",27/06/2013,26/05/2023,16,"Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.",26/07/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi,NSKJTUFFDRENDM-ZVGUSBNCSA-N,"InChI=1S/C4H6O6.C2H7NS/c5-1(3(7)8)2(6)4(9)10;3-1-2-4/h1-2,5-6H,(H,7,8)(H,9,10);4H,1-3H2/t1-,2-;/m1./s1",227.23799999999994
1413,Human,Cystagon,Cystinosis,mercaptamine bitartrate,MERCAPTAMINE BITARTRATE,EMEA/H/C/000125,no,Authorised,A16AA04,no,no,no,no,no,no,23/06/1997,,Recordati Rare Diseases,"Other alimentary tract and metabolism products, ",,21/10/2021,17,"Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.",24/07/2018,05/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon,NSKJTUFFDRENDM-ZVGUSBNCSA-N,"InChI=1S/C4H6O6.C2H7NS/c5-1(3(7)8)2(6)4(9)10;3-1-2-4/h1-2,5-6H,(H,7,8)(H,9,10);4H,1-3H2/t1-,2-;/m1./s1",227.23799999999994
1615,Human,Zerit,HIV Infections,stavudine,STAVUDINE,EMEA/H/C/000110,no,Withdrawn,J05AF04,no,no,no,no,no,no,08/05/1996,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,13/02/2019,31,Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.,11/08/2006,13/10/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/zerit,XNKLLVCARDGLGL-JGVFFNPUSA-N,"InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1",224.216
351,Human,Fortacin,"Sexual Dysfunction, Physiological","lidocaine, prilocaine",PRILOCAINE,EMEA/H/C/002693,no,Authorised,N01BB20,no,no,no,no,no,no,15/11/2013,,Recordati Ireland Ltd.,Anesthetics,19/09/2013,15/09/2023,12,Treatment of primary premature ejaculation in adult men.,25/11/2013,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/fortacin,MVFGUOIZUNYYSO-UHFFFAOYSA-N,"InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",220.316
1206,Human,Senstend,Premature Ejaculation,"lidocaine, prilocaine",PRILOCAINE,EMEA/H/C/005298,no,Withdrawn,N01BB20,no,no,no,no,no,no,14/11/2019,,Plethora Pharma Solutions Limited,Anesthetics,19/09/2019,14/11/2019,,Senstend is indicated for the treatment of primary premature ejaculation in adult men.,29/11/2019,05/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/senstend,MVFGUOIZUNYYSO-UHFFFAOYSA-N,"InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",220.316
342,Human,Opfolda,Glycogen Storage Disease Type II,miglustat,MIGLUSTAT,EMEA/H/C/005695,no,Authorised,A16AX06,no,no,no,no,no,no,26/06/2023,,Amicus Therapeutics Europe Limited,Other alimentary tract and metabolism products,26/04/2023,19/09/2023,1,Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid ?- glucosidase [GAA] deficiency).,24/04/2023,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",219.281
539,Human,Miglustat Dipharma,Gaucher Disease,miglustat,MIGLUSTAT,EMEA/H/C/004904,no,Authorised,A16AX06,no,yes,no,no,no,no,18/02/2019,,Dipharma Arzneimittel GmbH,Other alimentary tract and metabolism products,13/12/2018,25/07/2023,7,Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.,11/12/2018,26/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/miglustat-dipharma,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",219.281
907,Human,Miglustat Gen.Orph,Gaucher Disease,miglustat,MIGLUSTAT,EMEA/H/C/004366,no,Authorised,A16AX06,no,yes,no,no,no,no,09/11/2017,,Gen.Orph,"Other alimentary tract and metabolism products, ",,13/03/2023,9,Miglustat Gen.Orph is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.,02/03/2018,17/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/miglustat-genorph,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",219.281
951,Human,Yargesa,Gaucher Disease,miglustat,MIGLUSTAT,EMEA/H/C/004016,no,Authorised,A16AX06,no,yes,no,no,no,no,22/03/2017,,Piramal Critical Care B.V.,"Other alimentary tract and metabolism products, ",26/01/2017,17/02/2023,5,Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.,10/05/2017,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/yargesa,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",219.281
1301,Human,Zavesca,Gaucher Disease;  Niemann-Pick Diseases,miglustat,MIGLUSTAT,EMEA/H/C/000435,no,Authorised,A16AX06,no,no,no,no,no,no,20/11/2002,16/06/2009,Janssen Cilag International NV,"Other alimentary tract and metabolism products, ",,01/07/2021,33,Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.,03/05/2018,02/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/zavesca,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",219.281
1095,Human,Cufence,Hepatolenticular Degeneration,trientine dihydrochloride,TRIENTINE DIHYDROCHLORIDE,EMEA/H/C/004111,no,Authorised,A16A,no,no,no,no,no,no,25/07/2019,,Univar Solutions BV,"Other alimentary tract and metabolism products, ",29/05/2019,17/10/2022,5,"Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.",29/07/2019,08/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/cufence,WYHIICXRPHEJKI-UHFFFAOYSA-N,"InChI=1S/C6H18N4.2ClH/c7-1-3-9-5-6-10-4-2-8;;/h9-10H,1-8H2;2*1H",219.16000000000008
803,Human,Axura,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/000378,no,Authorised,N06DX01,no,no,no,no,no,no,17/05/2002,,Merz Pharmaceuticals GmbH,Other anti-dementia drugs,21/02/2002,18/04/2023,27,Treatment of patients with moderate to severe Alzheimer's disease.,26/06/2018,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/axura,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
874,Human,Memantine Mylan,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002660,no,Authorised,N06DX01,no,yes,no,no,no,no,21/04/2013,,Mylan Pharmaceuticals Limited,"Other anti-dementia drugs, Psychoanaleptics, ",,24/03/2023,10,Treatment of patients with moderate to severe Alzheimer’s disease.,08/01/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-mylan,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1214,Human,Memantine ratiopharm,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002671,no,Authorised,N06DX01,no,yes,no,no,no,no,12/06/2013,,Ratiopharm GmbH,"Psychoanaleptics, ",,03/06/2022,8,Treatment of patients with moderate to severe Alzheimer’s disease,24/07/2018,30/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-ratiopharm,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1259,Human,Memantine Merz,Alzheimer Disease,memantine hydrochloride,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002711,no,Authorised,N06DX01,no,no,no,no,no,no,22/11/2012,,Merz Pharmaceuticals GmbH  ,Other anti-dementia drugs,20/09/2012,18/03/2021,7,Treatment of patients with moderate to severe Alzheimer’s disease.,13/07/2017,20/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-merz,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1353,Human,Memantine Accord,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002766,no,Authorised,N06DX01,no,yes,no,no,no,no,03/12/2013,,Accord Healthcare S.L.U.,Other anti-dementia drugs,18/09/2013,10/01/2022,7,Treatment of patients with moderate to severe Alzheimer’s disease.,08/08/2017,13/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-accord,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1363,Human,Ebixa,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/000463,no,Authorised,N06DX01,no,no,no,no,no,no,15/05/2002,,H. Lundbeck A/S,Other anti-dementia drugs,,17/12/2021,26,Treatment of patients with moderate to severe Alzheimer's disease.,14/10/2016,05/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ebixa,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1381,Human,Marixino (previously Maruxa),Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002658,no,Authorised,N06DX01,no,yes,no,no,no,no,28/04/2013,,"KRKA, d.d.",Other anti-dementia drugs,17/01/2013,06/12/2021,8,Treatment of patients with moderate to severe Alzheimer’s disease.,04/04/2018,08/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/marixino,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
1604,Human,Memantine LEK,Alzheimer Disease,memantine,MEMANTINE HYDROCHLORIDE,EMEA/H/C/002630,no,Authorised,N06DX01,no,yes,no,no,no,no,21/04/2013,21/02/2013,Pharmathen S.A.,"Psychoanaleptics, , Other anti-dementia drugs",,20/10/2020,5,Treatment of patients with moderate to severe Alzheimer’s disease.,08/01/2018,16/11/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-lek,LDDHMLJTFXJGPI-UHFFFAOYSA-N,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",215.768
953,Human,Namuscla,Myotonic Disorders,mexiletine hcl,MEXILETINE HYDROCHLORIDE,EMEA/H/C/004584,no,Authorised,C01BB02,no,no,no,no,no,yes,18/12/2018,,Lupin Europe GmbH,Cardiac therapy,18/10/2018,20/02/2023,5,Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.,01/02/2019,22/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla,NFEIBWMZVIVJLQ-UHFFFAOYSA-N,"InChI=1S/C11H17NO.ClH/c1-8-5-4-6-9(2)11(8)13-7-10(3)12;/h4-6,10H,7,12H2,1-3H3;1H",215.724
79,Human,Carmustine medac (previously Carmustine Obvius),"Hodgkin Disease;  Lymphoma, Non-Hodgkin",carmustine,CARMUSTINE,EMEA/H/C/004326,no,Authorised,L01AD01,no,yes,no,no,no,no,18/07/2018,,medac Gesellschaft für klinische Spezialpräparate mbH,Antineoplastic agents,26/04/2018,15/11/2023,9,"Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , 	Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, 	Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, 	as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , ",19/07/2018,24/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius,DLGOEMSEDOSKAD-UHFFFAOYSA-N,"InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)",214.05200000000002
132,Human,Briviact (in Italy: Nubriveo),Epilepsy,brivaracetam,BRIVARACETAM,EMEA/H/C/003898,no,Authorised,N03AX23,no,no,no,no,no,no,13/01/2016,,UCB Pharma SA,"Antiepileptics, ",,13/11/2023,22,Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.,11/07/2018,20/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo,MSYKRHVOOPPJKU-BDAKNGLRSA-N,"InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1",212.293
698,Human,Zonisamide Mylan,Epilepsy,zonisamide,ZONISAMIDE,EMEA/H/C/004127,no,Authorised,N03AX15,no,yes,no,no,no,no,31/03/2016,,Mylan Pharmaceuticals Limited,"Antiepileptics, ",28/01/2016,07/06/2023,9,"Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.",26/03/2018,08/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan,UBQNRHZMVUUOMG-UHFFFAOYSA-N,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",212.23
942,Human,Zonegran,"Epilepsies, Partial",zonisamide,ZONISAMIDE,EMEA/H/C/000577,no,Authorised,N03AX15,no,no,no,no,no,no,10/03/2005,,Amdipharm Limited,"Antiepileptics, ",15/12/2004,15/02/2023,36,"Zonegran is indicated as:monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.",08/01/2018,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran,UBQNRHZMVUUOMG-UHFFFAOYSA-N,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",212.23
179,Human,Champix,Tobacco Use Cessation,varenicline,VARENICLINE,EMEA/H/C/000699,no,Authorised,N07BA03,no,no,no,no,no,no,25/09/2006,,Pfizer Europe MA EEIG,Other nervous system drugs,,26/10/2023,38,Champix is indicated for smoking cessation in adults.,30/07/2018,31/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/champix,JQSHBVHOMNKWFT-DTORHVGOSA-N,"InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+",211.268
1240,Human,Amifampridine SERB,"Lambert-Eaton Myasthenic Syndrome;  Paraneoplastic Syndromes, Nervous System;  Nervous System Neoplasms;  Paraneoplastic Syndromes;  Nervous System Diseases;  Autoimmune Diseases of the Nervous System;  Neurodegenerative Diseases;  Neuromuscular Diseases;  Neuromuscular Junction Diseases;  Immune System Diseases;  Autoimmune Diseases;  Autoimmune Diseases of the Nervous System;  Cancer;  Neoplasms",amifampridine,AMIFAMPRIDINE PHOSPHATE,EMEA/H/C/005839,no,Authorised,N07XX05,no,yes,no,no,no,no,19/05/2022,,SERB SA,Other nervous system drugs,24/03/2022,,,Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.,22/03/2022,24/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/amifampridine-serb,KAICRBBQCRKMPO-UHFFFAOYSA-N,"InChI=1S/C5H7N3.H3O4P/c6-4-1-2-8-3-5(4)7;1-5(2,3)4/h1-3H,7H2,(H2,6,8);(H3,1,2,3,4)",207.126
1096,Human,Pedea,"Ductus Arteriosus, Patent",ibuprofen,IBUPROFEN,EMEA/H/C/000549,no,Authorised,C01EB16,no,no,no,no,no,no,28/07/2004,,Recordati Rare Diseases,Cardiac therapy,,07/11/2022,15,Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.,14/02/2017,08/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pedea,HEFNNWSXXWATRW-UHFFFAOYSA-N,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",206.28499999999997
985,Human,Dexmedetomidine Accord,Premedication,dexmedetomidine,DEXMEDETOMIDINE,EMEA/H/C/005152,no,Authorised,N05CM18,no,yes,no,no,no,no,13/02/2020,,Accord Healthcare S.L.U.,Psycholeptics,12/12/2019,24/01/2023,6,"For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.",19/02/2020,25/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord,CUHVIMMYOGQXCV-NSHDSACASA-N,"InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1",200.285
1273,Human,Teysuno,Stomach Neoplasms,"tegafur, gimeracil, oteracil",TEGAFUR,EMEA/H/C/001242,no,Authorised,L01BC53,no,no,no,no,no,no,14/03/2011,,Nordic Group B.V.,Antineoplastic agents,,24/01/2022,21,"Teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.",07/03/2018,04/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno,WFWLQNSHRPWKFK-UHFFFAOYSA-N,"InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)",200.16899999999998
739,Human,Galafold,Fabry Disease,migalastat,MIGALASTAT HYDROCHLORIDE,EMEA/H/C/004059,no,Authorised,A16AX,yes,no,no,no,no,yes,25/05/2016,,Amicus Therapeutics Europe Limited,migalastat,30/03/2016,26/04/2023,16,Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (?-galactosidase A deficiency) and who have an amenable mutation.,30/04/2018,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/galafold,ZJIHMALTJRDNQI-OLALXQGDSA-N,"InChI=1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5+,6-;/m1./s1",199.63400000000001
744,Human,Trisenox,"Leukemia, Promyelocytic, Acute",arsenic trioxide,ARSENIC TRIOXIDE,EMEA/H/C/000388,no,Authorised,L01XX27,no,no,no,no,no,no,05/03/2002,,Teva B.V.,Antineoplastic agents,,25/05/2023,31,"Trisenox is indicated for induction of remission, and consolidation in adult patients with:Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/µl) in combination with all?trans?retinoic acid (ATRA)Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.",07/12/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox,MOQADKPFYVWPSE-UHFFFAOYSA-N,InChI=1S/As2O3/c3-1-2(4)5,197.84099999999998
876,Human,Arsenic trioxide Mylan,"Leukemia, Promyelocytic, Acute",arsenic trioxide,ARSENIC TRIOXIDE,EMEA/H/C/005235,no,Authorised,L01XX27,no,yes,no,no,no,no,01/04/2020,,Mylan Ireland Limited,Antineoplastic agents,30/01/2020,24/03/2023,4,"Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with:- Newly diagnosed low to intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/?l) in combination with all trans retinoic acid (ATRA)- Relapsed/refractory acute promyelocytic leukaemia (APL) (Previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RAR alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not beenexamined.",17/04/2020,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-mylan,MOQADKPFYVWPSE-UHFFFAOYSA-N,InChI=1S/As2O3/c3-1-2(4)5,197.84099999999998
1251,Human,Arsenic trioxide Accord,"Leukemia, Promyelocytic, Acute",arsenic trioxide,ARSENIC TRIOXIDE,EMEA/H/C/005175,no,Authorised,L01XX27,no,yes,no,no,no,no,14/11/2019,,Accord Healthcare S.L.U.,Antineoplastic agents,19/09/2019,10/05/2022,5,"Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/?l) in combination with all-trans-retinoic acid (ATRA)Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.",26/11/2019,12/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-accord,MOQADKPFYVWPSE-UHFFFAOYSA-N,InChI=1S/As2O3/c3-1-2(4)5,197.84099999999998
1257,Human,Arsenic trioxide medac,"Leukemia, Promyelocytic, Acute",arsenic trioxide,ARSENIC TRIOXIDE,EMEA/H/C/005218,no,Authorised,L01XX27,no,yes,no,no,no,no,17/09/2020,,medac Gesellschaft für klinische Spezialpräparate mbH,Antineoplastic agents,23/07/2020,22/04/2022,2,"Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 10³/?l) in combination with all-trans-retinoic acid (ATRA)Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR?) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.",01/10/2020,26/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-medac,MOQADKPFYVWPSE-UHFFFAOYSA-N,InChI=1S/As2O3/c3-1-2(4)5,197.84099999999998
793,Human,Inbrija,Parkinson Disease,levodopa,LEVODOPA,EMEA/H/C/004786,no,Authorised,N04BA01,no,no,no,no,no,no,19/09/2019,,Acorda Therapeutics Ireland Limited,Anti-Parkinson drugs,25/07/2019,28/04/2023,5,Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.,30/09/2019,02/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",197.18999999999997
943,Human,Stalevo,Parkinson Disease,"levodopa, carbidopa, entacapone",LEVODOPA,EMEA/H/C/000511,no,Authorised,N04BA03,no,no,no,no,no,no,17/10/2003,,Orion Corporation,Anti-Parkinson drugs,,12/01/2023,29,Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",197.18999999999997
998,Human,Levodopa/Carbidopa/Entacapone Orion,Parkinson Disease,"levodopa, carbidopa, entacapone",LEVODOPA,EMEA/H/C/002441,no,Authorised,N04BA03,no,no,no,no,no,no,23/08/2011,,Orion Corporation,Nervous system,,12/01/2023,13,Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levodopa-carbidopa-entacapone-orion,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",197.18999999999997
1002,Human,Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz),Parkinson Disease,"levodopa, carbidopa, entacapone",LEVODOPA,EMEA/H/C/002785,no,Authorised,N04BA03,no,no,no,no,no,no,11/11/2013,,Orion Corporation,Anti-Parkinson drugs,19/09/2013,12/01/2023,10,Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.,06/07/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/corbilta,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",197.18999999999997
1746,Human,Numient,Parkinson Disease,"levodopa, carbidopa",LEVODOPA,EMEA/H/C/002611,no,Withdrawn,N04BA02,no,no,no,no,no,no,19/11/2015,,Amneal Pharma Europe Ltd,Anti-Parkinson drugs,24/09/2015,03/08/2018,3,Symptomatic treatment of adult patients with Parkinson’s disease,03/08/2018,09/08/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/numient,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",197.18999999999997
1345,Human,Ytracis,Radionuclide Imaging,yttrium [90Y] chloride,YTTRIUM (90Y) CHLORIDE,EMEA/H/C/000460,no,Withdrawn,V09,no,no,no,no,no,no,24/03/2003,,CIS bio international,Diagnostic radiopharmaceuticals,,29/05/2015,7,To be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.Radiopharmaceutical precursor - Not intended for direct application to patients.,29/05/2015,19/01/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ytracis,PCMOZDDGXKIOLL-SGNQUONSSA-K,InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3/i;;;1+1,196.2661519
1576,Human,Yttriga,Radionuclide Imaging,yttrium [90Y] chloride,YTTRIUM (90Y) CHLORIDE,EMEA/H/C/000596,no,Authorised,V09,no,no,no,no,no,no,19/01/2006,,Eckert  Ziegler Radiopharma GmbH,Diagnostic radiopharmaceuticals,15/09/2005,18/12/2020,10,"To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.Radiopharmaceutical precursor - Not intended for direct use in patients.",21/07/2014,29/01/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/yttriga,PCMOZDDGXKIOLL-SGNQUONSSA-K,InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3/i;;;1+1,196.2661519
2010,Human,Theryttrex,Radionuclide Imaging,yttrium [90Y] chloride,YTTRIUM (90Y) CHLORIDE,EMEA/H/C/000445,no,Withdrawn,V09,no,no,no,no,no,no,07/01/2003,,MDS Nordion S.A.,Diagnostic radiopharmaceuticals,,02/02/2006,1,To be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.Radiopharmaceutical precursor - Not intended for direct application to patients.,02/02/2006,02/03/2006,https://www.ema.europa.eu/en/medicines/human/EPAR/theryttrex,PCMOZDDGXKIOLL-SGNQUONSSA-K,InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3/i;;;1+1,196.2661519
644,Human,Temozolomide Accord,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/001125,no,Authorised,L01AX03,no,yes,no,no,no,no,15/03/2010,,Accord Healthcare S.L.U.,Antineoplastic agents,17/12/2009,26/06/2023,23,"For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",23/05/2018,27/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
675,Human,Temodal,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/000229,no,Authorised,L01AX03,no,no,no,no,no,no,26/01/1999,,Merck Sharp & Dohme B.V. ,Antineoplastic agents,,16/06/2023,37,"Temodal hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",23/08/2018,20/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/temodal,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
920,Human,Temozolomide Sandoz,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/001128,no,Withdrawn,L01AX03,no,yes,no,no,no,no,15/03/2010,,Sandoz GmbH,Antineoplastic agents,,15/09/2022,17,"For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",06/07/2018,06/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-sandoz,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
928,Human,Temozolomide Hexal,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/001127,no,Withdrawn,L01AX03,no,yes,no,no,no,no,15/03/2010,,Hexal AG,Antineoplastic agents,,15/09/2022,17,"For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",19/06/2018,27/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-hexal,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
1280,Human,Temomedac,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/001124,no,Authorised,L01AX03,no,yes,no,no,no,no,25/01/2010,,medac Gesellschaft für klinische Spezialpräparate mbH,Antineoplastic agents,19/11/2009,25/03/2022,15,"Temomedac hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",01/06/2018,28/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temomedac,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
1291,Human,Temozolomide Sun,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/002198,no,Authorised,L01AX03,no,yes,no,no,no,no,13/07/2011,,Sun Pharmaceutical Industries Europe B.V.,Antineoplastic agents,,15/03/2022,19,"Temozolomide Sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",03/08/2018,17/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-sun,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
1311,Human,Temozolomide Teva,Glioma;  Glioblastoma,temozolomide,TEMOZOLOMIDE,EMEA/H/C/001126,no,Authorised,L01AX03,no,yes,no,no,no,no,28/01/2010,,Teva B.V. ,Antineoplastic agents,,18/02/2022,21,"For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.",23/05/2018,18/02/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-teva,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",194.154
554,Human,Carbaglu,"Amino Acid Metabolism, Inborn Errors;  Propionic Acidemia",carglumic acid,CARGLUMIC ACID,EMEA/H/C/000461,no,Authorised,A16AA05,no,no,no,no,no,no,24/01/2003,,Recordati Rare Diseases,"Other alimentary tract and metabolism products, ",,22/06/2023,19,Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.,04/07/2018,19/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu,LCQLHJZYVOQKHU-VKHMYHEASA-N,"InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1",190.155
1204,Human,Ucedane,"Hyperammonemia;  Amino Acid Metabolism, Inborn Errors",carglumic acid,CARGLUMIC ACID,EMEA/H/C/004019,no,Authorised,A16AA05,no,yes,no,no,no,no,23/06/2017,,Eurocept International BV,"Other alimentary tract and metabolism products, ",21/04/2017,05/07/2022,11,Ucedane is indicated in treatment of:hyperammonaemia due to N-acetylglutamate synthase primary deficiency;Hyperammonaemia due to isovaleric acidaemia;Hyperammonaemia due to methymalonic acidaemia;Hyperammonaemia due to propionic acidaemia.,19/07/2017,06/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ucedane,LCQLHJZYVOQKHU-VKHMYHEASA-N,"InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1",190.155
217,Human,Thiotepa Riemser,Hematopoietic Stem Cell Transplantation;  Neoplasms,thiotepa,THIOTEPA,EMEA/H/C/005434,no,Authorised,L01AC01,no,yes,no,no,no,no,26/03/2021,,Esteve Pharmaceuticals GmbH,Antineoplastic agents,28/01/2021,18/10/2023,4,"Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients",30/04/2021,23/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/thiotepa-riemser,FOCVUCIESVLUNU-UHFFFAOYSA-N,"InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2",189.22400000000002
864,Human,Tepadina,Hematopoietic Stem Cell Transplantation,thiotepa,THIOTEPA,EMEA/H/C/001046,no,Authorised,L01AC01,no,no,no,no,no,no,15/03/2010,,ADIENNE S.r.l. S.U.,Antineoplastic agents,17/12/2009,28/03/2023,19,"In combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients."". It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.",29/11/2017,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tepadina,FOCVUCIESVLUNU-UHFFFAOYSA-N,"InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2",189.22400000000002
637,Human,Luminity,Echocardiography,perflutren,PERFLUTREN,EMEA/H/C/000654,no,Authorised,V08DA04,no,no,no,no,no,no,20/09/2006,,Lantheus EU Limited,Contrast media,27/07/2006,01/06/2023,17,"This medicinal product is for diagnostic use only.Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.",04/05/2018,28/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/luminity,QYSGYZVSCZSLHT-UHFFFAOYSA-N,"InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11",188.017
1218,Human,Optison,Echocardiography,perflutren,PERFLUTREN,EMEA/H/C/000166,no,Authorised,V08DA01,no,no,no,no,no,no,17/05/1998,,GE Healthcare AS,Contrast media,,19/05/2022,19,"This medicinal product is for diagnostic use only.Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.Optison should only be used in patients where the study without contrast enhancement is inconclusive.",08/05/2014,27/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/optison,QYSGYZVSCZSLHT-UHFFFAOYSA-N,"InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11",188.017
1033,Human,Ammonaps,Ornithine Carbamoyltransferase Deficiency Disease;  Citrullinemia;  Carbamoyl-Phosphate Synthase I Deficiency Disease,sodium phenylbutyrate,SODIUM PHENYLBUTYRATE,EMEA/H/C/000219,no,Authorised,A16AX03,no,no,no,no,no,no,07/12/1999,,Immedica Pharma AB,"Other alimentary tract and metabolism products, ",,12/12/2022,21,"Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.",28/06/2017,16/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps,VPZRWNZGLKXFOE-UHFFFAOYSA-M,"InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1",186.18599999999998
1378,Human,Pheburane,Carbamoyl-Phosphate Synthase I Deficiency Disease,sodium phenylbutyrate,SODIUM PHENYLBUTYRATE,EMEA/H/C/002500,no,Authorised,A16AX03,no,no,no,no,no,no,30/07/2013,,Eurocept International B. V.,Various alimentary tract and metabolism products,21/02/2013,10/12/2021,10,Treatment of chronic management of urea-cycle disorders.,20/07/2017,13/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane,VPZRWNZGLKXFOE-UHFFFAOYSA-M,"InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1",186.18599999999998
58,Human,Pirfenidone Viatris,Idiopathic Pulmonary Fibrosis;  Lung Diseases;  Respiratory Tract Diseases,pirfenidone,PIRFENIDONE,EMEA/H/C/005862,no,Authorised,L04AX05,no,yes,no,no,no,no,10/01/2023,,Viatris Limited,Immunosuppressants,10/11/2022,20/11/2023,1,Pirfenidone Viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).,04/11/2022,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-viatris,ISWRGOKTTBVCFA-UHFFFAOYSA-N,"InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",185.22599999999997
410,Human,Esbriet,Idiopathic Pulmonary Fibrosis;  Lung Diseases;  Respiratory Tract Diseases,pirfenidone,PIRFENIDONE,EMEA/H/C/002154,no,Authorised,L04AX05,no,no,no,no,no,no,27/02/2011,,Roche Registration GmbH,Immunosuppressants,16/12/2010,24/03/2023,33,Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.,17/04/2018,08/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet,ISWRGOKTTBVCFA-UHFFFAOYSA-N,"InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",185.22599999999997
441,Human,Pirfenidone axunio (previously Pirfenidone AET),Idiopathic Pulmonary Fibrosis,pirfenidone,PIRFENIDONE,EMEA/H/C/005873,no,Authorised,L04AX05,no,yes,no,no,no,no,20/06/2022,,Axunio Pharma GmbH,Immunosuppressants,22/04/2022,26/07/2023,3,Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).,28/06/2022,25/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-axunio-previously-pirfenidone-aet,ISWRGOKTTBVCFA-UHFFFAOYSA-N,"InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",185.22599999999997
826,Human,Ceplene,"Leukemia, Myeloid, Acute",histamine dihydrochloride,HISTAMINE DIHYDROCHLORIDE,EMEA/H/C/000796,no,Authorised,L03AX14,yes,no,no,yes,no,no,07/10/2008,,Laboratoires Delbert,"Immunostimulants, ",,09/09/2022,12,Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.,26/07/2018,19/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene,PPZMYIBUHIPZOS-UHFFFAOYSA-N,"InChI=1S/C5H9N3.2ClH/c6-2-1-5-3-7-4-8-5;;/h3-4H,1-2,6H2,(H,7,8);2*1H",184.07000000000005
1217,Human,Bronchitol,Cystic Fibrosis,mannitol,MANNITOL,EMEA/H/C/001252,no,Authorised,R05CB16,no,no,no,no,no,no,13/04/2012,,Pharmaxis Europe Limited,Cough and cold preparations,,24/06/2022,19,Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.,08/08/2018,27/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol,FBPFZTCFMRRESA-KVTDHHQDSA-N,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1",182.172
1132,Human,Vaniqa,Hirsutism,eflornithine,EFLORNITHINE,EMEA/H/C/000325,no,Authorised,D11AX,no,no,no,no,no,no,19/03/2001,,"Almirall, S.A.",Other dermatological preparations,,26/09/2022,23,Treatment of facial hirsutism in women.,05/04/2017,26/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa,VLCYCQAOQCDTCN-UHFFFAOYSA-N,"InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)",182.17
310,Human,Clopidogrel / Acetylsalicylic acid Mylan,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",ACETYLSALICYLIC ACID,EMEA/H/C/004996,no,Authorised,B01AC30,no,yes,no,no,no,no,09/01/2020,,Mylan Pharmaceuticals Limited,Antithrombotic agents,14/11/2019,22/09/2023,5,Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).Clopidogrel/Acetylsalicylic acid Mylan is a fixed-dose combination medicinal product for continuation of therapy in:Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy,24/01/2020,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acetylsalicylic-acid-mylan,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",180.159
600,Human,DuoPlavin,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",ACETYLSALICYLIC ACID,EMEA/H/C/001143,no,Authorised,B01AC30,no,no,no,no,no,no,14/03/2010,,Sanofi Winthrop Industrie,Antithrombotic agents,17/12/2009,30/06/2023,30,DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI);ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.For further information please refer to section 5.1.,18/01/2018,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duoplavin-0,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",180.159
1676,Human,Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover),Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",ACETYLSALICYLIC ACID,EMEA/H/C/001144,no,Authorised,B01AC30,no,no,no,no,no,no,14/03/2010,,Sanofi-Aventis Groupe,Antithrombotic agents,,19/09/2019,22,Acute Coronary SyndromeMyocardial Infarction,18/01/2018,13/11/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acetylsalicylic-acid-zentiva-previously-duocover,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",180.159
1797,Human,Clopidogrel/Acetylsalicylic acid Teva,Acute Coronary Syndrome;  Myocardial Infarction,"clopidogrel, acetylsalicylic acid",ACETYLSALICYLIC ACID,EMEA/H/C/002272,no,Withdrawn,B01AC30,no,no,no,no,no,no,01/09/2014,,Teva Pharma B.V.,combinations,26/06/2014,03/06/2016,1,Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed?dose combination medicinal product for continuation of therapy in:Non?ST segment elevation acute coronary syndrome (unstable angina or non?Q?wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy,03/06/2016,28/04/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrelacetylsalicylic-acid-teva,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",180.159
463,Human,Nemdatine,Alzheimer Disease,memantine,MEMANTINE,EMEA/H/C/002680,no,Authorised,N06DX01,no,yes,no,no,no,no,22/04/2013,22/02/2013,Actavis Group PTC ehf.,"Psychoanaleptics, , Other anti-dementia drugs",21/02/2013,14/08/2023,13,Treatment of patients with moderate to severe Alzheimer’s disease.,08/01/2018,17/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/nemdatine,BUGYDGFZZOZRHP-UHFFFAOYSA-N,"InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3",179.307
458,Human,Azilect,Parkinson Disease,rasagiline,RASAGILINE,EMEA/H/C/000574,no,Authorised,N04BD02,no,no,no,no,no,no,21/02/2005,,Teva B.V.,Anti-Parkinson drugs,14/08/2023,14/08/2023,23,Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.,21/06/2018,18/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/azilect,RUOKEQAAGRXIBM-GFCCVEGCSA-N,"InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1",171.24300000000002
1414,Human,Rasagiline ratiopharm,Parkinson Disease,rasagiline,RASAGILINE,EMEA/H/C/003957,no,Authorised,N04BD02,no,no,no,no,no,no,12/01/2015,,Teva B.V.,Anti-Parkinson drugs,20/11/2014,21/10/2021,8,Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.,21/06/2018,05/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-ratiopharm,RUOKEQAAGRXIBM-GFCCVEGCSA-N,"InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1",171.24300000000002
344,Human,Levetiracetam Sun,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002051,no,Authorised,N03AX14,no,yes,no,no,no,no,14/12/2011,,Sun Pharmaceutical Industries Europe B.V.,Other antiepileptics,20/10/2011,19/09/2023,19,Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. ,24/07/2018,22/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
603,Human,Levetiracetam Hospira,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002783,no,Authorised,N03AX14,no,yes,no,no,no,no,07/01/2014,,Pfizer Europe MA EEIG,"Antiepileptics, ",23/10/2013,05/07/2023,24,"Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.",01/11/2017,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-hospira,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
635,Human,Matever,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002024,no,Authorised,N03AX14,no,yes,no,no,no,no,03/10/2011,,Pharmathen S.A.,"Antiepileptics, ",,27/06/2023,27,"Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",02/07/2018,29/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/matever,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
650,Human,Levetiracetam ratiopharm,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002244,no,Authorised,N03AX14,no,yes,no,no,no,no,26/08/2011,,ratiopharm GmbH,"Antiepileptics, ",,22/06/2023,15,"Levetiracetam ratiopharm is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam ratiopharm is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. ",10/08/2017,26/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-ratiopharm,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
664,Human,Levetiracetam Actavis,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002355,no,Authorised,N03AX14,no,yes,no,no,no,no,03/10/2011,,Actavis Group PTC ehf,"Antiepileptics, ",,21/06/2023,19,"Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",21/03/2018,22/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-actavis,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
666,Human,Levetiracetam Actavis Group,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002305,no,Authorised,N03AX14,no,yes,no,no,no,no,04/12/2011,,Actavis Group PTC ehf,"Antiepileptics, ",,21/06/2023,18,"Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis Group is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",20/03/2018,22/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-actavis-group,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
671,Human,Levetiracetam Teva,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002316,no,Authorised,N03AX14,no,yes,no,no,no,no,25/08/2011,,Teva B.V.,Nervous system,19/05/2011,19/06/2023,20,"Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Teva is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",31/01/2018,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-teva,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
673,Human,Levetiracetam Accord,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/002290,no,Authorised,N03AX14,no,yes,no,no,no,no,03/10/2011,,Accord Healthcare S.L.U.,"Antiepileptics, ",21/07/2011,20/06/2023,16,"Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",29/06/2018,21/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-accord,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
889,Human,Keppra,Epilepsy,levetiracetam,LEVETIRACETAM,EMEA/H/C/000277,no,Authorised,N03AX14,no,no,no,no,no,no,29/09/2000,,UCB Pharma SA,"Antiepileptics, ",29/06/2000,23/02/2023,53,"Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",26/04/2018,22/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/keppra,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",170.212
740,Human,Xaluprine (previously Mercaptopurine Nova Laboratories),"Leukemia, Lymphoid",mercaptopurine,6-MERCAPTOPURINE MONOHYDRATE,EMEA/H/C/002022,no,Authorised,L01BB02,no,no,no,no,no,no,09/03/2012,,Nova Laboratories Ireland Limited,Antineoplastic agents,21/07/2011,17/05/2023,15,"Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.",13/07/2017,25/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine,WFFQYWAAEWLHJC-UHFFFAOYSA-N,"InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2",170.197
795,Human,Gliolan,Glioma,5-aminolevulinic acid hydrochloride,5-AMINOLEVULINIC ACID HYDROCHLORIDE,EMEA/H/C/000744,no,Authorised,L01XD04,no,no,no,no,no,no,07/09/2007,,Photonamic GmbH & Co. KG,Antineoplastic agents,21/06/2007,28/04/2023,8,Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV).,19/07/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan,ZLHFONARZHCSET-UHFFFAOYSA-N,"InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H",167.592
1283,Human,Ameluz,"Keratosis, Actinic;  Carcinoma, Basal Cell",5-aminolevulinic acid hydrochloride,5-AMINOLEVULINIC ACID HYDROCHLORIDE,EMEA/H/C/002204,no,Authorised,L01XD04,no,no,no,no,no,no,13/12/2011,,Biofrontera Bioscience GmbH,Antineoplastic agents,20/10/2011,22/03/2022,19,Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.,24/07/2018,23/03/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/ameluz,ZLHFONARZHCSET-UHFFFAOYSA-N,"InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H",167.592
40,Human,Omidria,"Lens Implantation, Intraocular;  Pain, Postoperative","phenylephrine, ketorolac",PHENYLEPHRINE,EMEA/H/C/003702,no,Authorised,S01,no,no,no,no,no,no,28/07/2015,,Rayner Surgical (Ireland) Limited,Ophthalmologicals,21/05/2015,24/11/2023,9,"Omidria is indicated in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.",31/01/2018,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/omidria,SONNWYBIRXJNDC-VIFPVBQESA-N,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",167.208
150,Human,Velmetia,"Diabetes Mellitus, Type 2","sitagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000862,no,Authorised,A10BD07,no,no,no,no,no,no,16/07/2008,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,24/04/2008,09/11/2023,37,For patients with type-2 diabetes mellitus:Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.,29/06/2018,09/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/velmetia,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
466,Human,Competact,"Diabetes Mellitus, Type 2","pioglitazone, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000655,no,Authorised,A10BD05,no,no,no,no,no,no,28/07/2006,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,11/08/2023,21,"Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.",12/12/2016,16/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/competact,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
494,Human,Ristfor,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/001235,no,Authorised,A10BD07,no,no,no,no,no,no,15/03/2010,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,17/12/2009,01/08/2023,27,For patients with type-2 diabetes mellitus:Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPAR?) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.,29/06/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ristfor,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
495,Human,Efficib,"Diabetes Mellitus, Type 2","sitagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000896,no,Authorised,A10BD07,no,no,no,no,no,no,15/07/2008,,Merck Sharp and Dohme B.V,Drugs used in diabetes,24/04/2008,01/08/2023,33,"For patients with type-2 diabetes mellitus:Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",22/05/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/efficib,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
496,Human,Janumet,"Diabetes Mellitus, Type 2","sitagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000861,no,Authorised,A10BD07,no,no,no,no,no,no,16/07/2008,18/02/2009,Merck Sharp & Dohme B.V.,Drugs used in diabetes,24/04/2008,01/08/2023,30,"For patients with type 2 diabetes mellitus:Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Janumet is indicated as triple combination therapy with a PPAR  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR  agonist.Janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",29/06/2018,04/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/janumet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
499,Human,Ebymect,"Diabetes Mellitus, Type 2","dapagliflozin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/004162,no,Authorised,A10BD15,no,no,no,no,no,no,15/11/2015,,AstraZeneca AB,Drugs used in diabetes,23/09/2015,30/05/2023,20,"Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ? 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.",20/12/2017,03/08/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
518,Human,Vokanamet,"Diabetes Mellitus, Type 2","canagliflozin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/002656,no,Authorised,A10BD16,no,no,no,no,no,no,23/04/2014,,Janssen-Cilag International NV,Drugs used in diabetes,,15/06/2023,22,"Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated doses of metformin alonein patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.in patients already being treated with the combination of canagliflozin and metformin as separate tabletsFor study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",15/03/2018,28/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
592,Human,Vipdomet,"Diabetes Mellitus, Type 2","alogliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/002654,no,Authorised,A10BD13,no,no,no,no,no,no,18/09/2013,,Takeda Pharma A/S,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/07/2013,07/09/2022,11,"Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.",16/10/2017,11/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
703,Human,Segluromet,"Diabetes Mellitus, Type 2","ertugliflozin, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/004314,no,Authorised,A10BD23,no,no,no,no,no,no,23/03/2018,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",25/01/2018,14/04/2023,7,Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.,26/04/2018,07/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
714,Human,Vildagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2",vildagliptin / metformin hydrochloride,METFORMIN HYDROCHLORIDE,EMEA/H/C/005738,no,Authorised,A10BD08,yes,yes,no,no,no,no,24/03/2022,,Accord Healthcare S.L.U.,Drugs used in diabetes,16/12/2021,01/06/2023,2,"Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone.- in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",14/12/2021,01/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
729,Human,Xigduo,"Diabetes Mellitus, Type 2","dapagliflozin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/002672,no,Authorised,A10BD15,no,no,no,no,no,no,16/01/2014,,AstraZeneca AB,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",20/11/2013,30/05/2023,21,"Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:•    in patients insufficiently controlled on their maximally tolerated dose of metformin alone •    in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products•    in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",20/12/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xigduo,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
731,Human,Komboglyze,"Diabetes Mellitus, Type 2","saxagliptin, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/002059,no,Authorised,A10BD10,no,no,no,no,no,no,24/11/2011,,AstraZeneca AB ,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,30/05/2023,20,Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.,26/06/2017,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
732,Human,Sitagliptin / Metformin hydrochloride Mylan,"Diabetes Mellitus, Type 2","sitagliptin hydrochloride monohydrate, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/005678,no,Authorised,A10BD07,no,yes,no,no,no,no,16/02/2022,,Mylan Ireland Limited,Drugs used in diabetes,16/12/2021,29/05/2023,2,"For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride Mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride Mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride Mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARg agonist.Sitagliptin/Metformin hydrochloride Mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",14/12/2021,30/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-mylan,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
873,Human,Eucreas,"Diabetes Mellitus, Type 2","vildagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000807,no,Authorised,A10BD08,no,no,no,no,no,no,14/11/2007,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,07/07/2022,23,"Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control",23/04/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/eucreas,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
900,Human,Zomarist,"Diabetes Mellitus, Type 2","vildagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/001049,no,Authorised,A10BD08,no,no,no,no,no,no,30/11/2008,,Novartis Europharm Limited ,Drugs used in diabetes,,14/10/2022,23,"Zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.",21/04/2017,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/zomarist,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
988,Human,Sitagliptin / Metformin hydrochloride Sun,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/005778,no,Authorised,A10BD07,no,yes,no,no,no,no,31/03/2023,,Sun Pharmaceutical Industries Europe B.V.,Drugs used in diabetes,26/01/2023,31/03/2023,,"For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",24/01/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-sun,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
1091,Human,Icandra (previously Vildagliptin / metformin hydrochloride Novartis),"Diabetes Mellitus, Type 2","vildagliptin, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/001050,no,Authorised,A10BD08,no,no,no,no,no,no,30/11/2008,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,14/10/2022,25,"Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",12/04/2018,09/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/icandra-previously-vildagliptin-metformin-hydrochloride-novartis,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
1108,Human,Glubrava,"Diabetes Mellitus, Type 2","pioglitazone, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000893,no,Withdrawn,A10BD05,no,no,no,no,no,no,11/12/2007,,Takeda Pharma A/S,Drugs used in diabetes,,04/02/2021,19,"Glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",10/11/2017,18/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
1147,Human,Sitagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride",METFORMIN HYDROCHLORIDE,EMEA/H/C/005850,no,Authorised,A10BD07,no,yes,no,no,no,no,22/07/2022,,Accord Healthcare S.L.U.,Drugs used in diabetes,19/05/2022,31/08/2022,1,"For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",03/08/2022,01/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-accord,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
1618,Human,Qtrilmet,"Diabetes Mellitus, Type 2","metformin hydrochloride, saxagliptin, dapagliflozin",METFORMIN HYDROCHLORIDE,EMEA/H/C/004910,no,Withdrawn,A10BD,no,no,no,no,no,no,11/11/2019,,AstraZeneca AB,Drugs used in diabetes,19/09/2019,14/08/2020,2,Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.when already being treated with metformin and saxagliptin and dapagliflozin.,10/12/2019,09/10/2020,https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
1817,Human,Avandamet,"Diabetes Mellitus, Type 2","rosiglitazone, metformin",METFORMIN HYDROCHLORIDE,EMEA/H/C/000522,no,Withdrawn,A10BD03,no,no,no,no,no,no,20/10/2003,,SmithKline Beecham Plc,Drugs used in diabetes,,03/12/2010,16,"AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).",03/12/2010,08/06/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/avandamet,OETHQSJEHLVLGH-UHFFFAOYSA-N,"InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H",165.62800000000001
85,Human,Pregabalin Sandoz,Anxiety Disorders;  Neuralgia;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/004010,no,Authorised,N03AX16,no,yes,no,no,no,no,19/06/2015,,Sandoz GmbH,"Antiepileptics, ",23/04/2015,16/11/2023,17,Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,05/02/2018,22/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
254,Human,Pregabalin Sandoz GmbH,Anxiety Disorders;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/004070,no,Withdrawn,N03AX16,no,yes,no,no,no,no,19/06/2015,,Sandoz GmbH,"Antiepileptics, ",23/04/2015,21/09/2023,16,EpilepsyPregabalin Sandoz GmbH is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz GmbH is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,26/01/2018,12/10/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz-gmbh,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
374,Human,Lyrica,Epilepsy;  Anxiety Disorders;  Neuralgia,pregabalin,PREGABALIN,EMEA/H/C/000546,no,Authorised,N03AX16,no,no,no,no,no,no,05/07/2004,,Upjohn EESV,"Antiepileptics, , Other antiepileptics",,15/09/2023,61,Neuropathic painLyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyLyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised anxiety disorderLyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.,16/11/2017,18/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
903,Human,Pregabalin Pfizer,Anxiety Disorders;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/003880,no,Authorised,N03AX16,no,no,no,no,no,no,10/04/2014,,Upjohn EESV,"Antiepileptics, ",20/02/2014,14/03/2023,29,Neuropathic painPregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,30/07/2018,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-pfizer,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
904,Human,Pregabalin Zentiva k.s.,Anxiety Disorders;  Neuralgia;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/004277,no,Withdrawn,N03AX16,no,yes,no,no,no,no,27/02/2017,,Zentiva k.s.,"Antiepileptics, ",15/12/2016,23/02/2023,13,Neuropathic painPregabalin Zentiva k.s. is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Zentiva k.s. is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised anxiety disorderPregabalin Zentiva k.s. is indicated for the treatment of generalised anxiety disorder (GAD) in adults.,18/05/2018,20/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-zentiva-ks,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
973,Human,Pregabalin Zentiva,Anxiety Disorders;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/003900,no,Authorised,N03AX16,no,yes,no,no,no,no,17/07/2015,,"Zentiva, k.s.","Antiepileptics, ",21/05/2015,07/02/2023,15,"Neuropathic pain, , , 	Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults., , , Epilepsy, , , 	Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation., , , Generalised anxiety disorder, , , 	Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults., , ",18/05/2018,09/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-zentiva,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
1003,Human,Pregabalin Mylan,Anxiety Disorders;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/004078,no,Authorised,N03AX16,no,yes,no,no,no,no,24/06/2015,,Mylan Pharmaceuticals Limited,"Antiepileptics, ",22/04/2015,13/01/2023,16,Neuropathic painPregabalin Mylan is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Mylan is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Mylan is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,04/06/2018,13/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
1014,Human,Pregabalin Accord,Anxiety Disorders;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/004024,no,Authorised,N03AX16,no,yes,no,no,no,no,28/08/2015,,Accord Healthcare S.L.U.,"Antiepileptics, ",25/06/2015,09/01/2023,15,EpilepsyPregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,05/02/2018,09/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-accord,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
1256,Human,Pregabalin Mylan Pharma,Anxiety Disorders;  Neuralgia;  Epilepsy,pregabalin,PREGABALIN,EMEA/H/C/003962,no,Withdrawn,N03AX16,no,yes,no,no,no,no,25/06/2015,,Mylan S.A.S.,"Antiepileptics, ",23/04/2015,14/01/2021,7,EpilepsyPregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.,09/03/2018,26/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan-pharma,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",159.229
1273,Human,Teysuno,Stomach Neoplasms,"tegafur, gimeracil, oteracil",OTERACIL,EMEA/H/C/001242,no,Authorised,L01BC53,no,no,no,no,no,no,14/03/2011,,Nordic Group B.V.,Antineoplastic agents,,24/01/2022,21,"Teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.",07/03/2018,04/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno,RYYCJUAHISIHTL-UHFFFAOYSA-N,"InChI=1S/C4H3N3O4/c8-2(9)1-5-3(10)7-4(11)6-1/h(H,8,9)(H2,5,6,7,10,11)",157.08499999999998
401,Human,Ledaga,Mycosis Fungoides,chlormethine,CHLORMETHINE,EMEA/H/C/002826,no,Authorised,L01AA05,no,no,no,no,no,yes,03/03/2017,,Helsinn Birex Pharmaceuticals Ltd.,Antineoplastic agents,15/12/2016,07/09/2023,9,Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.,20/11/2017,11/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga,HAWPXGHAZFHHAD-UHFFFAOYSA-N,"InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3",156.056
802,Human,Granupas (previously Para-aminosalicylic acid Lucane),Tuberculosis,para-aminosalicylic acid,PARA-AMINOSALICYLIC ACID,EMEA/H/C/002709,no,Authorised,J04AA01,no,no,no,no,no,yes,07/04/2014,,Eurocept International B. V.,Antimycobacterials,21/11/2013,18/04/2023,11,Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents.,29/06/2018,26/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/granupas-previously-para-aminosalicylic-acid-lucane,WUBBRNOQWQTFEX-UHFFFAOYSA-N,"InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)",153.137
705,Human,SonoVue,Ultrasonography;  Echocardiography,sulphur hexafluoride,SULPHUR HEXAFLUORIDE,EMEA/H/C/000303,no,Authorised,V08DA04,no,no,no,no,no,no,26/03/2001,,Bracco International B.V.,Contrast media,,10/11/2022,20,"This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography.",26/04/2018,05/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue,SFZCNBIFKDRMGX-UHFFFAOYSA-N,"InChI=1S/F6S/c1-7(2,3,4,5)6",146.055
1273,Human,Teysuno,Stomach Neoplasms,"tegafur, gimeracil, oteracil",GIMERACIL,EMEA/H/C/001242,no,Authorised,L01BC53,no,no,no,no,no,no,14/03/2011,,Nordic Group B.V.,Antineoplastic agents,,24/01/2022,21,"Teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.",07/03/2018,04/04/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno,ZPLQIPFOCGIIHV-UHFFFAOYSA-N,"InChI=1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)",145.545
364,Human,Tecfidera,Multiple Sclerosis,dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/002601,no,Authorised,L04AX07,no,no,no,no,no,no,30/01/2014,,Biogen Netherlands B.V.,Immunosuppressants,21/03/2013,15/09/2023,28,Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).,09/11/2017,20/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
407,Human,Dimethyl fumarate Mylan,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/005956,no,Authorised,L04AX07,no,yes,no,no,no,no,13/05/2022,,Mylan Ireland Limited,Immunosuppressants,24/02/2022,05/09/2023,4,Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.,22/02/2022,08/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-mylan,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
632,Human,Dimethyl fumarate Polpharma,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/005955,no,Authorised,L04AX07,no,yes,no,no,no,no,13/05/2022,,Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.,Immunosuppressants,24/02/2022,30/06/2023,4,Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.,22/02/2022,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-polpharma,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
836,Human,Dimethyl fumarate Neuraxpharm,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/006039,no,Authorised,L04AX07,no,yes,no,no,no,no,13/05/2022,,Laboratorios Lesvi S.L.,Immunosuppressants,24/02/2022,12/04/2023,4,Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.,22/02/2022,13/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
947,Human,Dimethyl fumarate Accord,"Multiple Sclerosis, Relapsing-Remitting;  Multiple Sclerosis",dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/005950,no,Authorised,L04AX07,no,yes,no,no,no,no,15/02/2023,,Accord Healthcare S.L.U.,Immunosuppressants,13/10/2022,15/02/2023,,Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).,22/02/2023,,https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-accord,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
1022,Human,Dimethyl fumarate Teva,"Multiple Sclerosis, Relapsing-Remitting;  Multiple Sclerosis",dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/005963,no,Authorised,L04AX07,no,yes,no,no,no,no,12/12/2022,,Teva GmbH,Immunosuppressants,13/10/2022,12/12/2022,,Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).,12/10/2022,21/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-teva,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
1130,Human,Skilarence,Psoriasis,dimethyl fumarate,DIMETHYL FUMARATE,EMEA/H/C/002157,no,Authorised,L04AX07,no,no,no,no,no,no,23/06/2017,,Almirall S.A,Immunosuppressants,21/04/2017,22/09/2022,11,Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.,20/06/2018,27/09/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",144.126
930,Human,Ferriprox,beta-Thalassemia;  Iron Overload,deferiprone,DEFERIPRONE,EMEA/H/C/000236,no,Authorised,V03AC02,no,no,no,no,no,no,25/08/1999,,Chiesi Farmaceutici S.p.A.,All other therapeutic products,,30/09/2022,32,"Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.",04/07/2017,27/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox,TZXKOCQBRNJULO-UHFFFAOYSA-N,"InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3",139.15400000000002
1196,Human,Deferiprone Lipomed,Iron Overload;  beta-Thalassemia,deferiprone,DEFERIPRONE,EMEA/H/C/004710,no,Authorised,V03AC02,no,yes,no,no,no,no,19/09/2018,,Lipomed GmbH,All other therapeutic products,26/07/2018,26/06/2023,7,"Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.",27/07/2018,14/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/deferiprone-lipomed,TZXKOCQBRNJULO-UHFFFAOYSA-N,"InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3",139.15400000000002
1630,Human,Duzallo,Gout,"allopurinol, lesinurad",ALLOPURINOL,EMEA/H/C/004412,no,Withdrawn,M04AA51,yes,no,no,no,no,no,23/08/2018,,Grunenthal GmbH,Antigout preparations,28/06/2019,31/07/2019,2,Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.,06/08/2020,,https://www.ema.europa.eu/en/medicines/human/EPAR/duzallo,OFCNXPDARWKPPY-UHFFFAOYSA-N,"InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)",136.114
1210,Human,Cuprymina,Radionuclide Imaging,copper (64Cu) chloride,COPPER (64CU) CHLORIDE,EMEA/H/C/002136,no,Authorised,Not yet assigned,no,no,no,no,no,no,23/08/2012,,A.C.O.M. - Advanced Center Oncology,Various diagnostic radiopharmaceuticals,,01/07/2022,8,"Cuprymina is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.",30/04/2018,01/07/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/cuprymina,ORTQZVOHEJQUHG-OUMJLSBWSA-L,InChI=1S/2ClH.Cu/h2*1H;/q;;+2/p-2/i;;1+0,134.452
307,Human,Synjardy,"Diabetes Mellitus, Type 2","empagliflozin, metformin",METFORMIN,EMEA/H/C/003770,no,Authorised,A10BD20,no,no,no,no,no,no,27/05/2015,,Boehringer Ingelheim,Drugs used in diabetes,26/03/2015,30/08/2023,26,"Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets. ",31/05/2018,27/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/synjardy,XZWYZXLIPXDOLR-UHFFFAOYSA-N,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",129.167
699,Human,Jentadueto,"Diabetes Mellitus, Type 2","linagliptin, metformin hydrochloride",METFORMIN,EMEA/H/C/002279,no,Authorised,A10BD11,no,no,no,no,no,no,19/07/2012,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,,02/03/2023,21,"Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.",20/07/2018,07/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto,XZWYZXLIPXDOLR-UHFFFAOYSA-N,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",129.167
1400,Human,Kigabeq,"Spasms, Infantile;  Epilepsies, Partial",vigabatrin,VIGABATRIN,EMEA/H/C/004534,no,Authorised,N03AG04,no,no,no,no,no,no,20/09/2018,,ORPHELIA Pharma SAS,"Antiepileptics, ",28/06/2018,09/11/2021,5,"Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.",27/07/2018,22/11/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq,PJDFLNIOAUIZSL-UHFFFAOYSA-N,"InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)",129.159
620,Human,Xyrem,Cataplexy;  Narcolepsy,sodium oxybate,SODIUM OXYBATE,EMEA/H/C/000593,no,Authorised,N07XX04,no,no,no,no,no,no,13/10/2005,,UCB Pharma Ltd,Other nervous system drugs,,11/10/2022,36,Treatment of narcolepsy with cataplexy in adult patients.,13/08/2018,05/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem,XYGBKMMCQDZQOZ-UHFFFAOYSA-M,"InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1",126.08699999999997
1886,Human,Trevaclyn,Dyslipidemias,"laropiprant, nicotinic acid",NICOTINIC ACID,EMEA/H/C/000897,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd,Lipid modifying agents,,10/04/2013,11,"Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/trevaclyn,PVNIIMVLHYAWGP-UHFFFAOYSA-N,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",123.11099999999999
1887,Human,Pelzont,Dyslipidemias,"laropiprant, nicotinic acid",NICOTINIC ACID,EMEA/H/C/000903,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd,Lipid modifying agents,,10/04/2013,11,"Pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Pelzont.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/pelzont,PVNIIMVLHYAWGP-UHFFFAOYSA-N,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",123.11099999999999
1888,Human,Tredaptive,Dyslipidemias,"laropiprant, nicotinic acid",NICOTINIC ACID,EMEA/H/C/000889,no,Withdrawn,C10AD52,no,no,no,no,no,no,03/07/2008,,Merck Sharp  Dohme Ltd.,Lipid modifying agents,,10/04/2013,11,"Tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).Tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Tredaptive.",10/04/2013,16/05/2013,https://www.ema.europa.eu/en/medicines/human/EPAR/tredaptive,PVNIIMVLHYAWGP-UHFFFAOYSA-N,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",123.11099999999999
697,Human,Amversio,Homocystinuria,betaine anhydrous,BETAINE,EMEA/H/C/005637,no,Authorised,A16AA06,no,yes,no,no,no,no,05/05/2022,,SERB SA,"Other alimentary tract and metabolism products, ",24/02/2022,05/05/2022,,"Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (CBS),•         5,10 methylene tetrahydrofolate reductase (MTHFR),•         cobalamin cofactor metabolism (cbl).",21/02/2022,08/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/amversio,KWIUHFFTVRNATP-UHFFFAOYSA-N,"InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3",117.148
1461,Human,Cystadrops,Cystinosis,mercaptamine,MERCAPTAMINE HYDROCHLORIDE,EMEA/H/C/003769,no,Authorised,S01XA21,no,no,no,no,no,yes,18/01/2017,,Recordati Rare Diseases,Ophthalmologicals,,15/09/2021,8,Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.,30/05/2018,20/09/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/cystadrops,OGMADIBCHLQMIP-UHFFFAOYSA-N,"InChI=1S/C2H7NS.ClH/c3-1-2-4;/h4H,1-3H2;1H",113.61299999999999
1239,Human,Firdapse (previously Zenas),Lambert-Eaton Myasthenic Syndrome,amifampridine,AMIFAMPRIDINE,EMEA/H/C/001032,no,Authorised,N07XX05,yes,no,no,yes,no,no,23/12/2009,,SERB SA,Other nervous system drugs,22/10/2009,22/07/2021,21,Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.,13/07/2018,25/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse,OYTKINVCDFNREN-UHFFFAOYSA-N,"InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)",109.132
1253,Human,Fampridine Accord,Multiple Sclerosis,fampridine,FAMPRIDINE,EMEA/H/C/005359,no,Authorised,N07XX07,no,yes,no,no,no,no,24/09/2020,,Accord Healthcare S.L.U.,Other nervous system drugs,23/07/2020,06/05/2022,1,Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). ,02/10/2020,10/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord,NUKYPUAOHBNCPY-UHFFFAOYSA-N,"InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",94.117
1254,Human,Fampyra,Multiple Sclerosis,fampridine,FAMPRIDINE,EMEA/H/C/002097,no,Authorised,N07XX07,no,no,no,no,no,no,20/07/2011,,Biogen Netherlands B.V. ,Other nervous system drugs,,25/04/2022,16,Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4-7).,02/08/2018,05/05/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra,NUKYPUAOHBNCPY-UHFFFAOYSA-N,"InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",94.117
509,Human,Siklos,"Anemia, Sickle Cell",hydroxycarbamide,HYDROXYCARBAMIDE,EMEA/H/C/000689,no,Authorised,L01XX05,no,no,no,no,no,no,29/06/2007,,Theravia,Antineoplastic agents,,26/07/2023,24,Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.,31/05/2018,31/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/siklos,VSNHCAURESNICA-UHFFFAOYSA-N,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",76.055
879,Human,Xromi,"Anemia, Sickle Cell",hydroxycarbamide,HYDROXYCARBAMIDE,EMEA/H/C/004837,no,Authorised,L01XX05,no,no,no,no,no,no,01/07/2019,,Nova Laboratories Ireland Limited,Antineoplastic agents,,06/02/2023,6,Prevention of vaso-occlusive complications of sickle cell disease in patients over 2 years of age,08/07/2019,24/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xromi,VSNHCAURESNICA-UHFFFAOYSA-N,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",76.055
1697,Human,Wilzin,Hepatolenticular Degeneration,zinc,ZINC,EMEA/H/C/000535,no,Authorised,A16AX05,no,no,no,no,no,no,12/10/2004,,Recordati Rare Diseases,"Other alimentary tract and metabolism products, ",,16/05/2019,11,Treatment of Wilson's disease.,14/02/2017,14/06/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/wilzin,HCHKCACWOHOZIP-UHFFFAOYSA-N,InChI=1S/Zn,65.39
821,Human,INOmax,"Hypertension, Pulmonary;  Respiratory Insufficiency",nitric oxide,NITRIC OXIDE,EMEA/H/C/000337,no,Authorised,R07AX,no,no,no,no,no,no,01/08/2001,,Linde Healthcare AB,Other respiratory system products,,18/04/2023,23,"INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ?34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.",22/03/2018,20/04/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/inomax,MWUXSHHQAYIFBG-UHFFFAOYSA-N,InChI=1S/NO/c1-2,30.006
50,Human,Trixeo Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol, glycopyrronium bromide, budesonide",BUDESONIDE,EMEA/H/C/004983,no,Authorised,R03AL,no,no,no,no,no,no,09/12/2020,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",15/10/2020,23/11/2023,5,Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.,05/01/2021,29/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere,,,0
57,Human,Riltrava Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol fumarate dihydrate, glycopyrronium, budesonide",BUDESONIDE,EMEA/H/C/005311,no,Authorised,R03AL11,no,no,no,no,no,no,06/01/2022,,AstraZeneca AB,"Drugs for obstructive airway diseases, ",11/11/2021,23/11/2023,3,Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,10/11/2021,28/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/riltrava-aerosphere,,,0
90,Human,Gavreto,"Carcinoma, Non-Small-Cell Lung",pralsetinib,PRALSETINIB,EMEA/H/C/005413,no,Authorised,L01XE,yes,no,yes,no,no,no,18/11/2021,,Roche Registration GmbH ,Antineoplastic agents,16/09/2021,20/07/2023,6,Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.,14/09/2021,21/11/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto,GBLBJPZSROAGMF-BATDWUPUSA-N,,0
393,Human,Tandemact,"Diabetes Mellitus, Type 2","pioglitazone, glimepiride",GLIMEPIRIDE,EMEA/H/C/000680,no,Authorised,A10BD06,no,no,no,no,no,no,08/01/2007,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,07/09/2023,22,Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.,30/11/2016,13/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact,WIGIZIANZCJQQY-RUCARUNLSA-N,,0
421,Human,Revolade,"Purpura, Thrombocytopenic, Idiopathic",eltrombopag,ELTROMBOPAG,EMEA/H/C/001110,no,Authorised,B02BX05,no,no,no,no,no,no,11/03/2010,,Novartis Europharm Limited,"Other systemic hemostatics, Antihemorrhagics",17/12/2009,17/08/2023,34,"Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1).",06/07/2018,01/09/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/revolade,XDXWLKQMMKQXPV-QYQHSDTDSA-N,,0
584,Human,Ponvory,"Multiple Sclerosis, Relapsing-Remitting",ponesimod,PONESIMOD,EMEA/H/C/005163,no,Authorised,L04AA,yes,no,no,no,no,no,19/05/2021,,Janssen-Cilag International N.V.   ,Immunosuppressants,25/03/2021,04/07/2023,3,Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.,24/03/2021,13/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory,LPAUOXUZGSBGDU-STDDISTJSA-N,,0
604,Human,Tigecycline Accord,"Soft Tissue Infections;  Intraabdominal Infections;  Bacterial Infections;  Skin Diseases, Infectious",tigecycline,TIGECYCLINE,EMEA/H/C/005114,no,Authorised,J01AA12,no,yes,no,no,no,no,17/04/2020,,Accord Healthcare S.L.U.,"Antibacterials for systemic use, ",,06/07/2023,5,"Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)Complicated intra-abdominal infections (cIAI)Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.",24/04/2020,07/07/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord,FPZLLRFZJZRHSY-HJYUBDRYSA-N,,0
629,Human,Cibinqo,"Dermatitis, Atopic",abrocitinib,ABROCITINIB,EMEA/H/C/005452,yes,Authorised,D11AH08,yes,no,no,no,no,no,09/12/2021,,Pfizer Europe MA EEIG ,Other dermatological preparations,14/10/2021,28/06/2023,5,Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.,17/12/2021,30/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo,IUEWXNHSKRWHDY-PHIMTYICSA-N,,0
663,Human,Xerava,Infection;  Bacterial Infections,eravacycline,ERAVACYCLINE,EMEA/H/C/004237,no,Authorised,J01AA,no,no,no,no,no,no,20/09/2018,,PAION Deutschland GmbH,"Antibacterials for systemic use, ",,11/05/2023,7,Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.Consideration should be given to official guidance on the appropriate use of antibacterial agents.,27/07/2018,22/06/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/xerava,HLFSMUUOKPBTSM-ISIOAQNYSA-N,,0
773,Human,BiResp Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",BUDESONIDE,EMEA/H/C/003890,no,Authorised,R03AK07,no,no,no,no,no,no,28/04/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,04/05/2023,12,"Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) ",25/06/2018,15/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax,,,0
780,Human,DuoResp Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",BUDESONIDE,EMEA/H/C/002348,no,Authorised,R03AK07,no,no,no,no,no,no,28/04/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,04/05/2023,12,"Asthma DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.COPDDuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) ",10/07/2018,11/05/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/duoresp-spiromax,,,0
868,Human,Sancuso,Vomiting;  Cancer,granisetron,GRANISETRON,EMEA/H/C/002296,no,Authorised,A04AA02,no,no,no,no,no,no,20/04/2012,,Kyowa Kirin Holdings B.V.,"Antiemetics and antinauseants, , Serotonin (5HT3) antagonists",,09/02/2023,14,"Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.",19/07/2018,29/03/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso,MFWNKCLOYSRHCJ-BTTYYORXSA-N,,0
943,Human,Stalevo,Parkinson Disease,"levodopa, carbidopa, entacapone",CARBIDOPA,EMEA/H/C/000511,no,Authorised,N04BA03,no,no,no,no,no,no,17/10/2003,,Orion Corporation,Anti-Parkinson drugs,,12/01/2023,29,Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,23/02/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo,,,0
998,Human,Levodopa/Carbidopa/Entacapone Orion,Parkinson Disease,"levodopa, carbidopa, entacapone",CARBIDOPA,EMEA/H/C/002441,no,Authorised,N04BA03,no,no,no,no,no,no,23/08/2011,,Orion Corporation,Nervous system,,12/01/2023,13,Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,08/02/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/levodopa-carbidopa-entacapone-orion,,,0
1002,Human,Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz),Parkinson Disease,"levodopa, carbidopa, entacapone",CARBIDOPA,EMEA/H/C/002785,no,Authorised,N04BA03,no,no,no,no,no,no,11/11/2013,,Orion Corporation,Anti-Parkinson drugs,19/09/2013,12/01/2023,10,Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.,06/07/2018,16/01/2023,https://www.ema.europa.eu/en/medicines/human/EPAR/corbilta,,,0
1030,Human,Axumin,Prostatic Neoplasms;  Radionuclide Imaging,fluciclovine (18F),FLUCICLOVINE (18F),EMEA/H/C/004197,no,Authorised,V09IX12,no,no,no,no,no,no,21/05/2017,,Blue Earth Diagnostics Ireland Ltd,Diagnostic radiopharmaceuticals,22/03/2017,16/12/2022,16,This medicinal product is for diagnostic use only.Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.,11/06/2018,19/12/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/axumin,NTEDWGYJNHZKQW-DGMDOPGDSA-N,,0
1090,Human,Evra,Contraception,"norelgestromin, ethinyl estradiol",NORELGESTROMIN,EMEA/H/C/000410,no,Authorised,G03AA13,no,no,no,no,no,no,22/08/2002,,Gedeon Richter Plc.,"Sex hormones and modulators of the genital system, ",,09/11/2022,25,Female contraception.Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.,23/06/2017,09/11/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/evra,,,0
1119,Human,Tygacil,"Bacterial Infections;  Skin Diseases, Bacterial;  Soft Tissue Infections",tigecycline,TIGECYCLINE,EMEA/H/C/000644,no,Authorised,J01AA12,no,no,no,no,no,no,24/04/2006,,Pfizer Europe MA EEIG,"Antibacterials for systemic use, ",,15/09/2022,34,"Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections:, , , 	Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections, 	Complicated intra-abdominal infections (cIAI), , , Tygacil should be used only in situations where other alternative antibiotics are not suitable., , Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents., ",30/07/2018,11/10/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/tygacil,FPZLLRFZJZRHSY-HJYUBDRYSA-N,,0
1160,Human,Celsentri,HIV Infections,maraviroc,MARAVIROC,EMEA/H/C/000811,no,Authorised,J05AX09,no,no,no,no,no,no,18/09/2007,,ViiV Healthcare B.V.,Antivirals for systemic use,19/07/2007,19/08/2022,28,"Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable, ",12/04/2018,22/08/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/celsentri,GSNHKUDZZFZSJB-QYOOZWMWSA-N,,0
1216,Human,Starlix,"Diabetes Mellitus, Type 2",nateglinide,NATEGLINIDE,EMEA/H/C/000335,no,Withdrawn,A10BX03,no,no,no,no,no,no,03/04/2001,,Novartis Europharm Limited,Drugs used in diabetes,,08/11/2021,15,Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.,08/05/2018,28/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/starlix,OELFLUMRDSZNSF-BRWVUGGUSA-N,,0
1237,Human,Reagila,Schizophrenia,cariprazine,CARIPRAZINE HYDROCHLORIDE,EMEA/H/C/002770,no,Authorised,N05AX15,no,no,no,no,no,no,13/07/2017,,Gedeon Richter,Psycholeptics,18/05/2017,02/06/2022,7,Reagila is indicated for the treatment of schizophrenia in adult patients.,07/05/2018,07/06/2022,https://www.ema.europa.eu/en/medicines/human/EPAR/reagila,GPPJWWMREQHLQT-BHQIMSFRSA-N,,0
1382,Human,Budesonide/Formoterol Teva Pharma B.V.,"Asthma;  Pulmonary Disease, Chronic Obstructive","budesonide, formoterol fumarate dihydrate",BUDESONIDE,EMEA/H/C/004882,no,Authorised,R03AK07,no,no,no,no,no,no,03/04/2020,,Teva Pharma B.V. ,"Drugs for obstructive airway diseases, ",30/01/2020,07/12/2021,2,"Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) ",07/04/2020,08/12/2021,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonide-formoterol-teva-pharma-bv,,,0
1715,Human,Altargo,Impetigo;  Staphylococcal Skin Infections,retapamulin,RETAPAMULIN,EMEA/H/C/000757,no,Withdrawn,D06AX13,no,no,no,no,no,no,24/05/2007,,Glaxo Group Ltd,Antibiotics and chemotherapeutics for dermatological use,,09/11/2015,15,"Short term treatment of the following superficial skin infections:, , , 	impetigo;, 	infected small lacerations, abrasions or sutured wounds., , , See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus., , Consideration should be given to official guidance on the appropriate use of antibacterial agents., ",09/11/2015,15/03/2019,https://www.ema.europa.eu/en/medicines/human/EPAR/altargo,STZYTFJPGGDRJD-NHUWBDDWSA-N,,0
1746,Human,Numient,Parkinson Disease,"levodopa, carbidopa",CARBIDOPA,EMEA/H/C/002611,no,Withdrawn,N04BA02,no,no,no,no,no,no,19/11/2015,,Amneal Pharma Europe Ltd,Anti-Parkinson drugs,24/09/2015,03/08/2018,3,Symptomatic treatment of adult patients with Parkinson’s disease,03/08/2018,09/08/2018,https://www.ema.europa.eu/en/medicines/human/EPAR/numient,,,0
1802,Human,Budesonide/Formoterol Teva,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",BUDESONIDE,EMEA/H/C/003951,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,16/12/2016,2,"Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.",16/12/2016,31/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonideformoterol-teva,,,0
1803,Human,Budesonide/Formoterol Teva Pharma B.V.,Asthma,"budesonide, formoterol fumarate dihydrate",BUDESONIDE,EMEA/H/C/003953,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,16/12/2016,1,"Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists. ",16/12/2016,30/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/budesonideformoterol-teva-pharma-bv,,,0
1804,Human,Vylaer Spiromax,"Pulmonary Disease, Chronic Obstructive;  Asthma","budesonide, formoterol",BUDESONIDE,EMEA/H/C/003952,no,Withdrawn,R03AK07,no,no,no,no,no,no,19/11/2014,,Teva Pharma B.V.,"Drugs for obstructive airway diseases, ",,09/01/2017,3,"Vylaer Spiromax is indicated in adults 18 years of age and older only.AsthmaVylaer Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.COPDSymptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.",09/01/2017,26/01/2017,https://www.ema.europa.eu/en/medicines/human/EPAR/vylaer-spiromax,,,0
1822,Human,Foscan,"Head and Neck Neoplasms;  Carcinoma, Squamous Cell",temoporfin,TEMOPORFIN,EMEA/H/C/000318,no,Authorised,L01XD05,no,no,no,no,no,no,24/10/2001,,Biolitec Pharma Ltd,Antineoplastic agents,,29/03/2016,18,"Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.",29/03/2016,18/04/2016,https://www.ema.europa.eu/en/medicines/human/EPAR/foscan,LYPFDBRUNKHDGX-LWQDQPMZSA-N,,0
1934,Human,Avaglim,"Diabetes Mellitus, Type 2","rosiglitazone, glimepiride",GLIMEPIRIDE,EMEA/H/C/000675,no,Withdrawn,A10BD04,no,no,no,no,no,no,27/06/2006,,SmithKline Beecham Ltd,Drugs used in diabetes,,26/07/2011,11,"AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.",26/07/2011,12/08/2011,https://www.ema.europa.eu/en/medicines/human/EPAR/avaglim,WIGIZIANZCJQQY-RUCARUNLSA-N,,0
1956,Human,Turvel,Bacterial Infections,trovafloxacin,TROVAFLOXACIN,EMEA/H/C/000158,no,Withdrawn,J01MA13,no,no,no,no,no,no,08/07/1998,,Pfizer Limited,"Antibacterials for systemic use, ",,12/01/2010,0,"Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.Acute Exacerbations of Chronic BronchitisAcute SinusitisComplicated Intra-abdominal Infections and Acute Pelvic InfectionsSalpingitisUncomplicated Gonococcal Urethritis and CervicitisChlamydial CervicitisComplicated Skin and Soft Tissue InfectionsConsideration should be given to official guidance on the appropriate use of antibacterial agents.",12/01/2010,12/01/2010,https://www.ema.europa.eu/en/medicines/human/EPAR/turvel,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,,0
1957,Human,Turvel IV,Bacterial Infections,trovafloxacin,ALATROFLOXACIN MESILATE,EMEA/H/C/000159,no,Withdrawn,J01MA13,no,no,no,no,no,no,03/07/1998,,Pfizer Limited,"Antibacterials for systemic use, ",,12/01/2010,0,"Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.Acute Exacerbations of Chronic BronchitisAcute SinusitisComplicated Intra-abdominal Infections and Acute Pelvic InfectionsSalpingitisUncomplicated Gonococcal Urethritis and CervicitisChlamydial CervicitisComplicated Skin and Soft Tissue InfectionsConsideration should be given to official guidance on the appropriate use of antibacterial agents.",12/01/2010,12/01/2010,https://www.ema.europa.eu/en/medicines/human/EPAR/turvel-iv,CYETUYYEVKNSHZ-LGOOQLFJSA-N,,0
1958,Human,Trovan IV,Bacterial Infections,trovafloxacin,ALATROFLOXACIN MESILATE,EMEA/H/C/000161,no,Withdrawn,J01MA13,no,no,no,no,no,no,03/07/1998,,Pfizer Limited,"Antibacterials for systemic use, ",,31/12/2009,0,"Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.Acute Exacerbations of Chronic BronchitisAcute SinusitisComplicated Intra-abdominal Infections and Acute Pelvic InfectionsSalpingitisUncomplicated Gonococcal Urethritis and CervicitisChlamydial CervicitisComplicated Skin and Soft Tissue InfectionsConsideration should be given to official guidance on the appropriate use of antibacterial agents.",31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/trovan-iv,CYETUYYEVKNSHZ-LGOOQLFJSA-N,,0
1963,Human,Trovan,Bacterial Infections,trovafloxacin,TROVAFLOXACIN,EMEA/H/C/000160,no,Withdrawn,J01MA13,no,no,no,no,no,no,03/07/1998,,Pfizer Limited,"Antibacterials for systemic use, ",,31/12/2009,0,"Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:Pneumonia:Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.Acute Exacerbations of Chronic BronchitisAcute SinusitisComplicated Intra-abdominal Infections and Acute Pelvic InfectionsSalpingitisUncomplicated Gonococcal Urethritis and CervicitisChlamydial CervicitisComplicated Skin and Soft Tissue InfectionsConsideration should be given to official guidance on the appropriate use of antibacterial agents.",31/12/2009,31/12/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/trovan,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,,0
1975,Human,Trazec,"Diabetes Mellitus, Type 2",nateglinide,NATEGLINIDE,EMEA/H/C/000383,no,Withdrawn,A10BX03,no,no,no,no,no,no,03/04/2001,,Novartis Europharm Ltd.,Drugs used in diabetes,,23/07/2007,5,Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.,23/07/2007,24/08/2009,https://www.ema.europa.eu/en/medicines/human/EPAR/trazec,OELFLUMRDSZNSF-BRWVUGGUSA-N,,0
